MX2008009724A - 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them - Google Patents

Abstract

This invention relates to certain pyrimidine derivative inhibitors of JAK-2, having Formula (I):wherein D, E, L, Z, R1, R2, R25, and n1 are as defined in the specification, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof.

Description

4-ARIL-2-AMINO-PYRIMIDINES AND 4-ARIL-2-AMINOALQUIL- PYRIMIDINES AS JA US 2 KINASE MODULATORS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM FIELD OF THE INVENTION This invention relates to certain 4-aryl-2-amino-pyrimidines and 4-aryl-2-aminoalkyl-pyrimidines as inhibitors of protein-tyrosine kinases. In particular, the invention relates to JAK-2 inhibitors comprising the signaling pathways of cytokine receptors.

BACKGROUND OF THE INVENTION Janus kinases (JAK) are protein tyrosine kinases ubiquitously expressed in cells. JAKs are involved in membrane signaling events that are activated by a variety of extracellular factors that interact with cell surface receptors. JAKs initiate cascades of cytoplasmic signal transduction of cytokine receptors that lack a protein-tyrosine kinase domain. Signal transduction cascades are initiated after oligomerization of surface receptors due to ligand binding. The JAKs associated with cytoplasmic receptor are then activated which subsequently phosphorylates the tyrosine residues along the chains of the receptor.

REF. : 194985 These phosphotyrosine residues are targets for a variety of transducing proteins that contain SH2 domains, such as signal transducer proteins and transcription protein activators (STATs). After the STATs bind to the receptor chains, they are phosphorylated by the JAK proteins, dimerized and translocated in the nucleus. In the nucleus, STATs alter the expression of genes regulated by cytokine. The mammalian JAK-2 corresponds to a family of cytokines including JAK-1, JAK-3 and TYK-2. JAK-1, JAK-2 and TYK-2 are ubiquitously expressed, whereas JAK-3 is predominantly expressed in hematopoietic cells. These kinases consist of approximately 1150 amino acids, with molecular weights of approximately 120 kDa to 130 kDa. The amino acid sequences of the JAK kinase family are characterized by the presence of highly conserved domains. These domains include the homology domains of JAK (JH), the C-terminal domain (JH1) responsible for the function of tyrosine kinases, the tyrosine-kinase domain (JH2) that shows high similarity to functional kinases but does not they possess no catalytic activity, and the N-Terminal domain encompassing JH7 to JH3) that is important for receptor association and non-catalytic activity. Although the function of the N-terminal domain is not well established, there is some evidence of a regulatory role in the JH1 domain, modulating the catalytic activity in this way. Substrates downstream of the JAK family of kinases include signal transducing proteins and transcription activators (STATs). JAK / STAT signaling has been implicated in the mediation of many abnormal immune responses such as allergies, asthma, autoimmune diseases such as transplant rejection, rheumatoid arthritis, amyotrophic lateral sclerosis and multiple sclerosis as well as in solid and hematological malignancies such as leukemias and lympholas The signal transducer and transcription activator (STAT) proteins are activated by the kinases of the JAK family. Recent studies suggested the possibility of modulating the JAK / STAT signaling pathway by targeting the JAK family kinases with specific inhibitors for the treatment of leukemia (see Sudbeck, et al., Cancer Clin. Res. 5: 1569-1582 ( 1999)). In animal models, TEL / JAK-2 fusion proteins induced myeloproliferative disorders (Schwaller, et al., EMBO J. 17: 5321-5333 (1998)). In hematopoietic cell lines, the introduction of TEL / JAK2 resulted in activation of STAT1, STAT3, STAT5, and cytokine-independent growth (Schwaller, et al., EMBO J. 17: 5321-5333 (1998)). The JAK / STAT pathway is comprised in abnormal cell growth (Yu, et al., J. Immunol 159: 5206-5210 (1997)). STAT3, STAT5, JAK1 and JAK2 are constitutively activated in mouse T-cell lymphoma initially characterized by overexpression of LCK. In addition, activation of STAT3 mediated by IL-6 was blocked by inhibition of JAK, leading to sensitization of myeloma cells to apoptosis (Catlett-Falcone, et al., Immunity 10: 105-115 (1999)). A particularly attractive target for the modulation of small molecules, with respect to antiproliferative and antiangiogenic activity, is JAK-2. Accumulating activity shows that the constitutive activation of the JAK / STAT pathway promotes growth, survival, differentiation, neoplastic transformation and cellular angiogenesis in response to growth factors, cytokines, and hormones. JAK-2 is also activated in a wide variety of human cancers such as prostate, colon, ovarian, breast, melanoma, leukemia and other hematopoietic malignancies. In addition, it has been identified that the somatic point mutation of the JAK-2 gene is highly associated with classical myeloproliferative disorders (MPD) and infrequently in other myeloid disorders. The constitutive activation of JAK-2 activity is also caused by chromosomal translocation in hematopoietic malignancies, such as in TEL-JAK-2 which is mainly associated with T-ALL, and in PCM1-JAK-2 which is associated with B-ALL and CML. It has been shown that inhibition of the JAK / STAT pathway, and in particular the inhibition of JAK-2 activity, results in anti-proliferative and pro-apoptotic effects for the most part due to the inhibition of STAT phosphorylation. . In addition, the inhibition of JAK-2 activity by pharmacological agents or by dominant negative JAK-2 expression effectively blocks tumor growth and induces apoptosis by reducing STAT phosphorylation in cell culture and in human tumor xenografts in vivo . Therefore, the JAK / STAT signal transduction pathway is a well-validated target route for therapeutic intervention. Accordingly, the identification of small molecule compounds that specifically inhibit, regulate and / or modulate the signal transduction of kinases, particularly JAK-2, is desirable as a means to treat or prevent diseases and conditions associated with cancers. Thus, an object of this invention is the identification of JAK-2 inhibitors as new therapeutic agents to treat human diseases.

BRIEF DESCRIPTION OF THE INVENTION The invention relates to compounds for inhibiting JAK-2 and pharmaceutical compositions of the compounds for inhibiting JAK-2. The invention also relates to methods for treating a disease mediated at least in part by JAK-2 using a compound of the invention, or a pharmaceutical composition thereof, as well as in combination with other therapies. The foregoing only summarizes certain aspects of the invention and is not proposed to be of a limiting nature. These aspects and other aspects and modalities are described more fully below. All references of any kind referred to in this specification are hereby incorporated by reference in their entirety. In the case of a discrepancy between the express description of this specification and the references incorporated as reference, you must control the express description of this specification.

DETAILED DESCRIPTION OF THE INVENTION A first aspect of the invention relates to a compound of Formula I I or a pharmaceutically acceptable salt thereof, wherein D is hydrogen, halo, -CF3, heterocycloalkyl or alkyl; E is hydrogen, halo, -CF3, heterocycloalkyl or alkyl; or D and E, together with the carbon atoms to which they are attached, form a 5-7 membered heteroaryl or a 5-7 membered heterocycloalkyl, wherein the 5-7 membered heteroaryl or 5-7 membered heterocycloalkyl each is fused to the pyrimidinyl moiety to which D and E are attached; L is a bond, -O- or -N (H) -; Z is selected from alkoxy, cycloalkyl, heteroaryl optionally substituted with alkyl, halo, C (0) OR26, -C (= N-OH) alkyl, -C (0) R8, -C (O) NR30R30a, -CH2R2, - (CH2) n5NR26R26a, -CF3, -CN, -S02R12, -S -R12a, -OR32a, Z and R25, together with the carbon atoms to which they are attached, join to form a 5- or 6-membered heterocycloalkyl, a 5- or 6-membered heteroaryl, or a or 6 membered cycloalkyl ring, wherein the 5- or 6-membered heterocycloalkyl, 5- or 6-membered heteroaryl, and 5 or 6 membered cycloalkyl ring are fused to the phenyl portion to which Z and R25 are attached, and wherein the 5 or 6 membered heterocycloalkyl, or 5 or 6 membered heteroaryl, or 5 or 6 membered cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected groups of oxo, alkyl, alkoxy and halo; neither is 0, 1, 2, 3 or 4, and each nor is independently selected when more than one ni is present; n2 is 0, 1, 2, 3 or 4, and each n2 is independently selected when more than one n2 is present; n3 is 0, 1, 2 or 3, and each n3 is independently selected when more than one n3 is present; n4 is 0, 1, 2, 3 or 4, and each n4 is independently selected when more than one n4 is present; n5 is 0, 1, 2, 3 or 4, and each n5 is independently selected when more than one n5 is present; p is 0-3; r is 1-3; R1 is hydrogen; R2 is a group of the formula: - (CHj NW-SiOfe (q) R7, R7 ', R9, R10, R12 and R15 are each independently hydrogen, alkyl, alkoxy, or alkoxyalkyl; R8 is selected from hydrogen, hydroxy, alkyl, alkenyl, lower alkynyl, hydroxylamino, hydroxyalkyl, alkoxyalkyl, dihydroxyalkyl, alkylamino, dialkylamino, aminoalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, alkylaminoalkyl, dialkylaminoalkyl, - (CH2) rC (O) OR7, - (CH2) rC (O) NR7R7 ', aryl, heteroaryl, cycloalkyl, arylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the aryl, heteroaryl, cycloalkyl, arylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl are each independently optionally substituted at the ring position with one, two, three, four or five groups independently selected from alkyl, alkenyl, lower alkynyl, halo, hydroxy, haloalkyl, haloalkoxy, lower alkoxy, amino, aryl, alkylamino, dialkylamino, heterocyclylalkoxy, oxo and haloalkyl; each R 11, wherein R 11 is present, is independently selected from alkyl, alkenyl, lower alkynyl, -CF 3, alkoxy, halo, haloalkoxy, haloalkyl, aminoalkyl, aminoalkoxy, alkylaminoalkyl, alkylaminoalkoxy, dialkylaminoalkyl, dialkylaminoalkoxy, oxo, thioalkyl, alkylthioalkyl, - (CH2) p-OR17, -CN, -0-CH2-C (0) -R17, -C (0) R16, -CH2) pC (O) OR17, -S (0) 2R17, -S (O) 2NR15R17, aryl, heteroaryl, cycloalkyl, arylalkyl, arylalkoxy, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the aryl, heteroaryl, cycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl are each independently optionally substituted at any ring position with 1, 2, 3 or 4 R21; R 12 is hydrogen or alkyl; R12a is hydrogen or alkyl; R13 is selected from hydrogen, hydroxy, alkyl, alkenyl, lower alkynyl, hydroxylamino, haloalkyl, alkyl substituted with halo and hydroxy, hydroxyalkyl, alkoxyalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, (CH2) r-, C (0) OR7, - ( CH2) rC (0) NR7R7 ', aryl, heteroaryl, cycloalkyl, arylalkyl, diarylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the aryl, heteroaryl, cycloalkyl, arylalkyl, diarylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl are each independently optionally substituted at the ring position with 1, 2, 3, 4 or 5 independently selected groups of alkyl, alkenyl, lower alkynyl, halo, hydroxy, hydroxyalkyl, alkoxycarbonyl, alkylcarbonyl, haloalkyl, haloalkoxy, lower alkoxy, amino, aryl, alkylamino, dialkylamino, heterocyclylalkoxy, oxo and haloalkyl; and wherein the alkyl of cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, and heteroarylalkyl are independently optionally substituted with 1, 2, 3, 4 or 5 groups selected from halo and hydroxy; R14 is a bond, heterocycloalkyl or cycloalkyl; R16 is selected from hydrogen, hydroxy, alkyl, alkenyl, lower alkynyl, hydroxyamino, haloalkyl, alkyl substituted with halo and hydroxy, hydroxyalkyl, alkoxyalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, dialkylaminoalkyl, - (CH2) rC (O) OR7, aryl, heteroaryl, cycloalkyl, arylalkyl, diarylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the aryl, heteroaryl, cycloalkyl, arylalkyl, diarylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl are each independently independently substituted at the ring position with one, two, three, four or five groups independently selected from alkyl, alkenyl, lower alkynyl, halo, hydroxy, hydroxyalkyl, alkoxycarbonyl, alkylcarbonyl, haloalkyl, haloalkoxy, lower alkoxy, amino, aryl, alkylamino, dialkylamino, heterocyclylalkoxy, oxo and haloalkyl; and wherein the alkyl of cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl and heteroarylalkyl are optionally substituted with 1, 2, 3, 4 or 5 groups selected from halo and hydroxy; R17 is selected from hydrogen, hydroxy, alkyl, alkenyl, lower alkynyl, hydroxyamino, haloalkyl, alkyl substituted with halo and hydroxy, hydroxyalkyl, alkoxyalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, dialkylaminoalkyl, - (CH2) rC (O) OR7, - ( CH2) rC (O) NR7R7 ', aryl, heteroaryl, cycloalkyl, arylalkyl, diarylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; where the aryl, heteroaryl, cycloalkyl, arylalkyl, diarylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl are each independently optionally substituted at the ring position with one, two, three, four or five groups independently selected from alkyl, alkenyl, lower alkynyl, halo, hydroxy, hydroxyalkyl, alkoxycarbonyl, alkylcarbonyl, haloalkyl, haloalkoxy, lower alkoxy, amino, aryl, alkylamino, dialkylamino, heterocyclylalkoxy, oxo and haloalkyl; and wherein the alkyl of cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, and heteroarylalkyl are independently optionally substituted with 1, 2, 3, 4 or 5 groups selected from halo and hydroxy; each R21, when R21 is present, is independently selected from alkyl, alkenyl, lower alkynyl, cyano, halo, haloalkoxy, haloalkyl, hydroxyalkyl, amino, alkylamino, dialkylamino, dialkylaminoalkyl, dialkylaminoalkyloxy, haloalkyl, oxo, -OR13, -NHS ( ) 2R17, -S (0) 2R17, -C (0) R17, -C (0) OR17, C (0) NR15R17, -NR15C (0) R17, aryl, arylalkyl, heteroarylalkyl, aryloxy, and heteroaryl; wherein each of the aryl, arylalkyl, heteroarylalkyl, aryloxy, and heteroaryl within R21 are optionally substituted at any ring position with 1, 2 or 3 groups selected from alkyl, lower alkoxy, halo, phenyl, heteroaryl and alkylheteroalkyl; R25 is selected from alkyl, alkenyl, lower alkyl, halo, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, -0R12, cyano, -C (0) R8, -CH2NHC (0) OR7, -CH2NHC (O ) R7, -SR7, -S (0) 2R7, - -C (0) 0R8, -C (0) NR7R8, cycloalkyl, heterocycloalkyl, aryl and heteroaryl; wherein the cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each optionally substituted with one, two or three groups independently selected from alkyl, alkenyl, halo, haloalkoxy, haloalkyl, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, -OR8, NHS ( 0) 2R8, cyano, -C (0) R8, -CH2NHC (O) OR7, -CH2NHC (O) R7, -SR7, -S (0) 2R7, -S (0) 2NR7R8, -C (0) OR8 , -C (0) NR7R8, -NR7'C (0) -CH3-OR8, -NR7'C (0) -CHR3-NR7R8, and -NR7C (0) R8; R26 is hydrogen, -C (0) -phenyl or alkyl, wherein the -C (0) -phenyl is optionally substituted at any ring position with 1, 2 or 3 halo; R26a is hydrogen, alkyl, heteroaryl, -C (0) R32, -C (0) NHR32a, -S (0) 2R9, -SR9, -C (0) OR32, or -C (0) NR32aR32; R27 and R28 are each independently selected from alkyl, alkenyl, hydroxy, alkoxy, and alkoxyalkyl; R27a and R28a are independently selected from hydrogen, alkyl, alkenyl, alkoxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, dialkylaminoalkyl, arylcarbonylalkyl, aryloxyalkyl, dialkylaminoalkyl, alkyl-O-C (0) heterocycloalkyl, - (CH 2) n 4 -heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, (CH2) n4-C (0) R29, - (CH2) n4NR28R28a, - (CH2) n4NHR28a, -CH (phenyl) 2, -S (0) 2R29, -C (0) R29, -C (0) OR29 , and -C (O) NR9aR29, wherein the aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl groups within R27a and R8a are each independently optionally substituted at any ring position with 1, 2, 3, 4 or 5 groups selected from halo, alkyl, alkoxy, alkylcarbonyl, phenyl, phenoxy, arylcarbonyl, -CF3, oxo, -0CF3, alkoxyphenyl and heteroaryl optionally substituted with alkyl or halo; or R27 and R7, together with the nitrogen to which they are attached, form heterocycloalkylamino, heterocycloalkyl or heteroaryl, wherein the heterocycloalkylamino and heteroaryl are each independently optionally substituted with 1, 2, 3, 4 or 5 R31; or R28 and R28a 'together with the nitrogen to which they are attached form heterocycloalkyl or heteroaryl, wherein the heterocycloalkyl and heteroaryl are each optionally substituted with 1, 2, 3, 4 or 5 R31; R29a is hydrogen or alkyl; R29 is selected from alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the aryl, arylalkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl groups within R29 are each optionally substituted at any ring position with 1, 2, 3, 4 or 5 groups selected from halo, alkyl, alkoxy, alkylcarbonyl, phenyl, phenoxy, arylcarbonyl, -CF 3, oxo, -OCF 3 alkoxyphenyl, and heteroaryl optionally substituted with alkyl or halo; R30a is hydrogen or alkyl; R 30 is selected from hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, alkoxycarbonylalkyl, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aryl, arylalkyl, phenoxyalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, arylheteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the groups aryl, arylalkyl, phenoxyalkyl, cycloalkyl, arylheteroarylalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl within R30 are each independently optionally substituted at any ring position with 1, 2, 3, 4 or 5 groups selected from halo, alkyl, alkoxy, alkoxyalkyl, -C (0) OCH3, -CF3, -OCF3 , alkylcarbonyl, phenyl, phenoxy, alkylphenoxy, dialkylaminoalkoxy and heteroaryl; R31 is selected from alkyl, hydroxyalkyl, alkoxy, alkoxyalkyl, alkylthioalkyl, -C (0) R30, C (O) NR30R30a, -C (0) OR30, -S (0) 2R30, amino, dihydroxyalkyl, arylcarbonyl, alkylcarbonylamino, alkoxyphenyl phenylalkoxyalkyl, arylheteroarylalkyl, alkylamino, -O-dialkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, dialkylaminoalkoxy, oxo, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, spirocyclic cycloalkyl, spirocyclic heterocycloalkyl, and heterocycloalkylalkyl, wherein aryl, arylalkyl, cycloalkyl, arylheteroarylalkyl, arylalkoxyalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl groups within R31 are each independently independently substituted at any ring position with 1, 2, 3, 4 or 5 groups selected from halo, alkyl, -CF3, -OCF3, cyano, alkoxy, alkoxyalkyl, -C (0) OCH3, alkylcarbonyl, phenyl optionally substituted at any ring position with halo, phenoxy, alkylphenoxy, arylalkoxyalkyl, dialkylaminoalkoxy and heteroaryl; R32a is hydrogen, -OCF3, -CF3, or alkyl; R 32 is selected from aryl, arylalkyl, arylalkoxy, arylcycloalkyl, alkoxycarbonylalkoxy, cycloalkyl, cycloalkylalkyl, cycloalkylhydroxyalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl, wherein aryl, arylalkyl, cycloalkyl, arylcycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl are each independently independently substituted at any ring position with 1, 2, 3, 4 or 5 groups selected from hydroxy, oxo, alkyl, alkoxy, amino, hydroxyalkyl, alkylcarbonyl, alkoxycarbonyl, halo, -CF3, -OCF37 aminoalkyl , alkylaminoalkyl, aryl and dialkylaminoalkyl, and wherein the alkyl portion of the heteroarylalkyl may be substituted with amino; or R32 is an alkyl optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from hydroxy, alkoxycarbonyl, alkoxy, -CF3, halo, aminocarbonyl, alkylaminocarbonyl, alkoxycarbonylalkylamino, dialkylaminocarbonyl, -NR34R34a and phenyl optionally substituted with 1, 2 or 3 halo; or R32 is alkylamino or arylalkylamino; R34 is hydrogen or alkyl; R34a is selected from hydrogen, alkyl, heteroaryl, aryl, aminoalkyl, aminocarbonylalkyl, heteroarylalkyl, arylalkoxy, and arylalkyloxycarbonylalkyl; wherein the heteroaryl, aryl, heteroarylalkyl, arylalkoxy or arylalkyloxycarbonylalkyl are each independently independently substituted at any ring position with 1, 2, 3, 4 or 5 groups selected from hydroxy, oxo, alkyl, amino, hydroxyalkyl, alkylcarbonyl, alkoxycarbonyl, halo, aminoalkyl, alkylaminoalkyl, and dialkylaminoalkyl; and R35 is selected from halo, - (CH2) pC (O) OR17, cycloalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the heterocycloalkyl and heterocycloalkylalkyl are each optionally substituted with 1, 2, 3, 4 or 5 groups each independently selected from alkyl, alkoxy and halo. Another embodiment of the first aspect of the invention relates to a compound of Formula II: wherein E, D, L, Z, R1, R2 and R25 are as defined above for the compound of Formula I. Another embodiment of the first aspect of the invention relates to a compound of Formula III: wherein E, D, L, Z, R1, R2 and R25 are as defined above for the compound of Formula I. Another embodiment of the first aspect of the invention relates to a compound of Formula IV: where D, E, R25 and R32 are as defined above for Formula I, and R28 and R28, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R31, and wherein R31 is as defined above in Formula I . Another embodiment of the first aspect of the invention relates to a compound of Formula V: wherein D, E, R25 and R32 are as defined above for Formula I, and R28 and R28a, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R31, and wherein R31 is as defined above in Formula I. Another embodiment of the first aspect of the invention relates to a compound of Formula VI: wherein D, E, R25 and R32 are as defined above for Formula I, and R28 and R28a, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R31, and wherein R31 is as defined above in Formula I. In other embodiments of the first aspect of the invention, D, E, and R25 for Formula IV, or Formula V or Formula VI are each hydrogen. In other embodiments of the first aspect of the invention, R32 for Formula IV, Formula V or Formula VI is heterocycloalkyl. In other embodiments of the first aspect of the invention, R32 for Formula IV, Formula V or Formula VI is alkyl optionally substituted with alkoxy, hydroxy, amino, alkylamino, or dialkylamino. In other embodiments of the first aspect of the invention, R2 in Formula I, II, or III is wherein R27a, R11 and n2 are as defined above for the compound of Formula I. In other embodiments of the first aspect of the invention, R2 in the Formula wherein R28, R11 and n2 are as defined above for the compound of Formula I, and R28 is arylalkyl or heteroarylalkyl, wherein the arylalkyl or heteroarylalkyl are each optionally substituted with 1, 2, 3, 4 or 5 selected substituents of halo or lower alkyl. In other embodiments of the first aspect of the invention, R2 in Formula I, II, or III is wherein R28, R11 and n2 are as defined above for the compound of Formula I. In other embodiments of the first aspect of the invention, R2 in Formula I, II, or III is wherein R28, R11 and n2 are as defined above for the compound of Formula I, and R28 is selected from lower alkyl, dialkylaminoalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, and heterocycloalkylalkyl. In other embodiments of the first aspect of the invention, R2 in Formula I, II, or III is wherein R11 and n2 are as defined above for the compound of Formula I, and R28 and R28a, together with the nitrogen atom to which they are attached, are joined together to form a ring structure selected from thiazolidinyl, piperazinyl, piperidinyl , morpholinyl, thiomorpholinyl, pyrimidinyl, and pyridinyl, wherein the ring structure is optionally substituted with 1, 2, 3, 4 or 5 substituents selected from halo, lower alkyl or alkoxy. In other embodiments of the first aspect of the invention, R2 in Formula I, II, or III is wherein R27a, R11 and n2 are as defined above for the compound of Formula I. Other embodiments of the first aspect of the invention relate to a compound of Formula I, II or III, wherein L is a bond, and Z is 26th Other embodiments of the first aspect of the invention relate to a compound of Formula I, II or 5 N III, wherein Z is ^ 26a and R25 is hydrogen. Other embodiments of the first aspect of the invention relate to a compound of Formula I, II or III, where Z is R a, R 25 is hydrogen and E and D are hydrogen. Other embodiments of the first aspect of the invention relate to a compound of Formula I, II or III, wherein R25 is in the 3-position. Another embodiment of the first aspect of the invention refers to a compound of Formula I, II or III, in where Z is and R26a is -C (0) R32. Other embodiments of the first aspect of the invention relate to a compound of Formula I, II or III, where Z is , R26a is -C (0) R32, and R32 is selected from lower alkyl, cycloalkyl, diaminoalkyl, aminoalkyl, arylalkyl, heterocycloalkyl, alkoxyalkyl, alkylamino, and hydroxyalkyl optionally substituted by amino. Other embodiments of the first aspect of the invention relate to a compound of Formula I, II or III, where Z is , R26a is -C (0) R32, and R32 is cycloalkyl. Other embodiments of the first aspect of the invention relate to a compound of Formula I, II or R26 III, wherein Z is, R26a is -C (0) R32, and R32 is lower alkyl. Other embodiments of the first aspect of the invention relate to a compound of Formula I, II or "R26 \ 26a III, wherein Z is R R26a is -C (0) R32, R26 is hydrogen, wherein R is selected from aryl, arylalkyl, cycloalkyl, alkoxycarbonylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl, wherein R 32 is optionally substituted with 1, 2, 3, 4 or 5 groups selected from hydroxyl, oxo, alkyl, alkoxy, amino, hydroxyalkyl or halo. Other embodiments of the first aspect of the invention relate to a compound of Formula I, II or III, wherein Z is R26a, R26a is -C (0) R32, R26 is hydrogen, wherein R32 is selected from tetrahydrofuran, pyrrolidinyl or pyrimidinyl, wherein R32 is optionally substituted with 1, 2, 3, 4 or 5 groups selected from hydroxyl, oxo, alkyl, alkoxy, amino, hydroxyalkyl or halo. Other embodiments of the first aspect of the invention relate to a compound of Formula I, II or III, wherein Z is r263, R26a is -C (0) R32, R26 is hydrogen, wherein R32 is lower alkyl optionally substituted with 1, 2, 3, 4 or 5 groups selected from dialkylaminocarbonyl, hydroxy and -NR34R34a, in wherein R34 and R34 are as defined above for Formula I. Other embodiments of the first aspect of the invention relate to a compound of formula I, II or j- (CHz H- O) - where R2 is (Rri ",) nr2 In another embodiment of the first aspect of the invention, R32 is methyl In another embodiment of the first aspect of the invention, R32 is alkyl substituted with -NR34R34a. Other embodiments of the first aspect of the invention relate to a compound of Formula I, II or III, wherein R32 is U or -CH2-U, wherein U is selected from pyrolidinyl, thiazolidinyl, morpholinyl, azetidinyl, cyclobutyl, cyclopropyl. , tetrahydrofuranyl, pyrazinyl, imidazolyl, piperazinyl, thienyl, thienylmethyl, furanyl, phenyl, prolinamidyl, pyridinyl, tetrahydronaphthalene, tetrazolyl, isoindolinyl, pyranyl, cyclopentyl, and octahydro-1H-indolyl. Other embodiments of the first aspect of the invention relate to a compound of Formula I, II or III, wherein R 11, when present, is halo or lower alkyl. Other embodiments of the first aspect of the invention relate to a compound of Formula I, II or III, wherein R 11, when present, is lower alkyl. Other embodiments of the first aspect of the invention relate to a compound of Formula I, II or III, wherein R35 is heterocycloalkylalkyl, wherein the Heterocycloalkyl is selected from piperazyl, piperidinyl, morpholinyl and dioxanyl. Other embodiments of the first aspect of the invention relate to a compound of Formula I, II or III, wherein n2 is 0. Other embodiments of the first aspect of the invention relate to a compound of Formula I, II or III, where R is Other embodiments of the first aspect of the invention relate to a compound of Formula I, II or III, where R2 is and wherein R28 and R: 28a together with the nitrogen atom to which they are attached form a heterocycloalkyl. Other embodiments of the first aspect of the invention relate to a compound of Formula I, II, or III, IV, or V, or where R25 is hydrogen. A second aspect of the invention relates to a pharmaceutical composition comprising a compound of formula I, II, III, IV, V, or VI, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient or diluent. A third aspect of the invention relates to a method for inhibiting JAK-2 in a cell, which comprises putting in contact the cell, in which the inhibition of JAK-2 is desired, with a compound of Formula I, II, III, IV, V or VI, or a pharmaceutically acceptable salt thereof. A fourth aspect of the invention relates to a method for inhibiting JAK-2 in a cell, which comprises contacting the cell, in which inhibition of JAK-2 is desired, with a pharmaceutical composition comprising a compound of the invention. Formula I, II, III, IV, V or VI, or a pharmaceutically acceptable salt thereof. A fifth aspect of the invention relates to a method for treating a disease, disorder or syndrome mediated, at least in part, by inhibiting JAK-2, which method comprises administering to an animal in need of this treatment a therapeutically effective amount of a compound of Formula I, II, III, IV, V or VI, or a pharmaceutically acceptable salt thereof. A sixth aspect of the invention relates to a method for treating a disease, disorder or syndrome mediated, at least in part, by inhibiting JAK-2, which method comprises administering to an animal in need of this treatment a pharmaceutical composition comprising a Therapeutically effective amount of a compound of Formula I, II, III, IV, V or VI, or a pharmaceutically acceptable salt thereof. The disease that is treated in these aspects of the invention may be a raieloproliferative disorder, cancer, cardiovascular disease, and / or hematopoietic abnormality where hyperactivation of JAK-STAT signaling is present. Non-limiting examples of myeloproliferative disorder which are contemplated as being treatable by the compounds of the invention include myelofibrosis, thrombocythemia, polycythemia vera (PV), essential thrombocythemia (ET), agnogenic myeloid metaplasia (AMM), also referred to as idiomatic myelofibrosis ( IMF), and chronic myelogenous leukemia (CML). Non-limiting examples of cancers that are contemplated as being treatable by the compounds of the invention include leukemias, lymphoras, multiple myeloma, prostate cancers, lung cancers, breast cancers, and ovarian cancers. Non-limiting examples of cardiovascular diseases that are contemplated as being treatable by the compounds of the invention include congestive heart failure and hypertension. Non-limiting examples of hematopoietic abnormalities that are contemplated as being treatable by the compounds of the invention include thrombocytosis. A seventh aspect of the invention relates to a method for treating a disease, disorder, or syndrome mediated, at least in part, by inhibition of JAK-2, method characterized in that it comprises administering to an animal a compound of Formula I, II, III, IV, V or VI, or a pharmaceutically acceptable salt thereof, in combination with one or more treatments selected from surgery, one or more therapeutic agents, platelet pheresis and radiation. An eighth aspect of the invention relates to a method for treating a disease, disorder or syndrome mediated, at least in part, by inhibiting JAK-2, which method comprises administering to an animal a pharmaceutical composition comprising a therapeutically effective amount of a Compound of Formula I, II, III, IV, V or VI, or a pharmaceutically acceptable salt thereof, in combination with one or more treatments selected from surgery, one or more therapeutic agents, plateletpheresis and radiation. When treating myeloproliferative disorders, the compound of Formula I, II, III, IV, V or VI can also be administered with one or more additional treatments selected from plateletpheresis and one or more therapeutic agents selected from interferon-a; aspirin; a platelet-lowering drug, such as anagrelide; and a myelosuppressive agent (such as a radiophosphorus and alkylating agents). Non-limiting examples of the myelosuppressive agent include hydroxyurea, melphalan, and busulfan. When treating cancer, the compound of Formula I, II, III, IV, V or VI can be administered in combination with one or more chemotherapeutic agents selected from fludaribine, vinblastine, adriamycin and cisplatin.

Abbreviations and Definitions The following abbreviations and terms have the indicated terms of end-to-end: As used in the present specification, words and phrases are generally proposed to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise or is expressly defined to mean a different thing . The symbol "-" means an individual link. "=" means a double bond, "=" means a triple bond, "means an individual or double bond." When a group removed from its formula of origin is represented, the symbol it will be used at the end of the link that was theoretically split in order to separate the group from its structural formula of origin. When chemical structures are represented or described, unless otherwise explicitly stated, all carbons are assumed to have hydrogen substitution to fit a valence of four. For example, in the structure on the left side of the subsequent schematic presentation there are nine hydrogens involved. The nine hydrogens are represented in the structure of the right side. Sometimes, a particular atom in a structure is described in the formula textual as having a hydrogen or hydrogens as substitution (hydrogen expressly defined), for example, -CH2CH2-. It is understood by one skilled in the art that the aforementioned descriptive techniques are common in clinical techniques to provide brevity and simplicity to the description of otherwise complex structures.

If another group "R" is represented "floating" in a ring structure, as for example in the formula: then, unless otherwise specified, a "R" substituent may reside on any ring system atom, assuming replacement of a hydrogen represented, implied or expressly defined from one of the ring atoms, so long as it is formed a stable structure. If a group "R" is represented as floating in a fused ring system, as for example in the formulas: then, unless otherwise defined, a "R" substituent may reside on any atom of the fused ring system, assuming the replacement of a hydrogen represented (e.g., -NH- in the above formula), hydrogen involved (for example as in the previous formula, where the hydrogens are not shown but are understood to be present), or hydrogen expressly defined (for example where in the above formula "X" is equal to = CH-) of one of the atoms of ring, as long as a stable structure is formed. In the example shown, the group "R" may reside in either the 5-membered ring or the 6-membered ring of the fused ring ring system. In the formula represented above, when y is 2 for example, then the two "R" s can reside in any of the two atoms of the ring system, assuming again that each replaces a hydrogen represented, implied or expressly defined in the ring. When a group "R" is represented as existing in a ring system containing saturated carbons, as for example in the formula: where, in this example, "and" may be more than one, assuming that each replaces a hydrogen currently represented, implied, or expressly defined in the ring; then, unless otherwise defined, where the resulting structure is stable, two "Rs" can reside on the same carbon. A simple example is when R is the methyl subgroup; there may be a germinal dimethyl on a carbon of the represented ring (an "annular" carbon). In another example, two Rs on the same carbon, including this carbon, can form a ring, thereby creating a spirocyclyl ring structure (a "spirocyclyl" group) with the ring represented as for example in the formula: "Administration" and variants thereof (eg, "administering" are compounds) in reference to a compound of the invention means introducing the compound or a prodrug of the compound into the system of the animal in need of treatment. When a compound of the invention or prodrug thereof is provided in combination with one or more other active agents (eg, surgery, radiation, and chemotherapy, etc.), "Administration" and its variants are each understood to include concurrent and sequential introduction of the compound or prodrug thereof and other agents. "Alkyl" is intended to include linear or branched structures of C ^ -C ^, more typically, C ^ -C ^ and combinations of the same, inclusive. "Lower alkyl" is intended to include linear or branched structures of C ^ -C6 and combinations of the same, inclusive. For example, "C6 alkyl" may refer to a n-hexyl, iso-hexyl, cyclobutylethyl, and the like. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, isobutyl, pentyl, hexyl, and the like. "Upper alkyl" refers to alkyl groups containing more than 6 carbon atoms. In this application, alkyl refers to alkanyl, alkenyl and alkynyl residues (and combinations thereof); it is proposed to include cyclohexylmethyl, vinyl, allyl, isoprenyl, and the like. Thus, when a residue or alkyl having a specific number of carbons is named, all geometric isomers having that number of carbons are proposed to be supplied; thus, for example, either "butyl" or "C4 alkyl" is proposed to include / 2-butyl, _? ec-butyl, isobutyl, ü-butyl, isobutenyl and but-2-ynyl groups; and for example, "propynyl" or "C3 alkyl" each includes? -propyl, profenyl, and isopropyl.

"Cycloalkyl" means a non-aromatic mono- or multi-cyclic ring system comprising from about 3 to about 14 carbon atoms, from 5 to 10 carbon atoms, or from 5 to about 7 ring atoms, the non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like. Non-limiting examples of multicyclic cycloalkyls include 1-decalin, norbornyl, adamantyl, and the like. Cycloalkyls or ring-bridge systems or spirocyclic systems can be fused. "Alkyl substituted with halo and hydroxy" means an alkyl group substituted with 1, 2 or 3 hydroxy and 1, 2, 3, 4 or 5 halo. "Alkylene" refers to a straight or branched chain divalent group consisting solely of carbon and hydrogen atoms, which does not contain saturation and which has from one to ten carbon atoms, for example, methylene, ethylene, propylene, .ra. -butylene, and the like. Alkylene is an alkyl group, which refers to the same residues as alkyl, but which has two binding sites and specifically, completely saturated. Examples of alkylene include ethylene (-CH2CH2-), propylene (-CH2CH2CH2-) dimethylpropylene (-CH2C (CH3) 2CH2-), and cyclohexylpropylene (-CH2CH2CH (C6H13)).

"Alkylidene" refers to a branched or straight chain unsaturated divalent group consisting solely of carbon atoms to hydrogen, having from two to ten carbon atoms, for example, ethylidene, propylidene, 2-butylidene and the like. Alkylidene is a subset of alkyl, which refers to the same residues as alkyl, but which has two points of attachment and, specifically, double bonding. The present instauration includes at least one double bond. "Alkylidino" refers to a branched or straight chain unsaturated divalent group consisting solely of carbon and hydrogen atoms having from two to ten carbon atoms, for example, propylid-2-ynyl, n-butylid-1-ynyl , and similar. Alkylidene is a subset of alkyl, which refers to the same residues as alkyl, but that has two points of union, and specifically, instauration of triple bond. The present instauration includes at least one triple bond. Any of the above groups, "alkylene", "alkylidene" and "alkylidino", when optionally substituted, may contain alkyl substitution which contains unsaturation by itself. For example, 2- (2-phenylethynyl-but-3-enyl) -naphthalene (IUPAC name) contains a / 3-butylid-3-ynyl group with a vinyl substituent at the 2-position of that group.

"Alkoxy" or "alkoxy" refers to the -0-alkyl group, wherein the term "alkyl" is as defined hereinbefore. Examples include methoxy, ethoxy, propoxy, isopropoxy, and the like. "Lower alkoxy" refers to groups containing from one to six carbon atoms. "Substituted alkoxy" refers to the group -0- (substituted alkyl), the substitution in the alkyl group containing in general more than just carbon (as defined for alkoxy). Another example substituted alkoxy group is hydroxyalkoxy or -O-alkyl-OH. "Aryl" means a mono- or multi-cyclic ring, of five to fourteen members, monovalent, wherein the monocyclic ring is aromatic and at least one of the rings in the multicyclic ring is aromatic. An aril can also be from five to ten members, or six members. Representative non-limiting examples of aryl include phenyl, naphthyl and the like. "Arylalkyl" means a residue in which a portion of aryl, as defined above, is attached to a structure of origin by one of an alkylene, alkylidene, or alkylidino group. Examples include benzyl, phenethyl, phenylvinyl, phenylallyl and the like. The "alkyl" portion of the group may be from one to ten carbons, and in another embodiment, one to six carbons; the latter is also It can refer to CX.6 arylalkyl. When referring to a group such as (C 1 -CJ-alkylaryl, a portion of aryl is attached to a structure of origin by an alkylene group Examples include benzyl, phenethyl and the like In some examples, as appreciated by an expert In the art, two adjacent groups in an aromatic system can be fused together to form a ring structure The fused ring structure can contain heteroatoms and can be optionally substituted with one or more groups. saturated with these fused groups (ie, saturated ring structures) may contain two substitution groups: "Fused-polycyclic" or "fused ring system" refers to a polycyclic ring system containing bridged or fused rings; say, where two rings have more than one atom shared in their ring structures In this application, fused-polycyclic systems and ring systems fused include non-aromatic and aromatic systems. Typically, but not necessarily, the polycyclic fused ones share a neighborhood set of atoms, for example naphthalene or 1,2,3,4-tetrahydro-naphthalene. A spiro-ring system is not a polycyclic fused by this definition, but the fused polycyclic ring systems of the invention may have by themselves spiro rings attached to themselves by a single ring atom of the polycyclic fused. "Halogen" or "halo" refers to fluorine, chlorine, bromine or iodine. "Haloalkyl" or "haloaryl" refer generically to alkyl and aryl groups that are substituted with one or more halogens, respectively. Non-limiting examples of "haloalkyl" include -CH2F, CHC12 or -CF3. "Heteroatom" refers to O, S, N, or P. "Heterocyclyl" refers to a stable three to fifteen member ring substituent consisting of carbon atoms and one to five heteroatoms selected from the group consisting of nitrogen , phosphorus, oxygen and sulfur. For purposes of this invention, the herocyclyl substituent may be a monocyclic, bicyclic or tricyclic ring system, which may include fused or bridged ring systems as well as spirocyclic systems. The terms "heterocycloalkyl" and "heteroaryl" are groups that are encompassed by the broad term "heterocyclyl". The nitrogen, or phosphorus, carbon or sulfur atoms in the heterocyclyl group may be optionally oxidized to various oxidation states. In a specific example, the group -S (O) 0_2-, refers to -S- (sulfur), -S (O) - (sulfoxide), and -S02- (sulfone), respectively. For convenience, the nitrogens, particularly non-exclusively, those defined as annular aromatic nitrogens, it is proposed that they include their corresponding N-oxide form, although not explicitly defined as such in a particular example. Thus, for a compound of the invention having, for example, a pyridyl ring; the corresponding pyridyl-N-oxide is proposed to be included as another compound of the invention. In addition, the ring hydrogen atoms can optionally be quaternized; and the ring substituent may be partially or completely saturated or aromatic. Examples of heterocyclyl groups include, but are not limited to, azetidinyl, acridinyl, benzodioxolyl, benzodioxanyl, benzofuranyl, carbazoyl, cinnolinyl, dioxolanyl, indolizinyl, naphthyridinyl, perhydroazepinyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazin, pteridinyl, purinyl, quinazolinyl, quinoxalinyl , quinolinyl, isoquinilinyl, tetrazoyl, tetrahydroisoquinolyl, piperidinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, dihydropyridinyl, tetrahydropyrridinyl. , pyridinyl, pyrazinyl, pyrimidinyl, pyridizinyl, oxazolyl, oxazolinyl, oxazolidinyl, trazolyl, isoxazolyl, isoxazolidinyl, norfolinyl, thiazolyl, thiazolyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, isoindolyl, indolinyl, isoindolinyl, octahydroindoyl, octahydroisoindolyl, quinolyl, isoquinolyl, decahydroisoquinolyl, benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl, thienyl, benzothienyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfonate, dioxaphospholanyl, oxadiazolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, and tetrahydroquinolinyl. "Heterocycloalkyl" refers to a stable monocyclic, bicyclic or tricyclic 4-12 membered ring containing one or more heteroatoms. "Heterocyloalkyalkyl" refers to a heterocyloalkyl, as defined herein, attached to the source portion through an "alkyl", as defined herein. A non-limiting example of heterocycloalkyl includes piperadynyl. Another non-limiting example of heterocycloalkyl includes piperadynyl. Another non-limiting example of heterocycloalkyl includes piperazinyl. Another non-limiting example of heterocycloalkyl includes furanyl. Another non-limiting example of heterocycloalkyl includes pyrrolidinyl. Another non-limiting example of heterocycloalkyl includes morpholinyl. "Amino" refers to -NH2. "Alkylamino" refers to -H (alkyl), wherein "alkyl" is as defined above, and wherein the source portion is attached to the nitrogen atom. "Dialkylamino" refers to - (alkyl) 2, wherein "alkyl" is as defined above, and wherein the source portion is attached to the nitrogen atom. "Dialkylaminoalkyl" refers to (alkyl) (alkyl) 2, wherein "alkyl" is as defined above. A non-limiting example of "dialkylaminoalkyl" includes -CH2C (CH3) 2CH2N (CH3) 2. "Aminoalkyl" refers to - (alkyl) NH, wherein "alkyl" is as defined above, and wherein the origin portion is attached to the alkyl group . "Aminoalkyl" refers to - (alkyl) H2, wherein "alkyl" is as defined above, and wherein the source portion is attached to the alkyl group. The amino group can be attached at any point along the alkyl group. Non-limiting examples of aminoalkyl include CH (NH2) CH3. "Phenoxy" refers to an -alkyl-O-phenyl group, wherein "alkyl" is as defined above, and the source portion is attached to the alkyl group. "Heteroaryl" means a ring system monocyclic aromatic heterocyclyl (where heterocyclyl is defined herein) or bicyclic heterocyclyl (where at least one of the rings in the bicyclic system is aromatic) of 5-12 members where the monocyclic ring and at least one of the rings in the system bicyclic ring contains one, two, three, four or five heteroatoms selected from nitrogen, oxygen, phosphorus and sulfur. The ring containing the heteroatom can be aromatic or non-aromatic. Representative examples include pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzodioxolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, triazolyl, thiadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl. Fused, bridged and spiro portions are also included within the scope of this definition. "Carbonyl" refers to the group "-C (O) -", which is bivalent, "Aminocarbonyl" refers to the group "-C (0) -NH2", where the source portion is attached to the amino group.

"Alkoxycarbonyl" refers to the group "-C (0) alkoxy", wherein alkoxy is as defined above, and the source portion is attached to the carbonyl. A non-limiting example includes -C (0) -0C (CH3) 3. When a group is referred to as alkyl-heterocyclyl "heterocyclyl is attached to a structure of origin by one of an alkylene, alkylidene, or alkylidino group, Examples include (4-methylpiperazin-1-yl) methyl, (morpholin-4-yl) methyl, (pyridine -4-yl) methyl, 2- (oxazolin-2-yl) ethyl, 4- (4-methylpiperazin-1-yl) -2-butenyl, and the like, both the heterocyclyl and the corresponding alkylene, alkylidene or alkylidino portion of a heterocyclylalkyl group may be optionally substituted "Hydroxyalkyl" means -alkyl-OH, wherein alkyl is as defined herein above "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes cases where this event or circumstance is presented and cases in which it will not be understood by one skilled in the art that with respect to any molecule described as containing one or more optional substituents, it is proposed to include only the These are sterically practical and / or synthetically feasible. "Optionally substituted" is refers to all subsequent modifiers in a term. Thus, for example, in the term "optionally substituted arylalkyl", both the "alkyl" portion and the "aryl" portion of the molecule may or may not be substituted. A list of example optional substitutions is presented later in the definition of "substituted." "Saturated bridge ring system" refers to a bicyclic or polycyclic ring system that is not aromatic. This system may contain isolated or conjugated unsaturation, but not aromatic or heteroaromatic rings in its core structure (but may have aromatic substitution therein). For example, hexahydro-furo [3,2-b] furan, 2, 3, 3a, 4, 7, 7a-hexahydro-lH-indene, 7-aza-bicyclo [2.2.1] heptane, and 1, 2, 3, 4, 4a, 5, 8, 8a-octahydro-naphthalene are all included in the class "saturated bridge ring system". "Spirocyclyl" or "spirocyclic ring" refers to a ring that originates from a particular ring carbon of another ring. For example, as shown below, a ring atom of a saturated bridged ring system (rings B and B '), but not a bridging atom, may be a shared atom between the saturated bridged ring system and a spirocyclyl (ring A) attached to it. A spirocyclyl can be carboxylic or hetoroalicyclic.

"Substituted" alkyl, aryl, and hetoricyclic, refers respectively to alkyl, aryl, and heterocyclyl, one or more (eg, up to about five, up to about three) hydrogen atoms are replaced by a substituent independently selected from: (e.g., fluoromethyl), aryl (e.g., 4-hydroxyphenyl), arylalkyl (e.g., 1-phenyl-ethyl), heterocyclylalkyl (e.g., l-pyrridin-3-yl-ethyl), heterocyclyl (e.g. 5-chloro-pyridin-3-yl or 1-methyl-piperidin-4-yl), alkoxy, alkylenedioxy (e.g., methylenedioxy), amino (e.g., alkylamino and dialkylamino), amidino, aryloxy (e.g., phenoxy) , arylalkyloxy (for example, benzyloxy), carboxy (-C02H), carboalkoxy (ie, acyloxy or -OC (= 0) R), carboxyalkyl (ie, esters or -C02R), carboxamido, benzyloxycarbonylamino (CBZ-amino), cyano, acyl, halogen, hydroxy, nitro, sulfanyl, sulfinyl, sulfonyl, thiol, allogen, hydroxy, oxo, carbamyl, acylamino, and sulfonamido. And each substituent of a substituted group is optionally substituted but these optional substituents by themselves they are not replaced in an additional way. In this manner, an optionally substituted portion is one which may or may not have one or more substituents, and each of the substituents may or may not have one or more substituents. But, the substituents of the substituents may not be substituted. Some of the compounds of the invention may have imino, amino, oxo or hydroxy substituents of aromatic heterocyclyl systems. For purposes of this description, it is understood that these imino, amino, oxo or hydroxy substituents may exist in their corresponding tautomeric form, ie, amino, imino, hydroxy or oxo, respectively. "Patient" for the purposes of the present invention include humans and other animals, particularly mammals, and other organisms. In this way, the methods are applicable both in human application and in veterinary applications. In a preferred embodiment, the patient is a mammal, and in a more preferred embodiment the patient is human. "Diseases or conditions dependent on kinases" refers to pathological conditions that depend on the activity of one or more protein kinases. The kinases participate either directly or indirectly in the signal transduction pathways of a variety of activities Cells that include proliferation, adhesion, migration, differentiation and invasion. Diseases associated with kinase activities include tumor growth, pathological neovascularization that supports growth of solid tumors, and associated with other diseases where excessive local vascularization is included such as ocular diseases (diabetic retinopathy, age-related macular degeneration, and the like). ) and inflammation (psoriasis, rheumatoid arthritis, etc.). While not wishing to be bound by a theory, phosphatases can also play a role in "kinase dependent diseases or conditions" as kinase cognates; that is, phosphorylate kinases and dephosphorylates of phosphatases, for example, protein substrates. Therefore, the compounds of the invention, while modulating the kinase activity as described herein, can also modulate, either directly or indirectly, the phosphatase activity. This additional modulation, if present, may be synergistic (or not) to the activity of the compounds of the invention to a related or otherwise interdependent kinase or family of kinases. In any case, as noted above, the compounds of the invention are useful for treating diseases characterized in part by abnormal levels of cell proliferation (i.e., tumor growth), programmed cell death (apoptosis), migration and cellular invasion and angiogenesis associated with tumor growth. "Therapeutically effective amount" is an amount of a compound of this invention, which when administered to a patient, ameliorates a symptom of the disease. The amount of a compound of the invention that constitutes a "therapeutically effective amount" will vary depending on the compound, the disease state and its severity, the age of the patient to be treated, and the like. The therapeutically effective amount can be determined routinely by one skilled in the art having considered his knowledge and this description. "Cancer" refers to disease states of cell proliferation, including but not limited to: Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma, and teratoma; Pulmonary: bronchogenic carcinoma (squamous cells, small undifferentiated cells, undifferentiated large cells, adenocarcinoma), alveolar carcinoma (bronchiolar), bronchial adenoma, sarcoma, lymphoma, chondromatosis hanlartoma, inesotelioma; Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinorna, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Karposi sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large intestine (adenocarcinoma, tubular adenoma, vile adenoma, hematoma, leiomyoma); of the genitourinary tract: kidney (adenocarcinoma, Wilm tumor [neproblastoma], lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testicular ( seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lymphoma); Hepatic: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, angioma; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochondroma (osteochondral exostosis), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; of the nervous system: of the skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meningis (mengioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinora [pinealoma], gliobastoma multiforme, oligobendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterine (endometrial carcinoma), cervical (cervical carcinoma, pre-tumoral cervical dysplasia), ovarian (ovarian carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma], granulosa-thecal cell tumors, SertoliLeydig cell tumors , dysgerminoma, malignant teratoma), vulvar (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma) of the vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma) ); Hemotalgic: blood (myeloid leukemia [acute and chronic], acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma [malignant lymphoma]; Cutaneous: malignant myeloma , basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma , moles, dysplastic moles, lipoma, angioma, dermatofibroma, keloids, psoriasis; and Adrenal glands: neuroblastoma. In this manner, the term "cancer cell" as provided herein, includes a cell afflicted by any of the conditions identified above. A "pharmaceutically acceptable salt" of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. It is understood that pharmaceutically acceptable salts are non-toxic. Additional information on suitable pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 17th ed. , Mack Publishing Company, Easton, PA, 1985, which is incorporated herein by reference or in S.M. Berge, et al., "Pharmaceutical Salts," J. Pharm Sci., 1977; 66: 1-19, both of which are incorporated herein by reference. Examples of pharmaceutically acceptable acid addition salts include those formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; as well as organic acids such as acetic acid, trifluoroacetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid , benzoic acid, cinnamic acid, 3- (4-hydroxybenzoyl) benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, glucoheptonic acid, 4,4'-methylenebis- (3-hydroxy acid) 2-ene-l-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl-sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, p-toluenesulfonic acid, and salicylic acid and the like. Examples of a pharmaceutically acceptable base addition salt include those formed when an acidic proton present in the parent compound is replaced by a metal ion, such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper. , manganese, aluminum salts and the like. The preferable salts are the ammonium, potassium, sodium, calcium and magnesium salts. Salts derived from non-toxic, pharmaceutically acceptable organic bases include, but are not limited to, primary, secondary and tertiary amine salts, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins. Examples of organic bases include isopropylamine, trimethylamine, diethylamine, triethylamine resins, tripropyraine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, diclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, botain, ethylenediamine, glucosaline, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, tromethamine, N-methylglucamine, polyaraine, and the like. Exemplary organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine. "Prodrug" refers to compounds that are transformed (typically rapidly) in vivo to produce the parent compound of the above formulas, for example, by hydrolysis in blood. Common examples include, but are not limited to, ester and amide forms of a compound having an active form having a carboxylic acid moiety. Examples of pharmaceutically acceptable esters of the compounds of this invention include, but are not limited to, alkyl esters (for example with between about one and about six carbons), the alkyl group is a straight or branched chain. Acceptable esters also include cycloalkyl esters and arylalkyl esters such as, but not limited to, benzyl. Examples of pharmaceutically acceptable amides of the compounds of this invention include, but are not limited to, primary amides, and secondary and tertiary aryl-amides (for example with between about one and about six carbons). The amides and esters of the compounds of the present invention can be prepared according to conventional methods. An analysis of prodrugs is provided in T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference for all purposes. "Metabolite" refers to the decomposition or final product of a compound or its salt produced by metabolism or biotransformation in the human or animal body, for example, biotransformation to a more polar molecule such as by oxidation, reduction or hydrolysis, or to a conjugate (see Goodman and Gilman, "The Pharmacological Basis of Therapeutics" S.sup.th Ed., Pergamon Press, Gilman et al., (eds), 1990 for an analysis of biotransformation). As used herein, the metabolite of a compound of the invention or its salt may be the biologically active form of the compound in the body. In one example, a prodrug such as the biologically active form, a metabolite, can be used in vivo. In another example, a biologically metabolite is beneficially discovered active, that is, no prodrug design per se was undertaken. An assay for this activity of a metabolite of a compound of the present invention is known to one skilled in the art in view of the present disclosure. The present invention also includes derivatives of N-oxide and protected derivatives of the compounds of Formula I. For example, when the compounds of Formula I contain an oxidizable hydrogen atom, the nitrogen atom can be converted to an N-oxide by methods well known in the art. . When the compounds of Formula I contain groups such as hydroxy, carboxy, thiol group or any group containing a hydrogen atom, these groups can be protected with a suitable "protecting group" or "protecting group". A comprehensive list of suitable protective groups in T. can be found. Greene, Protective Groups in Organic Synthesis, John wiley & Sons, Inc. 1991, the description of which is incorporated herein by reference in its entirety. The protected derivatives of the compounds of Formula I can be prepared by methods well known in the art. "Treating" or "treating" a disease, disorder, or syndrome, as used herein, includes (i) preventing the occurrence in a human of the disease, disorder or syndrome, i.e., causing them not to develop the clinical symptoms of the disease, disorder or syndrome, in an animal that may be exposed or predisposed to the disease, disorder or syndrome but does not yet experience or present symptoms of the disease, disorder or syndrome; (ii) inhibit the disease, disorder or syndrome, that is, stop its development; (iii) alleviating the disease, disorder or syndrome, i.e., causing the regression of the disease, disorder or syndrome. As is known in the art, adjustments may be necessary for systemic vs localized distribution, age, body weight, general health, sex, diet, time of administration, drug interaction and severity of the condition, and will be determinable with routine experimentation. by an expert in the art. One skilled in the art will understand that certain crystallized, protein-ligand complexes, in particular JAK-2-ligand complexes and their x-ray structure coordinates can be used to reveal new structural information useful for understanding the biological activity of kinases. as described herein. Also, the key structural features of the aforementioned proteins, particularly, the shape of the ligand binding site, are useful in the methods for designing and identifying selective kinase modulators and in solving the structures of these proteins with similar characteristics. These protein complexes ligand, which have compounds of the invention as their ligand component, are one aspect of the invention. Also, one skilled in the art will appreciate that these suitable x-ray quality crystals can be used as part of a method to identify a candidate agent capable of binding to and modulating the activity of kinases. These methods can be characterized by the following aspects: a) entering into an appropriate computer program, information defining a ligand binding domain of a kinase in a conformation (eg, as defined by x-ray structure coordinates obtained of suitable crystals of x-ray quality as described above) wherein the computer program creates a model of the three-dimensional structures of the ligand-binding domain, b) introducing a model of the three-dimensional structure of a candidate agent into the program of computer, c) superimposing the model of the candidate agent on the ligand binding domain model, and d) assessing whether the candidate agent model is especially suited in the ligand binding domain. Aspects a-d are not necessarily carried out in the order mentioned above. These methods can additionally entail: performing rational drug design with the model of the three-dimensional structure, and selecting a potential candidate agent in conjunction with modeling by computer . Additionally, one skilled in the art will appreciate that these methods may additionally entail: employing a candidate agent, thus determined to spatially adjust in the ligand-binding domain, in a biological activity assay for modulating kinases, and determining if this candidate agent modulates the kinase activity in the assay. These methods may also include administering the candidate agent, determined to modulate kinase activity, to a mammal suffering from a condition treatable by kinase modulation, such as those described above. Also, one skilled in the art will appreciate that the compounds of the invention can be used in a method for evaluating the ability of a test agent to associate with a molecule or molecular complex comprising a ligand binding domain of a kinase. This method can be characterized by the following aspects: a) create a computer model of a kinase binding cavity using structural coordinates obtained from appropriate quality x-ray crystals of the kinase, b) use computation algorithms to perform an operation of adjustment between the test agent and the computer model of the joint cavity, and c) analyze the results of the adjustment operation to quantify the association between the test agent and the computer model of the joint cavity. In addition to the preferred embodiments cited hereinabove, embodiments comprising combinations of the preferred embodiments are also preferred. Representative compounds of Formula I and / or II are represented below. The examples are illustrative only and do not limit the scope of the invention in any way. The compounds in Table 1 (Part A and Part B) below can be prepared using methods recognized in the art.

Table 1 (Part A) It can be elaborated Name Structure Agreement Al No. Example of Synthesis No. 3- ( { 4- [4- (acetylamino) phenyl] -pyrimidin-2-yl-yl.} -amino) -N-29-methyl-N-. { [2- (methyloxy) - phenyl] methyl} - benzamide 3- ( { 4- [4- (acetylamino) phenyl] -pyrimidin-2-yl-yl}. amino) -N- 29 [(2-fluoro- phenyl) -methyl] -N-methyl-benzamide It can be elaborated Name Structure Agreement Al No. Example of Synthesis No.

N- [4- (2- { [4- (4-D-prolyl-piperazin-1-yl) 880 phenyl] amino.} - 52 pyrimidine-4- il) phenyl] -tetrahydrofuran-2-carboxamide 1-methyl-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) -881 amino] pyrimidin-12 4-yl.}. phenyl) - 1 HOUR- pyrrole-2-carboxamide In another embodiment, the compound of the invention is selected from the compound of Table 2: Table 2 N- [4 - (2- {[[4- (4-ethylpiperazin-1-yl) phenyl] amino]} - pyrimidin-4-yl) phenyl] acetamide; N- (4 - {2 - [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) cyclopropanecarboxamide; N- (4-. {5-methyl-2-2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -cyclopropane-carboxamide; N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) valinamide; N- (4- {2 - [(4- {4- [(l-methyl-lH-imidazol-2-yl) -ethyl] -piperazin-1-yl}. Phenyl) -amino] -pyrimidin-4 -yl.} phenyl) acetamide; N- (4 -. {2 - [(3,5-dimorpholin-4-ylphenyl) amino] -5-phenyl-pyrimidin-4-yl} phenyl) acetamide; N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -D-alaninamide; N-. { 4- [2- (. {4- [4- (2-methylpropanoyl) iperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} -acetamide; 2-amino-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -2-phenylacetamide; N- (4-. {5-methyl-2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) acetamide; 3- (methyloxy) -N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) propanamide; N- (4 -. {2 - [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) prolinamide; N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -L-alaninamide; N- (4- { 2- [(4. {4- [3- (dimethylamino) -2,2-dimethylpropyl] piperazin-1-yl} phenyl) amino] irimidin-4-yl} phenyl) acetamide; N- (4- {2 - [(4- {4- [3- (methyloxy) propanoyl] piperazin-1-yl} phenyl) amino] pyrimidin-4-yl}. Phenyl) - acetamide; N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -D-prolinamide; N- [4- (2-. {[[3- (methyloxy) -4-morpholin-4-ylphenyl] amino] pyrimidin-4-yl) phenyl] -D-prolinamide; N- (4-. {-2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) tetrahydrofuran-3-carboxamide; O-methyl-N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -L-serinamide; 1-ethyl-3-. { 4- [2- ( { 4- [4- (2-methylpropanoyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyljurea; N-ethyl-4- (4- { [4- (4-. {[[(Ethylamine) carbonyl] amino} phenyl) pyrimidin-2-yl] amino} phenyl) -piperazine-1 carboxamide; N2, N2-dimethyl-N- (4- {2 - [(4- {4- [3- (methyloxy) propanoyl] piperazin-1-yl} phenyl) amino] -pyrimidin-4- il.} phenyl) glycinamide; N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -D-serinamide; (3R) -3-hydroxy-N- (4 -. {2- 2- [(-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) butanamide; (3S) -3-hydroxy-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) butanamide; N-. { 4- [2- (. {4- [4- (tetrahydrofuran-2-ylcarbonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} -D-prolinamide; 2-hydroxy-2-methyl-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) propanamide; N- (4-. {2- 2- (4-morpholin-4-ylphenyl) amino] pyrimidine-4- il} phenyl) prolinamide; N- (4- {2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} -L-prolinamide; N- (-. {2- (4-morpholine- 4-ylphenyl) amino] pyrimidin-4-yl.} Phenyl) -D-prolinamide; O-methyl-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4 -yl.} phenyl) -L-serinamide; O-methyl-N- (4- {2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -D -serinamide, O-methyl-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl] phenyl) -D-serinamide, and N- (4- {.2- [(3-Fluoro-4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -D-prolinamide In another embodiment, the invention relates to a pharmaceutical composition comprising a compound according to Table 1 or Table 2, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient or diluent In another embodiment, the invention relates to a method for inhibiting JAK-2 in a cell, which comprises putting the cells in contact, in which inhibition of JAK-2 is desired, with a compound according to Table 1 or Table 2, or a pharmaceutical salt thereof. In another embodiment, the invention relates to a method for inhibiting JAK-2 in a cell, which comprises putting in contact with the cell, in which inhibition of JAK-2 is desired with a pharmaceutical composition comprising a compound according to Table 1 or Table 2, or a pharmaceutically acceptable salt thereof. In another embodiment, the invention relates to a method for treating a disease, disorder, or syndrome mediated, at least in part, by inhibiting JAK-2, which method comprises administering to an animal in need of treatment a therapeutically effective amount of a compound according to Table 1 or Table 2, or pharmaceutically acceptable salt thereof. In another embodiment, the invention relates to a method for treating a disease, disorder, or syndrome mediated, at least in part, by the inhibition of JAK-2, which method comprises administering to an animal in need of this treatment a pharmaceutical composition. comprising a therapeutically effective amount of a compound according to Table 1 or 'Table 2, or a pharmaceutically acceptable salt thereof.

General Administration In certain preferred referred modalities, administration may preferably be by the oral route. The administration of the compounds of the invention, or their pharmaceutically acceptable salts, in pure form or in An appropriate pharmaceutical composition can be carried out by any of the accepted modes of administration or agents to serve similar utilities. Thus, the administration can be, for example, orally, nasally, parenterally (intravenously, intramuscularly or subcutaneously), topically, transdermally, intravaginally, intravesically, intracisternally, or rectally, in the form of a powder solid, semi-solid, lyophilized, or liquid dosage forms, such as, for example, tablets, suppositories, pills, hard and soft elastic gelatin capsules, powders, solutions, suspensions, aerosols, or the like, preferably in unit dosage forms suitable for simple administration of precise doses. The compositions will include a conventional pharmaceutical carrier or excipient and a compound of the invention as the active agent, and, in addition, may include carrier and adjuvants, etc. Adjuvants include preservatives, wetting agents, suspending agents, sweeteners, flavoring agents, flavoring agents, emulsifiers and distributors. The prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include agents isotonic, for example, sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be caused by the use of agents that delay absorption, for example, aluminum monostearate and gelatin. If desired, a pharmaceutical composition of the invention may also contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, antioxidants, and the like, such as, for example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylated hydroxytoluene. , etc. The choice of formulation depends on several factors such as the mode of administration of the drug (for example, for oral administration, formulations in the form of tablets, pills or capsules are preferred) and the bioavailability of the drug substance. Recently, pharmaceutical formulations have been developed especially for drugs that show poor bioavailability based on the principle that bioavailability can be increased by increasing surface area, i.e., decreasing particle size. For example, US Pat. No. 4,107,288 includes a pharmaceutical formulation having particles in the size range of 10 to 1,000 nm in which it is supported the active material in a reticulated matrix of macromolecules. U.S. Patent No. 5,145,684 describes a production of a pharmaceutical formulation in which the drug substance is sprayed to a nanoparticle (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium. to give a pharmaceutical formulation exhibiting remarkably high bioavailability. Compositions suitable for parenteral injection may comprise sterile, physiologically acceptable, aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile, injectable solutions or dispersions. Examples of suitable aqueous and non-aqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, and the like) suitable mixtures thereof, vegetable oils (such as olive oil) and esters injectable organics such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, for the maintenance of the required particle size in the case of dispersions and by the use of surfactants. A preferred route of administration is oral, using a conveniently daily dose regimen that is can adjust according to the degree of severity of the disease state to be treated. Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one usual, inert excipient (or carrier), such as sodium citrate or dicalcium phosphate or (a) filling agents or enlighters, such as, for example, starches , lactose, sucrose, glucose, mannitol, and salicylic acid, (b) binders, such as, for example, cellulose derivatives, starch, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and acacia gum, (c) humectants, such as example glycerol, (d) disintegrating agents, such as, for example, agar-agar, calcium carbonate, potato starch or tapioca, alginic acid, croscarmellose sodium, complex silicates, and sodium carbonate, (e) solution retarders, as example paraffin, (f) absorption accelerators, such as, for example, quaternary ammonium compounds, (g) wetting agents, such as, for example, cetyl alcohol, and glycerol monostearate, magnesium stearate and the like, (h) absorbers, as example, kaolin and bent onita, e (i) lubricants, such as, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, (sodium sulfate), or mixture thereof. In the case of capsules, Tablets and pills, the dosage forms may also comprise buffering agents. Solid dosage forms, as described above, can be prepared with coatings and shells, such as enteric coatings and others well known in the art. They may contain appeasement agents, and may also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedded compositions that can be used are polymeric substances and waxes. The active compounds may also be in the microencapsulated form, if appropriate, with one or more of the aforementioned excipients. Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. These dosage forms are prepared, for example, by dissolving, dispersing, etc., a compound (s) of the invention, or a pharmaceutically acceptable salt thereof, and optional pharmaceutical adjuvants in a carrier, such as for example , water, saline, aqueous dextrose, glycerol, ethanol and the like; solubilizing and emulsifying agents, such as, for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3- butylene glycol, dimethylformamide; oils, in particular, cottonseed oil, peanut oil, wheat germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and sorbitan fatty acid esters; or mixture of these substances, and the like, to thereby form a solution or suspension. The suspensions, in addition to the active compounds, may contain suspending agents, such as, for example, ethoxylated isostearyl ethers, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or a mixture thereof. substances, and the like. Compositions for rectal administrations are, for example, suppositories which can be prepared by mixing the compounds of the present invention with for example suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository silk, which are solid at temperatures originating but are liquid at body temperature and therefore, they melt as long as they are in an adequate body cavity and release the active component therein. Dosage forms for topical administration of a compound of this invention include ointments, powders, sprays and inhalants. The active component is mixed under sterile conditions with a physiologically acceptable carrier and any preservative, buffer or propellant as may be required. Ophthalmic formulations, ointments for eyes, powders and solutions are also contemplated as being within the scope of this invention. Compressed gases can be used to disperse a compound of this invention in the form of an aerosol. Inert gases suitable for this purpose are nitrogen, carbon dioxide, etc. In general, depending on the proposed mode of administration, acceptable pharmaceutical compositions will contain from about 1% to about 99% by weight of a compound (s) of the invention, or a pharmaceutically acceptable salt thereof, and from 99% to 1% by weight. weight of a suitable pharmaceutical excipient. In one example, the composition will be between about 5% and about 75% by weight of a compound (s) of the invention, or a pharmaceutically acceptable salt thereof, with the remainder being suitable pharmaceutical excipients. Current methods for preparing these dosage forms are known, or will be apparent, to those skilled in the art; for example, see Remington's Pharmaceutical Sciences, 18th Ed., (Mack Publishing Company, Easton, Pa., 1990). The composition to be administered will contain, in any case, a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, for treatment of a disease state in accordance with the teachings of this invention. The compounds of the invention, or their pharmaceutically acceptable salts, are administered in a therapeutically effective amount which will vary depending on a variety of factors including the activity of the specific compound employed, the metabolic stability and duration of action of the compound, age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, combination of drugs, the severity of the particular disease states, and the host that undergoes therapy. The compounds of the present invention can be administered to a patient at dose levels in the range of about 0.1 to about 1,000 mg per day. For a normal human adult who has a body weight of about 70 kilograms, a dose in the range of about 0.01 to about 100 mg per kilogram of body weight per day is an example. The specific dose used, however, may vary. For example, the dose may depend on several factors including the requirements of the patient, the severity of the condition being treated, and the physiological activity of the compound being used. The Determination of optimal doses for a particular patient is well known to those skilled in the art. The compositions will include a conventional pharmaceutical carrier or excipient and a compound of the invention as the active agent, and in addition, may include other medicinal agents and pharmaceutical agents. The compositions of the invention can be used in combination with anticancer and / or other agents that are generally administered to a patient being treated for cancer, eg, surgery, radiation and / or chemotherapeutic agents. Chemotherapeutic agents that may be useful for administration in combination with the compounds of Formula I in the treatment of cancer include alkylating agents, platinum-containing agents. If formulated as a fixed dose, these combination products employ the compounds of this invention within the dose range described above and the other pharmaceutically active agents within their approved dose range. The compounds of the present invention may alternatively be used sequentially with known pharmaceutically acceptable agents when a combination formulation is inappropriate. Representative pharmaceutical formulations containing a compound of Formula I are described below.

Utility The compounds of this invention are inhibitors of JAK-2. As such, the compounds of Formula I are useful for treating diseases, particularly myeloproliferative disorders, for example, myelofibrosis, thrombocythemia, polycythemia vera (PV), essential thrombocythemia (ET), agnogenic myeloid metaplasm (AMM), also referred to as idiomatic myelofibrosis (IMF), and chronic myelogenous leukemia (CML); and cancer, for example, ovarian cancer, cervical cancer, breast cancer, colorectal cancer, glioblastomas, prostate cancer, colon, melanoma, leukemia, and hematopoietic malignancies, as described above, in which the activity of JAK-2 contributes to the pathology and / or symptomatology of the disease. Suitable in vitro assays are known for measuring the activity of JAK-2 and the inhibition thereof by the compounds. For further details of an in vitro assay for measuring the activity of JAK-2 see Biological Examples, Example 1, infra. We describe trials to measure the efficacy in the treatment of several cancers in Biological Examples, Examples 3, 5 and 6, infra. Suitable in vivo models of various cancers are known to those skilled in the art. For further details of in vivo assays see Biological Examples 2 and 4, infra.

Utility of Compounds of the Invention as Detection Agents To employ the compounds of the invention in a method for detecting candidate agents that bind to, for example, JAK-2, the protein binds to a support, and is added slowly and a composed the invention. Alternatively, the compound of the invention binds to the support and the protein is added. Candidate agent classes among which new binding agents can be searched include specific antibodies, natural binding agents identified in detections of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for candidate agents that have low toxicity to human cells. A wide variety of assays can be used for this purpose, including labeled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like.

The determination of the binding of the candidate agent to, for example, JAK-2 can be done in several ways. In one example, the candidate agent (the compound of the invention) is labeled, for example, with a fluorescent or radioactive moiety and the binding is directly determined. For example, this can be done by joining all or a portion of the JAK-2 protein to a solid support, adding a labeled agent (for example a compound of the invention in which at least one atom has been replaced by a detectable isotope), washing the excess reagent, determining whether the amount of the label is that present in the solid support. Various blocking and washing steps can be used as is known in the art. The term "labeled" as used herein is intended to include both direct and indirect labeling with a compound that provides a detectable signal, eg, radioisotope, fluorescent label, enzyme, antibody, particle such as magnetic particles, chemiluminescent label, or specific binding molecules, and the like. Specific binding molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin, and the like. For specific binding members, the complementary member will normally be labeled with a molecule that provides detection, according to known procedures, as summarized above. The The mark can directly or indirectly provide a detectable signal. In some modalities, only one of the components is marked. For example, the JAK-2 protein can be labeled at the tyrosine positions using 125I, or with fluorophores. Alternatively, more than one component may be labeled with different labels, using 125 I for the proteins, for example, and a fluorophore for the candidate agents. The compounds of the invention can also be used as competitors to detect additional drug candidates. The terms "candidate bioactive agent" "drug candidate" or grammatical equivalents as used herein describe any molecule, eg, oligopeptide protein, small organic molecule, polysaccharide, polynucleotide, etc., that is to be tested for bioactivity. They may be capable of directly or indirectly altering the cell proliferation genotype by the expression of a cell proliferation sequence, including both nucleic acid sequences and protein sequences. In other cases, the alteration of the binding and / or activity of the cell proliferation protein is detected. In the case where the binding or activity of the protein is detected, some modalities include molecules that are known to bind to that protein particular. The exemplary assay modalities described herein include candidate agents, which do not bind the target protein in its native endogenous state, hereinafter referred to as "exogenous" agents. In one example, the exogenous agents further include JAK-2 antibodies. The candidate agents can encompass numerous chemical classes, although typically they are organic molecules having a molecular weight of more than 100 and less than 2,500 daltons. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding and lipophilic binding, and typically include at least one amino, carbonyl, hydroxyl, ether or carboxyl group, for example, at least two of the functional chemical groups. The candidate agents frequently comprise cyclic carbon or heterocyclyl structures and / or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs, or combinations thereof. Candidate agents obtain from a wide variety of sources including libraries of scientific or natural compounds. For example, they are available numerous means for random and directed synthesis of a wide variety of organic compounds and molecules, including expression of randomized oligonucleotides. Alternatively, the library of natural compounds in the form of bacterial, fungal, plant and animal extracts are readily available or produced. Additionally, natural or synthetically produced libraries, and compounds are easily modified through conventional chemical, physical and biochemical means. Known pharmacological agents can be subjected to targeted or random chemical modifications, such as ascilation, alkylation, esterification, amidation to produce structural analogues. In one example, the binding of the candidate agent is determined through the use of competitive binding assays. In this example, the competitor is a known binding portion that binds to IGF1R, such as an antibody, peptide, binding partner, ligand, etc. Under certain circumstances, competitive binding may exist as between the candidate agent and the binding portion, with the binding portion displacing the candidate agent. In some modalities, the candidate agent is marked. Either the candidate agent or the competing agent, or both, are first added to the JAK-2 protein during enough time to allow the union, if present. Incubations can be performed at any temperature which facilitates the optimal activity, typically between 4 ° C and 40 ° C. Incubation periods are selected for optimal activity, but they can also be optimized to facilitate rapid detection of high performance. Typically, there are enough between 0.1 and 1 hour. In general the residue is removed in excess or washed. The second component is then added, and the presence or absence of the labeled component is followed, to indicate the binding. In one example, the competitor is added first, followed by the candidate agent. Displacement of the competidos is an indication of the candidate agent that is the binding to JAK-2 and thus is able to bind to, and potentially modulate, the activity of JAK-2. In this mode, you can mark any component. In this way, for example, if the competitor is marked, the presence of the mark in the wash solution indicates displacement by the agent. Alternatively, if the candidate agent is marked, the presence of the mark on the support indicates displacement. In an alternative embodiment, the candidate agent is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor may indicate that the candidate agent binds to JAK-2 with greater affinity. In this way, if the candidate agent is marked, the presence of the mark on the support, coupled with a lack of binding to the competitor, may indicate that the candidate agent is capable of binding to JAK-2. It may be of value to identify the JAK-2 binding site. This can be done in a variety of ways. In one embodiment, once JAK-2 is identified as binding to the candidate agent, JAK-2 is fragmented or modified and assays are repeated to identify the components required for binding. Modulation is tested by detecting candidate agents capable of modulating JAK-2 activity comprising the steps of combining a candidate agent with JAK-2, as above, and determining an interaction on the biological activity of JAK-2. Thus, in this embodiment, the candidate agent must both join (although this may not be necessary), and alter its biological or biochemical activity as defined herein. The methods include both in vitro detection methods and in vivo detection of cells for alterations in cell viability, morphology, and the like. Alternatively, differential detection can be used to identify drug candidates that are they bind to native JAK-2, but do not bind to modified JAK-2. Positive controls and negative controls can be used in the assays. For example, all samples of test controls are performed in at least triplicate to obtain statistically significant results. The inclusion of samples is for a sufficient time for the binding of the agent to the protein. After incubation, the samples are washed from the unbound material in a specific manner and the amount of bound agent, generally labeled, is determined. For example, where a radio marker is used, the samples can be counted in a scintillation counter to determine the amount of bound compound. A variety of these reagents can be included in the detection assays. These include reagents such as salts, neutral proteins, for example albumin, detergents, etc., which can be used to facilitate optimal protein-protein binding and / or to reduce nonspecific or background interactions. All reagents that otherwise improve assay efficiency, such as protease inhibitors, nuclease inhibitors, antimicrobial agents, etc., can be used. The mixture of components can be added in any order which provides the necessary union. One skilled in the art will understand that certain crystallized, protein-ligand complexes, in particular JAK-2-ligand complexes, and their corresponding x-ray structure candidates can be used to reveal new structural information useful for understanding the biological activity of JAK-2 kinase as described herein. Thus also, the key structural features of the aforementioned proteins, particularly, the shape of the ligand-binding site, are useful in the methods for designing or identifying selective modulators of the JAK-2 kinase and in the solution of the structures of other proteins with similar characteristics. The ligands of these complexes can include compounds of the invention as described herein. Also, one skilled in the art will appreciate that these suitable x-ray quality crystals can be used as part of a method to identify a candidate agent capable of binding to and modulating the activity of JAK-2 kinases. These methods can be characterized by the following aspects: a) entering in a suitable computer program information defining a ligand binding domain of a JAK-2 kinase in a conformation (for example as defined by light structure coordinates) x obtained from suitable crystals of x-ray quality as described above), the computer program creates a model of the three-dimensional structures the ligand-binding domain, b) introduce a model of the three-dimensional structure of a candidate agent in the computer program, c) superimpose the model of the candidate agent on the model of the ligand-binding domain, and d) assess whether the candidate agent model fits spatially in the ligand binding domain. Aspects a-d are not necessarily carried out in the order mentioned above. These methods may also involve: performing rational drug design with the model of the three-dimensional structure, and selecting a potential candidate agent in conjunction with computer modeling. Additionally, one skilled in the art will appreciate that these methods may further involve: employing a candidate agent, thus determined to spatially adjust in the ligand binding domain, in a biological activity assay for JAK kinase modulation. 2, and determine if this candidate agent modulates the JAK-2 kinase activity in the assay. These methods may also include administering the candidate agent, determined to modulate JAK-2 kinase activity, to a mammal suffering from a condition treatable by modulation of JAK-2 kinase, such as those described above. Also, one skilled in the art will appreciate that the compounds of the invention can be used in a method for evaluating the ability of a test agent to associating with a molecule or molecular complex comprising a ligand-binding domain of a JAK-2 kinase. This method can be characterized by the following aspects: a) create a computer model of a JAK-2 kinase binding cavity using structural coordinates obtained from appropriate X-ray quality crystals of the JAK-2 kinase, b) use algorithms of computation to perform an adjustment operation between the test agent and the computer model of the junction cavity, and c) analyze the results of the adjustment operation to quantify the association between the test agent and the computer model of a joint cavity. The descriptions in this application of all reference articles, including patents, are incorporated herein by reference.

Synthesis Procedures The compounds of the invention, or their pharmaceutically acceptable salts, may have asymmetric carbon atoms, oxidized sulfur atoms or quaternized nitrogen atoms in their structure. The compounds of the invention and their pharmaceutically acceptable salts can exist as individual stereoisomers, racemates, and as mixtures of enantiomers and diastereomers. The compounds can also exist as geometric isomers. All of these individual stereoisomers, racemates and mixtures thereof, and geometric isomers are proposed to be within the scope of this invention. It is assumed that when considering generic descriptions of the compounds of the invention for the purpose of constructing a compound, these constructions result in the creation of a stable structure. That is, a. The person skilled in the art will recognize that theoretically some constructions will not normally be considered as stable compounds (ie, sterically practical and / or synthetically feasible, supra). Methods for the preparation and / or separation and isolation of individual stereoisomers of racemic mixtures or non-racemic mixtures of stereoisomers are well known in the art. For example, optimally active (R) - and (S) -isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. Enantiomers (R- and S- isomers) can be resolved by methods known to one skilled in the art, for example by: formation of diastereomeric salts or complexes that can be separated, for example, by crystallization; by formation of diastereoisomeric derivatives that can be separated, for example, by crystallization, selective reaction of an enantiomer with a specific reagent of the enantiomer, for example, enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; liquid or gas-liquid chromatography in a chiral environment, for example on a chiral support, such as silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where a desired enantiomer is converted to another chemical entity by one of the separation methods described above, an additional step may be required to release the desired enantiomeric form. Alternatively, the specific enantiomer can be synthesized by asymmetric synthesis using optimally active reagents, substrates, catalysts or solvents and by converting the other enantiomer by asymmetric transformation. For a mixture of enantiomers, enriched in a particular enantiomer, the main component enantiomer can be further enriched (with concomitant loss in yield) by recrystallization. In addition, the compounds of the present invention can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like. In general, solvated forms are considered equivalent to unsolvated forms for the purposes of the present invention. In addition, it is proposed that the present invention cover compounds made either using normal techniques of organic synthesis, including combination chemistry or by biological methods, such as by bacterial ingestion, metabolism, enzymatic conversion, and the like. Reaction Scheme 1 represents the general synthetic procedure for the compounds of the invention. The synthesis and the compounds of the invention are not limited by the procedure of the Reaction Scheme 1. One skilled in the art will know that other methods can be used to synthesize the compounds of the invention, and that the process described in the Reaction Scheme 1 is just one of these procedures. In the descriptions below, one skilled in the art will recognize that specific reaction conditions, added reagents, and solvents and reaction temperatures can be modified for the synthesis of the specific compounds of the invention. In this manner, the general synthesis procedure depicted in Reaction Scheme 1 in conjunction with the specific examples that follow provides sufficient information and sufficient guidance to enable one skilled in the art to synthesize the compounds of the invention. The compounds of Formula I can be prepared according to Reaction Scheme 1.

Reaction scheme 1 LG ^ ÍOJR4 The synthesis of the compounds of Formula I proceeds from commercially available reagents and employs normal techniques. Normal reaction conditions of Suzuki couplings can be used to convert dichloropyrimindines of formula A (commercially available from Sigma Aldrich) and boronic acids of formula B (commercially available from Sigma Aldrich, Fisher Scientific, or Combi-Blocks Inc.), where R25, Z and ni they are as defined in the detailed description of the invention, to 4-substituted-2-chloropyrimidines of the formula C. The compounds of the Formula DI and I can be generated by reaction of C with the corresponding amines (Fl, available from Fluka) or anilines (F2, available from Aldrich). The compounds of the formula DI can be further transformed into amides of the formula E using normal conditions of coupling peptides with carboxylic acids or reaction with acid chlorides. For example, DI can be made with an intermediate compound of the formula LG1C (0) R4 where LG1 is a leaving group under acylation conditions and R4 is phenyl optionally substituted with 1, 2, 3, 4, or 5 R11 groups, wherein R11 is as defined in the detailed description of the invention to produce a compound of formula E.

EXAMPLES The following examples serve to describe more fully the manner of making the compounds of the invention, as well as to set forth the best modes contemplated for carrying out the invention. These examples do not serve in any way to limit the scope of the invention, but rather they are presented for illustrative purposes. All references cited herein are incorporated by reference in their entirety. In general, each example is discussed below with a corresponding multi-step synthesis procedure. The following specific examples are a list of compounds that were made in a similar manner.

EXAMPLE 1 N- (4- {2- [(3-aminophenyl) amino] pyrimidin-4-yl} phenyl) acetamide (Compound 58) a) N- (4- (2-chloropyrimidin-4-yl) Phenyl) acetamide (Cj) A, B, A flask was charged with 2, 4-dichloropyrimidine Ai (650 mg, 4.4 mmol), 4-acetoamidophenylboronic acid ?? (820 mg, 4.6 mmol), dichloro [1,1] bis (diphenylphosphino) ferrocenpaladium (480 mg, 0.56 mmol, 15 mol%), and triethylamine (1.5 mL, 11 mmol). Ethylene glycol dimethyl ether (30 mL) was added to the flask and the mixture was purged with 2 for 5 minutes. The reaction mixture was stirred under an N2 atmosphere at 80 ° C for 12 hours, after which time, ether was added and the reaction mixture was filtered. The product, Ci, was isolated by removal of the solvent with a rotary evaporator and used without purification additional. LCMS: m / z 248 (M + H) +.

N- (4- { 2- [(3-aminophenyl) amino] pyrimidin-4-yl}. Phenyl) amide (58) A flask containing a solution of Cx (500 mg, 2.0 mmol) and 3-boc-amino-aniline F (687 mg, 3.3 mmol) in nBuOH (5 mL) was immersed in an oil bath at 180 ° C for 30 minutes. minutes The mixture was cooled to room temperature and the aqueous residue was added aqueous HC1 and MeOH. The aqueous layer was washed twice with ethyl acetate. The aqueous layer was then basified with NaOH and extracted twice with ethyl acetate. The organic layer was washed with brine and dried with sodium sulfate. The solvent was removed on a rotary evaporator and the product was purified by HPLC with TFA / ACN as eluent. The TFA salt was removed by extraction with sodium hydroxide and ethyl acetate to give the title compound 58.

Example 2 N- [3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) phenyl] -2,6-dichlorobenzamide (Compound 7) One flask was charged with 58 (638 mg, 2.0 mmol), 2,6-dichlorobenzoylchloride G (350 μL, 2.4 mmol), diisopropylethylamine (1.1 mL, 6 mmol) and THF (50 mL). The reaction mixture was stirred at 70 ° C for 6 hours. The crude mixture was concentrated on a rotary evaporator and the crude product was purified by HPLC with TFA / ACN as eluent. The title compound 7 was isolated by precipitation of ACN and washed with ether. NMR1H (400MHz, d6-DMSO): 10.718 ppm (s, 1H), 10.269 ppm (s, 1H), 9.678 ppm (s, 1H), 8.507 ppm (d, 1H), 8.419 ppm (s, 1H), 8.215 ppm (d, 2H), 7,758 ppm (d, 2H), 7,608 ppm (d, 2H), 7,532 ppm (t, 1H), 7,472 ppm (d, 1H), 7,380 ppm (d, 1H), 7,301 ppm (d, 2H), t, 1H), 7.216 ppm (d, 1H), 2085 ppm (s, 3H); MS (El) C 25 H 19 Cl 2 502: 492.2 (MH +).

Example 3 N- (4-. {2- [(4-morpholin-4-ylphenyl) amino] irimidin-4-yl] phenyl) acetamide (18) One flask was charged with q (500 mg, 2.0 mmol), 4-morpholinoaniline H (540 mg, 3.0 mmol) and., BuBuOH (10 mL). The flask was immersed in an oil bath of 180 ° C for 30 minutes. The reaction mixture was cooled to room temperature and the black residue was dissolved in DMF and MeOH. The product was purified by HPLC with TFA / AC as eluent. The TFA salt was removed by extracting with sodium hydroxide and ethyl acetate to give compound (18). RMISH (400MHz, dg-DMSO): 10,533 ppm (s, 1H), 9,408 ppm (s, 1H), 8,447 ppm (d, 1H), 8,114 ppm (d, 2H), 7,813 ppm (d, 2H), 7,705 ppm (d, 2H), 7,288 ppm (d, 1H), 6,982 ppm (br s, 2H), 4.65 pmm (br, s 4H), 3072 ppm (br, s 2H), 2108 ppm (s, 3H); MS (El) Cyy¾0a: 390.3 (MH *).

Example 4 N-. { l- [(2,6-dichlorofenyl) carbonyl] piperidin-4-yl} -4- (4-methyl-2-thienyl) pyrimidin-2-amine G2 a solution of hydrochloride. { 4- [4- (5-Met thiophen-2-yl) -phenyl] -pyrimidin-2-yl} -piperidin-4-yl-amine I (274 mg, 1 L branch) and TEA (0.69 mL, 5 mmol) in DMF (5 raL) was added 2,6-dichlorobenzoyl chloride G (0.21 mL, 1.5 mmol) and the solution was stirred for 4 hours. To the resulting solution was added ethyl acetate (100 mL) and the organic layer was washed with 5% LiCl (3 x 50 mL), dried over anhydrous sodium sulfate, filtered and concentrated to yield a residue. This residue was purified by reverse phase HPLC to yield the product G2 (195 mg, 38.9% yield, acetate salt) as a light brown solid. NMR'H (400MHz, ds-DMS0): 8.28 (m, 1H), 7.73 (m, 1H), 7.58-7.54 (m, 2H), 7.48-7.46 (m, 1H), 7.32 (s, 1H), 7.27 (m, 1H), 7.01 (m, 1H), 4.47 (m, 1H), 4.03 (m, 1H), 3.30-3.05 (m, 2H), 2.25 (s, 3H), 2.03 (m, 1H) , 1.88 (m, 1H), 1.58-1.48 (m, 3H); MS (El) for C21H20C12N4OS: 447 (MH +).

Example 5 N- (4-. {5-methyl-2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) acetamide (Compound 574) a) N- (4- (2-chloro-5-methylpyrimidin-4-yl) phenyl) acetamide (C7) A flask charged with 5-methyl-2,4-dichloropyrimidine C2 (2.45 g, 15.0 mmol), 4-acetoaraidophenylboronic acid (2.95 g, 16.5 mmol), dichloro [1,1-bis (diphenyl-phosphino) ferrocenepalladium B1 (1.22 g, 1.5 mmol, 10 mol%), and triethylamine (5.23 mL 37.5 mmol). Ethylene glycol dimethyl ester (20 mL) and H20 (5 mL) were added to the flask and the mixture was purged with N2 for 5 minutes. The reaction mixture was stirred under an N2 atmosphere at 90 ° C for 2 hours, after which time, ether was added and the reaction mixture was filtered. The product, C2, was isolated by removal of the solvent with a rotary evaporator and used without further purification. LCMS: m / z 262 (M + H) +. b) N- (4-. {5-methyl-2- [(morpholin-4-ylphenyl) amino] irimidin-4-yl}. pheni1) acetamide A flask containing a solution of C2 (523 mg, 2.0 mmol) and H (392 mg, 2.2 mmol) in 2-BuOH (6 mL) was immersed in an oil bath at 180 ° C for 3 hours. The mixture was cooled to room temperature and concentrated in vacuo. The residue was purified by HPLC with Ammonium acetate / ACN as eluent to give the title compound 574 (531 mg, 66%).

R NXH (400MHZ, d6-DMSO): 10.15 ppm (s, 1H), 9.27 ppm (s, 1H), 8.31 ppm ppm (s, 1H), 7.72 ppm (d, J = 8.8 Hz, 2 H), 7.66 -7.62 ppm (m, 4H), 6.88 ppm (d, J = 8.8 Hz, 2H), 3.73 (t, J = 4.8 Hz, 4H), 3.01 (t, J = 4.8Hz, 4H), 2.21 ppm (s) , 3H), 2.09 (S, 3H); MS (El) C23H25N502: 404 (M + H) +.

Example 6 N- (4- (2- (3,5-dimorpholinophenylamino) -5-methylpyrimidin-4-yl) phenyl) acetamide (Compound 570) A flask containing a solution of C2 (288 mg, 1. 1 mmol) and ^ (263 mg, 1.1 mmol) in 72-BuOH (3 mL) was immersed in an oil bath at 180 ° C for 4 hours. The mixture was cooled to room temperature and concentrated in vacuo. The residue was purified by HPLC with ammonium acetate / acetonitrile (ACN) as eluent to give the title compound 570 (205 mg, 42%). NMR1H (400MHz, d6-DMSO): 10.15 ppm (s, 1H), 9.22 ppm (s, 1H), 8.34 (s, 1H), 7.72 ppm (d, J = 9.2Hz, 2H), 7.69 ppm (d, J = 8.8 Hz, 2H), 7.10 ppm (d, J = 2.0Hz, 2H), 6.09ppm (s, 1H), 3.71 (t, J = 4.8Hz, 8H), 3.3 (t, J = 4.8Hz, 8H), 2.26 ppm (s, 3H), 2.07 (s, 3H); MS (El) C27H32N, 03: 489 (M + H) Example 7 x -. { 4- [2- (. {4- [4- (2-methylpropanoyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide A solution of N- (4- (2- (4- (piperazin-1-yl) phenylamino) pyrimidin-4-yl) phenyl) acetamide (300 mg, 0.6 mmol) and DIPEA (261 [mu], 1.50 mmol) is treated with isobutyryl chloride at room temperature. After stirring for 10 minutes, the reaction mixture was concentrated directly in vacuo and the residue was purified by HPLC TFA / ACN as eluent. The TFA salt was removed by using basic resin to use 111 mmg (40%) of the title compound 572. R N'H (400MHz, d6-DMSO): 10.21 ppm (s, 1H), 9.40 ppm (s, 1H ), 8.44ppm (d, J = 4.8Hz, 1H), 8.11ppm (d, J = 9.2Hz, 2H), 8.10ppm (s, 1H), 7.74ppm (d, J = 8.8Hz, 2H), 7.68 ppm (d, J = 8.8Hz, 1H), 7.28ppm (d, J = 5.6Hz, 1H), 6.97 (d, J = 9.6Hz, 2H), 3.65-3.61 (ra, 4H), 3.08-3.02 ( m, 4H), 2.92 ppm (penth, J = 6.8Hz, 1H), 2.09 ppm (s, 3H), 1.03 ppm (s, 3H), 1.01 ppm (s, 3H); MS (El) C 26 H 30 N 602: 459 (M + H) +.

Example 8 (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl] carbamate (Compound 248) To a solution of 4- (4-aminophenyl) -N- (4-morpholinophenyl) pyrimidin-2-amine 55 (100 mg, 0.29 mmol) and DIEA (0.435 mmol, 75 μ) in THF (50 mL) was added Methyl chloroformate (0.348 mmol, 27 μ) and the solution was stirred at room temperature for 2 hours. The mixture in solution was concentrated, redissolved with MeOH and purified using reverse phase HPLC. The product obtained from the reverse phase HPLC was the free base 248, converted to HCl salt using 3N HCl and lyophilized to yield compound 248 (60 mg, 47% yield) as a yellow solid. RMIN H (400MHz, d6-DMSO): 10,063 ppm (s, 1H), 9,976 ppm (s, 1H), 8,521 ppm (d, 1H), 8,153 ppm (d, 2H), 7,878 ppm (d, 2H), 7,661 ppm (d, 2H), 7,554 ppm (bs, 2H), 7,432 ppm (d, 1H), 3,983 (bs, 4H), 3,707 ppm (s, 3H), 4,435 ppm (bs, 4H); MS (El) C22H23N503HC1: 475.4 (MH +).

Example 9 4- [4- (dimethylamino) phenyl] -N- (4-morpholin-4-ylphenyl) pyrimidin-2 -amine (67) a) 4- (2-chloropyrimidin-4-yl) -N, N- dimethylaniline (C3) B2 A, -3 A flask was charged with A1 (650 mg, 4.4 mmmol), 4 - (dimethyl-lamino) f eni lboronium B2 (797 mg, 4.8 mmol), dichloro [1,1 '-bis (di f eni 1 fos f ino) ferrocenopalladium (480 mg, 0.56 mmol, 15 mol%), and triethylamine (1.5 mL, 11 mmol). Ethylene glycol dimethyl ether (30 mL) was added to the flask and the mixture was purged with N2 for 5 minutes. The reaction mixture was stirred under an N2 atmosphere at 80 ° C for 12 hours, after which time, ether was added and the reaction mixture was filtered. The product, C3, was isolated by removal of the solvent with a rotary evaporator and used without further purification. LCMS: m / z 234 (M + H) +. b) 4- [4- (dimethylamino) phenyl] -N- (4-morpholin-4-phenyl) pyrimidin-2-amine (67) C3 67 A flask was charged with C3 (500 mg, 2.1 ramol), 4-morpholinoaniline (573 mg, 3.2 mmol) and nBuOH (10 mL). The flask was immersed in an oil bath at 180 ° C for 30 minutes. The reaction mixture was cooled to room temperature and the black residue was dissolved in DMF and MeOH. The product 67 was purified by HPLC with TFA / ACN as eluent. The TFA salt was removed by extracting with sodium hydroxide and ethyl acetate to give the free base of 67. RMN'H (400MHZ, d6-DMSO): 9.24 ppm (s, 1H), 8.33 (d, 1H), 8.03 (d, 2H), 7.68 (d, 2H), 7.18 (d, 1H), 6.92 (d, 2H), 6.81 (d, 2H), 3.72-3.77 (m, 4H), 3.04-3.08 (m, 4H), 3.00 (s, 6H). MS (El) C22H25N50: 376.1 (MH +).

Example 10 4- [4- (3-methyl-1,2,4-oxadiazol-5-yl) phenyl] -N- (4-morpholin-4-phenyl) pyrimidin-2 -amine (Compound 319) a) 4- (2-chloropyrimidin-4-yl) benzonitrile A flask was charged with A1 (763 mg, 5.16 mmol), 4-cyanophenylboronic acid B3 (848 mg, 5.77 mmol), dichloro [1,1-bis (diphenylphosphino) ferrocenepalladium (375 mg, 0.437 mmol, 10% in mol), and triethylamine (1.76 mL, 12.9 mmol). Ethylene glycol dimethyl ether (5.0 mL) was added to the flask and the mixture was purged with N2. The reaction mixture was stirred under an N2 atmosphere at 90 ° C for 1 hour, after which time it was cooled to room temperature and filtered. The product, C4 was isolated by removal of the solvent with a rotary evaporator and used without further purification. LCMS: m / z 216 (M + H) +. b) 4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) benzoni tri1o A flask containing a solution of C4 (400 mg, 1.85 mmol) and 4-morpholinoaniline (362 mg, 2.04 mmol) in 1-butanol (10 mL) was immersed in an oil bath at 180 ° C for 2 hours. The mixture was cooled to room temperature, was concentrated, and the crude product S was used without further purification. LCMS: m / z 358 (M +) +. c) 4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) benzoic acid A flask containing a solution of S (600 mg, 1.68 mmol) and ION HCl (aqueous, 20 mL) was immersed in an oil bath at 100 ° C for 5 hours. The mixture was cooled to room temperature, after which 5N LiOH was added until the reaction mixture was pH 6. The white precipitate was filtered and dried to give product T, which was used without further purification. LCMS: m / z 377 (M + H) +. d) 4- [4- (3-methyl-1,2,2-oxadiazol-5-yl) phenyl] -N- (4-morpholin-4-ylphenyl) pyrimidin-2-amine (323) To a flask containing a solution of T (570 mg, 1.47 mmol) and THF (10 mL) was added 1,1 '-carbonyldiimidazole (475 mg, 2.93 mmol). The reaction mixture was immersed in an oil bath at 60 ° C for 2 hours, after which it was cooled to room temperature. ambient. To the reaction mixture was added a mixture of acetamide-oxime (120 mg, 1.62 mmol) and NaH (39 mg, 1.6 mmol) in DMF (5 mL), after which time, the reaction mixture was immersed in a bath of oil at 80 ° C for 2 hours. The reaction mixture was then cooled to room temperature, quenched with saturated H 4 Cl (aqueous, 10 mL), extracted with ethyl acetate (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to yield a waste The residue was purified by reverse phase HPLC to yield product 319 (49.6 mg, 8.10% yield) as a light brown solid. R Sfa (400MHz, dg-DMSO): 9.57 ppm (s, 1H), 8.57 ppm (d, 1H), 8.38 ppm (d, 2H), 8.25 ppm (d, 2H), 7.67 ppm (d, 2H), 7.44 (d, 1H), 6.95 ppm (d, 2H), 3.75 pmm (t, 4H), 3.06 ppm (t, 4H), 2.46 ppm (s, 3H); MS (El) CW ^: 415.0 (MtT).

EXAMPLE 11 N- (4- {2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -2-pyrrolidin-1-ylacetamide (Compound 292) a) 2- Chloro-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) pheny1) acetamide To a flask charged with 4- (4-aminophenyl) -N- (4-morpholinophenyl) pyrimidin-2-amine (100 mg, 0.286 mmol) and THF (1 mL) was added chloroacetyl chloride (0.0230 mL 0.286 mmol). The solution was stirred at room temperature for 1 hour. The crude mixture was then concentrated and used without further purification. LCMS: m / z 424 (M + H) +. b) N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl) phenyl-2-pyrrolidin-1-yl acetamide (292) To a flask loaded with U (100 mg, 0.236 mmol), diisopropylethylamine (0.2 mL, 1 mmol) and dimethylacetimide (1 mL) was added pyrrolidine (0.021 mL, 1.3 mmol). The reaction mixture was stirred at 80 ° C for 1 hour. The crude mixture was concentrated on a rotary evaporator and the product 292 was purified by reverse phase HPLC. RM ^ H (400MHz, d6-DMSO): 10.90 ppm (s, 1H), 10.20 ppm (br. S, 1H), 9.64 ppm (s, 1H), 8.50 ppm (d, 1H), 8.19 ppm (d, 2H), 7.78 ppm (d, 2H), 7.74 ppm (d, 2H), 7.36 ppm (d, 1H), 7.11 ppm (d, 2H), 4.32 ppm (s, 2H), 3.80 ppm (t, 4H) 3.70-3.65 ppm (m, 2H), 3.19-3.06 ppm (m, 6H), 2.10-1.86 (m, 4H); MS (El) C 26 H 30 N 602: 459.4 (MH +).

Example 12 3-methoxy-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) propanamide (Compound 575) 249 (a) To a solution of 249 (a) (0.18 g, 0.05 mmol), HATU (0.4 g, 1.1 mmol) and DIEA (0.5 mL, 4.0 mmol) in DMA (5 mL) was added 3-methoxypropanoic acid (0.1 mL, 1.5 mmol) and the solution was stirred at 60 ° C for 2 hours. The mixture in solution was diluted with ethyl acetate and the mixture was extracted with 10% LiCl (3X) and brine (IX). The resulting organic layer was dried with sodium sulfate and concentrated in vacuo. The product was purified by silica column chromatography (5% MeOH / DCM as eluent) to give 0.1 g of the title compound 575 (49% yield) as a white solid. NMR'H (400MHz, d6-DMSO): 10.20 ppm (s, 1H), 9.37 ppm (s, 1H), 8.42 ppm (d, 1H), 8.10 ppm (d, 2H) 7.74 ppm (d, 2H), 7.65 ppm (d, 2H), 7.25 ppm (d, 1H), 6.91 ppm (d, 2H), 3.72 ppm (m, 4H), 3.61 ppm (t, 2H), 3.23 ppm (s, 3H), 3.03 ppm (m, 4H), 2.57 ppm (t, 2H); MS (El) C22H23N503HC1: 434.3 (MH +).

Example 13 N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl.} Phenyl) prolinamide (576) To a solution of 249 (a) (5HC1) (0.2 g, 0.37 mmol) in DMA (5 mL) was added a solution of 1- (tert-butylcarbonyl) pyrrole idro-2-carboxylic acid. { d, 1-boc-proline) (0.1 g, 0.46 mmol), Hunigs base (0.5 mL, 2.5 mmol), HATU (0.2 g, 0.52 mmol) and the solution is stirred at room temperature for 14 hours. The resulting solution was loaded on silica gel and purified by silica gel column chromatography (gradient of 10-100% ethyl acetate / hexanes) to yield Z (160 mg) in 79% yield as a yellow solid. . LCMS: m / z 545 (M + H) +. d) N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) pyrrolidine-2-carboxamide (Compound 585) A 576 A flask containing a solution of Z (160 mg, 0.29 mmol) in 4M HC1 in 1,4-dioxane (5 mL) and MeOH (5 mL) was stirred at 50 ° C for 1 hour. The concentration of the solvent gave a yellow solid which was purified by reverse phase HPLC using an ammonium acetate buffer to yield 105 mg (68%) of 576 as a yellow solid. NMR'H (400MHz, d4-MeOD): 8.36 (m, 1H), 8.14 (m, 2H), 7.78 (m, 2H), 7.62 (m, 2H), 7.22 (ra, 1H), 6.98 (ra, 2H), 4.15 (m, 1H), 3.83 (m, 4H), 3.21 (m, 2H), 3.13 (m, 4H), 2.41 (m, 1H), 2.06-1.91 (m, 3H); LCMS: for C25H28N602: 445 (M + H) +.

Example 14 2-amino-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) propanamide (Compound 208) 249 (a) 208 One flask was charged with 249 (a) (140 mg, 0.3 mmol), N- (tert-butoxycarbonyl) -alanine (57 mg, 0.3 mmol, purchased from Chem-Impex International), HATU (140 mg, 0.37 mmol), diisopropylethylamine (0.6 mL, 3.0 mmol) and DMA (5 mL). The reaction mixture was stirred at room temperature for 12 hours. The crude mixture was concentrated on a rotary evaporator and the residue was dissolved in 10 mL of MeOH and 5 mL of 4N HCl in dioxane. The reaction mixture was stirred at 70 ° C for 1 hour. The crude mixture was concentrated on a rotary evaporator and the product was purified by HPLC with NH4OAc / ACN as eluent. The resulting solution was concentrated on a rotary evaporator and the final product, 208, was dried by lyophilization. NMR'H (400MHz, d6-DMSO): 9,387 ppm (s, 1H), 8,443 ppm (d, 1H), 8,127 ppm (d, 2H), 7,825 ppm (d, 2H), 7.676 ppm (d, 2H) , 7,287 ppm (d, 1H), 6,939 ppm (d, 2H), 3,747 ppm (m, 4H), 3,457 ppm (q, 1H), 3,050 ppm (m, 4H), 1,896 (s, 3H), (AcOH) )) 1,243 ppm (d, 3H); MS (El) C 23 H 26 N 602: 419.1 (MH +).

Example 15 N- (4- (2- (3-methoxy-4-morpholinophenylamino) pyrimidin-4-yl) phenyl) acetamide (Compound 341) a) 4- (2-methoxy-4-nitrophenyl) morpholine (AA) A pressure bottle was charged with l-chloro-2-methoxy-4-nitrobenzene (10.0 g mg, 53.3 mmol, purchased from TCI America) and morpholine (15 mL, 172.0 mmol). The reaction mixture was stirred at 120 ° C for 15 hours and allowed to cool to room temperature on its own. The resulting solid was suspended in 20 mL of ethyl acetate, filtered, and washed with 20 mL of methyl tert-butyl ether. 8.8 g of yellow solid was collected as the desired product AA (69% yield). NMR'H (400MHZ, d6-DMSO): 7.83 (dd, 1H), 7.67 (d, 1H), 6.98 (d, 1H), 3.88 (s, 3H), 3.71 (m, 4H), 3.16 (m, 4H). MS (El) C1XH14N204: 239 (M + H) +. b) 3-methoxy-4-morpholinoaniline To a solution of AA (8.8 g, 37.0 mmol) in ethyl acetate (30 mL) and methanol (10 mL) in a Parr bottle was added 1 g of 10% palladium in carbon. The reaction mixture was hydrogenated at 40 psi of H20 for 1 hour, filtered and concentrated. 8.0 g of a pink solid was obtained as the product BB, as a crude product and was used without further purification. MS (El) C11H16N202: 209 (M + H) +. c) N- (4- (2- (3-methoxy-4-morpholinophenylamino) pyrimidin-4-yl) phenyl) acetamide A flask was charged with BB (51 mg, 0.24 mmol), N- (4- (2-chloropyrimidin-4-yl) phenyl) acetamide (50 mg, 0.2 mmol) and nBuOH (2 mL). The flask was immersed in an oil bath of 180 ° C for 30 minutes, and then cooled to room temperature. The residue was suspended in 5 mL of ethyl acetate ethyl, stirred for 1 hour, filtered, and washed with 10 mL of ethyl acetate. 50 mg of an off-white powder was obtained as the title compound (341) (60% yield). R N'H (400MHZ, d6-DMSO): 10.33 (s, 1H), 9.50 (br, 1H), 8.54 (d, 1H), 8.54 (d, 1H), 8.15 (d, 2H), 7.95 (br , 1H), 7.77 (d, 2H), 7.42 (m, 2H), 3.94 (s, 3H), 3.77 (br, 4H), 3.40 (br, 2H), 2.15 (s, 2H). MS (El) C 23 H 25 N 503: 420 (M + H) +.

Example 16 N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) methanesulfonamide (Compound 326) 82 (500 mg, 0.94 mmol) was dissolved in 4 mL of pyridine. Methanesulfonyl chloride (730 μ:? -, 9.4 mmol) was added dropwise to the vigorously stirred pyridine solution. The addition of the sulfonyl chloride was isothermal and caused a significant increase in the temperature of the reaction. The reaction was maintained at 80 ° C for several hours. After cooling, the solvent was removed under The residue was purified by reverse phase HPLC to give 200 mg (52% yield) of the title compound (326). NMR'H (400MHZ, d6-DMSO): 10.16 ppm (s, 1H), 9.41 (s, 1H), 8.45 ppm (d, 1H), 8.13 ppm (d, 2H), 7.67 ppm (d, 2H), 7.33 ppm (d, 2H), 7.28 ppm (d, 1H), 6.94 ppm (d, 2H), 3.74 ppm (br s, 4H), 3.09 ppm (s, 3H), 3.05 ppm (br s, 4H); MS (El) C21H23N503S: 426 (MH +).

Example 17 (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) carbamate (Compound 248) To a solution of 4 - (4-aminophenyl) -N- (4-morpholinophenyl) pyrimidin-2-amine 249 (a) (100 mg, 0.29 mmol) and DIEA (0.435 mmol, 75 μ) in THF (50 mL) ) Methyl chloroformate (0.348 mmol), 27 μm) was added and the solution was stirred at room temperature for 2 hours. The mixture in solution was concentrated, redissolved with MeOH and purified using reverse phase HPLC. The product obtained of the reverse phase HPLC was free base 248, converted to 3N HC1 salt and lyophilized to yield product 248 (60 mg, 47% yield) as a yellow solid. RM ^ H (400MHz, d6-DMSO): 10,063 ppm (s, 1H), 9,976 ppm (s, 1H), 8,521 ppm (d, 1H), 8,153 ppm (d, 2H), 7,878 ppm (d, 2H) , 7,661 ppm (d, 2H), 7,554 ppm (bs, 2H), 7,432 ppm (d, 1H), 3,983 ppm (bs, 4H), 3,707 ppm (s, 3H), 4,435 ppm (bs, 4H); MS (El) C22H23NS03HC1: 475.4 (MH +).

Example 18 (S) -3-hydroxy-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) butanamide (Compound 363) To a solution of. { S) -3-hydroxybutyrate (0.18 g, 1. 73 mmol), HATU (0.602 g, 1.58 mmol) DIEA (1.0 mL, 5.4 mmol) in DMF (3.0 mL) was added a solution of 4- (4-aminophenyl) -N- (4-morpholinophenyl) pyrimidin-2 - Amine (0.500 g, 1.44 mmol) in DMF (1.0 mL). The reaction mixture was stirred at room temperature for 2 hours, at which time it was quenched with NaHCO3 (10 mL, aqueous), extracted into DCM (3X), and washed with brine (IX). The organic layers dried with sodium sulfate and concentrated. The product was purified by reverse phase HPLC to give (S) -3-hydroxy-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) butanamide (0.136 g, 22% yield) as a light brown solid. (363) R N'H (400MHZ, DMSO-d6): 10.14 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.77 (d, 2H), 7.68 (d, 2H), 7.27 (d, 1H), 6.94 (d, 2H), 4.79 (d, 1H), 4.11 (m, 4H), 3.74 (m, 4H), 3.05 (m, 4H), 2.47 (dd, 1H), 2.35 (dd, 1H), 1.15 (d, 3H); MS (El) m / z for C 24 H 28 N 503: 434.3 (MH +).

Example 19 2-Hydroxy-2-methyl-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) propanamide (Compound 366) To a solution of 4- (4-aminophenyl) -N- (4-morpholinophenyl) irimidin-2-amine (1.0 g, 2.8 mmol) 249 (a) and DIPEA (0.5 mL, 1 eq) in anhydrous DMA (5 g. mL) was added dropwise 2-acetoxy-2-methylpropionyl chloride (3 mol, 1.0 eq, 0.44 mL) at 0 ° C. The mixture was stirred for 20 minutes at room temperature. The solution was diluted with water and EtOAc. The organic layer was concentrated in vacuo. Residue 366 (a) was suspended in MeOH (10 mL) and a LiOH-H20 solution (8.3 eq. 0.35 g) in water (3 mL). The reaction was completed in the space of 20 minutes and then neutralized. The organic solvent was removed in vacuo. The residue was purified to give 2-hydroxy-2-methyl-N- (4- (2- (4-morpholino-phenylamino) pyrimidin-4-yl) phenyl) propanamide (366) (1.0 g, 85% yield) as a pale yellow solid. NMR'H (400MHz, DMSO-d6): 9.86 (s, 1H), 9.41 (s, 1H), 8.47 (d, 1H), 8.12 (d, 2H), 7.94 (d, 2H), 7.68 (d, 2H), 7.30 ppm (d, 1H), 6.94 (d, 2H), 5.82 (s, 1H), 3.75 (m, 4H), 3.08 (m, 4H), 1.38 (s, 6H); MS (El) m / z for C22H23N503HC1: 434.2 MH +).

Example 20 (R) -3-hydroxy-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) butanamide (Compound 364).

To a solution of (i?) -3-hydroxybutyrate (0.180 g, 1. 73 mmol), HATU (0.602 g, 1.58 mmol), DIEA (1.0 mL, 5.4 mmol) in DMF (3.0 mL) was added a solution of 4- (4-aminophenyl) -N- (4-morpholinophenyl) pyrimidin-2 -amine (249 (a)) (0.500 g, 1.44 mmol) in DMF (1.0 mL). The reaction mixture was stirred at room temperature for 2 hours, which was quenched with saturated NaHCO3 (10 mL, aqueous), extracted into DCM (3X), washed with brine (IX), and the organic layers were stirred over sodium sulfate. The solution was concentrated and the product was purified by reverse phase HPLC (R) -3-hydroxy-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) butanamide (364) (0.129 g , 21% yield) as a light brown solid RMNXH (400MHz, DMSO) -d6: 10.14 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.77 ( d, 2H), 7.68 (d, 2H), 7.27 (d, 1H), 6.94 (d, 2H), 4.79 (d, 1H), 4.11 (m, 1H), 3.74 (m, 4H), 3.05 (m , 4H), 2.47 (dd, 1H), 2.35 (dd, 1H), 1.15 (d, 3H); MS (El) m / z for C 24 H 28 N 503: 434.3 (MH +).

Example 21 (i?) -2-amino-3-hydroxy-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) -propanamide (Compound 365) To a solution of 4- (4-aminophenyl) -N- (4-morpholinophenyl) pyrimidin-2-amino-249 (a) (521 mg, 1.5 mmol), N-CBZ-D-Serine (359 mg, 1.5 mmol) , and DIEA (0.653 mL, 3.75 mmol) in DMA (4 mL) was added HATU (855 mg, 2.25 mmol) and the solution was stirred at room temperature for 0.5 hours. Excess H20 was added to the reaction mixture. He The precipitate was collected and redissolved in CH2C12, washed with NaHCO3 (aqueous) (2X), brine, dried over Na2SO4, and concentrated in vacuo. The residue was purified by silica column chromatography (1% MeOH / DCM as eluent) to give 3-hydroxy-1- (4- (2- (4-morpholino-phenylamino) pyrimidin-4-yl) phenylamino) - L-oxopropan-2-ylcarbamate of (R) -benzyl 365 (a) (668 mg, 78% yield). To a stirred solution of 3-hydroxy-1- (4- (2- (4-morpholinophenylamino) -pyrimidin-4-yl) phenylamino) -1-oxopropan-2-ylcarbamate of (R) -benzyl from the previous step in MeOH (10 mL) was added Pd (OH) 2 (134 mg) and ammonium formate (369 mg, 5.85). The mixture was heated at 60 ° C for 2 hours, cooled to room temperature, and filtered on Celite on elution with MeOH. The filtrate was concentrated in vacuo and the residue was purified by preparative HPLC (TFA). The TFA salt was removed by using basic resin to give. { R) -2-amino-3-hydroxy-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) propanamide 365 (346 mg, 68%). NMR'H (400MHZ, DMSO-d6): 9.39 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.83 (d, 2H), 7.67 (d, 2H), 7.29 (d, 1H), 6.94 (d, 2H), 4.94 (m, 1H), 3.75 (m, 4H), 3.60 (m, 2H), 3.46 (m, 1H), 3.05 (m, 4H); MS (El) m / z for C 23 H 26 N 603: 435.4 (MH +).

Example 22 N-. { 4- [2- ( { 3- [(4-ethylpiperazin-1-yl) methylphenyl} amino) pyrimidin-4-yl] phenyl} -acetamide (Compound 122) it gave 122 Intermediate A (0.5 g) was dissolved in THF (5 ml), then an aqueous solution of 20% H2SO4 (5 ml) was added to the solution. The mixture was stirred at 50 ° for 2 hours and monitored by LC / MS (MH +, 333). The solution was then neutralized with 2N NaOH solution and extracted with ethyl acetate. The organic layer was washed with brine, dried over Na 2 SO 4, and concentrated to give 0.38 g of aldehyde B. (90% yield). A flask was charged with aldehyde B (0.1 g, 0.3 mmol), dichloromethane (10 ml), sodium triacetoxyborohydride. (0.32 g, 1.5 mmol) and 1-ethylpiperazine (0.19 ml, 1.5 mmol). The reaction mixture was stirred at room temperature overnight and checked with LC / MS. The product 122 was isolated by removal of the solvent with a rotary evaporator and then purified with a preparative HPLC. NMR'H (400MHZ, d6-DMSO): 10.23 (s, 1H), 9.6 (s, 1H), 8.5 (d, 1H), 8.14 (d, 2H), 7.9 (s, 1H), 7.76 (d, 2H), 7.65 (d, 1H), 7.36 (d, 1H), 7.24 (t, 1H), 6.89 (d, 1H), 3.43 (s, 2H), 2.4 (br, 6H), 2.3 (q, 2H), 2.1 (s, 3H), 0.96 (t, 3H). MS (El) for C 25 H 30 N 6 O: 431 (MH +).

Example 23 2- (3- (1H-imidazol-1-yl) propylamino) -N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) acetamide (Compound 143) 143 A flask was charged with aniline A1 (100 mg, 0.29 mmol), and THF (1.0 mL). Chloroacetyl chloride (23 μ ??, 0.29 mmol) was added and the mixture was stirred at room temperature for 1 hour, after which time it was concentrated. The product, B1 (was isolated by solvent removal with a rotary evaporator and used without further purification) charged a flask with alkyl chloride B (20 mg, 0.047 mmol), Na2CO3 (30 mg, 0.28 mmol), 1- (3 -aminopropyl) imidazole (5.6 μ? .., 0.047 mmol) and DMF (1.0 mL) The mixture was stirred at 150 ° C for 1 hour, after which time it was concentrated, Product 143 was purified by reverse phase HPLC. to give 9.7 mg (40% yield from B as a white solid) RMNXH (400MHz, d6-DMSO): 8.35 (d, 1H), 8.13 (d, 2H), 7.78-7.63 (m, 3H), 7.61 (d, 2H), 7.22 (d, 1H), 7.17 (s, 1H), 7.05-6.95 (m, 2H), 4.62 (s, br, 1H), 4.16 (t, 2H), 3.87-3.77 ( m, 4H), 3.49 (s, 1H), 3.34 (s, 1H), 3.15-3.07 (m, 4H), 2.67 (t, 2H), 2.11-2.01 (m, 2H), 1.95 (s, 2H). MS (El) C28H32N802: 513.1 (MH +).

Example 24 N-Chloro-N- (4- (2- (3-methoxy-4-morpholinophenylamino) pyrimidinyl) phenyl) -2- (lH-tetrazol-1-yl) acetamide (Compound 554) 4- (4-aminophenyl) -N- (3-methoxy-4-morpholinophenyl) pyrimidin-2-amine hydrochloride: The flask was charged with tert-butyl 4- (2-chloropyrimidin-4-yl) phenylcarbamate (12.2) g, 40.0 mmol), 3-methoxy-4-morpholinoaniline (9.7 g, 40.76 mmol) and 50 mL of n-butanol. The reaction mixture was stirred under an N2 atmosphere at 100 ° C for 12 hours, after which time, then, it was cooled to room temperature. 25 mL of 4N HC1 in dioxane was added, the reaction mixture was stirred at 50 ° C for 5 hours. After cooling at room temperature, it was filtered, washed with ethyl acetate, dried in air to collect 16 g of a yellow-green solid as the desired product. NMR (400MHz, d6-DMSO): 10.40 (s, 1H), 8.60 (d, 1H), 8.20 (s, 2H), 7.94 (s, 1H), 7.84 (d, 1H), 7.54 (d, 1H) , 7.41 (d, 1H), 7.30 (m, 2H), 4.10 (m, 2H), 3.99 (s, 3H), 3.60 (br, 2H), 3.39 (m, 2H), 1.25-1.42 (m, 4H) ). MS (El) for C21H23NS02: 378 (MH +). A flask was charged with 4- (4-aminophenyl) -N- (3-methoxy-4-morpholinophenyl) pyrimidin-2-amine B hydrochloride (471.0 mg, 0.84 mmol), 2- (lH-tetrazol-1-hydrochloride. il) acetic (216.0 mg, 1.69 mmol) HATU (1276.0 mg, 3.38 mmol) and 2 mL of DMA. The reaction mixture was stirred at room temperature for 24 hours, and then quenched with 50 mL of water, extracted with ethyl acetate (3 x 50 mL). The combined organics were washed with water and then with brine (50 mL each), dried over anhydrous sodium sulfate, and then concentrated. The crude product was purified with a column of silica gel (ethyl acetate to 10% methanol ethyl acetate), 345.0 mg of the desired product 554 was obtained as a yellowish powder. NMR (400MHz, d6-DMSO): 10.85 (s, 1H), 9.50 (s, 1H), 9.43 (s, 1H), 8.47 (s, 1H), 8.19 (d, 2H), 7.75 (d, 2H) , 7.63 (s, 1H), 7.20 (m, 3H), 6.84 (d, 1H), 5.56 (s, 2H), 3.80 (s, 3H), 3.74 (m, 4H), 2.94 (m, 4H). MS (El) for C 24 H 25 N 903: 488 (MH +).

Example 25 4- [4- (1, l-Dioxidoisothiazolidin-2-yl) phenyl] -N- (4-morpholin-4-phenyl) pyrimidin-2 -amine (compound 374) A 374 dissolved aniline A (300 mg, 0.78 mmol) in 4 mL of dry pyridine. 3-Chloropropanesulfonyl chloride (950 μ ?, 7.8 mmol) was added dropwise. The reaction mixture was heated to 80 ° C and stirred overnight under a nitrogen atmosphere. The solvent was removed under vacuum and the residue was redissolved in 25 mL of ethyl acetate. The reaction mixture was washed once each time with 10 mL portions of water, 0.1M HCl and saturated aqueous NaCl. The organic layer was dried with MgSO 4 and concentrated in vacuo. The residue was taken in DMF (4 mL) and triethylamine (1100 L, 7.9 mmol). The reaction mixture was heated to 80 ° C and stirred overnight. The product was purified by preparative HPLC to give 85 mg of 374. RMN1 !. (400MHz, d6-DMSO): 9.78 (S, 1H), 8.49 (d, 1H), 8.20 (d, 2H), 7.78 (d, 2H), 7.39 (d, 1H), 7.33 (d, 2H), 7.25 (brs, 2H), 3.84 (brs, 4H), 3.73 (t, 2H), 3.60 (t, 2H), 2.54 (m, 2H), 2.45 (m, 2H), 2.01 (m, 2H); MS (El) for C 23 H 25 N 503 S: 452 (MH +).

Example 26 N- (4-morpholin-4-ylphenyl) -4- [4- (lH-tetrazol-1-yl) phenyl] pyrimidin-2-amine Aniline A (200 mg, 0.52 mmol), sodium azide (45 mg, 0.69 mmol), triethyl orthoformate (280 μ ??, 1.7 mmol) and acetic acid (480 μL, 8.4 mmol) were combined in a 25-well round bottom flask. mL. The reaction mixture was stirred for 2 hours at 80 ° C. The reaction mixture was allowed to cool to room temperature and then further cooled in an ice bath. A solution of 670 uL of 6.0 M HCl in 1.25 mL of water was added to the reaction mixture. After stirring in the ice bath for 5 minutes, another solution of sodium nitrite (50 mg, 0.72 mmol) in water (200 uL) was slowly added. The precipitate was completely filtered and purified by reverse phase HPLC to give 24 mg of 375. RM ^ H (400MHz, d6-DMSO): 10.19 (s, 1H), 9.51 (s, 1H), 8.53 (d, 1H ), 8.40 (dd, 2H), 8.10 (d, 2H), 7.65 (d, 2H), 7.43 (d, 1H), 6.92 (d, 2H), 3.73 4H), 3.03 (m, 4?); MS (El) for C21H20N8O: 401 (MH +) Example 27 N- [3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) propyl] -2-fluoro-6-iodobenzamide (Compound 289) A flask was charged with Cl (5.0 g, 20.2388 mmol) and (3-aminopropyl) -carbamic acid t-butyl ester (6 mL, 30.3582 mmol). N-butanol (40 mL) was added to the flask and heated at 175 ° C for one hour. The solvent was evaporated and the reaction mixture was checked with LC / MS. The reaction mixture was cooled to room temperature and ethyl acetate was added. The precipitate, B, was filtered and used without further purification. LC / MS: m / z 386 (M + H) +. A flask was charged with B. 4N HCl in dioxane was added and stirred at room temperature for 3 hours. The reaction mixture was verified with LC / MS. The product, E, was isolated by solvent removal with rotary evaporation and was used without further purification. LC / MS: m / z 286 (M + H) +. A flask was charged with E (254 mg, 0.8902 mmol), 2-fluoro-6-iodobenzoyl chloride (90 μl 1 ?, 0.6231 mmol), tetrahydrofuran (25 mL), and n-ethyldiisopropylamine (108 μL, 0.6231 mmol). The reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was monitored with LC / MS. The product, 289, was isolated by removal of the solvent with a rotary evaporator and purified with preparative HPLC with TFA (10:90, 11 minutes run). RMN1 !. (400MHz, d6-DMSO): 10.16 ppm (s, 1H), 8.64 ppm (t, 1H), 8.30 ppm (d, 1H), 8.06 ppm (d, 2H), 7.70 ppm (m, 3H), 7.30 ppm (m, 1H), 7.20 ppm (m, 1H), 7.13ppm (m, 1H), 7.07ppm (m, 1H), 3.34ppm (m, 4H), 2.08ppm (s, 3H), 1.83ppm (m 2H); MS (El) for C22H21FINs02: 533.9 (MH +).

Example 28 N- (4- {2 - [(3- {[[2,6-dimethylphenyl) methyl] amino} phenyl) amino] pyrimidin-4-yl} phenyl) acetamide: ( Compound 51) A flask was charged with Cl (5.0 g, 20.2388 mmol) -tert-butyl aminophenylcarbamate (4.6 g, 22.2627 mmol) N-butanol (40 μL) was added to the flask and heated at 175 ° C for 4 hours. The solvent was evaporated and the reaction mixture was checked with LC / MS. The reaction mixture was cooled to room temperature and ethyl acetate was added. The precipitate, D, was filtered and used without further purification. LC / MS: m / z 320 (M + H) +. One flask was charged D (463 mg, 1.4514 mmol), dichloromethane / tetrahydrofuran (2: 1, 15 mL), sodium triacetoxyborohydride (615 mg, 2.9028 mmol), and 2,6-dimethylbenzaldehyde (196 μL, 1.4514 mmol). The reaction mixture was stirred at room temperature for 12 hours and monitored with LC / MS. The product, 51, was isolated by removing the solvent with a rotary evaporator and purified with a preparative HPLC with TFA (10:90, 11 minutes run). RMN1 !. (400MHz, d6-DMSO): 10.20 ppm (s, 1H), 9.36 ppm (s, 1H), 8.47 ppm (d, 1H), 8.16 ppm (d, 2H), 7.72 ppm (d, 2H), 7.35 ppm (s, 1H), 7.31 ppm (d, 1H), 7.12 ppm (m, 1H), 7.07 ppm (m, 2H), 6.99 ppm (m, 3H), 6.38 ppm (d, 1H), 5.46 ppm (t , 1H), 4.14 ppm (d, 2H), 2.36 ppm (s, 6H), 2.08 ppm (s, 3H); MS (El) for C27H27N50: 401 (MH +).

Example 29 3- ( { 4- [4- (acetylamino) phenyl] pyrin-2-yl} amino) -N- [2- (dimethylamino) ethyl] benza (Compound 9) A flask was charged with 2,4-dichloropyrine (22.7 g, 152.38 mmol), 4-acetoaphenylboronic acid (30.0 g, 167.62 mmol), dichloro [1,1-bis (diphenylphosphino) -ferrocenepalladium (16.726 g, 22.86 mmol, 15 g). % in mol), and triethylamine (53 mL, 380.95 mmol). Ethylene glycol dimethyl ether (500 mL) and H20 (20 mL) were added to the flask. The reaction mixture was stirred at 80 ° C for 4 hours. The product, Intermediate A, was isolated by solvent removal with rotary evaporator and purified using glass column chromatography and eluted with ethyl acetate to give 30.5 g (123.14 mmol, 81% yield) of intermediate A as a yellow solid. A sealed tube with the compound was charged intermediate A (400 mg, 1.62 mmol) and 3-aminobenzoic acid (222 mg, 1.62 mmol). N-butanol (15 mL) was added to the sealed tube and stirred at 180 ° C. The reaction was done in 1 hour according to LCMS to give intermediate B as a yellow solid. Intermediate B was placed in a rotary evaporator to remove excess n-butanol. Intermediate B was taken to the next step without further purification. A flask was charged with intermediate B (282 mg, 0.81 mmol), HATU (464 mg, 1.22 mmol), DMF (15 mL) and DIEA (212 μL, 1.22 mmol). The reaction mixture was stirred at room temperature and completed in 30 minutes to give the final product (9). The final product was purified using Preparative HPLC and ammonium acetate buffer and lyophilized to give the product as an ACE salt (170 mg, 0.41 mmol). NMR'H (400MHz, d6-CD3OD): 8.523 ppm (t, 1H), 8.45 ppm (d, 1H), 8.176 ppm (m, 2H), 7.828 ppm (m, 1H), 7.2 ppm (d, 2H) , 7.475-7.404 ppm (m, 2H), 7.326 ppm (d, 1H), 3738 ppm (t, 2H), 3.244 ppm (t, 2H), 2.877 ppm (s, 6H), 2.162 ppm (s, 3H) , 1955 (s, 3H, ACE). MS (El) for C 23 H 26 N 602: 419.1 (MH +).

Example 30 N- [5- ( { 4- [4- (acetylamino) phenyl] pyrin-2-yl} amino) -2-morpholin-4-ylphenyl] -2,6-dichlorobenza (compound 62) Intermediate Compound C Intermediate Compound A A sealed tube was charged with intermediate A (500 mg, 2.02 mmol) and 4-morpholinobenzene-1,3-diamine (400 mg, 2.02 mmol, Zerenex Limited). N-butanol (15 mL) was added to the sealed tube and stirred at 180 ° C. The reaction was done in 1 hour according to LCMS to give intermediate C as a yellow solid. Intermediate C was placed on a rotary evaporator to remove excess n-butanol. Intermediate C was taken to the next step without further purification. A flask was charged with intermediate C (816 mg, 2.02 mmol), THF (100 mL), DIEA (705 μL, 4.04 mmol), and 2,6-dichlorobenzoyl chloride (290 μL, 2.02 mmol). The reaction mixture was stirred at room temperature overnight to give the final product 62. The final product it was purified using preparative HPLC and TFA buffer, and then made free base and lyophilized (165 mg, 0.28 mmol, 14% yield). NMR'H (400MHZ, DMSO): 10194 (s, 1H), 9.8 (s, 1H), 9.607 (s, 1H), 8.585 (s, 1H), 8.484 (d, 1H), 8.235 (d, 2H) , 7.711 (d, 2H), 7.592 (d, 2H), 7.496 (m, 2H), 7.356 (d, 1H), 7.183 (d, 1H), 3.74 (t, 4H), 2.89 (t, 4H), 2.07 (s, 3H). MS (El) for C29H26C12N603: 579.1 (MH +).

Example 31 N-. { 3- ( { 4- [4- (acetylamino) phenyl] pyrin-2-yl} amino) -5 - [(4-ethylpiperazin-1-yl) carbonyl] phenyl} -2,6-dichlorobenza (Compound 66).

THFVDMF Ambient temperature Intermediate compound A Intermediate compound D Intermediate compound E A sealed tube was charged with intermediate A (300 mg, 1.21 mmol) and 3,5-diaminobenzoic acid (204 mg, 1.34 mmol). N-butanol (15 mL) was added to the sealed tube and stirred at 180 ° C. The reaction was done in 1 hour according to LCMS to give intermediate D as a yellow solid. Intermediate D was placed on a rotary evaporator to remove excess n-butanol. Intermediate D was taken to the next step without further purification. A flask was charged with the intermediate compound D (439 mg, 1.21 mmol), THF (30 mL), DMF (5 mL), DIEA (632 μL, 3.63 mmol), and 2,6-dichlorobenzoyl chloride (174 μL, 1.21 mmol). The reaction mixture was stirred at room temperature overnight. The reaction mixture was quenched with 2M NaOH (100 mL) and extracted with ethyl acetate (3x) and the organic layer was discarded. The aqueous NaOH layer was neutralized with concentrated HC1. The solid formed was collected by filtration and washed with excess water to give intermediate E (274 mg, 0.51 mmol, 62% yield) as a yellow solid. Intermediate E was taken to the next step without further purification. A flask was charged with intermediate E (274 mg, 0.51 mmol), HATU (291 mg, 0.765 mmol), DMF (25 mL), ethylpiperazine (78 μL, 0.61 mmol) and DIEA (133 μL, 0.765). mmol). The reaction was stirred at room temperature and completed in 15 minutes. The final product 66 was purified using preparative HPLC and TFA buffer, free base was made and lyophilized to give the product (166 mg, 52% yield). NMR'H (400MHz, DMSO): 10,896 (s, 1H), 10.33 (s, 1H), 9,881 (s, 1H), 8,533 (d, 1H), 8,374 (s, 1H), 8,202 (d, 2H) , 7,776 (d, 2H), 7,636-7.6 (m, 3H), 7,529 (m, 1H), 7,419 (d, 1H), 7,296 (s, 1H), 3,628 (br, s, 2H), 3,415 (br s, 2H), 2.427-2.314 (m, 6H), 2.091 (s, 3H), 0.996 (t, 3H). MS (El) for C 32 H 31 C 12 N 703: 634.1 (MH +).

EXAMPLE 32 N-Methyl-N- (4- {2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) acetamide (Compound 118): A flask was charged with intermediate A (250 mg, 1.01 mmol), DMF (10 mL), NaH (30.0 g, 167.62 mmol), dichloro [1,1-bis (diphenylphosphino) ferrocenepalladium (60 mg, 1.5 mmol. ), and methyl iodide (94 L, 1.5 mmol). The reaction mixture was stirred at room temperature and completed in 30 minutes. minutes The reaction mixture was quenched with H20 and extracted with ethyl acetate (3X) and washed with 10% LiCl solution (IX), brine (IX), dried over sodium sulfate, and filtered. The organic layer was stirred with a rotary evaporator to give intermediate F (200 mg, 0.766 mmol) as a yellow gelatin. The intermediate compound F was taken to the next step without further purification. A sealed tube was charged with intermediate F (200 mg, 0.766 mmol), anhydrous DMA (15 mL), cesium carbonate (374 mg, 1.15 mmol), 2,2'-bis (diphenylphosphino) -1, 11- racemic binaphthyl (70 mg, 0.115 mmol), and tris (dibenzylideneacetone) dipalladium (0). The reaction was rinsed with N2 gas for five minutes and the sealed tube was sealed and stirred at 80 ° C overnight. The reaction was filtered and washed with ethyl acetate and the solid was discarded. The organic solvent was removed using the rotary evaporator. The final product 66 was purified using Preparative HPLC and TFA buffer, free base was made and lyophilized to give the product (95 mg, 0.235 mmol, 28% yield). NMR'H (400MHz, d6-DMSO): 9,464 ppm (s, 1H), 8,511 ppm (d, 1H), 8,209 ppm (d, 2H), 7.67 ppm (m, 2H), 7,516 ppm (d, 2H) , 7366 ppm (d, 1H), 6,926 ppm (m, 2H), 3,743 ppm (t, 4H), 3.22 ppm (s, 3H), 3048 ppm (t, 4H). MS (El) for C23H25N502: 404. 3 (MH +).

Example 33 N- (4- (2- (3- (3-morpholinopropoxy) phenylamine) pyrimidin-4-yl) Intermediate compound H A sealed tube was charged with intermediate A (500 mg, 2.02 mmol) and 3-benzyloxyaniline (404 mg, 2.02 mmol). N-butanol (15 mL) was added to the sealed tube and stirred at 180 ° C. The reaction was done in 1 hour according to LCMS to give intermediate G as a yellow solid. Intermediate G was placed in a rotary evaporator to remove excess n-butanol. Intermediate G was taken to the next step without additional purification. A flask was charged with intermediate G and HBr / acetic acid (33%, 10 mL) and stirred at room temperature overnight. The reaction was made and the solid was collected by filtration and washed with ether to give the intermediate compound H as a solid of the HBr salt and yellow (800 mg, 1.66 mmol, 82% yield). A flask was charged with intermediate H (250 mg, 0.52 mmol), DMF (15 mL), Cs2CO3 (847 mg, 2.6 mmol) and HC1 salt of 4- (3-chloropropyl) morpholine (135 mg, 0.676 mmol. , purchased from Apin Chemicals, Ltd.) and stirred at 80 ° C overnight. The reaction mixture has about 85% of the desired product and 15% bis-alkylated by-product. The solid was filtered and washed with ethyl acetate and discarded. The filtrate was concentrated using the rotary evaporator. The final product was purified using preparative HPLC and TFA buffer, free base was made, converted to HCl salt and lyophilized to give the product (115 mg, 0.237 mmol, 46% yield). NMR'H (400MHZ, DMSO): 11,058 (s, 1H), 10,403 (s, 1H), 9,761 (s, 1H), 8,532 (d, 1H), 8,158 (d, 2H), 7.81 (d, 2H) , 7.677 (s, 1H), 7.4-7.345 (m, 2H), 7.231 (t, 1H), 6,569 (m, 1H), 4,081 (t, 2H), 3,962 (m, 2H), 3.82 (t, 2H) ), 3.46 (m, 2H), 3.267 (m, 2H), 3.123 (m, 2H), 2.254 (m, 2H), 2.104 (s, 3H). MS (El) for C25H29N503: 448.3 (MH +).

Example 34 N- (4-. {2- 2- (2-methyl-4-piperazin-1-ylphenyl) amino] pyrimidin-4-yl-acetamide (Compound 35): A flask was charged with 5-fluoro-2-nitrotoluene (1 mL, 8.2 mmol), DMF (15 mL), Bocpiperazine (1.68 g, 9.02 mmol), and K2C03 (2.27 g, 16.4 mmol). The reaction mixture was stirred at 50 ° C for about 25 hours. The reaction was quenched with H20 and the solid was precipitated from the solution and collected by filtration and washed with excess H20 to obtain intermediate I (1765 g, 5.4 mmol). Intermediate I was taken to the next step without further purification. A flask was charged with intermediate I (290 mg, 0.9 mmol), ethanol (18 mL), ammonium formate (340 mg, 5.4 mmol) and Pt / S (10.2 mg, 0.04 mmol). The reaction mixture was stirred at 70 ° C for 3 hours and 78 ° C for 4 hours. The reaction mixture was filtered through celite and washed with ethanol. The filtrate was removed using the rotary evaporator and then treated with acetate of ethyl and washed with H20, dried over sodium sulfate, and filtered. The ethyl acetate layer was concentrated using the rotary evaporator to give intermediate J. A sealed tube was charged with intermediate A (200 mg, 0.81 mmol), and intermediate J (235 mg, 0.81 mmol). N-butanol (15 mL) was added to the sealed tube and stirred at 180 ° C. The reaction was done in 1 hour and concentrated to remove the excess n-butanol and then treated with 4N HCl / dioxane. The reaction mixture was stirred at room temperature for 1 hour to give the final product 35. The final product was purified using preparative HPLC and ammonium acetate buffer, then made free base and lyophilized (90 mg, 0.22 mmol, 27 % of performance). NMR'H (400MHZ, d6-DMSO): 10.31 ppm (s, 1H), 8.569 ppm (s, 1H), 8.323 ppm (d, 1H), 8.022 ppm (d, 2H), 7.715 ppm (d, 2H) , 7,271 ppm (d, 1H), 7,186 ppm (d, 1H), 6.8 ppm (m, 2H), 3,023 ppm (t, 4H), 2,844 ppm (t, 4H), 2,175 ppm (s, 3H), 2,077 ppm (s, 3H), 1605 ppm (s, 2H); MS (El) for C 23 H 26 N 60: 403.1 (MH +).

Example 35 N- [4- ( {2 - [(4-morpholin-4-ylphenyl) amino] -7H-pyrrol [2,3-d] pyrimidin-4-yl} amino) -phenyl] acetamide (Compound 306) A flask was charged with methyl sulfide (2.1 g, 11.6 mmol) and THF (50 mL). To this was added m-CPBA (7.9 g, 46 mmol) and the mixture was stirred at room temperature for 20 hours. The volatiles were removed under vacuum. The crude mixture was partitioned between EtOAc and DI-H20. The aqueous layer was extracted with EtOAc (3 x 15 mL). The combined organics were washed with 1N NaHC03 (x2), DI-H20 (x2), brine, (xl), dried over sodium sulfate, filtered and concentrated in vacuo. The product (1.8 g, 75%) was used without further purification. LCMS: m / z 214 (M + H) +.

A pressure tube was charged with methylsulfone (1.15 g, 5.4 mmol) and aniline (2.8, 16.2 mmol). The tube was sealed and the mixture was heated at 140 ° C for 30 minutes. The mixture was cooled. Methanol was added and the resulting solid was collected by filtration then washed with methanol. The product (270 mg, 8.7%) was used without further purification. LCMS: 312 (M + H) +.

A flask was charged with pyrrolopyrimidinone (250 mg, 0.8 mmol) and toluene (5 mL). Phosphorus oxychloride (218 μl, 2.41 mmol) and DIPEA (165 μL, 0.96 mmol) were added and the mixture was stirred at 110 ° C for 6 hours. The volatiles were removed under vacuum and the product was used without further purification. LCMS: 330 (M + H) +.

One flask was charged with pyrrolopyrimidine (100 mg, 0. 3 mmol) and isopropanol (1 mL). Aniline (55 mg, 0.36 mmol) and two drops of concentrated HCl were added and the mixture was heated to reflux for 6 hours. The volatiles were removed under vacuum. The product was purified by preparative HPLC to give the title compound (306) (12.8 mg, 9.6%). RMIS ^ H (400MHz, d6-DMSO): 11.13 (s, 1H), 9.95 (s, 1H), 9.04 (s, 1H), 8.56 (s, 1H), 7.86 (d, 2H), 7.66 (d, 2H), 7.54 (d, 2H), 6.88-6.82 (m, 3H), 6.65-6.61 (m, 1H), 3.78-3.71 (m, 4H), 3.05-2.99 (m, 4H), 2.04 (s, 3H). MS (El) for C24H25N702: 444 (MH +) Example 36 (N- (4- {2- [(3- {[[2,6-dichlorophenyl) sulfonyl] amino} phenyl) amino] -5-methylpyrimidin-4-yl} phenyl Acetamide) (Compound 26) gave 1 To a mixture of 2,4-dichloro-5-methylpyrimidine (4.17 g, 25.6 mmol) and 4-acetamidophenylboronic acid (5.0 g, 27.9 mmol) in DME (40 mL) was added Et3N (8.92 inL, 64.0 mmol), H20 (4 mL), and dichloro [1,1-bis (diphenylphosphino) ferrocenepalladium (2.81 g, 3.44 mmol, 13%). The mixture was allowed to stir at reflux for 5 hours. After the mixture was cooled to room temperature, the crude mixture was filtered directly on silica gel and eluted with EtOAc. The filtrate was concentrated in vacuo. The further purification was carried out by flash chromatography to give intermediate 1 (5.94 g, 89%) as a white solid. LCMS: m / z 262 (M + H) +.

To a stirred solution of chloropyrimidine (1.05 g, 4.0 mmol) in 1-butanol (10 mL) was added N-Boc-amino-3-aniline (920 mg, 4.4 mmol) and the mixture was heated in the sealed tube to 180 ° C for 1.5 hours. The mixture was cooled to room temperature and acidified with 1N HCl (20 mL). The aqueous layer was washed with EtOAc (50 mL). The separated aqueous layer was basified with 2N NaOH to pH 8-9 and extracted with EtOAc (50 mL * 3). The combined organic layer was washed over Na 2 SO 4, concentrated in vacuo, and purified by flash chromatography to give the product, intermediate K (943 mg, 71% as a light yellow solid LCMS: m / z 334 (M + H) +.

To a stirred suspension of aniline (250 mg, 0.75 mmol) in THF (5 mL) was added DIPEA (157 mL, 0.90 mmol) and 2,6-dichlorobenzenesulfonyl chloride (203 mg, 0.83 mmol) and the mixture containing intermediate K was stirred at reflux for 2 hours. After cooling to room temperature, the mixture was diluted with EtOAc, washed with H20, brine and dried over Na2SO4. After being concentrated in vacuo, the residue was purified by flash chromatography to give product 26 (299 mg, 73%) as a light pink solid. NMR'H (400MHz, d6-DMSO): 10.71 (s, 1H), 10.16 (s, 1H), 9.54 (s, 1H), 8.34 (s, 1H), 7.75-7.69 (m, 5H), 7.60 ( dd, 2H), 7. 51 (dd, 1H), 7.31 (dd, 1H), 7.09 (t, 1H), 6.66 (dd, 1H), 2.25 (s, 3H), 2.08 (s, 3H); MS (El) for C25H21C12N503S: 542.2 (MH +).

Example 37 N- (4-. {6-morpholin-4-yl-2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) acetamide (Compound 47) Intermediate compound L The mixture of 2,4,6-trichloropyrimidine (1.72 mL, mmol), 4-acetamidophenyl-boronic acid (1.79 g, 10 mmol) DME (20 mL) was added in Et3N (3.5 mL, 25.0 mmol), H20 (2 mL), and dichloro [1,1-bis (diphenylphosphino) ferrocenepalladium (1.22 g, 1.5 mmol, 15%). The mixture was allowed to stir at reflux for 2 hours. After the mixture was cooled to room temperature, the crude mixture was filtered directly on silica gel and eluted with EtOAc. The filtrate was concentrated in vacuo. The further purification was carried out by flash chromatography to give intermediate L (1.91 g, 68%) as a white solid. LCMS: m / z 282 (M + H) +.

Intermediate compound To a stirred suspension of pyrimidine (282 mg, 1.0 mmol) in 1-butanol (5 mL) was added morpholine (96 mL, 1.10 mmol) and DIPEA (209 μ ?, 1.2 mmol). The mixture was heated at 120 ° C for 1 hour, cooled to room temperature, and concentrated in vacuo. The residue was purified by flash chromatography to give intermediate M (176 mg, 53%) as well as the isomer (108 mg, 32%). LCMS: m / z 333 (M + H) +.

The mixture of chloropyrimidine (176 mg, 0.53 mmol) and 4-morpholinoaniline (104 mg, 0.58 mmol) in 1-butanol (5 ml) was heated in the sealed tube at 160 ° C for 3 hours. The reaction mixture was cooled to room temperature and the crude mixture was directly subjected on silica gel to give the product 47 (122 mg, 49%) as a pale pink solid. LCMS: m / z 475 (M + H) +. NMR'H (400MHZ, d6-DMSO): 10.13 (s, 1H), 8.87 (s, 1H), 8.07 (d, 2H), 7.70-7.64 (m, 4H), 6.90 (d, 2H), 6.71 ( d, 1H), 3. 74-3.68 (m, 12H), 3.03 (t, 4H), 2.08 (s, 3H); MS (El) for C 26 H 30 N 6 O 3: 475 (MH +).

Example 38 N- [6- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) pyridine- 2-yl] -2,6-dichloro-benzamide (Compound 299) To a mixture of 2,6-diaminopyridine A (9.2 mmol, 1.0 g), and diisopropylethylamine (6.9 mmol, 1.2 mL) in 20 mL of THF, 2,6-dichlorobenzoyl B chloride (4.6 mmol, 0.67 mL) was added. drop by drop. The mixture was stirred at room temperature for 1 hour and LCMS indicated that it was carried out (M + H: 283). THF was removed and replaced with ethyl acetate. The reaction mixture was then extracted with water, brine, and dried over sodium sulfate. The product, C, was isolated by removal of the solvent with a rotary evaporator and used without further purification. LCMS: 283 (M + H). 299 A sealed tube was charged with the intermediate compound Ax (0.2 g, 0.81 mmol), compound C from the previous step (0.56 g, 2.0 mmol), tris (dibenzylideneacetone) dipalladium (0) (0.15 g, 0.16 mmol), 2, 2 '-bis (diphenylphosphino) -1, 11 racemic binaphthyl (0.12 g, 0.2 mmol), cesium carbonate (0.4 g, 1.22 mmol). Dimethylacetamide (10 mL) was added and the mixture was purged with N2 for 5 minutes. The tube it was sealed and the reaction mixture was stirred at 80 ° C overnight. LCMS showed that the reaction was performed (M + H: 493). The reaction mixture was partitioned between ethyl acetate and water, the organic layer was extracted with 10% LiCl solution, followed by brine, dried over Na2SO4, and then evaporated. The crude product 299 was then purified by preparative HPLC. NMR'H (400MHZ, d6-DMSO): 11.12 (s, 1H), 10.25 (s, 1H), 9.43 (s, 1H), 8.58 (d, 1H), 8.2-8.13 (m, 3H), 7.9 ( t, 1H), 7.83 (d, 1H), 7.78 (d, 2H), 7.55 (d, 2H), 7.52-7.45 (m, 2H), 2.1 (s, 3H). MS (El) for C24H18C12N602: 493 (MH +).

Example 39 N- (3- (4- (4-Acetamidophenyl) pyrimidin-2-ylamino) phenyl) -3- (2-morpholinoethoxy) -benzamide (Compound 123) A flask was charged with 2,4-dichloropyrimidine (22.7 g, 152.38 mmol), 4-acetoamido-phenyl boronic acid (30.0 g, 167.62 mmol), dichloro [1,1-bis (diphenylphosphino) -ferrocene-palladium (16,726 g. , 22.86 mmol, 15 mol%), and triethylamine (53 mL, 380.95 mmol). Ethylene glycol dimethyl ether (500 mL) and H20 (20 mL) were added to the flask. The reaction mixture was stirred at 80 ° C for 4 hours. The product, intermediate Compound A, was isolated by solvent removal with a rotary evaporator and purified using glass column chromatography and eluted with ethyl acetate to give 30.5 g (123.14 mmol, 81% yield) of the intermediate compound A as a yellow solid.

A sealed tube was charged with intermediate A (400 mg, 1.62 mmol) and 3- (tert-butoxycarbonylamino) aniline (1.99 g, 9.57 mmol). N-butanol (50 mL) was added to the sealed tube and stirred at 180 ° C. The reaction was stopped after 2.5 hours, monitored by LCMS. The reaction mixture was diluted with methanol and the solid precipitate was filtered to give intermediate B as a yellow solid. The filter pad was washed with ethyl acetate, 72% yield. Intermediate B was taken to the next step without further purification. A flask was charged with intermediate B (159 mg, 0.5 mmol), 3- (2-morpholinoethoxy) benzoyl chloride (169 mg, 0.63 mmol), and pyridine (8 mL). The reaction mixture was stirred at room temperature under nitrogen. The reaction was complete after 1 hour. The final product 123 was purified using preparative HPLC and trifluoroacetic acid buffer then free base was made with hydroxide resin in methanol. The filtrate was then concentrated, the yellow oil was then frozen and lyophilized. RMNXH (400MHz, d6-DMSO): 10206 (s, br, 2H), 9.665 (s, br, 1H), 8.512 (d, 1H), 8.502 (s, 1H), 8.440 (d, 2H), 7.755 ( d, 2H), 7,582 (m, 2H), 7,483 (m, 2H), 7,375 (d, 1H), 7,287 (m, 2H), 7,163 (d, 1H), 4,188 (m, 2H), 3,595 (m , 4H), 3.174 (m, 4H), 2.732 (m, 2H), 2.083 (s, 3H). MS (El) for C 31 H 32 N 604: 553 (MH +).

Example 40 4- [4- (Methylamino) phenyl] -N- (4-morpholin-4-ylphenyl) pyrimidin-2-amine (Compound 124) A, B C A flask was charged with 2,4-dichloropyrimidine (810 mg, 5.5 mmol), 4- (tert-butoxycarbonyl (methyl) amino) phenylboronic acid B (4.93 g, 15 mmol), dichloro [1,1 '-bis (diphenylphosphino] ) ferrocenpaladium (590 mg, 0.81 mmol, 15 mol%), triethylamine (1.8 mL, 13 mmol), and water (2 mL). Ethylene glycol dimethyl ether (5.0 mL) was added to the flask and the mixture was purged with N2. The reaction mixture was stirred under an N2 atmosphere at 90 ° C for 1 hour, after which time it was cooled to room temperature and filtered. The product, C, was isolated by removal of the solvent with a rotary evaporator and used without further purification. LCMS: m / z 319 (M + H) \ C 124 A flask containing a solution of C (1.9 g, . 8 mmol) and 4-morpholinoaniline (1.5 g, 8.2 mmol) in 1-butanol (10 mL) was immersed in an oil bath at 180 ° C for 4 hours. The mixture was cooled to room temperature, concentrated, and the residue was dissolved in dichloromethane (10 mL) and 4N HCl in dioxane (10 mL). A portion of this crude product (200 mg) was purified by reverse phase HPLC to yield product 124 (20 mg) in > 99% purity. NMR'H (400MHz, d6-DMSO): 9.92-9.99 ppm (bs, 1H), 8.20-8.29 (bs, 1H), 8.02 (d, 2H), 7.52-7.68 (bs, 2H), 7.33 (d, 1H), 7.04-7.17 (bs, 1H), 6.67 (d, 2H), 3.71-3.82 (bs, 4H), 3.14-3.24 (bs, 4H) 2.78 (s, 3H). MS (El) for C21H23NS0: 362.1 (MH +).

Example 41 2, 6-Dichloro-N-. { 3 - [(4 - { [3-chloro-4 - (methyloxy) phenyl] oxy} pyrimidin-2-yl) amino] phenyl} -benzamide (Compound 304) B A flask was charged with 2,4-dichloropyrimidine (500 mg, 3.4 mmol), 2-chloro-4-methoxyphenol (580 mg, 3.7 mmol), and diisopropylethylamine (1.2 mL, 6.9 mmol). Dimethylformamide (20 mL) was added to the flask and the mixture was stirred at 70 ° C for 15 hours. The reaction mixture was diluted with water and the mixture extracted with 2X dichloromethane and 3% LiCl 3X. The crude product, B, was isolated by removal of the solvent with a rotary evaporator and the resulting brown oil was used without further purification. LCMS: m / z 272 A flask containing a solution of intermediate B (910 mg, 3.4 mmol) and benzene-1,3-diamine (540 mg, 5.0 mmol) in nBuOH (5 mL) was immersed in an oil bath at 180 ° C for 30 minutes. The intermediate compound, C, was isolated by removal of the solvent with a rotary evaporator and used without further purification. LCMS: m / z 343 (M + H) +.

A flask was charged with intermediate C (1.1 g, 3.4 mmol), 2,6-dichlorobenzoyl chloride (1.2 mL, 8.3 mmol), diisopropylethylamine (1.8 mL, 10 mmol) and THF (50 mL). The reaction mixture was stirred at 60 ° C for 15 hours. The reaction mixture was diluted with ethyl acetate, extracted with 5% LiCl 3X, and the organic fraction was concentrated on a rotary evaporator. The crude product was purified by silica column chromatography (ethyl acetate: hexanes 1: 1 as eluent) followed by reverse phase HPLC (TFA / ACN as eluent) to yield the product, 304 (24 mg, 1% yield). ). RM ^ H (400MHz, d6-DMSO): 10.7 (s, 1H), 9.65 (s, 1H), 8.36 (d, 1H), 7.77 (s, 1H), 7.58-7.47 (m, 3H), 7.36- 7.28 (m, 3H), 7.23 (d, 1H), 7.04-6.98 (m, 2H), 6.47 (d, 1H), 3.83 (s, 3H). MS (El) for C24H17C13N403: 514.8 (MH-).

Example 42 (3S) -1- (2-hydroxyethyl) -N- (4- { 2- [(4-morpholin-4-phenyl) amino] pyrimidin-4-yl} phenyl) pyrrolidine-3 - carboxamide (Compound 510) 249 (a) To a solution of 249 (a) (300 mg, 0.78 mmol) in DMA (10 mL) was added a solution of (S) -1- (tert-butoxycarbonyl) irrolidine-3-carboxylic acid (350 g, 1.6 mmol) , diisopropyl-ethylamine (0.5 mL, 2.7 mmol), and HATU (600 mg, 1.6 mmol) in DMA (10 mL) and the solution was stirred at room temperature for 15 hours. The solution was diluted with ethyl acetate (100 mL), washed with 10% LiCl (2X) and brine. The resulting solution was dried over Na 2 SO 4, filtered and concentrated to yield a residue which was purified by silica gel column chromatography (ethyl acetate / hexanes 3: 1). The intermediate compound Boc was isolated as a solid (340 mg, 78% yield). LC / MS: m / z 545 (M + H) +. A flask containing the Boc-intermediate compound was dissolved in 4N HC1 in dioxane (10 mL) and dichloromethane (10 mL) and the mixture was stirred at room temperature for 15 hours. Intermediate C was isolated as a yellow solid after filtration and used without purification.

A flask was charged with intermediate C (450 mg, 0.78 mmol), 2-hydroxy-acetaldehyde (45 mg, 0.75 mmol), sodium triacetoxyborohydride (150 mg, 0.71 mmol), diisopropylethylamine (0.7 mL, 3.8 mmol) and dichloromethane (20 mL) and the mixture stirred at room temperature for 4 hours. The reaction mixture was diluted with water and the solution extracted with saturated NaHC03 (2X) and brine. The residue was purified by reverse phase HPLC (ammonium acetate / ACN as eluent) to give product 510 (120 mg, 31% yield). NMR'H (400MHz, d6-DMSO): 10.2 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.75 (d, 2H), 7.67 (d, 2H), 7.28-7.27 (m, 1H), 6.93 (d, 2H), 4.47 (br, 1H), 3.76-3.73 (m, 4H), 3.49 (t, 2H), 3.06-3.03 (m, 4H) , 2.91 (t, 1H), 2.70-2.65 (m, 1H), 2.58-2.56 (m, 1H), 2.54-2.49 (m, 4H), 1.99 (t, 2H). MS (El) for C27H32N603: 489.2 (MH +).

Example 43 N- (4 -. {2 - [(4-morpholin-4-ylphenyl) amino] -7H-pyrrol [2,3-d] pyrimidin-4-yl} phenyl) acetamide (Compound 329) A B A mixture of 2- [(4-morpholin-4-ylphenyl) amino] 3,7-dihydro-4 H -pyrrol [2,3-d] pyrimidin-4 -one A (312 mg, 1 mmol), Phosphorous oxybromide (717 mg, 2.5 mmol), and diisopropylethylamine (130 mg, 1 mmol) in anhydrous toluene (15 mL) was heated to reflux under N2 overnight. The mixture was cooled to room temperature, and the solid was filtered, washed with saturated NaHCO3, water, and dried over MgSO4. The solvent was removed in vacuo to give the product 4-bromo-N- (4-morpholin-4-ylphenyl) -7H-pyrrol [2,3-d] pyrimidin-2-amino B (284 mg, 76%) as a solid black. This was cleaned and used as such without further purification.

A mixture of 4-bromo-N- (4-morpholin-4-ylphenyl) -7H-pyrrole [2, 3-d] pyrimidin-2-amine B (284 mg, 0.76 mmol), 4-acetoamidophenylboronic acid C (340 mg, 2.5 eq), tetrakis (triphenyl-phosphine) palladium (0) (120 mg, 0.1 mmol), and 1M Na 2 CO 3 (1 mL, 1 mmol) in 1,4-dioxane (15 mL) was heated to reflux during the night. The mixture was cooled and extracted with 3N HC1. The aqueous layer was washed with ethyl acetate, and then basified with 6N NaOH. The solid was filtered, and the crude product was purified by preparative HPLC to give the product N- (4 -. {2 - [(4-morpholin-4-ylphenyl) amino] -7H-pyrrole [2, 3-d ] pyrimidin-4-yl.}. phenyl) acetamide D (0.8 mg, 0.25%) as a solid yellow. NMR'H (400MHZ, CD3OD): 8.10 (d, 2H), 7.75 (d, 2H), 7.68 (d, 2H), 7.12 (d, 1H), 6.98 (d, 2H), 6.70 (d, 1H) , 3.85 (t, 4H), 3.09 (t, 4H), 2.17 (s, 3H). MS (El) for C24H24N602: 429 (MH +).

Example 44 2-methyl-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) prolinamide (Compound 367) room temperature, A 50 ml round bottom flask, oven dried, equipped with a Teflon stirrer and gas inlets was rinsed with dry nitrogen and allowed to dry at room temperature. The flask was charged with 4- (4-aminophenyl) -N- (4-morpholinophenyl) pyrimidin-2-amine pentachlorohydrate (1 equivalent, 0.52 g, 0.9631 mmol) and anhydrous dimethylacetamide (15 mL). The mixture was stirred for 10 minutes to allow the complete dissolution of the amine. Diisopropylethylamine (10 equivalents, 1.24 g, 1.67 ml, 9.631 mmol) was added in one batch and the reaction mixture was stirred for 5 minutes. 1- (Tert-butoxycarbonyl) -2-methylpyrrolidine-2-carboxylic acid (4 equivalent, 3.852 mmol, 0.883 g, purchased from Fluka-Sigma Aldrich) was added to the reaction mixture in one batch, followed by 2-hexafluorophosphate. (7-aza-lH-benzotriazol-1-yl) -1,1,3, 3-tetramethyluronium (HATU, 4 equivalents, 3,852 mmoles, 1464 g, purchased from Oakland Products). The reaction mixture was stirred at room temperature and the progress of the reaction was monitored by LC / MS. After 72 hours, the reaction mixture was quenched with ethyl acetate (20 mL), transferred to a separatory funnel. The reaction flask was further rinsed with ethyl acetate (20 mL), transferred to the separatory funnel, it was stirred and the layer separated. The aqueous layer was further washed with ethyl acetate (3 x 50 mL). The combined ethyl acetate solutions were washed with cold water (2 x 50 mL) and saturated sodium chloride solution (2 x 50 mL). The ethyl acetate solution was dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure to give orange oil. The resulting crude material was purified by silica phase flash chromatography (45 mm x 250 mm) using 3: 1 ethyl acetate-hexane to give 0.147 g of 2- methyl-2- (4- (2- (4-morpholinophenylamino) irimidin-4-yl) phenylcarbamoyl) -pyrrolidine-1-tert-butyl carboxylate as a white solid (27% yield). RMN1 !! (400MHz, d6-DMSO) 10.01 (br s, 1H), 9.45 (br s, 1H), 8.19 (d, 1H), 7.70 (d, 2H), 7.46 (d, 2H), 6.74 (d, 1H) , 6.66 (d, 2H), 6.28 (d, 2H), 3.67 (m, 4H), 3.40 (m, 1H), 3.30 (m, 1H), 2.29 (m, 4H), 1.76 (m, 1H), 1.64 (m, 1H), 1.58 (s, 3H), 1.54 (m, 1H), 1.40 (s, 9H). MS (El) for C 31 H 38 N 604: 559 (M +).

Preparation of 2-methyl-N- (4- {2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) prolinamide 2-Methyl-2- (4- (2- (4-morpholinophenylamino) irimidin-4-yl) phenylcarbamoyl) pyrrolidine-1-tert-butyl carboxylate (0.140 g, 0.250 mmol) was dissolved in ethyl acetate (5 mL ) and methanol (1 mL) in mixture. Then 4M hydrogen chloride in 1,4-dioxane (0.625 ml, 2.5 mmol, 10 equivalents, purchased from Sigma-Aldrich) was added dropwise during 5-10. minutes At the end of the addition, the reaction mixture was stirred at room temperature, and the progress of the reaction was monitored by LC / MS. After 16 hours, additional 4M hydrogen chloride in 1,4-dioxane (0.312 mL, 1.25 mmol, 5 equivalents) was added. After a total of 48 hours, the reaction was complete and a resulting slurry was filtered. The reaction flask was rinsed with ethyl acetate to ensure complete transfer of the product. The solid product was washed with ethyl acetate (3 x 10 mL) and diethyl ester (2 x 25 mL) and dried under reduced pressure to give 0.061 mg of 2-methyl-N- (4-. {2- [2- (4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl.} Phenyl) prolinamide 367 in its hydrochloride salt (53% yield). NMR'H (400MHz, d6-DMSO): 10.88 (s, 1H), 9.79 (br s, 1H), 8.47 (d, 1H), 8.12 (d, 1H), 8.10 (d, 1H), 7.80 (br d, 2H), 7.75 (d, 2H), 7.37 (d, 2H), 5.26 (br s, 3H), 3.72 (br s, 4H), 3.27 (br s, 4H), 2.80 (m, 1H), 2.70 (m, 1H), 2.01 (m, 1H), 1.76 (m, 1H), 1.64 (m, 1H), 1.54 (m, 1H), 1.38 (s, 3H). MS (El) for C 26 H 30 N 6 O 2: 459 (MH +).

Example 45 2-methyl-N- (4- {2- [(4-morpholin-4-ylphenyl) amino] -pyrimidin-4-yl} phenyl) prolinamide (Compound 360) . A 50 ml round bottom flask, oven dried, equipped with a Teflon stirrer and gas inlet was rinsed with dry nitrogen and allowed to cool to room temperature. The flask was charged with 4- (4-aminophenyl) -N- (4-morpholinophenyl) pyrimidin-2-amine pentachlorohydrate (1 equivalent, 0.4 g, 0.756 mmol) and anhydrous dimethylacetamide (15 ml). The mixture was stirred for 10 minutes to allow complete dissolution of the amine. Diisopropylethylamine (10 equivalents, 0.977 g, 1.31 ml, 7.561 mmol) was added in one batch and the reaction mixture was stirred for 5 minutes. N-Boc-D-proline (4 equivalents, 3.204 mmol, 0.65 g, purchased from Fluka-Sigma Aldrich) was added to the reaction mixture in one batch, followed by 2- (7-aza-1 H-benzotriazole- 1-yl) -1, 1, 3, 3-tetramethyluronium (HATU, 4 equivalents, 3024 mmol, 1149 g, purchased from Oakland Products). The mixture of The reaction was stirred at room temperature and the reaction progress was monitored by LC / MS. After 72 hours, the reaction mixture was quenched with ethyl acetate (20 mL), and transferred to a separatory funnel. The reaction flask was further rinsed with ethyl acetate (20 mL), transferred to the separatory funnel, stirred and the layer separated. The aqueous layer was further washed with ethyl acetate (3 x 50 mL). The combined ethyl acetate solutions were washed with chloride solution (2 x 50 mL). The ethyl acetate solution was dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure to give an orange oil. The resulting crude material was purified by silica phase flash chromatography (45 mm x 250 mm) using 3: 1 ethyl acetate-hexane to give 0.39 g of (2R) -2-. { [(4- {2- [4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) amino] carbonyl} 1,1-dimethylethyl pyrrolidine-1-carboxylate as a white solid (94% yield). NMR'H (400MHZ, d6-DMSO): 10.26 (br s, 1H), 9.38 (br s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.78 (d, 2H) < 7.68 (d, 2H), 7.28 (d, 1H), 6.94 (d, 2H), 4.22 (m, 1H), 3.74 (m, 4H), 3.43 (m, 1H), 3.34 (m, 1H), 3.04 (m, 4H), 2.20 (m, 1H), 1.90 (m, 1H), 1.81 (m, 1H) < 1.40 (s, 3H), 1.27 (s, 6H). MS (El) for C 30 H 36 N 6 O 4: 545 (MH +).

It was dissolved (2R) -2-. { [(4- {2- [4-morpholin-4-ylphenyl) amino] irimidin-4-yl} -phenyl) amino] carbonyl} 1, 1-dimethylethyl pyrrolidine-l-carboxylate (0.38 g, 0.698 mmol) in a mixture of ethyl acetate (10 mL) and methanol (2 mL). Then 4M hydrogen chloride in 1,4-dioxane (1.75 ml, 6.98 mmol, 10 equivalents, purchased from Sigma-Aldrich) was added dropwise for 5-10 minutes. At the end of the addition, the reaction mixture was stirred at room temperature, and the reaction progress was monitored by LC / MS. After 16 hours, additional 4M hydrogen chloride in 1,4-dioxane (0.87, 1.25 mmol, 5 equivalents) was added. After a total of 48 hours, the reaction was complete and the resulting slurry was completely filtered. The reaction flask was rinsed with ethyl acetate to ensure complete transfer of the product. The resulting solid was washed with ethyl acetate (3 x 10 mL), followed by diethyl ether (3 x 25 mL) and dried under reduced pressure to give 0.264 mg of 2-methyl- N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] -pyrimidin-4-yl.} Phenyl) rolinamide (68% yield). R ^ H (400MHz, d6-DMS0): 11.43 (br s, 1H), 10.07 (br s, 2H), 8.73 (d, 1H), 8.57 (d, 1H), 8.21 (d, 2H), 7.91 ( d, 2H), 7.98 (d, 2H), 7.71 (br s, 2H), 7.48 (d, 1H), 4.48 (m, 1H), 4.08 (s, 4H), 3.74 (m, 4H), 3.42 ( m, 1H), 3.36 (m, 1H), 3.04 (m, 1H), 2.22 (m, 1H), 1.90 (m, 2H), 1.82 (m, 2H). MS (El) for C25H28N602: 445 (MH +).

EXAMPLE 46 3- ( { 4- [4- (Acetylamino) phenyl] pyrimidin-2-yl}. Amino) -N - [(1-methyl-lH-benzimidazol-2-yl) methyl] benzamide (Compound 83) 7.9 grams (11.04 mmol, 1.9 eq) of PL-TFP resin were weighed in a pressure tube (source: Polymer Laboratories). 60 ml of DCM were added. 2 g (5.74 mmol) of 3- (4 - (3-acetamidophenyl) pyrimidin-2-ylamino) benzoic acid were dissolved in 15 ml of DMF and after 10 minutes, this solution was added to the pressure tube. Dimethylaminopyridine (4.41 mmol, .6 eq, source: Acros) was added to the Pressure tube as a solid, followed by 1,3-diisopropylcarbodiimide (33.08 mmol, 4.5 eq, source: Acros). The pressure tube was sealed and the reaction was placed on a vertical shaker overnight. The resin was filtered, and then washed three times with DMF, followed by three times with THF, followed by three times with DCM. The resin was then dried overnight under vacuum. 300 mg of resin prepared above (loading = 0.6 mmol / g, 0.18 mmol) were added to a jar of 1 dram. 2 ml of DMA were added. 1 ml of (1-methyl-lH-benzo [d] imidazol-2-yl) methanamine (0.12 mmol, 0.67 eq) dissolved in DMA was added to the flask. The reaction was stirred overnight at room temperature. The reaction was filtered and rinsed twice with 4 ml of MeOH. The solution was further purified by HPLC to yield (3- (4- (4-acetamidophenyl) pyrimidin-2-ylamino) -N- ((1-methyl-lH-benzo [d] imidazol-2-yl) methyl) benzamide 83 (10.2 mg, 17%). RMN'H (400MHz, d6-DMSO): 10.23 (s, 1H), 9.80 (s, 1H), 9.01 (t, 1H), 8.52 (t, 2H), 8.17- 8.19 (m, 2H), 7.91-7.93 (m, 1H), 7.75 (d, 2H), 7.50-7.59 (m, 3H), 7.39-7.43 (m, 2H), 7.16-7.26 (m, 2H), 4.80 (d, 2H), 3.86 (s, 3H), 2.10 (s, 3H), MS (El) for C28H25N702: 482.4 (MH +).

Example 47 N- (4-morpholin-4-ylphenyl) -4- [(propylamino) methyl] fe A flask was charged with 2,4-dichloropyrimindine (1.5 g, 10 mmol), 4-formylphenyl boronic acid (1.65 g, 11 mmol), dichloro [1,1-bis (diphenylphosphino) -ferrocenepalladium (731 mg, 1 mg). mmol, 10 mol%), and triethylamine (2.6 mL, 15 mmol). Ethylene glycol dimethyl ether (50 mL) and H20 (2 mL) were added to the flask. The reaction mixture was stirred at 80 ° C for 4 hours. The product, intermediate A, was isolated by removal of the solvent with a rotary evaporator and purified using glass column chromatography and eluted with ethyl acetate to give 1.0 g (4.58 mmol, 46% yield) of the intermediate A as a solid yellow . A flask was charged with intermediate A (150 mg, 0.668 mmol), sodium triacetoxy borohydride (220 mg, 1032 mmol), propylamine (63 μ ?, 0.756 mmol). Dichloromethane (50 mL) was added to the flask and the reaction mixture was stirred at room temperature for 48 hours. The reaction was quenched with 2N NaOH and extracted with ethyl acetate, washed with brine, dried over sodium sulfate, and filtered. The solvent was removed using the rotary evaporator to give intermediate B as a yellow solid (140 mg, 0.536 mmol, 80% yield). Intermediate B was carried without further purification. A sealed tube was charged with intermediate B (140 mg, 0.536 mmol) and 4 -mofolinoaniline (95 mg, 0.536 mmol). N-Butanol (15 mL) was added to the sealed tube and stirred at 180 ° C. The reaction was done in one hour according to LC S to give 283 as a yellow solid. Compound 283 was purified using preparative HPLC and TFA buffer. Compound 283 was made free base, converted to HCl salt, and lyophilized (20 mg, 0.455 mmol). NMR'H (400MHZ, DMSO): 9.93 (br s, 1H), 9.396 (br s, 2H), 8.607 (d, 1H), 8.233 (d, 2H), 7.905 (d, 2H), 7.767 (d, 2H), 7,571-7,494 (m, 3H), 4,226 (brs, 2H), 3,998 (brs, 4H), 3,436 (brs, 4H), 2,865 (m, 2H), 1,708 (m, 2H), 0.914 3H). MS (El) for C24H29N50: 404.4 (MH +) Example 48 N- [(4 - {2 - [(4-morpholin-4-phenyl) amino] pyrimidin-4-yl} phenyl) methyl] acetamide (Compound 282) Compound A 282 In a 20 ml round bottom flask, 36 mg (1 mmol) of compound A was dissolved in 5 ml of dichloromethane and 0.5 ml of triethylamine was added. This was cooled in an ice bath and 10 mg (1.2 mmol) of acetyl chloride was added and stirred. Compound 282 was precipitated and purified on a Waters preparative column. Yield 40 mg (90). RM ^ H (400MHz, CD3CN): 11.20-11.22 (b, 1H), 8.40 (d, 2H), 8.05 (d, 2H), 7.80 (d, 2H), 7.50 (d, 2H), 7.45 (s, 1H), 7.20 (d, 1H), 7.05-7.10 (b, 1H), 4.40-4.44 (b, 2H), 3.90 (t, 4H), 3.40 (t, 4H), 2.01 (s, 3H); MS (El) for C23H25N502: 404 (MH +).

Example 49 N- (4- {2 - [(4- {4 - [(2,4-dichlorophenyl) methyl] piperazin-1-yl} phenyl) amino] pyrimidin-4-yl} phenyl) acetamide (Compound 180) To a 1 ml flask was added N- (4-. {2 - [(4-piperazin-1-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) acetamide (38.85 mg, 0.1 mmol), 2,4-dichlorobenzaldehyde (350 mg, 2.0 mmol, 20 eq, source: Aldrich) and 1 mL of DMF. To this mixture was added sodium triacetoxyborohydride (106 mg, 0.5 mmol, 5 eq). The mixture was stirred overnight at room temperature. At the end of the reaction as determined by the LC / MS, 0.1 ml of 2M HCl was added. The residue was purified by reverse phase HPLC (ammonium acetate / ACN) to yield N- (4-. {2 - [(4- {4 - [(2,4-dichlorophenyl) methyl] piperazine-1 -yl.}. phenyl) amino] pyrimidin-4-yl.} phenyl) acetamide 180 (20.2 mg, 37%). NMR'H (400MHZ, d6-DMSO): 10.21 (s, 1H), 9.80 (s, 1H), 9.10 (t, 1H), 8.53 (d, 2H), 8.18 (d, 2H), 7.94-7.91 ( m, 1H), 7.75 (d, 1H), 7.69-7.57 (m, 4H), 7.48-7.39 (m, 2H), 4.58 (d, 6H), 2.50 (m, 4H), 2.09 (s, 3H) . MS (El) for C29H28C12N60: 548.5 (MH +).

Example 50 5-Fluoro-N ~ 4- [2- (methyloxy) phenyl] -N ~ 2- [3- (methyloxy) phenyl] pyrimidine-2,4-diamine (Compound 306) 306 A round bottom flask was charged with 2,4-dichloro-5-fluoropyrimidine (0.84 g, 5 mmol), 2-methoxylaniline (0.61 g, 5 mmol) and dioxane (5 mL). The reaction mixture was heated at 85 ° C overnight. The reaction was cooled and diluted with acetonitrile / water, stirred for 30 minutes and filtered. The collected solid was resuspended in acetonitrile / water, stirred and filtered to give 2-chloro-5-fluoro-N- (2-methoxyphenyl) pyrimidin-4-amine (0.9 g, 70% yield). To a sealed tube was added 2-chloro-5-fluoro-N- (2-methoxyphenyl) pyrimidin-4-amino (254 mg), 3-methoxyaniline (500 mg, 4 eq) and dioxane (5 mL). The mixture was heated at 130 ° C overnight. The reaction mixture was cooled and partitioned between EtOAc and water. The organic layer was concentrated; the residue was triturated with a 1: 1 mixture of dichloromethane and acetonitrile, then filtered to give the compound of the title as a white solid (150 mg). NMR'H (400MHZ, d6-DMSO): 9.16 (s, 1H), 8.37 (s, 1H), 8.09 (s, 1H), 7.88 (d, 1H), 7.26 (t, 2H), 7.22-7.16 ( m, 2H), 7.12- 7.08 (m, 1H), 7.08-6.93 (m, 2H), 3.81 (s, 3H), 3.62 (s, 3H). MS (El) for C18H17FN402: 341 (MH +).

Example 51 N- (4- {2- [(4-morpholin-4-ylphenyl) amino] -7H-pyrrolo [2,3-d] pyrimidin-4-yl} phenyl) -acetamide (Compound 329 ) 3" 329 To a flask containing a solution of 1 (0.25 g, 1 mmol), 4- (4-ethylpiperazin-1-yl) aniline (0.23 g, 1.1 mmol), cesium carbonate (0.5 g, 1.5 mmol), 2, 2'-bis (diphenylphosphino) -1,1-racemic (95 mg, 0.15 mmol) in N, N-dimethylacetamide (5 mL) purged with N2 was added tris (dibenzylideneacetone) dipalladium (0) (0.14 g, 0.15 mmol). This reaction was heated at 90 ° C for 16 hours under N2. At that time, the reaction was concentrated and the residue was purified by silica gel column chromatography. The column was eluted with ethyl acetate to remove the impurities and then with 85: 10: 5 (ethyl acetate / methanol / 7M ammonia in methanol) to elute the desired product. The solid obtained was treated with ultrasound first in acetone (5 mL) and then in ether (10 mL) to yield intermediate compound 2 (0.23 g, 48% yield) as a yellow solid. LCMS: m / z 417 (MH +). To a flask containing 2 (0.23 g, 0.45 mmol) was added 4N HCl in dioxane (5 mL) and the solution was heated at 50 ° C for 4 hours. To the cooled solution was added the 2N aqueous solution of sodium hydroxide (10 mL) and the resulting precipitate was filtered and dried to yield 3 (0.2 g, 99% yield) as a yellow solid. LCMS: m / z 375 (MH +) +. To a flask with 3 (0.3 g, 0.8 mmol), phenylacetic acid (0.125 mL, 1 mmol), triethylamine (0.97 mL, 7 mmol), and DMF (5 mL) was added 0- (7-azabenzotriazole-1 hexafluorophosphate). -yl) -N, N,, N'-tetramethyluronium (HATU) (0.46 g, 1.2 mmol). The reaction mixture was stirred at room temperature for 1 hour then it was diluted with 5% aqueous solution of lithium chloride (100 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with an aqueous 5% sodium bicarbonate solution, a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate, filtered and concentrated. The obtained residue was purified by silica gel column chromatography (ethyl acetate / methanol 98: 2) to provide Compound 329 (0.25 g, 63% yield) as an off-white solid.

Example 52 N-. { 4- [2- (. {4- [4- (Cyclobutylcarbonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} -D-prolinamide (Compound 662) A solution of chloropyrimidine (1) (0.28 g, 0.64 mmol) and 4- (4-aminophenyl) piperazine-1-tert-butyl carboxylate (0.18 g, 0.6 mmol) in n-butanol (5 mL) was heated to 180 ° C in a sealed tube for 7 hours. The reaction mixture was concentrated, the residue was dissolved in methanol (5 mL) and treated with HCl (3 mL, 4M in dioxane) for 1 hour at room temperature. After concentration, the residue was dissolved in H20 (200 mL) and the pH adjusted to approximately 8-9 with 1N NaOH. The aqueous layer was extracted with CH2C12 (2 x 10 mL) and the combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by column chromatography on silica gel (ethyl acetate / methanol 85:15) to give 2 (0.26 g, 69%). C33H35N703: 578 (MH +). 2. 3 To a solution of 2 (0.41 g, 0.7 mmol) and DIPEA (0.31 mL, 1.75 mmol) in CH2C12 (7 mL) was added cyclobutylcarbonyl chloride (0.80 mL, 0.7 mmol) at room temperature. After 10 minutes, the reaction mixture was diluted with H20 (10 mL) and CH2C12 (10 mL). The aqueous layer was extracted with CH2C12 (3 x 5 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated. The obtained residue was purified by silica gel column chromatography (ethyl acetate / methanol 98: 2) to give 3 (0.31 g, 68%) as a white powder. C, RH41N704: 660 (MH +). 662 The mixture of 3 (0.31 g, 0.47 mmol) and Pd / C (0.94 g) AcOH (1 mL) and MeOH (5 mL) was stirred at room temperature for 24 hours under a balloon of H2. The palladium was filtered through celite and the filtrate was concentrated. The residue was purified by column chromatography on silica gel (ethyl acetate / methanol 90:10) to give the product which was then washed with acetonitrile several times to give compound 662 (0.14 g, 59% yield).

Example 53 N-ethyl-4- [4- (. {4- {4- (D-prolylamino) phenyl] pyrimidin-2-amino) phenyl] piperazine-l-carboxamide (Compound 663) To a stirred solution of 2 (0.58 g, 1 mmol) in DMF (4 mL) was added ethyl isocyanate (3 mL) at room temperature. After stirring for 30 minutes, the mixture was diluted with H20 (5 mL) and CH2C12 (5 mL). The separated aqueous layer was extracted with CH2C12 (3 x 5 mL). The combined extracts were dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (ethyl acetate / methanol 98: 2) to give 4 (0.46 g, 71%) C36H40N8O4: 649 (M + H) +.

A solution of 4 (0.46 g, 0.71 mmol) and Pd / C (0.14 g) in AcOH (1 mL) and MeOH (5 mL) was stirred for 24 hours under a balloon of H2. The palladium was filtered through celite and the filtrate was concentrated. The obtained residue was purified by silica gel column chromatography (ethyl acetate / methanol 90:10) to give the product which was then washed with acetanitrile several times to give N-ethyl-4- [4- ( { 4- [4- (D-prolylamino) phenyl] pyrimidin-2-yl} amino) phenyl] piperazine-l-carboxamide (663) (0.19 g, 51%) as a white powder. 2- . { [2- (dimethylamino) ethyl] oxy} -3- (4-ethylpiperazin-1-yl) aniline To a solution of 2- (diethylamino) ethanol (0.59 g, 5 mmol) in DMA (5 mL), sodium hydride (0.24 g, 10 mmol) was added in one portion. Fifteen minutes later, 2-bromo-4-nitroaniline (1.1 g, 5 mmol) was added and the contents were stirred for 4 hours. Water (50 mL) was added to the reaction mixture followed by chloroform. The organic layer was separated, washed with saturated sodium bicarbonate followed by brine. The organic layer was dried over sodium sulfate and concentrated to an oil. The oil was dissolved in methanol and saturated with HC1 gas. The resulting solution was concentrated and added to diethyl ester. The resulting precipitate was washed with ether and dried to yield 0.8 g of 2- [(2-bromo-4-nitrophenyl) oxy] -N, -diethylethanamine hydrochloride as a solid. LCMS: m / z 318 (m + H) +.

A mixture of 2- [(2-bromo-4-nitrophenyl) oxy] -N, N-diethylethanamine hydrochloride (0.5 g, 1.4 mmol), Pd (dba) 2, (0.192 g, 021 mmol), BINAP (0.139) g, 0.21 mmol), 1-ethylpiperazine (0.182 g, 1.68 mmol), and cesium carbonate (0.91 g, 2.8 mmol) in DMA was heated at 80 ° C with stirring for 72 hours. Aqueous saturated sodium bicarbonate of ethyl acetate was added, the phases were separated, the solvent was removed under vacuum and the residue was chromatographed on silica with ethyl acetate / methanol to give 0.32 g of N, N-diethyl-2-. { [2- (4-ethylpiperazin-1-yl) -4-nitrophenyl] oxy} Ethanamine LCMS: m / z 351 (M + H) +. A solution of N, N-diethyl-2-. { [2- (4-ethylpiperazin-1-yl) -4-nitrophenyl] oxy} Ethanamine (0.280 mg, 0.8 mmol) in methanol (10 mL) was added 10% Pd / C and stirred under a hydrogen atmosphere at room temperature for 2 hours. The reaction mixture was filtered through a pad of Celite and concentrated in vacuo. The residue was taken up in methanol, and it was added to ether / HCl and the hydrochloride (0.270 mg) was precipitated. LCMS: m / z 321 (M + H) +.

Example 54 (R) -N- (4- (2- (3- (benzyloxy) -4-morpholino-phenylamino) -pyrimidin-4-yl) phenyl) -pyrrolidine-2-carboxamide (Compound 376) was synthesized (i) ?) -N- (4- (2 - (3- (benzyloxy) -4- morpholino-phenylamino) -pyrimidin-4-yl) phenyl) -pyrrolidine-2-carboxamide in a manner analogous to Example 3, wherein 4-morpholinoaniline was substituted with 3- (benzyloxy-4-morpholinoaniline to give the title compound. 3- (benzyloxy) -4-morpholinoaniline 4- (2- (benzyloxy) -4-nitrophenyl) morpholine: a flask was charged with 2-chloro-5-nitrophenol (3.5 g, 20.2 mmol), potassium carbonate (4.0 g, 30.3 mmol), benzyl bromide ( 2.9 mL, 24.24 mmol), and acetonitrile (25 mL). The reaction mixture was stirred under an N2 atmosphere at room temperature for 12 hours, after which time, the reaction mixture was filtered through a pad of celite and washed with ethyl acetate (50 mL). The product was isolated by removal of the solvent with a rotary evaporator and used without further purification. RMNXH (400MHz, CDC13): 7.80 (m, 2H), 7.27-7.58 (m, 6H), 5.24 (s, 2H). MS (El) for C 13 H 10 ClN 3: 264 (MH +). Example 55 (S) -2-amino-N- (4- (2- (3-methyl) -4-morpholinophenylamino) pyrimidin-4-yl) phenyl) propanamide (Compound 384) was synthesized in a manner analogous to Example 3 , where 4-morpholinoaniline was substituted with 3-methyl-4-morpholinoaniline to give the title compound. 3 - . 3-methyl-4-morpholinoaniline Intermediate compound 1 A flask was charged with 2-fluoro-5-nitrotoluene (3.0 mL, 20.2388 mmol). Excess morpholine (10 mL) was added to the flask and heated at 40 ° C for 6 hours. The reaction mixture was verified with LC / MS. Water was added to the reaction mixture and the precipitate, intermediate 1, was filtered and used without further purification. LC / MS: m / z 223 (M + H) +. A hydrogenation flask was charged with intermediate 1 (1.0 g, 4.4209 mmol) and palladium / carbon (200 mg). Ethyl alcohol (50 mL) was added to the flask and the hydrogenation technique was used. The reaction mixture was verified with LC / MS. The reaction mixture was filtered through a plug of celite and washed with methanol. The product, 3-methyl-4-morpholinoaniline, was isolated by solvent removal with a rotary evaporator and used without further purification. LC / MS: m / z 197 (M + H) +.

Example 56 N- [3- (. {4- [4- (Acetylamino) phenyl] pyrimidin-2-yl} amino) phenyl] -2-chloro-6-fluoro-3- (methyloxy) benzamide was synthesized (Compound 49) in a manner analogous to Example 2, wherein benzoyl chloride was substituted with 2-chloro-3-methoxy-6-flurobenzoyl chloride (JRD Fluroochemicals) to give the title compound.

Example 57 N- (4-. {2- [(3-Chloro-4-morpholin-4-ylphenyl) amino] pyrmidin-4-yl} phenyl) acetamide (Compound 296) was synthesized in a manner analogous to Example 3, wherein aniline was substituted with 3-chloro-4-morpholinoaniline (Pfaltz and Bauer, Inc.) to give the title compound.

Example 58 N- (4 -. {2- 2- (3-bromo-4-morpholin-4- ilphenyl) amino] pyrimidin-4-yl} phenyl) acetamide (Compound 315) in a manner analogous to Example 3, wherein aniline was substituted with 3-bromo-4-morpholinoaniline (Ryan Scientific, Inc.) to give the title compound.

Example 59 (i) N- (4- (2- (4-morpholino-3- (trifluoromethyl) -phenylamino) pyrimidin-4-yl) -phenyl) -pyrrolidine-2-carboxamide was synthesized in a manner analogous to Example 3, wherein aniline was substituted with 3-trifluoromethyl-4-morpholinaniline (Zerenex Limited) to give the title of the compound.

Example 60 (R) -N- (4- (2- (3-fluoro-4-morpholinophenylamino) pyrimidin-4-yl) phenyl) pyrrolidine-2-carboxamide was synthesized in a manner analogous to Example 3, where it was replaced aniline with 3-fluoro-4-morpholinoaniline (Astatech, Inc.) to give the title compound.

Example 61 N- [4- (2. {[[3- (1, 3-dioxan-2-yl) phenyl] amino] pyrimidin-4-yl) phenyl] acetamide was synthesized in a manner analogous to Example 3, where aniline was substituted with 3- (1, 3-dioxan-2-yl) aniline (Oakwood Products, Inc.) to give the composed of the title.

EXAMPLE 62 N- (4- {2- [(4-morpholin-4-ylphenyl) amino] -5- (trifluoromethyl) pyrimidin-4-yl} phenyl) acetamide was synthesized in a manner analogous to Example 5 , where pyrimidine was substituted with 5-trifluoromethyl-2,4-dichloropyrimidine (Astatech, Inc.) to give the title compound. Using the same or similar techniques as illustrated in the preceding examples, the following compounds were elaborated in the following. The person skilled in the art will be able to make the necessary modifications and / or substitutions in the above synthesis procedures to arrive at the following compounds: N- (4-. {2- [(3-morpholin-4-ylphenyl) amino] ] pyrimidin-4-yl.} phenyl) acetamide (Compound 21): RM ^ H (400MHz, d6-DMSO): 10.22 ppm (s, 1H), 9,511 ppm (s, 1H), 8,504 ppm (d, 1H) ), 8,154 ppm (d, 2H), 7.76 ppm (d, 3H), 7,343 ppm (d, 1H), 7,215-7,153 ppm (m, 2H), 6,584 ppm (d, 1H), 3,775 ppm (t, 4H) ), 3.14 ppm (t, 4H), 2.094 ppm (s, 3H); MS (El) C22H23N502: 390.1 (MH +). N- (4- { 2- [(3-piperidin-1-ylphenyl]) amino] irimidin-4-yl}. Phenyl) acetamide (Compound 22): R N'H (400MHz, d6-DMSO) : 10,231 ppm (s, 1H), 9,466 ppm (s, 1H), 8,497 ppm (d, 1H), 8. 16 ppm (d, 2H), 7,765 ppm (d, 3H), 7,337 ppm (d, 1H), 7,119 ppm (d, 2H), 6,553 ppm (m, 1H), 3,176 ppm (t, 4H), 2,092 ppm (s, 3H), 1658 ppm (m, 4H), 1571 ppm (m, 2H); MS (EI) C 23 H 25 N 50: 388.1 (MH +). _V- [4- (2- { [4- (4-ethylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] acetamide (Compound 33): RMIS ^ H (400MHz, d6 -DMSO): 10,269 ppm (s, 1H), 9,317 ppm (s, 1H), 8,411 ppm (d, 1H), 8,089 ppm (d, 2H), 7,743 ppm (d, 2H), 7,638 ppm (d, 2H) ), 7,243 ppm (d, 1H), 6,908 ppm (d, 2H), 3,048 ppm (br s, 4H), 2,350 ppm (q, 2H), 2.07 ppm (s, 3H), 1,027 ppm (t, 3H) ); MS (EI) C 24 H 28 N 60: 417.4 (MH +). N- (4- { 2- [(4-piperidin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) acetamide (Compound 34): NMR'H (400MHZ, d6-DMSO): 10.29 ppm (s, 1H), 9.53 ppm (s, 1H), 8,481 ppm (d, 1H), 8,135 ppm (d, 2H), 7.76 ppm (t, 4H), 17,325 ppm (d, 1H), 7,178 ppm (d, 1H), d, 2H), 3.025 ppm (br d, 2H), 2.59 ppm (m, 2H), 2.094 ppm (s, 3H), 2.08 ppm (br d, 2H), 1.54-1.439 ppm (m, 2H); MS (EI) C 23 H 25 N 50: 388.3 (MH +). N- [3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) phenyl] -2,6-dichloro-benzamide (Compound 17): RMIN H (400MHz, d6 -DMSO): 10.718 ppm (s, 1H), 10.269 ppm (s, 1H), 9.678 ppm (s, 1H), 8.507 ppm (d, 1H), 8.419 ppm (s, 1H), 8.215 ppm (d, 2H) ), 7,758 ppm (d, 2H), 7,608 ppm (d, 2H), 7,532 ppm (t, 1H), 7,472 ppm (d, 1H), 7,380 ppm (d, 1H), 7,301 ppm (t, 1H), 7.216 ppm (d, 1H), 2085 ppm (s, 3H); MS (El) C25H19C12N502: 492.2 (MH +). N-. { 4- [2- ( { 3- [(4-piperazin-1-yl) carbonyl] phenyl} amino) pyrimidin-4-yl] phenyl} Acetamide (Compound 8): RMN1 !! (400MHz, ds-MEOD): 8.455 ppm (d, 1H), 8.15 ppm (m, 3H), 7.76-7.7 ppm (m, 3H), 7.435 ppm (t, 1H), 7.311 ppm (d, 1H), 7.1 ppm (d, 1H), 3,832 ppm (br s, 4H), 3.13 ppm (br s, 4H), 3,016 ppm (q, 2H), 2,162 ppm (s, 3H), 1,975 ppm (s, 3H, ACE ), 1299 ppm (t, 3H); MS (El) C25H28N602: 445.4 (MH +). N- [3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) phenyl] -2-fluorobenzamide (Compound 10): NMR1H (DMSO-D6) 10.40 (S, 1H), 10.21 (S, 1H), 9.66 (S, 1H), 8.49 (D, 1H), 8. 41 (S, 1H), 8.20 (D, 2H), 7.74 (D, 2H), 7.69 (M, 1H), 7.58 (M, 1H), 7.48 (M, 1H), 7.37 (M, 3H), 7.28 (M, 2H), 2.09 (S, 3H). LCMS: M / Z 442 (M + H) +. N- [3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} mino) phenyl] -2-fluoro-6-iodobenzamide (Compound 11): NMR1! (DMSO-DJ 10.65 (S, 1H), 10.19 (S, 1H), 9.67 (S, 1H), 8.50 (D, 1H), 8.41 (S, 1H), 8.21 (D, 2H), 7.76 (M, 3H), 7.41 (M, 3H), 7.28 (M, 3H), 2.08 (S, 3H) LCMS: M / Z 567 (M + H) +. N- [3- ( { 4- [4 - (acetylamino) phenyl] pyrimidin-2-yl}. amino) phenyl] -2-bromobenzamide (Compound 23): NMR: H (DMSO-DJ 10.48 (S, 1H), 10.20 (S, 1H), 9.66 ( S, 1H), 8.49 (D, 1H), 8. 42 (S, 1H), 8.20 (D, 2H), 7.73 (D, 3H), 7.55 (M, 2H), 7.45 (M, 2H), 7.36 (M, 1H), 7.37 (D, 1H), 7.25 (M, 2H), 2.08 (S, 3H). LCMS: M / Z 502, 503, 504, 505 (M + H) +.

N- [3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) phenyl] -3-fluorobenzamide (Compound 24): NMR1! (DMSO-D6) 10.33 (S, 1H), 10.23 (S, 1H), 9.69 (S, 1H), 8.50 (D, 1H), 8.44 (S, 1H), 8.21 (D, 2H), 7.85 (M , 1H), 7.79 (M, 1H), 7.73 (D, 2H), 7.61 (M, 1H), 7.50 (M, 1H), 7.36 (M, 1H), 7.29 (M, 2H), 2.09 (S, 3H). LCMS: M / Z 442 (M + H) +. N- [3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl.}. Amino) phenyl] -2,6-dimethyl-benzamide (Compound 12): RM ^ H (DMSO-) D 10.37 (S, 1H) 10.20 (S, 1H), 8.55 (S, 1H), 8.49 (D, 1H), 8.22 (D, 2H), 7.72 (D, 2H), 7.36 (D, 2H), 7.22 (M, 3H), 7.12 (D, 2H), 2.33 (S, 6H), 2.08 (S, 3H) LCMS: M / Z 452 (M + H) +. N- [3- ( { 4 - [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) phenyl] pyridine-4-carboxamide (Compound 14): RMNXH (DMSO-D6) 10.59 (S, 1H), 10.34 (S, 1H) , 9.71 (S, 1H), 8.80 (DD, 2H), 8.50 (M, 2H), 8.21 (D, 2H), 7.90 (DD, 2H), 7.75 (D, 2H), 7.51 (M, 1H), 7.37 (D, 1H), 7.31 (M, 2H), 2.09 (S, 3H) LCMS: M / Z 425 (M + H) +. N- [3- ( { 4- [4- (acetylamino phenyl] pyrimidin-2-yl.}. amino) phenyl] -2, 3, 4, 5, 6-pentafluorobenzamide (Compound 15): NMR'H (DMSO-D 10.97 (S, 1H), 10.20 (S, 1H), 9.75 (S, 1H), 8.50 (D, 1H), 8.33 (S, 1H), 8.17 (D, 2H), 7.72 (D, 2H), 7.55 (M, 1H), 7.38 (D, 1H) ), 7.32 (T, 1H), 7.24 (D, 1H), 2.08 (S, 3H) LCMS: M / Z 5 14 (M + H) +. N- [3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl}. amino) propyl] -2,6-dichloro-benzamide (Compound 1): NMRH (DMSO-d6) 10.15 (s, 1H), 8.68 (t, 1H), 8.68 (t, 1H), 8.27 (d, 1H) , 8.04 (d, 2H), 7.67 (d, 2H), 7.49 (d, 2H), 7.41 (m, 1H), 7.13 (t, 1H), 7.06 (d, 1H), 3.41 (m, 2H), 3.30 (m, 2H), 2.06 (s, 3H), 1.80 (m, 2H). LCMS: M / Z 458 (M + H) +. 2,6-dichloro-N- (3- {[4- (2,4-dichlorophenyl) pyrimidin-2-yl] amino} propyl) benzamide (Compound 2): RMIS ^ H (DMSO-d6) 8.63 (s, 1H), 8.36 (d, 1H), 7.73 (s, 1H), 7.58 (d, 1H), 7.52 (d, 1H), 7.47 (m, 2H), 7.40 (m, 2H), 6.79 (d, 2H), 3.37 (m, 2H), 3.27 (m, 2H), 1.75 (t, 2H). LCMS: M / Z 471 (M + H) +. 4- (2,4-dichlorophenyl) -N-. { 3- [(2-piperidin-1-ylethyl) oxy] phenyl} pyrimidin-2-amine (Compound 19): NMRH (DMSO-d6) 9.79 (s, 1H), 8.58 (d, 1H), 7.77 (d, 1H), 7.38 (d, 1H), 7.58 (m, 2H) , 7.24 (d, 1H), 7.10 (m, 2H), 6.50 (dd, 1H), 3.98 (t, 2H), 2.60 (t, 2H), 2.47 (m, 4H), 1.46 (m, 4H), 1.36 (m, 2H). LCMS: M / Z 443 (M + H) + N- (3- ([4-aminophenyl) pyrimidin-2-yl] aminojpropyl) -2,6-dichlorobenzamide (Compound 6): NMR1 !. (400MHz, DMSO): d 8.76-8.79 (m, 1H), 8.45 (d, 6.0 Hz, 1H), 7.94-8.06 (m, 3H), 7.56 (m, 1H), 7.52-7.51 (m, 1H) , 7.50 (s, 2H), 7.43-7.52 (m, 2H), 7.36-7.42 (m, 1H), 7.22-7.34 (bs, 1H), 3.44-3.64 (bs, 2H), 3.23-3.40 (m, 2H), 1.02-1.52 (bs, 2H). LC / MS MH = 416. 2,6-dichloro-N- (3 { [4- (2, 3-dihydro-l-benzofuran-6-yl) pyrimidin-2-yl] amino.}. - propyl) benzamide (Compound 4) : RMNXH (400MHz, DMSO): d 8.724 (t, 5.6Hz, 1H), 8.29 (d, 5.6) Hz, 1H), 8.41-8.18 (bs, 1H), 7.92-8.15 (bs, 1H), 7.49-7.52 (m, 2H), 7.41-7.45 (m, 2H), 7.14-7.23 (bs, 1H), 6.88 (d, 8.4 Hz, 1H), 4.61-4.65 (m, 2H), 3.62-3.93 (bs, 1H), 3.39-3.51 (bs, 1H), 3.33-3.36 (m, 2H), 3.23-3.27 ( m, 2H), 1.80-1.87 (bs, 2H). LC / MS MH = 443. 2, 6-dichloro-N- [3- ( { 4- [4-dimethylamino) phenyl] pyrimidin-2-yl} amino) propyl] benzamide (Compound 3): RMIN H (400MHz, DMSO): d 8.66 (t, 5.6 Hz, 1H), 8.17 (d, 5.2 Hz, 1H), 7.95 (d, 8.8 Hz, 2H), 7.47 -7.49 (m, 2H), 7.38-7.42 (m, 1H), 6.95-6.97 (m, 2H), '6.72-6.75 (m, 2H), 3.37-3.43 (m, 2H), 3.26-3.32 (m , 2H), 2.96 (s, 6H), 1.79 (t, 6.8 Hz, 2H). LC / MS M-H = 442. N- [3- (. {4- (Acetylamino) phenyl] -5-methylpyrimidin-2-yl} amino) phenyl] -2,6-dichlorobenzamide (Compound 25): RMIS ^ H (400MHz, DMSO- d6) d (s, 1H), 10.15 (s, 1H), 9.57 (s, 1H), 8.38 (s, 1H), 8.16 (s, 1H), 7.72 (s, 4H), 7.60-7.50 (m, 4H), 7.26-7.23 (m, 2H), 2.26 (s, 3H), 2.09 (s, 3H). LCMS (EI) C2GH22C12N502: 506 (M + H). N- [3- ( { 4- [4- (acetylamino) phenyl] -5-fluoropyrimidin-2-yl} amino) phenyl] 2,6-dichlorobenzamide (Compound 28): RMIS ^ H (400MHz, DMSO-d6) d 10.72 (s, 1H), 10.25 (s, 1H), 9.78 (s, 1H), 8.59 (d, J = 4.0 Hz, 1H), 8.32 (s, 1H), 8.12 (d, J = 8.4 Hz, 2H), 7.77 (d, J = 8.8 Hz, 2H), 7.61-7.58 (m, 2H), 7.51 (dd, J = 8.8, 6.8 Hz, 1H), 7.44 (d, J = 8.4 Hz , 1H), 7.28 (t, J = 8.9 Hz, 1H), 7.23 (t, J = 8.0 Hz, 1H), 2.09 (s, 3H), LCMS (El) C25H18C12FNS02: 510 (M + H). N- (4- {2 - [(4- {[[2- (4-ethylpiperazin-1-yl) -2-oxoethyl] oxy} phenyl) amino] pyrimidin-4-yl}. phenyl) acetamide (Compound 64): RMNXH (400MHz, d6-DMSO): 10,222 ppm (s, 1H),. 9,445 ppm (s, 1H), 8,457 ppm (d, 1H), 8,119 ppm (d, 2H), 7.75 ppm (d, 2H), 7,686 ppm (d, 2H), 7,299 (d, 1H), 6,922 ppm (d, 1H), d, 2H), 4.76 ppm (s, 2H), 3.465 ppm (bs, 4H), 2.4 ppm (m, 4H), 2.31 ppm (m, 2H), 2091 ppm (s, 3H), 1.02 ppm (t, 3H); MS (El) C 26 H 30 N 603: 475.4 (MH +). l-ethyl-3- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. phenyl) urea (compound 250-HCl) (Compound 250): RMIS ^ H (400MHz, d6DMSO): 10,064 ppm (s, 1H), 9,305 ppm (s, 1H), 8,483 ppm (d, 1H), 8,105 ppm (d, 2H), 7,832 ppm (bd, 2H), 7,603 ppm ( d, 2H), 7.54 ppm (bs, 2H), 7.431 ppm (d, 1H), 6.55 ppm (bs, 1H), 3.89 ppm (bs, 4H), 3.426 ppm (bs, 4H), 3.15 ppm (m, 2H), 1.08 ppm (t, 3H); MS (El) C23H26N602HC1: (MH +). N- [6- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) pyrimidin-4-yl] -2,6-dichlorobenzamide (Compound 301): NMR'H ( 400MHZ, d6-DMSO); 11.55 (s, 1H), 10.5 (s, 1H), 10.2 (s, 1H), 9.32 (s, 1H), 8.68 (d, 1H), 8.6 (s, 1H), 8.4 (d, 2H), 7.74 (d, 2H), 7.64 (d, 1H), 7.62-7.5 (m, 3H), 2.03 (s, 3H); MS (El) for C23H17C12N702: 494 (MH +). N- [4- (2- { [4-morpholin-4-ylmethyl) phenyl] amino} pyrimidin-4-yl) phenyl] acetamide (Compound 232): RMNXH (400MHz, d6-DMSO): 10.3 (s, 1H), 9.6 (s, 1H), 8.46 (d, 1H), 8.13 (d, 2H), 7.78 (t, 4H), 7.35 (d, 1H), 7.47 (d, 1H), 7.23 (d, 2H), 3.58 (t, 4H), 3.4 (s, 2H), 2.33 (t, 4H), 2.1 (s, 3H); MS (El) for C23H25N502: 404 (MH +). 4- (l # -indol-5-yl) -N- (4 -raorfolin-4-ylphenyl) pyrimidin-2 -amine (Compound 254): RMIS ^ H (400MHz, d6-DMSO): 11.35 ppm (s, 1H), 9.33 ppm (s, 1H), 8.41 ppm (m, 2H), 7.94 ppm (dd, 1H), 7.71 ppm (d, 2H), 7.50 ppm (d, 1H), 7.44 (t, 1H), 7.33 (d, 1H), 6.94 ppm (d, 2H), 6.57 ppm (s, 1H), 3.75 ppm (m, 4H), 3.05 ppm (m, 4H), 2.09 ppm (s, 3H); MS (EI) C 24 H 25 N 502: 372.3 (MH +). N- (3- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-ylphenyl) acetamide (Compound 79): RM 'H (400MHZ, d6-DMSO): 10.14 ppm (s, 1H), 9.45 ppm (s, 1H), 8.49 ppm (d, 1H), 8.40 (s, 1H), 7.77 ppm (d, 1H), 7.70 ppm (d, 3H), 7.45 ppm (t, 1H), 7.20 ppm (d, 1H), 6.93 ppm (d, 2H), 3.74 ppm (m, 4H), 3.04 ppm (m, 4H), 2.09 ppm (s, 3H): MS (EI) C24H25N502: 390.1 (MH +) . 4- [4- (methyloxy) phenyl] -N- (4-morpholin-4-ylphenyl) pyrimidin-2-amine (Compound 252): NMR'H (400MHZ, d6-DMSO): 9.37 ppm (s, 1H) , 8.42 ppm (d, 1H), 8.13 ppm (d, 2H), 7.67 ppm (d, 2H), 7.27 ppm (d, 1H), 7.08 ppm (d, 2H), 6.92 ppm (d, 2H), 3.84 ppm (s, 3H), 3.74 ppm (m, 3H), 3.04 ppm (m, 4H); MS (EI) C 24 H 25 N 502: 363.1 (MH +). N- (4 - {2 - [(3-piperazin-1-ylphenyl) amino] pyrimidine-4- il-phenyl) acetamide (Compound 312): NMR'H (400MHZ, d6-DMSO): 10.32 ppm (s, 1H), 9.55 ppm (s, 1H), 8.50 ppm (d, 1H), 8.13 ppm (d, 2H) , 7.78 ppm (d, 2H), 7.68 ppm (s, 1H), 7.35 ppm (dd, 2H), 7.20 ppm (t, 1H), 6.63 (dd, 1H), 3.38 (m, 4H), 3.25 (m , 4H), 2.13 (s, 3H); MS (EI) C22H24NsO: 389.1 (MH +) 2-amino-iV- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) -2-phenyl-acetamido (Compound 573): RMI ^ H ( 400MHz, d6-DMSO): 11.93 ppm (s, 1H), 10.18 (s, 1H), 9.08 ppm (s, 2H), 8.58 ppm (d, 1H), 8.18 ppm (d, 2H), 7.98 ppm (m , 2H), 7.82-7.75 ppm (m, 2H), 7.60-7.40 (m, 6H), 7.30 ppm (s, 2H), 5.52-5.46 (m, 1H), 4.10 (t, 4H), 3.57 (t , 4H); MS (EI) C28H28N602: 481.3 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -L-alaninamide (Compound 577): 1-NMR! (400MHz, d6-DMSO): 9,387 ppm (s, 1H), 8,443 ppm (d, 1H), 8,127 ppm (d, 2H), 7,825 ppm (d, 2H), 7,676 ppm (d, 2H), 7,287 ppm (d, 1H), 6,939 ppm (d, 2H), 3,747 ppm (m, 4H), 3,457 ppm (q, 1H), 3,050 ppm (m, 4H), 1,896 ppm (s, 3H) (AcOH)), 1,243 ppm (d, 3H); MS (EI) C 23 H 26 N 602: 419.1 (MH +). N- (4 - {2 - [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-ylphenyl) valinamide (Compound 575): NMR1! (400MHZ, d6-DMSO): 9,390 ppm (s, 1H), 8,449 ppm (d, 1H), 8,124 ppm (d, 2H), 7,815 ppm (d, 2H), 7,686 ppm (d, 2H), 7,284 ppm (d, 1H), 6,939 ppm (d, 2H), 3,747 ppm (m, 4H), 3,147 ppm (d, 1H), 3,051 ppm (m, 4H), 1,953 ppm (m, 1H), 1,864 ppm (s) 3H (AcOH)), 0.943 ppm (d, 3H), 0.871 ppm (d, 3H); MS (EI) C 25 H 30 N 602: 446.2 (MH +). 2- (dimethylamino) -N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) -acetamide (Compound 197): 1 H-NMR (400MHz, d6-DMS0): 10,001 ppm (s, 1H) 9.384 ppm (s, 1H), 8. 440 ppm (d, 1H), 8,118 ppm (d, 2H), 7,836 ppm (d, 2H), 7,673 ppm (d, 2H), 7,287 ppm (d, 1H), 6,939 ppm (d, 2H), 3,745 ppm (m, 4H), 3.114 ppm (s, 2H), 3049 ppm (m, 4H), 2290 ppm (s, 6H); MS (EI) C 24 H 28 N 602: 432.5 (MH +). N- (4- { 2- [(4- { 4- [3- (dimethylamino) -2,2-dimethylpropyl] piperazin-1-yl}. Phenyl) -amino] pyrimidin-4-yl phenyl) acetamide (Compound 578): NMR'H (400MHz, d6-DMSO):): 10,208 ppm (s, 1H), 9,358 ppm (s, 1H), 8,433 ppm (d, 1H), 8,106 ppm (d, 2H), 7,741 ppm (d, 2H), 7,648 ppm (d, 2H), 7,262 ppm (d, 1H), 6,909 ppm (d, 2H), 3,050 ppm (m, 4H), 2,595 ppm (m , 4H), 2212 ppm (s, 6H), 2172 ppm (s, 2H), 2091 ppm (m, 5H), 0.843 ppm (s, 6H); MS (EI) C 29 H 39 N 70: 502.2 (MH +). N- (4-. {2- 2- [(4- {4- [(1-methyl-1H-imidazol-2-yl) methyl] piperazin-1-yl} phenyl) amino] -pyrimidine- 4-yl.}. Phenyl) acetamide (Compound 576): RMNXH (400MHz, d6-DMSO): 10.23 ppm (s, 1H), 9.37 ppm (s, 1H), 8.43 ppm (d, 1H), 8.106 ppm (d, 2H), 7.74 ppm (d , 2H), 7.65 ppm (d, 2H), 7.26 ppm (d, 1H), 7.10 ppm (s, 1H), 6.92 ppm (d, 2H), 6.78 ppm (s, 1H), 3.67 ppm (s, 3H) ), 3.58 ppm (s, 2H), 3.39-3.34 ppm (m, 4H), 3.02-3.08 ppm (M, 4H), 2.10 ppm (s, 3H); MS (EI) C27H30N8O 482.6 (MH +). N- (4- (2- (4- (4- (cyclopropanecarbonyl) pipierazin-1-yl) phenylamino) irimidin-4-yl) phenyl) acetaraide (Compound 349): NMR'H (400MHz, d6-DMSO): 10.22 ppm (s, 1H), 9.41 ppm (s, 1H), 8.44 ppm (d, 1H), 8.11 ppm (d, 2H), 7.74 ppm (d, 2H), 7.69 ppm (d, 2H), 7.28 ppm (d, 1H), 7.28 ppm (d, 1H), 6.97 ppm (d, 2H), 3.83 ppm (s, 2H), 3.62 ppm (s, 2H), 3.15 ppm (s, 2H), 3.03 ppm (s) , 2H), 2.09 ppm (s, 3H), 2.02-2.05 ppm (m, 1H), 0.74-0.76 ppm (ra, 4H); MS (EI) C 26 H 28 N 602: 456.5 (MH +). N-. { 4- [2- ( { 3- [(4-phenylpiperazin-1-yl) carbonyl] phenyl} amino) pyrimidin-4-yl] -phenyl} acetamide (Compound 78): NMR'H (400MHz, d6DMSO): 10.21 ppm (s, 1H), 9.83 ppm (s, 1H), 8.53 ppm (d, 1H), 8.13 ppm (d, 2H), 8.05 ppm ( s, 1H), 7.95 ppm (s, 1H), 7.87 ppm (d, 1H), 7.75 ppm (d, 2H), 7.38-7.43 (m, 2H), 7.20-7.242 (m, 2H), 7.02 ppm ( d, 2H), 6.95 ppm (d, 2H), 6.81 ppm (t, 1H), 3.68-3.88 ppm (m, 2H), 3.44-3.65 ppm (m, 2H), 3.02-3.11 ppm (m, 4H) 2.09 ppm (s, 3H); MS (EI) C 29 H 28 N 602: 492.6 (MH +). N- (4 - {2 - [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -D-alaninamide (Compound 578): 1H NMR (400MHz, d6DMSO): 11.13 ppm (s, 1H), 9.89 ppm (s, 1H), 8.53 ppm (d, 1H), 8.35 ppm (d, 3H), 8.20 ppm (d, 2H), 7.85 ppm (d, 4H), 7.49 ppm (br s, 2H) 7.43 ppm (d, 1H), 4.14 ppm (m, 1H), 3.96 pmm (br s, 4 H), 3.40 ppm (br s, 4H), 1.50 ppm (s, 3H); MS (El) C 23 H 26 N 602: 419 (MH +). (N- (4-. {5-methyl-2- [(3-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl-acetamide): RI ^ H (400MHz, ds-D SO ): . 17 (s, 1H), 9.41 (s, 1H), 8.38 (s, 1H), 7.84 (s, 1H), 7.72 (s, 4H), 7.09 (d, 2H), 6.51 (dd, 1H), 3.74 (t, 4H), 3.07 (t, 4H), 2.26 (s, 3H), 2.09 (s, 3H); MS (El) C23H25N502: 404.3 (M + H) +. (N- (4. {6-methyl-2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -acetamide): NMR'H (400MHz, d6-DMSO ): . 18 (s, 1H), 9.31 (s, 1H), 8.09 (d, 2H), 7.74-7.70 (m, 4H), 7.19 (s, 1H), 6.93 (d, 2H), 3.74 (t, 4H) , 3.04 (t, 4H), 2.38 (s, 3H), 2.09 (s, 3H), MS (El) C23H25N502: 404.3 (M + H) +. (N- (4- {2- [(4-morpholin-4-ylphenyl) amino] -5- (trifluoromethyl) pyrimidin-4-yl) -phenyl) acetamide): RMIS ^ H (400MHz, CDC13): 8.66 (s, 1H), 7.65-7.59 (m, 4H), 7.51 (d, 2H), 7.33 (d, 2H), 6.93 (d, 2H), 3.87 (t, 4H), 3.14 (t, 4H); MS (El) C 26 H 30 N 603: 458.1 (M + H) \ (N- (4- { 2- [(3-aminophenyl) amino] -5-methylpyrimidin-4-yl} phenyl) acetamide): NMR ' H (400MHZ, d6DMSO): 10.14 (s, 1H), 9.19 (s, 1H), 8.33 (d, 1H), 7.72 (d, 2H), 7.67 (dd, 2H), 7.03 (t, 1H), 6.94 (dd, 1H), 6.87 (t, 1H), 6.17-6.14 (m, 1H), 4.92 (s, 2H), 2.23 (s, 3H), 2.08 (s, 3H); MS (El) C19H19N50: 334.0 (M + H) +. (N- (4- {2- [(3-aminophenyl) amino] -5-fluoropyrimidin-4-yl} phenyl) acetamide): NMRH (400MHz, d6-DMSO): 10.26 (s, 1H), 9.41 (s, 1H), 8.54 (d, 1H), 8.04 (d, 2H), 7.78 (d, 2H), 7.03 (s, 1H), 6.95-6.91 (m, 2H), 6.20 (d , 1H), 5.00 (s, 2H), 2.10 (S, 3H); MS (EI) C 18 H 16 FN 50: 338.3 (M + H) +. (N- [4- (2- { [4- (4-ethylpiperazin-1-yl) phenyl} amino-5-fluoropyrimidin-4-yl) phenyl] acetamide): RMIS ^ H (400MHz, d6 -DMSO): 10.26 (s, 1H), 9.45 (s, 1H), 8.52 (d, 1H), 8.02 (d, 2H), 7.78 (d, 2H), 7.59 (d, 2H), 6.91 (d, 2H), 3.35 (bs, 4H), 3.07 (bs, 4H), 2.50 (q, 2H), 2.10 (s, 3H), 1.04 (t, 3H); MS (EI) C 24 H 27 FN 60: 435.3 (M + H) +. (N- [3- ( { 4- [4- (acetylamino) phenyl] -5-methylpyrimidin-2-yl} amino) phenyl] -2,6-dimethylbenzamide): NMRH (400MHz, d6-DMSO ): 10.32 (s, 1H), 10.15 (s, 1H), 9.51 (s, 1H), 8.37 (s, 1H), 8.29 (s, 1H), 7.76-7.70 (m, 4H), 7.42-7.41 ( m, 1H), 7.25-7.17 (m, 3H), 7.11 (d, 2H), 2.29 (s, 6H), 2.26 (s, 3H), 2.09 (S, 3H); MS (EI) C 28 H 27 N 502: 466.2 (M + H) +. (N- (4- {2 - [(3,5-dimorpholin-4-ylphenyl) amino] -5-fluoropyrimidin-4-yl}. Phenyl) -acetamide): NMRH (400MHz, d6-DMSO) : 10.27 (s, 1H), 9.45 (s, 1H), 8.58 (d, 1H), 8.07 (d, 2H) 7.77 (d, 2H), 7.06 (s, 2H), 6.17 (s, 1H), 3.75 (t, 8H), 3.10 (t, 8H), 2.10 (s, 3H); MS (EI) C 26 H 29 FN 603: 493.4 (M + H) +. (N- {4- [2- (lH-indazol-6-ylamino) -5-methylpyrimidin-4-yl] phenyl} acetamide): NMR'H (400MHz, d6-DMSO): 12.80 (s) , 1H), 10.18 (s, 1H), 9.72 (s, 1H), 8.44 (d, 1H), 8.37 (d, 1H), 7.90 (s, 1H), 7.77-7.70 (m, 4H), 7.59 ( d, 1H), 7.28 (dd, 1H), 22.7 (s, 3H), 2.10 (s, 3H); MS (EI) C20H18N60: 359.3 (M + H) +. (N- {4- [2- (lH-indol-5-ylaraine) -5-methylpyrimidin-4-yl] phenyl} acetamide): NMR'H (400MHZ, d6-DMSO): 10.90 (s) , 1 HOUR) , . 15 (s, 1H), 9.21 (s, 1H), 8.32 (d, 1H), 8.00 (d, 1H), 7.72 (dd, 2H), 7.66 (dd, 2H), 7.36 (dd, 1H), 7.28 -7.25 (m, 2H), 6.33 (t, 2H), 2.22 (s, 3H), 2.09 (s, 3H); MS (EI) C21H19N50; 358.3 (M + H) +. (N- (4. {5-fluoro-2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -acetamide): RM ^ H (400MHz, d6-DMSO ): 10.26 (s, 1H), 9.48 (s, 1H), 8.52 (d, 1H), 8.02 (d, 2H), 7.77 (d, 2H), 7.61 (d, 2H), 6.93 (d, 2H) 3.74 (t, 4H), 3.03 (t, 4H); MS (EI) C 22 H 22 FN 502: 408.3 (M + H) +. N- (4-. {5-methyl-2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -cyclopropanecarboxamide: RMIS ^ H (400MHz, d6-DMSO): 10.41 (s, 1H), 9.28 (s, 1H), 8.31 (d, 1H), 7.73 (d, 2H), 7.66-7.62 (m, 4H), 6.89 (d, 2H), 3.73 (bs, 4H) , 3.02 (bs, 4H), 2.22 (s, 3H), 1.85-1.79 (m, 1H), 0.84-0.81 (m, 4H); MS (EI) C 25 H 27 N 502: 430 (MH +). N-. { 4- [2- (lH-indazol-5-ylamino) -5-methylpyrimidin-4-yl] phenyl} acetamide: NMR'H (400MHz, d6-DMSO): 12.88 (s, 1H), . 16 (s, 1H), 9.49 (s, 1H), 8.37 (s, 1H), 8.29 (d, 1H), 7.97 (s, 1H), 7.73 (d, 2H), 7.67 (d, 2H), 7.59 (dd, 1H), 7.44 (d, 1H), 2.24 (s, 3H), 2.10 (s, 3H); MS (EI) C 20 H 18 N 60: 359 (MH +). N- (4- { 2- [(3,4-dimorpholin-4-ylphenyl) amino] pyrimidin-4-yl) phenyl) acetamide: RMNXH (400MHz, d6-DMSO): 10.21 (s, 1H), 9.36 (s, 1H), 8.48 (d, 1H), 8.15 (d, 2H), 7.74 (d , 2H), 7.32 (d, 1H), 7.12 (d, 2H), 6.17 (s, 2H), 3.75 (t, 4H), 3.11 (t, 4H), 2.09 (s, 3H); MS (EI) C 26 H 30 N 603: 475 (M + H) +. 4- . { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} Benzonitrile: RM 'H (400MHz, d6-DMSO): 9.60 (s, 1H), 8.57 (d, 1H), 8.32 (d, 2H), 8.03 (d, 2H), 7.65 (d, 2H), 7.44 ( d, 1H), 6.94 (d, 2H), 3.75 (t, 4H), 3.05 (t, 4H); MS (EI) C 21 H 19 N 50: 358 (MH +). 4- (4-fluorophenyl) -N- (4-morpholin-4-ylphenyl) pyrimidin-2 -amine: NMR'H (400MHz, d6-DMSO): 9.46 (s, 1H), 8.49 (d, 1H), 8.22 (dd, 2H), 7.66 (d, 2H), 7.38 (t, 2H), 7.33 (d, 1H), 6.93 (dd, 2H), 3.74 (t, 4H), 3.05 (t, 4H),; MS (EI) C20H19FN40: 358.3 (+ H) +. N- (4-morpholin-4-ylphenyl) -4- (4-pyrimidin-5-ylphenyl) pyrimidine-2 -amine: R N'H (400MHz, d6-DMSO): 9.50 (s, 1H), 9.26 ( s, 2H), 9.24 (s, 1H), 8.53 (d, 1H), 8.32 (d, 2H), 8.02 (d, 2H), 7.69 (d, 2H), 7.44 (s, 1H), 6.94 (d , 2H), 3.75 (t, 4H), 3.06 (t, 4H); MS (EI) C 24 H 22 N 60: 411 (MH +). N- (4-morpholin-4-ylphenyl) -4- [4- (pyridin-2-ylamino) phenyl] pyrimidin-2-amine: RM 'H (400MHz, d6-DMSO): 9.42 (s, 1H), 9.33 (s, 1H), 8.40 (d, 1H), 8.23 (dd, 1H), 8.09 (dd, 2H), 7.86 (d, 2H), 7.70 (d, 2H), 7.65-7.61 (m, 1H) , 7.25 (d, 1H), 6.96-6.90 (m, 3H), 6.84-6.81 (m, 1H), 3.75 (t, 4H), 3. 05 (t, 4H); MS (El) C25H24N60: 425 (MH +). N- (4-morpholin-4-ylphenyl) -4- [4- (pyridin-3-ylamino) phenyl] irimidin-2 -amine: NMR'H (400MHZ, d6-DMSO): 9.33 (s, 1H), 8.81 (s, 1H), 8.45 (d, 1H), 8.40 (d, 1H), 8.14 (dd, 1H), 8.08 (d, 2H), 7.68 (d, 2H), 7.63-7.60 (m, 1H) , 7.32 (dd, 1H), 7.23 (d, 1H), 7.19 (dd, 2H), 6.93 (d, 2H), 3.74 (t, 4H), 3.05 (t, 4H); MS (EI) C 25 H 24 N 60: 425 (MH +). N- [4- (2- ([4- (4-D-alanylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] -D-prolinamide: NMR1 !. (400MHz, d6- DMSO): 10.23 (s, 1H), 9.42 (s, 1H), 8.45 (d, 1H), 8.31 (s, 1H), 8.13 (d, 2H), 7.84 (d, 2H), 7.69 (d, 2H) ), 7.30 (d, 1H), 6.97 (d, 2H), 4.09-4.04 (m, 1H), 3.77-3.73 (m, 1H), 3.67-3.61 (m, 4H), 3.09-3.03 (m, 4H) ), 2.92 (t, 2H), 2.10-2.03 (tn, 1H), 1.85-1.77 (m, 1H), 1.71-1.64 (m, 2H), 1.19 (d, 3H), MS (EI) C28H34N802: 515 (MH +). N- [4- (2- { [4- (4-L-alanylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] -D-prolinamide: RMI ^ H (499 MHz, d6-DMSO): 10.23 (s, 1H), 9.42 (s, 1H), 8.45 (d, 1H), 8.34 (s, 1H), 8.13 (d, 2H), 7.84 (d, 2H) ), 7.69 (d, 2H), 7.30 (d, 1H), 6.97 (d, 2H), 4.06-4.01 (m, 1H), 3.77-3.73 (m, 1H), 3.67-3.61 (m, 4H), 3.09-3.02 (m, 4H), 2.92 (t, 2H), 2.10-2.03 (m, 1H), 1.85-1.77 (m, 1H), 1.71-1.64 (m, 2H), 1.18 (d, 3H); MS (EI) C 28 H 34 N 802: 515 (MH +). N- { 4 - [2- ( { 4 - [4- (piperazin-1-ylacetyl) piperaz. in-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} -D-prolinamide: RMNXH (400MHz, d6-DMSO): 10.22 (s, 1H), 9.41 (s, 1H), 8.45 (d, 1H), 8.28 (S, 1H), 8.13 (d, 2H), 7.84 (d, 2H), 7.68 (d, 2H), 7.30 (d, 1H), 6.96 (d, 2H), 3.76-3.73 (m, 1H), 3.69-3.59 (ra, 4H), 3.19 (s, 2H), 3.10-3.02 ( m, 4H), 2.91 (t, 2H), 2.81 (bs, 4H), 2.44 (bs, 4H), 2.10-2.04 (m, 1H), 1.85-1.77 (m, 1H), 1.71-1.64 (m, 2H); MS (EI) C 31 H 39 N 902: 570 (MH +). N-. { 4- [2- (. {4- [4- (2-methylpropanoyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} -D-alaninamide; RMIS ^ H (400MHz, d6-DMSO): 9.43 (s, 1H), 8.47 (d, 1H), 8.17 (d, 2H), 7.80 (d, 2H), 7.69 (d, 2H), 7.31 (d, 1H), 6.98 (d, 2H), 3.82-3.78 (m, 4H), 3.66-3.62 (ra, 4H), 3.09-3.03 (m, 4H), 2.97-2.90 (m, 1H), 1.39 (d, 3H), 1.03 (d, 6H); MS (EI) C 27 H 33 N 702: 488 (MH +). N- [4- (2- { [4- (4-D-alanylpiperazin-1-yl) phenyl] amino.} Pyrimidin-4-yl) phenyl] -D-alaninamide: NMRH (400MHz, d6- DMSO): 9.42 (s, 1H), 8.45 (d, 1H), 8.33 (s, 1H), 8.13 (d, 2H), 7.82 (d, 2H), 7.69 (d, 2H), 7.30 (d, 1H) ), 6.98 (d, 2H), 4.13-4.07 (m, 1H), 3.70-3.59 (m, 5H), 3.11-3.01 (ra, 4H), 1.27 (d, 3H), 1.21 (d, 3H); MS (EI) C 26 H 32 N 802: 489 (MH +). N-. { 4- [2- (. {4- [4- (tetrahydrofuran-3-ylcarbonyl) piperazin-1-yl] phenyl} amino) -pyrimidin-4-yl] -phenyl} -D-prolinamide: NMR'H (400MHz, d6-DMSO): 10.19 (s, 1H), 9.42 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.84 (d, 2H) , 7.68 (d, 2H), 7.30 (d, 1H), 6.96 (d, 2H), 3.89 (t, 1H), 3.74-3.69 (m, 4H), 3.67-3.63 (m, 4H), 3.45-3.37 (m, 1H), 3.09-3.02 (m, 4H), 2. 90 (t, 2H), 2.08-1.99 (m, 3H), 1.84-1.76 (m, 1H), 1.70-1.64 (m, 2H); MS (EI) C 30 H 35 703: 542 (MH +). N-. { 4- [2- (. {4- [4- (tetrahydrofuran-2-ylcarbonyl) piperazin-1-yl] phenyl} amino) -pyrimidin-4-yl] phenyl} -D-prolinamide; NMR'H (400MHz, d6-DMSO): 10.22 (s, 1H), 9.41 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.83 (d, 2H), 7.68 (d, 2H), 7.30 (d, 1H), 6.96 (d, 2H), 4.72 (dd, 1H), 3.82-3.72 (m, 3H), 3.68-3.58 (m, 4H), 3.08-3.02 (m, 4H) , 2.91 (t, 2H), 2.11-1.99 (m, 3H), 1.88-1.79 (m, 3H), 1.71-1.66 (m, 2H); MS (EI) C 30 H 35 N 703: 542 (MH +). N- (4-. {5-chloro-2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -D-prolinamide: RM ^ H (400MHz, d6-DMSO ): 10.30 (s, 1H), 9.67 (s, 1H), 8.52 (s, 1H), 7.82 (s, 4H), 7.59 (d, 2H), 6.90 (dd, 2H), 3.84 (dd, 1H) , 3.74-3.72 (m, 4H), 3.04-3.02 (m, 4H), 2.97 (t, 2H), 2.15-2.09 (m, 1H), 1.86-1.79 (m, 1H), 1.75-1.69 (m, 2H); MS (EI) C25H27CIN602: 479 (MH +). (R) -N- (4- (2- (4- (4- (2- (pyrrolidin-1-yl) acetyl) piperazin-1-yl) phenylamino) pyrimidin-4-yl) phenyl) pyrrolidine-2 carboxamide: NMRH (400MHz, d6-DMSO): 10.21 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.84 (d, 2H), 7.68 (d , 2H), 7.30 (d, 1H), 6.95 (d, 2H), 3.75-3.71 (m, 1H), 3.69-3.59 (m, 4H), 3.07-3.01 (m, 4H), 2.91 (t, 2H ), 2.50 (t, 4H), 2.48 (s, 2H), 2.11-2.02 (m, 1H), 1.86-1.78 (m, 1H), 1.72-1.63 (m, 6H); MS (EI) C 31 H 38 N 802: 555 (MH +).

(R) -N- (4- (2- (4- (4- (2-morpholinoacetyl) piperazin-1-yl) phenylamino) pyrimidin-4-yl) phenyl) pyrrolidine-2-carboxamide: RMN'H (400MHZ , d6-DMSO): 10.19 (s, 1H), 9.41 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.84 (dd, 2H), 7.68 (d, 2H), 7.30 (d, d, 1H), 6.96 (d, 2H), 3.74-3.69 (m, 3H), 3.61-3.57 (m, 6H), 3.19 (s, 2H), 3.11-3.09 (m, 2H), 33.04-3.01 ( m, 2H), 2.90 (t, 2H), 2.41 (bs, 4H), 2.11-2.02 (m, 1H), 1.84-1.76 (m, 1H), 1.70-1.63 (m, 2H); MS (EI) C 31 H 38 N 803: 571 (MH +). N-. { 4- [2- ( { 4- [2- (methyloxy) ethyl] -3,4-dihydro-2H-l, 4-benzoxazin-7-yl} amino) -pyrimidin-4-yl] phenyl } -D-prolinamide: R N'H (400MHz, d6MHz, d6-DMSO): 10.19 (s, 1H), 9.25 (s, 1H), 8.42 (d, 1H), 8.11 (d, 2H), 7.83 (d , 2H), 7.28-7.25 (m, 2H), 7.17 (dd, 1H), 6.68 (d, 1H), 4.15 (t, 2H), 3.72 (dd, 1H), 3.52 (t, 2H)), 3.41 -3.36 (m, 4H), 3.27 (s, 3H), 2.90 (t, 2H), 2.10-2.01 (m, 1H), 1.84-1.75 (m, 1H), 1.70-1.63 (m, 2H); MS (EI) C 26 H 30 N 603: 475 (MH +). N- (4- { 2- [(4- {4- [(2R) -tetrahydrofuran-2-ylcarbonyl] piperazin-1-yl} phenyl) amino] pyrimidin-4-yl}. phenyl-D-prolinamide: NMR'H (400MHZ, d6-DMSO): 10.20 (s, 1H), 9.41 (S, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.84 (d, 2H) ), 7.68 (d, 2H), 7.30 (d, 1H), 6.96 (d, 2H), 4.72 (dd, 1H), 3.82-3.72 (m, 3H), 3.69-3.58 (m, 4H), 3.08- 3.03 (m, 4H), 2.90 (t, 2H), 2.11-1.98 (m, 3H), 1.88-1.75 (m, 3H), 1.70-1.65 (m, 2H); MS (EI) C30H35N703: 542 (MH + ).

N- (4 - { 2- [(4 - { 4 - [(2S) -tetrahydrofuran-2-ylcarbonyl] piperazin-1-yl}. Phenyl) -amino] pyrimidin-4-yl.} phenyl) -D-prolinamide: RM ^ H (400MHz, d6-DMSO): 10.20 (s, 1H), 9.41 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.84 (d , 2H), 7.68 (d, 2H), 7.30 (d, 1H), 6.96 (d, 2H), 4.72 (dd, 1H), 3.82-3.72 (m, 3H), 3.69-3.58 (m, 4H), 3.08-3.03 (m, 4H), 2.91 (t, 2H), 2.09-1.98 (m, 3H), 1.88-1.75 (m, 3H), 1.70-1.63 (m, 2H); MS (EI) C 30 H 35 N 703: 542 (MH +). N-. { 4- [2- (1,2,3,4-tetrahydroquinolin-6-ylamino) pyrimidin-4-yl] phenyl} -D-prolinamide: RM ^ H (400MHz, d6-DMSO): 10.17 (s, 1H), 9.05 (s, 1H), 8.38 (d, 1H), 8.10 (dd, 2H), 7.84-7.81 (m, 2H), 7.29 (s, 1H), 7.21-7.18 (m, 2H), 6.40 (d, 1H), 5.36 (s, 1H), 3.72 (dd, 1H), 3.15 (t, 2H), 2.90 (t , 2H), 2.67 (t, 2H), 2.10-2.01 (m, 1H), 1.84-1.76 (m, 3H), 1.69-1.63 (m, 2H); MS (EI) C 24 H 26 N 60: 415 (MH +). N-. { 4- [2- ( { 4- [(phenylmethyl) oxy] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: R ^ H (400MHz, d6-DMSO): 10.20 (s, 1H), 9.42 (s, 1H), 8.42 (d, 1H), 8.06 (d, 2H), 7.75-7.65 (m, 4H), 7.42-7.24 (m, 6H), 6.95 (d, 2H), 5.04 (s, 2H), 2.04 (S, 3H), MS (El) for C25H22N402: 411 (MH +). 4- (4-Aminophenyl) -N- [4- (phenyloxy) phenyl] pyrimidin-2-amine: NMR'H (400MHZ, d6-DMSO): 10.42 (s, 1H), 8.43 (d, 1H), 8.08 (d, 2H), 7.72 (d, 2H), 7.43-7.37 (m, 3H), 7.26-7.15 (m, 3H), 7.07-6.95 (m, 3H). MS (El) for C22H18N40: 355 (M + H). N- [4- (2- {[[4- (phenyloxy) phenyl] amino} pyrimidin-4-yl) phenyl] acetamide: RMNXH (400MHz, d6-DMSO): 10.20 (s, 1H), 9.64 (S, 1H), 8.49 (d, 1H), 8.11 (d, 2H), 7.85 (d, 2H), 7.75 ( d, 2H), 7.38-7.32 (m, 3H), 7.10-7.03 (m, 3H), 6.97 (d, 1H). MS (El) for C 24 H 20 N 4 O 2: 397 (MH +). N- (4- { 2- [(4- {[[2-methyloxy) ethyl] amino} phenyl) amino] pyrimidin-4-yl} -4-phenyl) acetamide: R ^ H (d6-DMSO): 10.18 (s, 1H), 9.08 (s, 1H), 8.38 (d, 1H), 8.05 (d, 2H), 7.73 (d, 2H) , 7.43 (d, 2H), 7.19 (d, 1H), 6.58 (d, 2H), 5.20 (t, 1H), 3.43 (t, 2H), 3.25 (s, 3H), 3.16 (t, 2H), 2.04 (s, 3H). MS (EI) for C21H23N502: 378 (MH +). N-. { 4- [2- ( { 4- [(pyridin-4-ylmethyl) oxy] phenyl} araino) pyrimidin-4-yl] phenyl} acetamide: RMN1 !! (400MHz, ds-DMSO): 10.20 (s, 1H), 9.43 (s, 1H), 8.60 (s, 2H), 8.43 (d, 1H), 8.10 (d, 2H), 7.79-7.72 (m, 4H) ), 7.43 (d, 1H), 7.30 (d, 1H), 7.01 (d, 2H), 5.08 (s, 1H), 2.03 (s, 3H). MS (El) for C24H21N502: 412 (MH +). N- (4 - {2 - [(4-cyclohexylphenyl) amino] pyrimidin-4-yl} phenyl) acetamide: NMR'H (400MHz, ds-DMSO): 10.21 (s, 1H), 9.53 ( s, 1H), 8.45 (d, 1H), 8.15 (d, 2H), 7.78-7.70 (m, 4H), 7.35 (d, 1H), 7.18 (d, 1H), 2.43-2.40 (m, 1H) 2.08 (s, 3H), 1. 82-1.68 (m, 4H), 1.42-1.20 (m, 6H). MS (El) for C 24 H 26 N 40: 387 (MH +). N-. { 4- [2- ( { 4 [(tetrahydrofuran-2-ylmethyl) amino] phenyl} amino) pyrimidin-4-yl) phenyl} acetamide: RMN1 !! (400MHz, d6-DMSO): 10.20 (s, 1H), 9.18 (s, 1H), 8.39 (d, 1H), 8.08 (d, 2H), 7.76 (d, 2?), 7.45 (d, 2?), 7.20 (d, 1?), 6.60 (d, 2H), 5.23 (t, 1H), 4.02-3.97 (m, 1H), 3.80-3.77 (ra, 1H), 3.65-3.60 (m, 1H), 3.08-3.00 (m, 2H), 2.07 (s, 3H), 2.00-1.80 (m, 3H), 1.62-1.57 (m, 1H) ). MS (El) for C23H25N502: 404 (MH +). N-. { 4 - [2- ( { 4- [(phenyl-arayl) araino] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: RM ^ (400MHz, d6-DMSO): 10.20 (s, 1H), 9.17 (s, 1H), 8.05 (d, 2H), 7.72 (d, 2H), 7.44-7.27 (m, 5H), 7.22 -717 (m, 2H), 6.57 (d, 2H), 6.00 (t, 1H), 4.25 (d, 2H), 2.08 (s, 3H). MS (El) for C2SH23N50: 410 (MH +). [4- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) phenyl] ethyl acetate: R N'H (400MHz, d6-DMSO): 10.21 (s, 1H ), 9.53 (s, 1H), 8.45 (d, 1H), 8.15 (d, 2H), 7.78-7.70 (m, 4H), 7.32 (d, 1H), 7.17 (d, 2H), 4.05 (q, 2H), 3.45 (s, 2H), 1.35 (t, 3H). MS (El) for C22H22N403: 391 (MH +). N- (4-. {2- [(3-chloro-4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl] phenyl) -acetate: NMR! (400MHz, d6-DMSO): 10.25 (s, 1H), 9.73 (s, 1H), 8.55 (d, 1H), 8.12 (d, 2H), 8.05 (s, 1H), 7.80-7.70 (m, 3H), 7.37 (d, 2H), 7.20 (d, 2H), 3.75 (t, 4H), 2.95 (t, 4H), 2.05 (s, 3H). MS (El) for C22H22CIN502: 425 (MH +). N- [4- (2- { [3- (methyloxy) -4-morpholin-4-ylphenyl] amino} pyrimidin-4-yl) phenyl] -L-serinamide: NMRH (400MHz, d6-DMSO ): 9.50 (s, 1H), 8.45 (d, 1H), 8.18 (d, 2H), 7.83 (d, 2H), 7.70 (s, 1H), 7.37-7.30 (m, 2H), 6.90 (d, 1H), 3.82 (s, 3H), 3.72 (t, 4H), 3.60-3.57 (m, 2H), 3.43 (t, 1H), 2.92 (t, 4H). MS (EI): 465 (MH +). N- (4- {2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl-2- (1H-tetrazol-1-yl) acetamide: NMR'H (400MHz , d6-DMSO): 10.90 (s, 1H), 9.47 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.18 (d, 2H), 7.77 (d, 2H), 7.67 ( d, 2H), 7.30 (d, 1H), 6.95 (d, 2H), 5.58 (s, 2H), 3.77 (t, 4H), 3.03 (t, 4H).

(EI): 458 (MH +). (3S) -3-hydroxy-N- [4- (2. {[[3- (methoxyloxy) -4-morpholin-4-ylphenyl] amino} pyrimidin-4-yl) phenyl] butanamide: NMR ' H (400MHZ, d6-DMSO): 10.19 (s, 1H), 9.48 (s, 1H), 8.48 (s, 1H), 8.17 (d, 2H), 7.78 (d, 2H), 7.65 (s, 1H), 7.31 (d, 2H), 6.88 (d, 1H), 4.80 (s, 1H), 4.15- 4.07 (m, 1H), 3.81 (s, 3H), 3.75 (t, 4H), 2.96 (t, 4H), 2.44-2.37 (m, 2H), 1.14 (d, 3H). MS (EI): 464 (MH +). (3R) -3-hydroxy-N- [4- (2. {[[3- (methyloxy) -4-morpholin-4-ylphenyl] amino]} pyrimidin-4-yl) phenyl] butanamide: NMRH (400MHz, d6-DMSO): 10.19 (s, 1H), 9.48 (s, 1H), 8.17 (d, 2H), 7.78 (d, 2H), 7.65 (s, 1H), 7.31 (d, 2H), 6.88 (d, 1H), 4.80 (S, 1H), 4.15-4.07 (m, 1H), 3.83 (s, 3H), 3.75 (t, 4H), 2.96 (t, 4H), 2.44-2.37 (m, 2H), 1.14 (d, 3H). MS (EI): 464 (MH +). N- (4-. {2- [(Morpholin-4-ylphenyl) amino] pyrimidin-4-yl] phenyl) -2,5-dihydro-lH-pyrrole-2-carboxamide: NMRH (400MHz, d6 -DMSO): 10.19 (s, 1H), 9.40 (s, 1H), 8.43 (s, 1H), 8.17 (d, 2H), 7.83 (d, 2?), 7.68 (d, 2?), 7.30 (s, 1?), 6.96 (d, 2H), 6.02-5.98 (m, 1H), 5.93-5.89 (m, 1H) ), 4.60 (s, 1H), 3.82 (s, 2H), 3.75 (t, 4H), 3.05 (t, 4H). MS (EI): 443 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-ylphenyl) -2- [(2S) -pyrrolidin-2-yl] acetamide: NMR'H (400MHZ, d6-DMSO): 10.86 (s, 1H), 10.10 (s, 1H), 9.37 (s, br, 1H), 9.28 (s, br, 1H), 8.55 (d, 1H), 8.20 (d, 2H) , 7.95-7.85 (m, 4H), 7.70 (s, 2H), 7.45 (d, 1H), 4.10 (t, 4H), 3.83-3.78 (m, 2H), 3.73 (t, 4H), 3.25-3.18 (m, 1H), 3.03-2.95 (m, 2H), 2.20-2.10 (m, 1H), 2.00-1.80 (m, 2H), 1.68-1.56 (m, 1H). MS (EI): 459 (MH +). 2,3-dihydroxy-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) propanamide: RMIS ^ H (400MHz, d6-DMSO) : 9.95 (s, 1H), 9.40 (s, 1H), 8.43 (d, 1H), 8.12 (d, 2H), 7.90 (d, 2H), 7.68 (d, 2H), 7.25 (s, 1H), 6.96 (d, 2H), 5.95 (s, br, 1H), 4.95 (s, br, 1H), 4.08 (t, 1H), 3.78-3.60 (m, 6H), 3.03 (t, 4H). MS (EI): 436 (MH +). l-. { 4- [2- (. {4- [4- (N, N-dimethylglycyl) piperazin-1-yl] phenyl} amino) pyriraidin-4-yl) phenyl} -3-ethylurea: RM ^ H (d6-DMSO): 9.37 (s, 1H), 9.19 (s, 1H), 9.40 (d, 1H), 8.03 (d, 2H), 7.70 (d, 2H), 7.58 (d, 2H), 7.23 (d, 2H), 6.95 (d, 2H), 6.75 (t, 1H), 3.58 (t, 4H), 3.60 (t, 3H), 3.15-3.00 (m, 8H), 2.18 (s, 6H), 1.05 (t, 3H). MS (EI): 503 (MH +). N-. { 4- [2- ( { 4- [4-N, N-dimethylglycyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} -3- (methyloxy) propanamide: NMR'H (400MHZ, d6-DMSO): 10.22 (s, 1H), 9.40 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.78 (d, 2H), 7.67 (d, 2H), 7.27 (d, 1H), 6.95 (d, 2H), 3.73-3.58 (ra, 6H), 3.24 (s, 3H), 3.14-3.00 (m, 6H), 2.60 (t, 3H), 2.20 (s, 6H). MS (El): 518 (MH +). N-. { 4- [2- (. {4- [4- (N, N-dimethylglycyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} Cyclopropanecarboxamide: NMR'H (400MHZ, d6-DMSO): 10.26 (s, 1H), 9.40 (s, 1H), 8.43 (d, 1H), 8.14 (d, 2H), 7.78 (d, 2H), 7.67 ( d, 2H), 7.27 (d, 1H), 6.95 (d, 2H), 3.70-3.58 (m, 4H), 3.10-3.00 (m, 6H), 2.20 (s, 6H), 1.84-1.80 (m, 1H), 0.83-0.80 (m, 4H). MS (El): 500 (MH +). N-. { 4- [2- (. {4- [4- (N, -dimethylglycyl) piperazin-1-yl] phenylamino) pyrimidin-4-yl] phenyl} butanamide: RM ^ H (400MHz, d6-DMSO): 10.18 (s, 1H), 9.40 (s, 1H), 8.43 (d, 1H), 8.12-8.05 (m, 3H), 7.80-7.68 (m, 3H) ), 7.28 (d, 1H), 6.99 (d, 2H), 2H), 3.70-3.60 (m, 4H), 3.28 (s, 2H), 3.14-3.00 (m, 4H), 2.35-2.20 (m, 8H), 1.64-1.58 (m, 2H), 0.95-0.88 (m, 3H). MS (El): 502 (MH +). N-. { 4- [2- (. {4- [4- (N, -dimethylglycyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} -N2, N2-dimethylglycinamide: NMR'H (400MHz, d6-DMSO): 10.00 (s, 1H), 9.40 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.82 (d, 2H), 7.65 (d, 2H), 7.25 (d, 1H), 6.95 (d, 2H), 3.65-3.57 (m, 4H), 3.23 (s, 2H), 3.12-3.00 (m, 6H), 2.28 (s, 6H), 2.20 (s, 6H). MS (El): 517 (MH +). N-. { 4- [2- ( { 4- [4- (?,? - dimethylglycyl) iperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} -D-alaninamide: RMIS ^ H (400MHz, d6-DMSO): 9.40 (s, 1H), 8.43 (d, 1H), 8.15 (d, 2H), 7.85 (d, 2H), 7.70 (d, 2H) , 7.30 (d, 1H), 6.95 (d, 2H), 3.70-3.57 (m, 4H), 3.50 (q, 1H), 3.18-3.00 (m, 6H), 1.83 (s, 6H), 1.21 (d) , 3H), MS (EI): 503 (MH +). N-. { 4- [2- (. {4- [4- (N, N-dimethylglycyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} tetrahydrofuran-3-carboxamide: RMNXH (400MHz, d6-DMS0): 10.30 (s, 1H), 9.40 (s, 1H), 8.43 (d, 1H), 8.15 (d, 2H), 7.78 (d, 2H), 7.68 (d, 2H), 7.25 (d, 1H), 6.95 (d, 2H), 3.97 (t, 1H), 3.70 (m, 3H), 3.67-3.60 (m, 4H), 3.22-3.17 (m, 1H), 3.12-3.00 (m 4H), 2.35 (s, 6H), 2.12-2.05 (m, 2H). MS (EI) 530 (MH +). (2R) -N-. { 4- [2- ( { 4- [4- (N, -dimethylglycyl) iperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} tetrahydrofuran-2-carboxamide: NMR'H (400MHz, d6-DMS0): 9.95 (s, 1H), 9.40 (s, 1H), 8.43 (d, 1H), 8.16 (d, 2H), 7.88 (d, 2H) ), 7.70 (d, 2H), 7.30 (d, 1H), 6.97 (d, 2H), 4.44-4.41 (m, 1H), 4.02-3.98 (m, 1H), 3.85-3.80 (m, 1H), 3.68-3.57 (m, 4H), 3.18-3.00 (m, 6H), 2.20 (s, 6H), 2.05-1.85 (m, 4H). MS (EI): 530 (MH +). (2S) -N-. { 4 - [2- ( { 4- [4- (?,? - dimethylglycyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} tetrahydrofuran-2-carboxamide: NMRH (400MHz, ds-DMSO): 9.95 (s, 1H), 9.40 (s, 1H), 8.43 (d, 1H), 8.16 (d, 2H), 7.88 (d, 2H), 7.70 (d, 2H), 7. 30 (d, 1H), 6.98 (d, 2H), 4.45-4.42 (m, 1H), 4.02-3.98 (m, 1H), 3.85-3.80 (m, 1H), 3.70-3.57 (m, 4H), 3.20 (s, 2H), 3.10-3.00 (m, 6H), 2.22 (s, 6H), 2.05-1.85 (m, 4H). MS (EI): 530 (MH +). N- (4- {2- [(6-morpholin-4-ylpyridin-3-yl) amino] pyrimidin-4-yl} phenyl) -D-prolinamide: NMR1! (400MHz, d6-DMSO): 11.38 (s, 1H), 10.10 (s, 2H), 9.03 (s, br, 1H), 8.75 (s, br, 1H), 8.60 (d, 2H), 8.30-8.20 (m, 3H), 7.85 (d, 2H), 7.55 (d, 2H), 4.48-4.42 (m, 1H), 3.82-3.70 (m, 8H), 3.37-3.20 (m, 2H), 2.43-2.40 (m, 1H), 2.10-1.95 (m, 3H). MS (EI): 446 (MH +). 1-hydroxy-N- (4-. {2- [. {4-morpholin-4-ylphenyl) araino] pyrimidin-4-yl} phenyl) -cyclopentanecarboxamide: RM ^ H (400MHz, d6-DMSO): 9.95 (s, 1H), 9.45 (s, 1H), 8.42 (d, 1H), 8.10 (d, 2H), 7.95 (d, 2H) , 7.70 (d, 2H), 7.30 (d, 1H), 7.05-6.95 (m, 2H), 5.68 (s, br, 1H), 3.80-3.70 (ra, 4H), 3.15-3.05 (m, 4H) , 2.10-1.97 (m, 3H), 1.87-1.68 (m, 5H). MS (EI): 460 (MH +). 2-hydroxy-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -acetamide: R ^ H (400MHz, d5-DMSO): 9.95 (s, 1H), 9.39 (s, 1H), 8.43 (d, 1H), 8.12 (d, 2H), 7.90 (d, 2H), 7.70 (d, 2H), 7.28 (d, 1H), 6.95 (d, 2H), 5.75 (t, 1H), 4.03 (d, 2H), 3.78-3.70 (m, 4H), 3.10-3.00 (m, 4H). MS (EI): 4.06 (MH +). 3-chloro-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) pyridine-4-carboxamide: NMR1! (400MHz, ds-DMSO): 11.68 (s, 1H), 11.00 (s, 1H), 9.43 (s, 2H), 8.83 (s, 1H), 8.70 (d, 1H), 8.50 (d, 1H), 8.20 (d , 2H), 7.87 (d, 2H), 7.75-7.65 (m, 3H), 7.32 (d, 1H), 6.95 (d, 2H), 3.75 (t, 4H), 3.05 (t, 4H). MS (EI): 4.87 (MH +). N-. { 4- [2- (. {4- [4- (N, N-dimethylglycyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} -D-prolineraide: RMN1 !! (400MHz, d6-DMSO): 10.24 (s, br, 1H), 9.41 (s, 1H), 8.44 (d, 2H), 8.13 (d, 2H), 7.82 (d, 2H), 7.68 (d, 2H) ), 7.27 (d, 1H), 6.95 (d, 2H), 3.78-3.57 (m, 5H), 3.15-3.00 (m, 6H), 2.93 (t, 2H), 2.18 (s, 6H), 2.08- 2.00 (m, 1H), 1.93-1.88 (m, 1H), 1.90-1.80 (m, 2H). MS (EI): 529 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyriraidin-4-yl}. Phenylpropanamide: NMR ^ (400MHz, d6-DMSO): 10.18 (s, br, 1H) , 9.18 (s, 1H), 8.40 (d, 1H), 8.13 (d, 2H), 7.78 (d, 2H), 7.63 (d, 2H), 7.25 (d, 1H), 6.93 (d, 2H), 3.77 (t, 4H), 3.07 (t, 4H), 2.16 (q, 2H), 1.10 (t, 3H), MS (EI): 404 (MH +), N- (4- { 2- [( 4-morpholin-4-ylphenyl) amino] pyrimidin-4-ylphenyl) -2-pyridin-3-ylacetamide: NMR'H (400MHz, d6-DMSO): 10.90 (s, 1H), 9.40 (s, 1H), 8.43 (s, 1H), 8.18 (d, 2H), 7.88 (d, 2H), 7.73-7.45 (m, 5H), 7.32 (d, 1H), 6.95 (d, 2H), 3.77 (t, 4H) 3.03 (t, 4H) .MS (EI): 467 (MH +). N- (4-. {2- [4-Rhorpholin-4-ylphenyl] amino] pyrimidin-4-yl] phenyl) pyrimidine-5-carboxamide: NMR1 !! (400MHz, d6-DMSO): 10.82 (s, 1H), 9.42 (s, 1H), 9.38 (s, 1H), 9.31 (s, 2H), 8.45 (d, 1H) ), 8.20 (d, 2H), 7.97 (d, 2H), 7.70 (d, 2H), 7.33 (d, 1H), 6.95 (d, 2H), 3.77 (t, 4H), 3.03 (t, 4H). MS (EI): 454 (MH +). N- [4- (2- { [3- (morpholin-4-ylmethyl) phenyl] amino} pyrimidin-4-yl) phenyl] acetamide: RM ^ H (400MHz, d6-DMSO): 10.25 ( s, 1H), 9.62 (s, 1H), 8.5 (d, 1H), 8.16 (d, 2H), 7.94 (S, 1H), 7.76 (d, 2H), 7.62 (d, 1H), 7.36 (d , 1H), 7.26 (t, 1H), 6.9 (d, 1H), 3.6 (t, 4H), 3.45 (s, 2H), 2.39 (t, 4H), 2.1 (s, 3H), 1.86 (s, 3H). MS (El) for C23H25N502: 404 (MH +). N- [4- (2 - { [3- (1, 3-dioxan-2-yl) phenyl-] amino} pyrimidin-4-yl) phenyl] acetamide: NMR! (400MHz, ds-DMSO): 10.22 (s, 1H), 9.68 (s, 1H), 8.5 (d, 1H), 8.32 (s, 1H), 8.21 (d, 2H), 7.77 (d, 2H), 7.58 (d, 1H), 7.39 (d, 1H), 7.28 (t, 1H), 6.98 (d, 1H), 5.52 (s, 1H), 4.2 (dd, 2H), 4.0 (t, 2H), 2.1 (s, 3H), 2.05 (m, 1H), 1.5 (dd, 1H). MS (El) for C22H22N403: 391 (MH +). N- (4- {2- [(6-aminopyridin-2-yl) amino] pyrimidin-4-yl} phenyl) acetamide: NMR1! (400MHz, d6-DMSO): 10.22 (s, 1H), 8.93 (s, 1H), 8.55 (d, 1H), 8.14 (d, 2H), 7.75 (d, 2H), 7.57 (d, 1H), 7.45-7.4 (m, 2H), 6.12 (d, 1H), 5.78 (s, 2H), 2.08 (s, 3H). MS (El) for C17H16N60: 321 (MH +). N- (4- {2- [(6-aminopyrimidin-4-yl) amino] pyrimidin-4-yl} phenyl) acetamide: NMR ^ (400MHz, d6-DMSO): 10.25 (s, 1H) , 9.72 (s, 1H), 8.6 (d, 1H), 8.2-8.15 (m, 3H), 7.8 (d, 2H), 7.52 (d, 1H), 7.42 (s, 1H), 6.8 (br, 2H) ), 2.08 (s, 3H). MS (El) for C 16 H 15 N 70: 322 (MH +).

N- (4-morpholin-4-ylphenyl) -4-quinolin-6-ylpyrimidin-2-amino: NMR'M (400MHZ, dS-DMSO): 9.57 (s, 1H), 9.0 (d, 1H), 8.8 (s, 1H), 8.58 (d, 1H), 8.52 (d, 2H), 8.18 (d, 1H), 7.72 (d, 2H), 7.63 (q, 1H), 7.51 (d, 1H), 6.96 ( d, 2H), 3.75 (t, 4H), 3.07 (4H). MS (EI) for C23H21N50: 384 (MH +). N- (4-Rhorpholin-4-ylphenyl) -4 -quinolalin-6-pyrimidin-2-amino: NMR'H (400MHz, d6-DMSO): 9.6 (s, 1H), 9.04 (d, 2H), 8.88 (s, 1H), 8.63 (d, 1H), 8.6 (d, 1H), 8.27 (d, 1H), 7.7 (d, 2H), 7.63 (d, 1H), 6.95 (d, 2H), 3.75 ( t, 4H), 3.06 (t, 4H), MS (El) for C22H20N6O: 385 (MH +). N- [4- (2- {[4- (4-ethylpiperazin-1-yl) phenyl] amino} - 5-methylpyrimidin-4-yl) phenyl] -D-alaninamide: R N1! (400MHz, d6-DMSO): 9.25 (s, 1H), 8.3 (s, 1H), 7.7 (d, 2H), 7.66 (d, 2H), 7.6 (d, 2H), 6.85 (d, 2H), 3.5 (q, 1H), 3.03 (t, 4H), 2.5 (t, 4H), 2.35 (q, 2H), 2.12 (s, 3H), 1.23 (d, 3H), 1.02 (t, 3H). MS (El) for C 26 H 33 N 70: 460.5 (MH +) - N - [4- (2- { [4- (4-ethylpiperazin-1-yl) phenyl] amino.} - 5-methylpyrimidin-4-yl) phenyl] -D-prolineraide: RMN1 !. (400MHz, ds-DMSO): 10.27 (s, 1H), 9.25 (s, 1H), 8.3 (s, 1H), 7.8 (d, 2H), 7.65 (d, 2H), 7.61 (d, 2H), 6.86 (d, 2H), 3.73 (m, 1H), 3.03 (t, 4H), 2.9 (t, 2H), 2.5 (t, 4H), 2.36 (q, 2H), 2.2 (s, 3H), 2.1 -2.02 (m, 1H), 1.85-1.75 (m, 1H), 1.67 (p, 2H), 1.02 (t, 3H). MS (El) for C2SH35N70: 486 (MH +). N-ethyl-4-. { 4- [(4- { 4- [(tetrahydrofuran-2-ylcarbonyl) amino] phenyl] pyrimidin-2-yl) amino] phenyl} piperazine-l- carboxamide: NMR2H (400MHz, d6-DMSO): 9.93 (s, 1H), 9.4 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.88 (d, 2H), 7.67 (d, 2H), 7.3 (d, 1H), 6.96 (d, 2H), 6.6 (t, 1H), 4.34 (t, 1H), 4.0 (q, 1H), 3.86 (q, 1H), 3.42 (t, 4H) ), 3.05 (, 2H), 3.01 (t, 4H), 2.27-2.17 (m, 1H), 2.06-1.97 (m, 1H), 1.88 (p, 2H), 1.02 (t, 3H). MS (El) for C28H33N703: 516 (MH +). N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) -1H-imidazole-4-carboxamide: NMRH (400MHz, ds-DMSO): 12.76 (br, 1H), 10.12 (s, 1H), 9.39 (s, 1H), 8.43 (d, 1H), 8.13 (d, 2H), 8.01 (d, 2H), 7.87 (s, 2H), 7.7 (d, 2H), 7.3 (d, 1H) ), 6.93 (d, 2H), 3.74 (t, 4H), 3.05 (t, 4H). MS (El) for C24H23N702: 442 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -lH-pyrrole-2 -carboxamide: RM ^ H (400MHz, d6-DMSO ): NMRH (400MHZ, d6-DMSO): 11.75 (s, 1H), 10.0 (s, 1H), 9.39 (s, 1H), 8.44 (d, 1H), 8.15 (d, 2H), 7.92 (d, 2H), 7.7 (d, 2H), 7.3 (d, 1H), 7.12 (s, 1H), 7.0 (s, 1H), 6.93 (d, 2H), 6.2 (d, 1H), 3.74 (t, 4H) ), 3.05 (t, 4H) .MS (El) for C25H24N602: 441 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) .amino] pyrimidin-4-yl. phenyl) -1H-imidazole-2-carboxamide: RIVUS ^ H (400MHz, d6-DMSO): 13.2 (br, 1H), 10.65 (s, 1H), 9.4 (s, 1H), 8.44 (d, 1H), 8.15 (d, 2H), 8.04 (d, 2H), 7.68 (d, 2H), 7.4-7.2 (m, 3H), 6.95 (d, 2H), 3.74 (t, 4H), 3.05 (t 4H) MS (El) for C24H23N702: 442 (MH +).

N- (4- (2- (4-morpholinophenylamino) irimidin-4-yl) phenyl) -2- (2- (pyrimidin-3-yl) -ethylamino) acetamide: RMI ^ H (400MHz, ds-DMSO): 9.0 (s, 1H), 8.92 (d, 1H), 8.64 (d, 1H), 8.35 (d, 1H), 8.17-8.14 (m, 3H), 7.75 (d, 2H), 7.61 (d, 2H) , 7.22 (d, 1H), 7.00 (d, 2H), 3.89-3.79 (m, 4H), 3.33-3.21 (ra, 2H), 3.15-3.07 (m, 4H), 1.92 (s, 2H); MS (EI): 510.4 (MH +). 2- (3- (4-methylpiperazin-1-yl) propylamino) -N- (4- (2- (4-morpholinophenyl) amino) pyrimidin-4-yl) phenyl) acetamide: RMIS ^ H (400MHz, d6- DMSO): 8.36 (d, 1H), 8.14 (d, 2H), 7.75 (d, 2H), 7.61 (d, 2H), 7.22 (d, 1H), 6.99 (d, 2H), 3.87-3.81 (m , 4H), 3.68 (s, 2H), 3.13-3.07 (m, 4H), 2.98-2.88 (m, 2H), 2.82-2.62 (m, 8H), 2.39 (s, 3H), 1.93 (s, 3H) ), 1.89-1.79 (m, 2H); MS (EI): 512.6 (MH +). 2- (L-methylpiperidin-4-ylamino) -N- (4- (2- (4-morpholinophenylamino) -pyrimidin-4-yl) phenyl) acetamide: NMRH (400MHz, d6-DMSO): 8.35 (d, 1H ), 8.14 (d, 2H), 7.75 (d, 2H), 7.61 (d, 2H), 7.22 (d, 1H), 6.99 (d, 2H), 3.87-3.81 (m, 4H), 3.47 (s, 2H), 3.15-3.09 (m, 4H), 3.06-2.95 (m, 2H), 2.69-2.55 (m, 1H), 2.39 (s, 3H), 2.38-2.22 (m, 2H), 2.03-1.93 ( m, 2H), 1.90 (S, 2H), 1.63-1.43 (m, 2H); MS (EI): 545.2 (MH +). 2- (2-amino-2-oxoethylamino) -N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) acetamide: NMRH (400MHz, d6-DMSO): 8.27 (d, 1H) , 8.04 (d, 2H), 7.68 (d, 2H), 7.53 (d, 2H), 7.13 (d, 1H), 6.91 (d, 2H), 4.54 (s, 2H), 3.79-3.73 (m, 4H ), 3.39 (s, 2H), 3.06-3.00 (m, 4H), 1.86 (s, 2H); MS (El): 462.1 (MH +). 2-morpholino-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) -acetamide: RMIS ^ H (400MHz, d6-DMSO): 10.0 (s, 1H), 9.40 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.82 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.94 (d, 2H), 3.78-3.70 (m, 4H), 3.69-3.61 (m, 4H), 3.08-3.02 (m, 4H), 2.56-2.46 (m, 4H); MS (EI): 475.3 (MH +). 2- ((2-aminoethyl) methyl) amino) -N- (4- (2- (4-morpholinophenylamino) -pyrimidin-4-yl) phenyl) acetamide: RMI H (400MHz, d6-DMSO): 8.36 (d, 1H), 8.13 (d, 2H), 7.76 (d, 2H), 7.62 (d, 2H), 7.22 (d, 1H), 7.00 (d, 2H), 3.89-3.81 (m, 4H), 3.51 (s, 2H), 3.14-3.07 (m, 4H), 3.03-3.96 (m, 2H), 2.94-2.88 (m, 2H), 2.67 (s, 3H); MS (EI) C 25 H 31 N 702: 462.4 (MH +). 2- (1H-pyrazol-5-ylamino) -N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) -phenyl) acetamide: NMR1 ?. (400MHz, d6-DMSO): 8.35 (d, 2H), 8.12 (d, 2H), 7.74 (d, 2H), 7.61 (d, 2H), 7.40 (s, 1H), 7.21 (d, 1H), 6.99 (d, 2H), 5.69 (s, 1H), 3.95 (s, 2H), 3.86-3.80 (m, 4H), 3.14-3.07 (m, 4H), 1.96 (S, 2H); MS (EI): 471.1 (MH +). N- (4- (2- (4-morpholinophenylamino) irimidin-4-yl) phenyl) -2- (piperazin-1-yl) -acetamide: NMR'H (400MHZ, d6-DMSO): 10.39 (s, 1H ), 9.53 (s, 1H), 8.87 (s, 2H), 8.48 (d, 1H), 8.17 (d, 1H), 7.80 (d, 2H), 7.10 (d, 2H), 7.33 (d, 1H) 7.04 (d, 2H), 3.82-3.74 (m, 4H), 3.32-3.24 (m, 2H), 3.19-3.09 (m, 4H), 3.08-3.02 (m, 2H), 2.95 (s, 2H), 2.79 (s, 2H), 1.96 (s, 2H); MS (El): 474.2 (MH +). (S) -benzyl-2- (2- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenylamino) -2-oxoethylamino) propanoate: NMR1! (400MHz, CD30D): 8.25 (d, 2H), 8.01 (d, 2H), 7.61 (d, 2H), 7.51 (d, 2H), 7.30-7.08 (m, 5H), 7.12 (d, 1H), 6.90 (d, 2H), 5.15-5.05 (m, 2H), 3.78-3.73 (m, 4H), 3.43 (q, 1H), 3.33 (d, 2H), 3.05-2.97 (m, 4H), 1.28 ( d, 3H); MS (EI): 567.2 (MH +). N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) -2- (pyrimidin-4-yl-amino) acetamide: NMR1! (400MHz, CD30D): 10.90 (s, 1H), 9.63 (s, 1H), 9.18 (d, 2H), 8.78 (s, 1H), 8.50 (s, 1H), 8.26 (d, 1H), 8.18 ( d, 2H), 7.82-7.68 (m, 4H), 7.36 (d, 1H), 7.11 (d, 2H), 6.84 (s, 1H), 5.16 (s, 2H), 3.83-3.77 (m, 4H) , 2.54-2.47 (m, 4H); MS (EI): 483.2 (MH +). N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) -2- (piperidin-1-yl) -acetamide: R ^ H (400MHz, d6-DMSO): 10.98 (s, 1H ), 9.84 (s, 1H), 9.65 (s, 1H), 8.50 (d, 1H), 8.20 (d, 2H), 7.90-7.70 (m, 4H), 7.36 (d, 1H), 7.11 (d, 2H), 4.12-4.07 (m, 2H), 3.87-3.77 (m, 4H), 3.62-3.42 (m, 2H), 3.23-3.13 (m, 4H), 2.51 (s, 2H), 1.94-1.64 ( m, 6H), 1.45-1.38 (m, 2H); MS (EI): 473.4 (MH +). 2- (ethylamino) -N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) acetamide: RMN'H (400MHZ, d6-DMSO): 10.78 (s, 1H), 9.45 (s) , 1H), 8.87 (s, 2H), 8.48 (d, 1H), 8.17 (d, 2H), 7.77 (d, 2H), 7.71 (d, 2H), 7.33 (d, 1H), 7.04 (d, 2H), 4.04-3.97 (m, 2H), 3.82-3.74 (m, 4H), 3.19-3.02 (m, 6H), 1.12 (t, 3?); MS (El): 433.3 (MH +). 2- (1H-imidazol-1-yl) -N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) -acetamide: RM 1.! (400MHz, d6-DMSO): 10.87 (s, 1H), 9.56 (s, 1H), 9.11 (s, 1H), 8.45 (d, 1H), 8.15 (d, 2H), 7.76 (d, 2H), 7.70 (d, 2H), 7.32 (d, 1H), 7.05 (d, 2H), 5.26 (s, 2H), 3.82-3.72 (ra, 4H), 3.18-3.08 (m, 4H); MS (EI): 456.3 (MH +). 4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) benzoic acid: RMNXH (400MHz, d6-DMSO): 9.56 (s, 1H), 8.55 (d, 1H), 8.27 (d, 1H), 8.27 (d, 2H), 8.09 (d, 2H), 7.68 (d, 2H), 7.41 (d, 1H), 6.97 (d, 2H), 3.80-3.72 (m, 4H), 3.11-3.03 (m, 4H) ); MS (EI): 377.3 (MH +). N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) -2- (phenylamino) -acetaraide: RMI H (400MHz, d6-DMSO): 10.29 (s, 1H), 9.59 (s) , 1H), 8.46 (d, 1H), 8.14 (d, 2H), 7.79 (d, 2H), 7.73 (d, 2H), 7.33 (d, 1H), 7.19-7.00 (m, 4H), 6.70- 6.50 (m, 3H), 3.96-3.88 (m, 4H), 3.22-3.12 (m, 4H); MS (EI): 481.1 (MH +). 4- (4- (5-methyl-1,3,4-oxadiazol-2-yl) phenyl) -N- (4-morpholinophenyl) -pyrimidin-2-amide: RM ^ H (400MHz, d6-DMSO): 9.53 (s, 1H), 8.54 (d, 1H), 8.35 (d, 2H), 8.12 (d, 2H), 7.65 (d, 2H), 7.40 (d, 1H), 6.92 (d, 1H), 3.76 -3.70 (m, 4H), 3.06-3.00 (m, 4H), 2.59 (s, 3H); MS (EI): 415.3 (MH +) (R) -4- (4- (4- (4- (2-aminopropanamido) phenyl) pyrimidin-2-ylamino) phenyl) -N-ethylpiperazine-1-carboxamide: NMR'H (400MHZ, d6-DMSO): 9.41 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.82 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.96 (d, 2H), 6.59 (t, 1H), 3.54-3.46 (m, 1H), 3.44-3.36 (m, 4H), 3.12-2.97 (m, 6H), 1.24 (d, 3H) , 1.02 (t, 2H), 0.95 (t, 2H); MS (El): 487.1 (MH-). (R) -2-amino-N- (4- (2- (4- (4- ((R) -pyrrolidine-2-carbonyl) iperazin-1-yl) phenylamino) pyrimidin-4-yl) phenyl ) propanamide: RMNXH (400MHz, d6-DMSO): 9.41 (s, 1H), 8.45 (d, l'H), 8.13 (d, 2H), 7.82 (d, 2H), 7.69 (d, 2H), 7.29 (d, 1H), 6.97 (d, 2H), 3.97-3.92 (m, 1H), 3.72-3.58 (m, 4H), 3. 51-3.42 (m, 2H), 3.14-2.99 (m, 4H), 2.68-2.62 (m, 1H), 2.12-2.00 (m, 1H), 1.74-1.70 (m, 1H), 1.70-1.56 (m , 2H), 1.24 (d, 3H); MS (El): 513.2 (MH-). (R) -2-amino-N- (4- (2- (4- (4- ((S) -pyrrolidine-2-carbonyl) piperazin-1-yl) phenylamino) pyrimidin-4-yl) phenyl ) propanamide: RMIS ^ H (400MHz, d6-DMSO): 9.41 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.83 (d, 2H), 7.69 (d, 2H), 7.29 (d, 1H), 6.97 (d, 2H), 4.65 (t, 1H), 3.89-3.81 (m, 1H), 3.75-3.58 (m, 3H), 3.54-3.28 (m, 2H), 3.15 -2.98 (m, 4H), 2.72-2.58 (m, 1H), 2.06-1.97 (m, 2H), 1.74-1.54 (m, 2H), 1.24 (d, 3H); MS (El): 515.4 (MH +). N- [4 - (2- {[[4- (4-L-alanylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] -D-alaninamide: 1H NMR (400MHz, d6- DMSO): 9.40 (S, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.83 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.97 (d, 2H) ), 3.57 (dd, 1H), 3.68- 3. 58 (m, 4H), 3.46 (dd (1H), 3.12-2.98 (ra, 4H), 1.23 (d, 3?), 1.12 (d, 3?); MS (El): 489.4 (MH +). R) -2-amino-N- (4- (2- (4- (4 ((S) -2-aminopropanoyl) piperazin-1-yl) phenylamino) pyrimidin-4-yl) phenyl) propanamide: NMR'H (400MHZ, d6-DMSO): 9.40 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.83 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.97 (d, 2H), 3.17 (s, 2H), 3.12-3.07 (m, 1H), 3.05-2.98 (m, 1H), 2.70-2.64 (m, 4H), 2.36-2.28 (m, 4H), 1.23 (d, 3H); MS (El): 544.4 (MH +). 3,3, 3-trifluoro-2-hydroxy-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) ropanamida: RMNXH (400MHz, d6-DMSO): 10.42 (br s, 1H), 9.41 (s, 1H), 8.46 (d, 1H), 8.15 (d, 2H), 7.89 (d, 2H), 7.68 (d, 2H) , 7.57 (br s, 1H), 7.31 (d, 6.94 (d, 2H), 4.83-4.74 (m, 1H), 3.78-3.70 (m, 4H), 3.09-3.01 (m, 4H); ): 474.3 (MH +). (R) -2-hydroxy-2-methyl-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) butanamide: RMl H (400MHz, d6-DMSO): 9.72 (s, 1H), 9.34 (s, 1H), 8.41 (d, 1H), 8.08 (d, 2H), 7.89 (d, 2H), 7.64 (d, 2H), 7.27 (d, 1H), 6.91 (d, 2H), 5.66 (s, 1H), 4.21-4.13 (m, 1H), 3.72 (q, 1H), 3.15 (d, 3H), 3.12-3.02 (m, 4H), 1.80-1.72 (m, 1H), 1.59-1.51 (m, / 1H), 1.32 (s, 3H), 0.82 (t, 3H); MS (El): 448.4 (MH +). (S) -2-hydroxy-2-methyl-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) butanamide: NMRH (400MHz, d6-DMSO): 9.72 (s, 1H) , 9.34 (s, 1H), 8.41 (d, 1H), 8. 08 (d, 2H), 7.89 (d, 2H), 7.64 (d, 2H), 7.27 (d, 1H), 6.91 (d, 2H), 5.66 (s, 1H), 4.21-4.13 (m, 1H) , 3.72 (q, 1H), 3.19-3.11 (d, 3H), 3.07-3.02 (m, 4H), 1.81-1.71 (m, 1H), 1.60-1.50 (m, 1H), 1.32 (s, 3H) 0.82 (t, 3H); MS (EI): 448.1 (MH +). (R) -2-methoxy-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) -propanamide: NMR1 (400MHz, d6-DMSO): 10.07 (s, 1H), 9.35 ( s, 1H), 8.41 (d, 1H), 8.11 (d, 2H), 7.84 (d, 2H), 7.64 (d, 2H), 7.26 (d, 1H), 6.90 (d, 2H), 3.89 (q , 1H), 3.75-3.67 (m, 4H), 3.30 (s, 3H), 3.04-2.96 (m, 4H), 1. 31 (d, 3H); MS (EI): 434.3 (MH +). (S) -2-methoxy-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) -propanamide: NMR1. (400MHz, d6-DMSO): 10.07 (s, 1H), 9.35 (s, 1H), 8.41 (d, 1H), 8.11 (d, 2H), 7.84 (d, 2H), 7.64 (d, 2H), 7.26 (d, 1H), 6.90 (d, 2H), 3.89 (q, 1H), 3.75-3.67 (m, 4H), 3.30 (s, 3H), 3.04-2.96 (m, 4H), 1.31 (d, 3H); MS (El): 434.3 (MH +). 1-amino-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) -cyclopentanecarboxamide: NMR1. (400MHz, d6-DMSO): 9.39 (s, 1H), 8.44 (d, 1H), 8.14 (d, 2H), 7.87 (d, 2H), 7.68 (d, 2H), 7.30 (d, 1H), 6.94 (d, 2H), 3.78-3.70 (m, 4H), 3.08-3.00 (m, 4H), 2.10-2.00 (m, 2H), 1.86-1.75 (m, 2H), 1.74-1.62 (m, 2H) ), 1.60-1.50 (m, 2H); MS (El): 459.4 (MH +). (S) -2-hydroxy-3, 3-dimethyl-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) butanamide: NMR1. (400MHz, d6-DMSO): 9.83 (s, 1H), 9.39 (s, 1H), 8.45 (d, 1H), 8.11 (d, 2H), 7.89 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.95 (d, 2H), 5.85 (d, 1H), 3.78-3.70 (m, 4H), 3.47 (q, 1H), 3.09-3.01 (m, 4H), 0.97 (d, 9H); MS (EI): 462.4 (MH +). (R) -2- (Cyclohexyl-2-hydroxy-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) acetamide: RMIS ^ H (400MHz, d6-DMSO): 9.91 (s, 1H), 9.39 (s, 1H), 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.89 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6. 94 (d, 2H), 5.76 (br s, 1H), 3.85 (d, 1H), 3.77-3.69 (m, 4H), 3.10-3.02 (m, 4H), 1.80-1.51 (m, 6H), 1.30 -1.02 (m, 5H); MS (EI): 488.1 (MH +). (S) -2-Cyclohexyl-2-hydroxy-N- (4- (2- (4-morpholinophenylamino) irimidin-4-yl) phenyl) acetamide: NMRH (400MHz, d6-DMSO): 9.91 (s, 1H) , 9.39 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.89 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.94 (d, 2H), 5.76 (br s, 1H), 3.85 (d, 1H), 3.77-3.69 (m, 4H), 3.07-2.98 (m, 4H), 1.78-1.50 (m, 6H), 1.25-1.00 (m, 5H); MS (EI): 488.1 (MH +). (S) -2- (hydroxy-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) -propanamide: NMR1H (400MHz, de-DMSO): 9. 95 (s, 1H), 9.39 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.90 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.94 (d, 2H), 5.87 (br s, 1H), 4.23-4.15 (m, 1H), 3.79-3.71 (m, 4H), 3.08-3.00 (m, 4H), 2.51 (d, 3H); MS (EI): 420.4 (MH +). 1-amino-N- (4- (2- (4-morpholinophenylamino) pyrimidine- 4-yl) phenyl) -cyclobutanecarboxamide: RMIS ^ H (400MHz, d6-DMSO): 9.39 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.87 (d, 2H), 7.68 ( d, 2H), 7.29 (d, 1H), 6.94 (d, 2H), 3.79-3.71 (m, 4H), 3.09-3.00 (m, 4H), 2.00-1.85 (m, 4H), 1.84-1.76 ( m, 2H); MS (EI): 445.4 (MH +). 4- (4- (3-methyl-1,2,4-oxadiazol-5-yl) phenyl) -N- (4-rhorpholinophenyl) pyrimidin-2-amine: RM ^ H (400MHz, d6-DMSO): 9.57 (s, 1H), 8.57 (d, 1H), 8.39 (d, 2H), 8.26 (d, 2H), 7.67 (d, 2H), 7.44 (d, 1H), 6.95 (d, 2H), 3.78- 3.72 (m, 4H), 3.09-3.03 (m, 4H), 2.46 (s, 3H); MS (EI): 415.0 (MH +). N- (4- (2- (4- (4-ethylpiperazin-1-yl) phenylamino) pyrimidin-4-yl) phenyl) -2-phenylacetamide: NMR1! (400MHz, d6-DMSO): 10.45 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.12 (d, 2H), 7.76 (d, 2H), 7.64 (d, 2H), 7.38-7.33 (m, 3H), 7.27 (d, 1H), 6.92 (d, 2H), 3.69 (s, 2H), 3.10-3.04 (m, 4H), 2.35 (q, 3H), 1.89 (s, 2H), 1.03 (t, 2H); MS (EI): 493.1 (MH +). 1- (4- (2- (4-Rhorpholinophenylaminopyrimidin-4-yl) phenyl) pyrrolodin-2-one: RM ^ H (400MHz, d6-DMSO): 8.26 (d, 1H), 8.14 (d, 2H), 7.77 (d, 2H), 7.65 (d, 2H), 7.36 (d, 1H), 7.25 (d, 2H), 3.92-3.84 (m, 5H), 3.82-3.74 (m, 1H), 3.74-3.60 ( m, 1H), 3.42-3.30 (m, 4H), 3.06-3.02 (m, 1H), 2.16-2.06 (m, 2H); MS (EI): 416.1 (MH +). (S) -2-hydroxy- 3-methyl-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) butanamide: R NXH (400MHz, d6-DMSO): 9.90 (s, 1H), 9.39 (s, 1H) , 8.45 (d, 1H), 8. 12 (d, 2H), 7.90 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.94 (d, 2H), 5.76 (d, 1H), 3.86 (dd, 1H), 3.78 -3.73 (m, 4H), 3.08-3.02 (m, 4H), 0.96 (d, 3H), 0.87 (d, 3H); MS (EI): 448.3 (MH +). (R) -2-hydroxy-3-methyl-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) butanaraide: RMIS ^ H (400MHz, d6-DMSO): 9.90 (s, 1H), 9.39 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.90 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.94 (d, 2H) ), 5.76 (d, 1H), 3.86 (dd, 1H), 3.78-3.73 (m, 4H), 3.08-3.02 (ra, 4H), 0.96 (d, 3H), 0.87 (d, 3H); MS (EI): 448.3 (MH +). (R) -2-amino-N- (4- (2- (4- (4- (cyclobutanecarbonyl) piperazin-1-yl) phenylamino) pyrimidin-4-yl) phenyl) propanamide: RMIS ^ H (400MHz, d6 -DMSO): 9.41 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.82 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.95 (d, 2H), 3.63-3.56 (m 2H), 3.43-3.37 (ra, 3H), 3.18 (d, 1H), 3.07-2.98 (m, 4H), 2.25-2.02 (m, 4H), 1.98-1.83 (m , 1H), 1.82 -1.70 (ra, 1H), 1.23 (d, 3H); MS (EI): 500.2 (MH +). (R) -2-amino-N- (4- (2- (4- (4-pivaloylpiperazin-1-yl) phenylamino) pyrimidin-4-yl) phenyl) propanamide: RM ^ H (400MHz, d6-DMSO) : 9.41 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.82 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.95 (d, 2H), 3.73-3.67 (m, 4H), 3.52-4.42 (m, 1H), 3.08-3.02 (m, 4H), 1.25 (s, 3H), 1.23 (d, 3H), MS (EI): 502.4 (MH +) . 4- [4- (ethylamino) phenyl] -N- (4-morpholin-4-ylphenyl) pyrimidin-2-amine: NMR ^ (400MHz, DMSO): 9.202 (s, 1H), 8.3 (d, 2H), 7.948 (d, 2H), 7.689 (q, 2H), 7.134 (d, 1H), 6.93 (d, 2H), 6,657 (d, 2H), 6,285 (t, 1H), 3,754 (t, 4H), 3,132-3,113 (m, 2H), 3.04 (t, 4H), 1187 (t, 3H). S (E) for C22H25NsO: 376.3 (MH +). N-. { 4- [2- (phenylamino) pyrimidin-4-yl] phenyl} acetamide: NMR1H (400MHz, DMSO); 10.233 (s, 1H), 9.63 (s, 1H), 8.513 (d, 1H), 8.147 (d, 2H), 7.854 (d, 2H), 7.774 (d, 2H), 7.362-7.305 (m, 3H) , 6.961 (t, 1H), 2.098 (s, 3H). MS (El) for C18H16N40: 305.3 (MH +). N-. { 4- [2- ( { 4- [(4-ethylpiperazin-1-yl) carbonyl] phenyl} amino) pyrimidin-4-yl] -phenyl} Acetamide: RMI ^ H (400MHz, DMSO): 10,236 (s, 1H), 9,889 (s, 1H), 8,549 (d, 1H), 8,167-8,134 (m, 2H), 7.93-7.903 (m, 2H), 7.782 (d, 2H), 7.418-7.369 (m, 3H), 3.509 (br s, 4H), 2.378-2.324 (m, 6H), 2.097 (s, 3H), 1.025 (t, 3H). MS (El) for C25H28N602; 445.4 (MH +). N- [4- (2- {[[3- (morpholin-4-ylcarbonyl) phenyl] amino} pyrimidin-4-yl) phenyl] -acetamide: NMR'H (400MHZ, DMSO): 10.237 (s) , 1H), 9,823 (S, 1H), 8,541 (d, 1H), 8,152 (d, 2H), 8,026 (t, 1H), 7,847 (d, 1H), 7,772 (d, 2H), 7,392 (m, 2H), 6,996 (d, 1H), 3.76-3.36 (br, s 8H), 2.094 (s, 3H). MS (El) for C23H23N503: 418.3 (MH +). N- (4- (2- (3- (2- (dimethylamino) ethoxy) phenylamine) pyrimidin-4-yl) phenyl) -acetamide: NMR'H (400MHZ, DMSO): 10,471 (br s, 1H), 10.42 (s, 1H), 9,816 (s, 1H), 8,534 (d, 1H), 8. 158 (d, 2H), 7.804 (d, 2H), 7.7 (t, 1H), 7.413-7.383 (m, 2H), 7.29 (t, 1H), 6.636 (m, 1H), 4.38 (t, 2H) , 3,531 (q, 2H), 2,883 (d, 6H), 2,106 (s, 3H). MS (El) for C22H25N502: 392.3 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) araino] pyrimidin-4-yl}. Phenyl) benzaraide: NMR'H (400MHZ, DMSO): 10.532 (s, 1H), 9.407 (s, 1H), 8.47 (d, 1H), 8.189 (d, 2H), 7.982 (m, 4H), 7.7-7.54 (m, 5H), 7.325 (d, 1H), 6.969 (d, 2H) , 3.747 (t, 4H), 3.054 (t, 4H). MS (El) for C27H25N502: 452.1 (MH +). N- [4- (2- { [4- (methyloxy) phenyl)] amino} pyrimidin-4-yl) phenyl] acetamide: NMR'H (400MHz, DMSO): 10,222 (s, 1H), 9,433 (s, 1H), 8,455 (s, 1H), 8,121 (d, 2H), 7,725 (q , 4H), 7.293 (d, 1H), 6.91 (d, 2H), 3.739 (s, 3H), 2.093 (s, 3H). MS (El) for C19H18N402: 335 (MH +). 4- (4-chlorophenyl) -N- (4-morpholin-4-ylphenyl) pyrimidin-2 -amine: NMR'H (400MHz, DMSO): 9488 (s, 1H), 8.514 (d, 1H), 8.185 ( d, 2H), 7.665-7.606 (q, 4H), 7.354 (d, 1H), 6.918 (d, 2H), 3.757 (t, 4H), 3.048 (t, 4H). MS (El) for C20H19CIN4O: 367 (MH +). N- [4- (2- { [3- (methyloxy) phenyl] amino} pyrimidin-4-yl) phenyl] acetamide: NMR'H (400MHz, DMSO): 10,235 (s, 1H), 9,633 (S, 1H), 8.52 (d, 1H), 8.15 (d, 2H), 7.65 (t, 1H), 7.369 (d, 2H), 7.209 (t, 1H), 6.535 (q, 1H), 3.77 ( s, 3H), 2.092 (s, 3H). MS (El) for C19H18N402: 335 (MH +). 1- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidine-4- il-phenyl) -3- (phenyl-methyl) urea: NMR'H (400MHZ, DMSO): 9.347 (s, 1H), 9 (s, 1H), 8.414 (d, 1H), 8.067 (d, 2H), 7.688 (d, 2H), 7,583 (d, 2H), 7,351-7.31 (m, 4H), 7,237 (d, 2H), 6,943 (d, 2H), 6,831 (t, 1H), 4.33 (d, 2H), 3.742 (t, 4H), 3.044 (t, 4H). MS (El) for C28H28N602: 481.4 (MH +). N- (4- {2 - [(4. {4 - [(2S) -pyrrolidin-2-ylmethyl] piperazin-1-yl} phenyl) amino] -pyrimidin-4-yl} phenyl) -D-prolinamide: NMR'H (400MHz, DMSO): 10,231 (br s, 1H), 9,376 (s, 1H), 8,443 (d, 1H), 8,134 (d, 2H), 7,848 (d, 2H), 7.663 (d, 2H), 7.29 (d, 1H), 6.936 (d, 2H), 3.74 (m, 1H), 3.505 (ra, 1H), 3.08-2.89 (ra, 6H), 2.64 (m , 2H), 2374 (m, 1H), 2.069 (m, 1H), 1938-1.648 (m, 9H), 1452 (m, 1H). MS (EI) for C30H38N8O: 527.3 (MH +). N- (4- {2- [(4-morpholin-4-ylphenyl) amino] pyriraidin-4-yl}. Phenyl) -2,3-dihydro-lH-isoindole-l-carboxamide: NMRH (400MHz , DMSO): 11,345 (s, 1H), 10,326 (brs, 1H), 9,525 (s, 1H), 9,479 (brs, 1H), 8,474 (d, 1H), 8.19 (d, 2H), 7,799 ( d, 2H), 7.7-7.627 (m, 3H), 7.469-7.415 (m, 3H), 7.323 (d, 1H), 7.025 (d, 2H), 5.688 (br s, 1H), 4.578 (ra, 2H) ), 3.757 (s, 4H), 3.105 (s, 4H). MS (El) for C29H28N602: 492.58 (MH +). N-. { 4- [2- ( { 4- [4- (2-piperazin-l-ylacetyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} tetrahydrofuran-2-carboxamide: NMRH (400MHz, DMSO): 9,938 (s, 1H), 9,412 (s, 1H), 8,456 (d, 1H), 7,135 (d, 2H), 7,886 (d, 2H), 7,691 ( d, 2H), 7.304 (d, 1H), 6.975 (d, 2H), 4.45 (m, 1H), 4.01 (q, 1H), 3,878 (q, 1H), 3,705 (brs, 4H), 3,592 (brs, 4H), 3,148 (s, 2H), 3.1 (brs, 2H), 3.02 (brs, 2H), 2,719 (br s, 4H), 2.354 (br s, 4H), 2.21 (m, 1H), 2.021 (m, 1H), 1862 (m, 2H). MS (El) for C 31 H 38 N 803: 571 (MH +). N- (4- {2 - [(4- {4- [(4-chloro-l-methyl-lH-pyrazol-3-yl) methyl] piperazin-1-yl} -phenyl) amino] pyrimidin-4-yl.} phenyl) -D-prolinamide: RM ^ (400MHz, DMSO): 10.215 (s, 1H), 9.363 (s, 1H), 8.439 (d, 1H), 8.131 (d, 2H), 7.901 (s, 1H), 7.841 (d, 2H), 7.651 (d, 2H), 7.286 (d, 1H), 6.916 (d, 2H), 3.802 (s, 3H), 3.7 (m, 1H) ), 3.47 (s, 2H), 3.048 (br s, 4H), 2.92 (t, 2H), 2.568 (t, 4H), 2.08 (m, 1H), 1.816 (m, 1H), 1691 (m, 2H) ). MS (El) for C30H34CIN90: 572.4 (MH +). N-. { 4- [2- (. {4- [4- (2-hydroxyethyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] -phenyl} -D-prolinamide: RMN1 !! (400MHz, DMSO): 10,176 (s, 1H), 9,927 (s, 1H), 8,374 (d, 1H), 8,065 (d, 2H), 7,773 (d, 2H), 7,587 (d, 2H), 7,219 (d, 1H), 6,857 (d, 2H), 4,396 (br s, 1H), 3,715 (t, 1H), 3,468 (br S, 4H), 2,996-2,954 (m, 6H), 2,873 (t, 2H), 2.74 (s, 1H), 2,368 (t, 2H), 2,369 (t, 2H), 2,368 (t t, 2H), 2038 (m, 1H), 1749 (m, 1H), 1.61 (m, 2H). MS (El) for C27H33N702: 488.3 (MH +). N- (4- {2 - [(4- {4- [(1-methyl-1H-pyrrol-2-yl) methyl] piperazin-1-yl} phenyl) amino] -pyrimidine- 4-yl] phenyl) -D-prolinamide: RM ^ H (400MHz, DMSO): 10,194 (s, 1H), 9,349 (s, 1H), 8.42 (d, 1H), 8.11 (d, 2H), 7,822 ( d, 2H), 7.636 (d, 2H), 7,267 (d, 1?), 7,076 (s, 1H), 6,902 (d, 2H), 6.75 (s, 1H), 3,738 (m, 1H), 3,701 (s, 3H), 3,553 (s, 2H), 3,306 (m, 4H), 3,031 (br s, 4H), 2,892 (t, 2H), 2,728 (s, 1H), 2,054 (m, 1H), 1,803 (m, 1H), 1,647 (m, 2H). MS (El) for C 31 H 36 N 80: 538.3 (MH +). N- (4- { 2- [(4- { 4- [(2R) -pyrrolidin-2-ylmethyl] piperazin-1-yl] phenyl) amino] -pyrimidin-4-yl) phenyl ) -D-prolinamide: NMR'H (400MHz, DMSO): 8,319-8,251 (m, 3H), 7.86 (d, 2H), 7.636 (s, 2H), 7.56 (d, 1H), 7.282 (d, 2H) ), 4,479 (t, 1H), 4,106 (m, 1H), 3,514 (br s, 4H), 3,496-3.303 (m, 11H), 2252 (m, 1H), 2342 (m, 1H), 2.19-2.094 (m, 6H), 1835 (m, 1H). MS (El) for C30H36N8O: 528.5 (MH +). (2S, 3aS, 7aS) -N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -octahydro-lH-indole-2-carboxamide : RIVIN1 *! (400MHz, DMSO): 10,857 (s, 1H), 9.84 (s, 1H), 9.714 (br s, 1H), 8,531 (d, 1H), 8,207 (m, 3H), 7,816 (d, 4H), 7.42 (d, 1H), 4,448 (m, 1H), 3,874 (t, 4H), 3,681 (br s, 1H), 3.322 (t, 4H), 2.504 (m, 2H), 2.09 (m, 1H), 1.913 (m, 1H), 1.615 (m, 4H), 1371-1.259 (m, 3H). MS (El) for C 29 H 34 N 602: 499.5 (MH +). N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -cyclopropanecarboxamide: NMR1! (400MHz, DMSO): 10,476 (s, 1H), 9,383 (s, 1H), 8,443 (d, 1H), 8,123 (d, 2H), 7,768 (d, 2H), 7,686 (d, 2H), 7,279 (d, 2H), d, 1H), 6,946 (d, 2H), 3.74 (t, 4H), 3046 (t, 4H), 1824 (m, 1H), 0.829 (m, 4H).

MS (El) for C 24 H 25 N 502: 416 (MH +). N- [4- (2- { [4- (dimethylamino) phenyl] amino} pyrimidin-4-yl) phenyl] acetamide: NMR'H (400MHZ, ds-DMSO): 10.38 (s, br, 1H), 9.92 (s, br, 1H), 8.85 (d, 2H), 8.11 (d, 2H), 7.92 (d, 2H), 7.79 (d, 2H), 7.67 (s, 2H), 7.42 (d , 1H), 3.10 (s, 6H), 2.10 (s, 3H). MS (El): 348 (MH +). N- (4 - {2 - [(4-chlorophenyl) amino] pyrimidin-4-yl.} Phenyl) acetamide: NMRH (400MHz, d6-DMSO): 10.30 (s, 1H), 9.88 (s, 1H), 8.53 (d, 1H), 8.14 (d, 2H), 7.87 (d, 2H), 7.75 (d, 2H), 7.41 (d, 2H), 7.37 (1H), 2.10 (s, 3). MS (El): 339 (MH +). N- [4- (2- {[[4- (lH-pyrrol-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl} acetamide: RMNXH (400MHz, d6-DMSO): 10.26 (br s, 1H), 9.78 (br s, 1H), 8.52 (d, 1H), 8.15 (d, 2H), 7.92 (d, 2H), 7.77 ( d, 2H), 7.54 (d, 2H), 7.38 (d, 1H), 7.31 (m, 2H), 6.24 (m, 2H), 2.09 (s, 3H). MS (El): 370 (MH +). 1- [4- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) phenyl] -piperidine-4-ethylcarboxylate: RMI ^ H (400MHz, d6-DMSO) : 10.25 (s, 1H), 9.49 (br s, 1H), 8.45 (d, 1H), 8.11 (d, 2H), 7.75 (d, 4H), 7.30 (d, 1H), 4.10 (q, 2H) , 3.56 (d, 2H), 2.86 (br s, 2H), 2.09 (s, 3H), 1.97 (br d, 2H), 1.35 (m, 2H), 1.30 (m, 2H), 0.88 (t, 3H) ). MS (El): 460 (MH +). N- [4 - (2- {[[4- (4-phenylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] -acetamide: NMRH (400MHz, d6-DMSO): 10.28 (s, 1H), 9.68 (br s, 1H), 9.49 (d, 1H), 8.14 (d, 2H), 7. 82 (br s, 1H), 7.70 (d, 2H), 7.35 (d, 1H), 7.28 (t, 2H), 7.08 (d, 2H), 6.88 (t, 1H), 3.45 (br s, 8H) 2.09 (s, 3H). MS (EI): 465 (MH +). N-. { 4- [2- ( { 4- [(2R, 6S) -2,6-dimethylmorpholin-4-yl] phenyl} amino) irimidin-4-yl] phenyl} acetaraide: RMl ^ H (400MHz, d6-DMSO): 10.28 (s, 1H), 9.79 (br s, 1H), 8.47 (d, 1H), 8.12 (d, 1H), 8.10 (d, 1H), 7.80 (br d, 2H), 7.75 (d, 2H), 7.37 (d, 2H), 3.69 (br s, 4H), 3.54 (d, 2H), 2.07 (s, 3H), 1.16 (s, 3H), 1.14 (s, 3H). MS (EI): 418 (MH +). 4-amino-N- (4 -. {2 - [(4-morpholin-4-ylphenyl) amino] irimidin-4-yl}. Phenyl) -tetrahydro-2H-thiopyran-1,1-dioxide -carboxamide: NMR ^ (400MHz, d6-DMSO): 11.06 (br s, 1H), 9.97 (br s, 1H), 9.29 (s, 2H0), 8.56 (d, 1H), 8.21 (d, 2H), 7.94 (d, 2H), 7.89 (d, 1H), 7.58 (s, 1H), 7.47 (d, 1H), 5.32 (br, 3H), 3.99 (s, 4H), 3.48 (m, 4H), 3.38 (m, 4H), 2.84 (m, 2H), 2.46 (m, 2H). MS (EI): 523 (MH +). (2R) -N- (4- { 2- [(4-morpholin-4-ylphenyl) araino] pyrimidin-4-yl} phenyl) -piperazine-2-carboxamide: RMIN H (400MHz, d6- DMSO): 10.33 (br s, 1H), 10.31 (br s, 1H), 8.58 (d, 1H), 8.22 (d, 2H), 7.94 (d, 2H), 7.89 (d, 2H), 7.77 (d , 2H), 7.53 (d, 1H), 4.55 (d, 1H), 4.08 (s, 5H), 3.54 (s, 5H), 3.43 (m, 2H), 3.28 (m, 2H). MS (EI): 460 (MH +). 2-amino-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -1,2,3,4-tetrahydronaphthalene-2-carboxamide : RMNXH (400MHz, d6-DMSO): 11.10 (br s, 1H), 10.07 (br s, 1H), 8.89 (d, 2H), 8.56 (d, 1H), 8.20 (d, 2H), 7.98 (d, 2H), 7.92 (d, 2H), 7.70 (d, 2H), 7.48 (d, 1H), 7.10 (m, 4H), 6.10 (br s, 3H), 4.40 (s, 4H), 3.70 (d, 1H), 3.50 (s, 4H), 3.39 (d, 4H), 2.89 (m, 1H), 2.71 (m, 1H), 2.1 (m, 1H), 1.26 (m, 1H), 1.17 (m, 1H). MS (EI): 521 (MH +). 4-amino-N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -tetrahydro-2H-pyran-4-carboxamide: R N ' H (400MHz, d6-DMSO): 10.85 (br s, 1H), 9.85 (br s, 1H), 8.97 (s, 2H), 8.53 (d, 1H), 8.20 (d, 2H), 7.94 (d, 2H), 7.83 (d, 2), 7.43 (d, 2H), 4.39 (br s, 3H), 3.94 (s, 4H), 3.87 (d, 4H), 3.72 (m, 4H), 2.45 (m, 2H), 1.97 (d, 2H). MS (EI): 475 (MH +). (4S) -4-hydroxy-N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) prolinamide: RMIN H (400MHz, d6-DMSO ): 11.38 (s, 1H), 10.25 (m, 1H), 10.31 (s, 1H), 8.84 (m, 1H), 8.57 (d, 1H), 8.21 (d, 2H), 7.93 (d, 2H) , 7.87 (d, 2H), 7.75 (d, 2H), 7.49 (d, 1H), 6.62 (m, 1H), 4.50 (s, 1H), 4.06 (s, 4H), 3.53 (s, 4H), 3.42 (m, 1H) < 3.17 (m, 1H), 2.45 (t, 1H). MS (EI): 461 (MH +). l-acetyl-4-amino-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl.} - phenyl) piperidine-4-carboxamide: RMIS ^ H (400MHz, d6-DMSO): 9.72 (s, 1H), 8.51 (d, 1H), 8.14 (dd, 2H), 8.12 (d, 1H), 8.08 (d, 1H), 7.00 (dd, 1H), 7.39 (d, 1H), 7.17 (d, 1H), 4.15 (d, 1H), 3.70 (m, 4H), 3.68 (d, 1H), 4.41 (m, 4H), 3.41 (m, 4H), 3.01 (m, 1H), 2.93 (m, 4H), 2.02 (s, 3H), 1.98 (m, 1H), 1.84 (m, 1H). MS (EI): 516 (MH +). O-methyl-N- (4- {2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -D-serinamide: RMIS ^ H (400MHz, d6-DMSO ): 11. 51 (br s, 1H), 9.99 (br s, 1H), 8.55 (d, 1H), 8.50 (br s, 2H), 8.19 (d, 2H), 7.88 (m, 4H), 7.46 (d, 1H) ), 5.19 (br s, 3H), 4.36 (m, 1H), 4.02 (br s, 4H), 3.88 (m, 1H), 3.46 (br S, 4H), 3.33 (S, 3H). MS (EI): 449 (MH +). N- [4- (2- {(4- (2,6-dimethylmorpholin-4-yl) phenyl] amino} pyriraidin-4-yl) phenyl] acetamide: RMI ^ H (400MHz, d6-DMSO ): 10.30 (brs, 1H), 9.83 (brs, 1H), 8.50 (d, 1H), 8.14 (d, 2H), 7.81 (br s, 1H), 7.77 (d, 2H), 7.39 (d, 1H), 4.10 (brs, 4H), 3.56 (d, 2H), 2.10 (s, 3H), 1.18 (s) , 3H), 1.71 (s, 3H). MS (EI): 418 (MH +). N- (4- { 2- [(4-piperidin-1-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) acetamide: NMR ^ (400MHz, d6-DMSO): 10.32 (br s, 1H), 9.89 (br s, 1H), 8.52 (d, 1H), 8.11 (d, 2H), 7.94 (d., 2H), 7.76 (d, 4H), 7.40 (d, 1H), 3.45 (Br s, 4H), 3.36 (6H), 2. 07 (s, 3H). MS (EI): 388 (MH +). O-methyl-N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -L-serinamide: NMR'H (400MHZ, d6-DMSO ): 11. 51 (br s, 1H), 9.99 (br s, 1H), 8.55 (d, 1H), 8.50 (br s, 2H), 8.19 (d, 2H), 7.88 (m, 4H), 7.46 (d, 1H), 5.19 (br s, 3H), 4.36 (m, 1H), 4.02 (br s, 4H), 3.88 (m, 1H), 3.46 (br S, 4H), 3.33 (S, 3H). MS (EI): 449 (MH +). 1, 1-dimethylethyl (2R) -2- carboxylate. { [(4- (2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) amino] carbonyl} pyrrolidine: NMR'H (400MHZ, d6-DMSO): 10.26 (br s, 1H), 9.38 (br s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.78 (d, 2H), 7.68 (d, 2H), 7.28 (d, 1H), 6.94 (d, 2H), 4.22 (m, 1H), 3.74 (m, 4H), 3.43 (m, 1H), 3.34 (m, 1H), 3.04 (m, 4H), 2.20 (m, 1H), 1.90 (m, 1H), 1.81 (m, 1H), 1.40 (s, 3H), 1.27 (s, 6H). MS (EI) 4: 545 (MH +). 4- [4- (Rethylsulfonyl) phenyl] -N- (4-morpholin-4-ylphenyl) pyrimidin-2-amine: NMRH (400MHz, d6-DMSO): 9.62 (s, 1H), 8.59 (d, 1H) , 8.39 (d, 2H), 8.09 (d, 2H), 7.68 (d, 2H), 7. 45 (d, 1H), 7.0 (s, br, 1H), 3.81-3.71 (m, 4H), 3.29 (s, 3H), 3.04-3.14 (m, 4H). MS (EI): 411 (MH +). 4- [3- (Methylsulfonyl) phenyl] -N- (4-morpholin-4-ylphenyl) pyrimidin-2-amine: RM ^ H (400MHz, d6-DMSO): 9.60 (s, 1H), 8.72 (s, 1H), 8.57 (d, 1H), 8.47 (d, 1H), 8.10 (d, 1H), 7.85 (d, 1H), 7.66 (d, 1H), 7.46 (d, 1H), 6.92 (d, 1H) ), 3.81-3.71 (m, 4H), 3.31 (s, 3H), 3.0-3.11 (m, 4H). MS (EI): 411 (MH +). 4- [4- (methylthio) phenyl] -N- (4-morpholin-4-ylphenyl) pyrimidin-2-amine: RM XH (400MHz, d6-DMSO): 9.42 (s, 1H), 8. 46 (d, 1H), 8.09 (d, 2H), 7.66 (d, 2H), 7.40 (d, 2H), 7.31 (d, 1H), 6.92 (d, 2H), 3.79-3.69 (m, 4H) , 3.1-3.0 (m, 4H), 2.55 (s, 3H). MS (EI): 379 (MH +). N- (4- { 2- [(3-bromo-4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -acetamide: RM 'H (400MHZ, d6-DMSO): . 23 (s, 1H), 9.72 (s, 1H), 8.52 (d, 1H), 8.27 (d, 1H), 8.13 (d, 2H), 7.81-7.71 (m, 3H), 7.42-7.32 (m, 1H), 7.18 (d, 1H), 3.78-3.69 (m, 4H), 2.97-2.87 (m, 4H), 2.09 (s, 3H). MS (EI): 469 (MH +). N- [4- (2- {[[4-. {[[2- (diethylamino) ethyloxy} -3- (4-ethylpiperazin-1-yl) phenyl] -amino} pyrimidin-4 il) phenyl] acetamide: NMR'H (400MHZ, d6-DMSO): 10.21 (s, 1H), 9.36 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.73 (d, 2H) ), 7.54 (s, 1H), 7.36-7.26 (m, 2H), 6.88 (d, 1H), 4.02-3.92 (ra, 2H), 2.81-2.71 (m, 2H), 2.59-2.49 (ra, 4H) ), 2.45-2.35 (m, 2H), 1.04 (t, 3H), 0.98 (t, 6H). MS (EI): 533 (MH +). N2, N2-dimethyl-N- (4- { 2- [(4- {4- [3- (methyloxy) propanoyl] piperazin-1-yl} phenyl) amino] pyrimidin-4-yl phenyl) glycinamide: NMR'H (400MHz, d6-DMSO): 9.99 (s, 1H), 9.41 (s, 1H), 8.45 (d, 1H), 8.11 (d, 2H), 7.84 (d, 2H), 7.68 (d, 2H), 7.28 (d, 1H), 6.95 (d, 2H), 3.63-3.59 (m, 4H), 3.25 (s, 3H), 3.11 (s, 2H), 3.10-3.05 (m, 2H), 3.04-2.99 (m, 2H), 2.65 (t, 2H), 2.29 (s, 6H). MS (EI): 519 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -cyclobutene-carboxamide: NMR ^ (400MHz, d6-DMSO): 9.99 (s) , 1H), 9.37 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.77 (d, 2H), 7.67 (d, 2H), 7.27 (d, 1H), 6.93 (d, 2H), 3.75 (m, 4H), 3.32 (m, 1H), 3.05 (m, 4H), 2.24 (m, 2H), 2.12 (m, 2H), 1.93 (m, 1H), 1.82 (m, 1H) ). MS (EI): 430 (MH +). N- (4-. {2- 2- (4-morpholin-4-ylphenyl) amino] pyrimidine-4- il} phenyl) azetidine-3-carboxamide: R ^ H (400MHz, d6-DMS0): 10.10 (s, 1H), 9.36 (s, 1H), 8.42 (d, 1H), 8.09 (d, 2H), 7.74 (d , 2H), 7.64 (d, 2H), 7.24 (d, 1H), 6.91 (d, 2H), 3.71 (m, 4H), 3.61 (m, 1H), 3.52 (m, 4H), 3.02 (m, 4H). MS (EI): 431 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) piperidine-3-carboxamide: RM ^ H (400MHz, d6-DMSO): 10.22 (s, 1H), 9.35 (s, 1H), 8.40 (d, 1H), 8.08 (d, 2H), 7.73 (d, 2H), 7.64 (d, 2H), 7.24 (d, 1H), 6.90 (d, 2H), d, 2H), 3.72 (m, 4H), 3.41 (m, 4H), 3.02 (m, 4H), 2.83 (m, 1H), 2.62 (m, 1H), 1.58 (m, 2H), 1.37 (m , 1 HOUR) . MS (EI): 459 (MH +). N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) piperidine-4-carboxamide: NMR1! (400MHz, d6-DMSO): 10.12 (s, 1H), 9.38 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.76 (d, 2H), 7.67 (d, 2H), 7.27 (d, 1H), 6.93 (d, 2H), 3.74 (m, 4H), 3.37 (m, 1H), 3.03 (m, 4H), 3.00 (m, 1H), 2.50 (m, 2H), 2.47 (m, 1H), 1.73 (m, 2H), 1.54 (m, 2H). MS (EI): 459 (MH +). 2- (methyloxy) -N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. -phenyl) acetamide: NMR'H (400MHz, d6-DMSO ): 10.05 (s, 1H), 9.36 (s, 1H), 8.42 (d, 1H), 8.09 (d, 2H), 7.82 (d, 2H), 7.65 (d, 2H), 7.26 (d, 1H) , 6.91 (d, 2H), 4.02 (s, 2H), 3.72 (m, 4H), 3.38 (s, 3H), 3.02 (m, 4H). MS (EI): 420 (MH +). N- (4- { 2 - [(4-morpholin-4-ylphenyl) amino] pyrimidine-4- il} phenyl) piperidine-2-carboxamide: RMIS ^ H (400MHz, d6-DMS0): 9.85 (s, br, 1H), 9.31 (s, 1H), 8.36 (d, 1H), 8.04 (d, 2H), 7.75 (d, 2H), 7.60 (d, 2H), 7.21 (d, 1H), 6.87 (d, 2H), 3.67 (m, 4H), 3.21 (m, 1H), 2.98 (m, 4H), 2.93 ( m, 1H), 2.47 (m, 1H), 1.70 (m, 2H), 1.37 (m, 4H). MS (EI) 2: 459 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) glycinamide: RMIS ^ H (400MHz, d6-DMSO): 9.37 (s, 1H ), 8.44 (d, 1H), 8.11 (d, 2H), 7.82 (d, 2H), 7.66 (d, 2H), 7.27 (d, 1H), 6.93 (d, 2H), 3.75 (m, 4H) , 3.62 (br s, 2H), 3.32 (m, 2H), 3.05 (m, 4H). MS (EI): 405 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) furan-2-carboxamide: RMIS ^ H (400MHz, d6-DMSO): 10.44 (s, 1H), 9.40 (s, 1H), 8.46 (d, 1H), 8.16 (d, 2H), 7.98 (m, 1H), 7.93 (m, 2H), 7.68 (d, 2H), 7.39 (d, d, 1H), 7.30 (d, 1H), 6.93 (d, 2H), 6.74 (d, 1H), 3.75 (m, 4H), 3.05 (m, 4H). MS (EI) 3: 442 (MH +). N- (4- {2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) tetrahydrofuran-2-carboxamide: RMIS ^ H (400MHz, d6-DMSO) : 9.91 (s, 1H), 9.36 (s, 1H), 8.41 (d, 1H), 8.09 (d, 2H), 7.84 (d, 2H), 7.67 (d, 2H), 7.22 (d, 1H), 6.91 (d, 2H), 4.41 (dd, 1H), 3.96 (q, 1H), 3.83 (q, 1H), 3.72 (m, 4H), 3.02 (m, 4H), 2.19 (m, 1H), 1.99 (m (1H), 1.88 (m, 2H)., MS (EI): 446 (MH +). 5-methyl-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl.}. phenyl) -pyrazine-2-carboxamide: RMI H (400MHz, d6-DMS0): 10.90 (s, 1H), 9.38 (s, 1H), 9.17 (s, 1H), 8.71 (s, 1H), 8.43 (d, 1H), 8.16 (d, 2H), 8.08 (d , 2H), 7.66 (d, 2H), 7.31 (d, 1H), 6.92 (d, 2H), 3.71 (m, 4H), 3.03 (m, 4H), 2.62 (s, 3H). MS (EI): 468 (MH +). 2- (Ethyloxy) -N- (4- [2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -acetamide: RM ^ H (400MHz, d6-DMSO): 9.94 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.80 (d, 2H), 7.65 (d, 2H), 7.26 (d, 1H), 6.91 (d, 2H), 4.05 (s, 2H), 3.72 (m, 4H), 3.55 (q, 2H), 3.02 (m, 4H), 1.17 (t, 3H). MS (EI): 434 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) araino] irimidin-4-ylphenyl) -2- (phenyloxy) acetamide: NMR'H (400MHZ, d6-DMSO): 10.37 (s) , 1H), 9.39 (s, 1H), 8.44 (d, 1H), 8.14 (d, 2H), 7.82 (d, 2H), 7.67 (d, 2H), 7.31 (m, 3H), 6.98 (m, 4H), 4.75 (s, 2H), 3.73 (m, 4H), 3.04 (m, 4H). MS (EI): 482 (MH +). 4- [(4- {2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) amino] -4-oxobutanoate methyl: 1 NMR! (400MHz, d6-DMSO): 10.28 (s, 1H), 9.37 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.67 (d, 2H), 7.27 (d, 1H), 6.93 (d, 2H), 3.74 (m, 4H), 3.60 (s, 3H), 3.06 (m, 4H), 2.65 (m, 4H). MS (EI): 462 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) butanamide: RM ^ H (400MHz, d6-DMSO): 10.15 (s, 1H ), 9.37 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.75 (d, 2H), 7.67 (d, 2H), 7.26 (d, 1H), 6.93 (d, 2H) , 3.73 (m, 4H), 3.04 (m, 4H), 2.33 (t, 2?), 1.63 (q, 2?), 0.93 (t, 3?). MS (El): 418 (MH +). 2- (2-methylphenyl) -N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) acetamide: R 1 H (400MHz, d6-DMSO): 10.44 (s, 1H), 9.38 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.76 (d, 2H), 7.67 (d, 2H), 7.27 (m , 2H), 7.16 (m, 3H), 6.93 (d, 2H), 3.75 (m, 6H), 3.03 (m, 4H), 2.31 (m, 3H). MS (El): 480 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -cyclopentane-carboxamide: RMIS ^ H (400MHz, d6-DMSO): 10.14 ( s, 1H), 9.38 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.77 (d, 2H), 7.67 (d, 2H), 7.27 (d, 1H), 6.93 (d , 2H), 3.75 (m, 4H), 3.04 (m, 4H), 2.80 (m, 1H), 1.87 (m, 2H), 1.72 (m, 4H), 1.55 (m, 2H). MS (El): 444 (MH +). (2S) -N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -zetidine-2-carboxamide: RI ^ H (400MHz, d6 -DMSO): 10.09 (br s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.86 (d, 2H), 7.67 (d, 2H), 7.29 (d, 1H), 6.94 (d, 2H), 4.32 (t, 1H), 3.73 (m, 4H), 3.62 (d, m, 1H), 3.06 (m, 4H), 2.58 (m, 1H), 2.29 (m, 1H), 0.99 (m, 1H). MS (El): 431 (MH +). N-. { 4- [2- ( { 4- [(3R) -3- (dimethylamino) pyrrolidin-1-yl] phenyl} amino) pyrimidin-4-yl) phenyl} -D-prolinamide: RI ^ H (400MHz, d6-DMSO): 10.19 (s, 1H), 9.19 (s, 1H), 8.40 (d, 1H), 8.11 (d, 2H), 7.83 (d, 2H) , 7.56 (d, 2H), 7.22 (d, 1H), 6. 53 (d, 2H), 3.72 (m, 1H), 3.41 (m, 1H), 3.33 (ra, 1H), 3.22 (m, 1H), 3.02 (m, 1H), 2.90 (m, 2H), 2.78 (m, 1H), 2.20 (s, 6H), 2.05 (m, 2H), 1.75 (m, 2H), 1.66 (m, 2H). MS (EI): 472 (MH +). 4 - (4-Aminophenyl) -N-. { 4- [(3R) -3- (dimethylamino) pyrrolidin-1-yl] phenyl} -pyrimidine-2 -amine: RMIN ^ H (400MHz, d6-DMSO): 8.99 (s, 1H), 8.25 (s, 1H), 7.87 (d, 2H), 7.57 (d, 2H), 7.05 (d, 1H), 6.63 (d, 2H), 6.52 (d, 2H), 5.70 (s, 2H), 3.41 (m, 1H), 3.31 (m, 1H), 3.21 (m, 1H), 3.01 (m, 1H) ), 2.77 (m, 1H), 2.20 (S, 6H), 2.15 (m, 1H), 1.77 (m, 1H). MS (EI): 375 (MH +). N-. { 4- [2- ( { 4- [(3R) -3- (dimethylamino) pyrrolidin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} -3 - (methyloxy) propanamide: NMR'H (400MHz, d6-DMSO): 10.21 (s, 1H), 9.19 (s, 1H), 8.40 (d, 1H), 8.10 (d, 2H), 7.75 (d, 2H), 7.58 (d, 2H), 7.23 (d, 1H), 6.54 (d, 2H), 3.63 (t, 2H), 3.41 ( m, 1H), 3.25 (m, 3H), 3.21 (m, 1H), 3.01 (m, 1H), 2.77 (m, 1H), 2.59 (t, 2H), 2.52 (m, 1H), 2.20 (s, 6H), 2.13 (m, 1H), 1.79 (m, 1H). MS (EI): 461 (MH +). l-ethyl-3 - (4- { 2- [(4. {4- [3- (methyloxy) ropanoyl] piperazin-1-yl} phenyl) -amino] pyrimidin-4-yl] phenyl) urea: RMIN H (400MHz, d6-DMSO): 9.35 (s, 1H), 8.76 (s, 1H), 8.41 (d, 1H), 8.04 (d, 2H), 7.68 (d, 2H), 7.54 (d, 2H), 7.23 (d, 1H), 6.95 (d, 2H), 6.26 (t, 1H), 3.59 (m, 4H), 3.56 (q, 2H), 3.23 (s, 3H), 3.14 ( m, 2H), 3.07 (m, 2H), 3.01 (m, 2H), 2.61 (t, 2H), 1. 06 (t, 3H). MS (El): 504 (MH +). 3- (methyloxy) -N- (4- { 2 - [(4- {4- [3- (methyloxy) propanoyl] piperazin-1-yl} phenyl) -amino] pyrimidin-4- phenyl) propanamide: NMR'H (400MHZ, d6-DMSO): 10.22 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.76 (d , 2H), 7.68 (d, 2H), 7.27 (d, 1H), 6.95 (d, 2H), 3.60 (m, 8H), 3.25 (s, 3H), 3.23 (s, 3H), 3.08 (m, 2H), 3.01 (m, 2H), 2.61 (m, 4H). MS (El): 519 (MH +). N-. { 4 - [2- ( { 4 - [4- (3-Hydroxypropanoyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} -D-Prolinamide: RMNXH (400MHz, d6-DMSO): 10.19 (s, 1H), 9.40 (s, 1H), 8.42 (d, 1H), 8.10 (d, 2H), 7.84 (d, 2H), 7.67 (d, 2H), 7.28 (d, 1H), 6.95 (d, 2H), 3.74 (dd, 1H), 3.66 (t, 2H), 3.62 (ra, 4H), 3.09 (m, 2H), 3.03 ( m, 2H), 2.91 (t, 2H), 2.52 (m, 2H), 2.05 (m, 1H), 1.79 (m, 1H), 1.66 (m, 2H). MS (El): 516 (MH +). N- (4- {2 - [(4- {4- [3- (methyloxy) propanoyl] piperazin-1-yl} phenyl) amino] -pyrimidin-4-yl}. Phenyl) -D-alaninamide: RMIS ^ H (400MHz, d6-DMSO): 9.40 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.82 (d, 2H), 7.68 (d, 2H) , 7.28 (d, 1H), 6.95 (d, 2H), 3.59 (m, 4H), 3.57 (t, 2H), 3.46 (m, 1H), 3.23 (s, 3H), 3.07 (m, 2H), 3.02 (m, 2H), 2.61 (t, 2H), 1.24 (d, 3H). MS (El): 504 (MH +). N- (4 - { 2- [(4. {4- [3- (methyloxy) propanoyl] piperazin-1-yl} phenyl) amino] -pyrimidin-4-yl}. Phenyl) -D-prolinamide: RM 1H (400MHz, d6-DMSO): 10.21 (s, 1H), 9.41 (s, 1H), 8.45 (d, 1H), 8.11 (d, 2H), 7.83 (d, 2H), 7.66 (d, 2H), 7.28 (d, 1H), 6.95 (d, 2H), 3.75 (dd, 1H), 3.60 (m, 4H) ), 3.56 (t, 2H), 3.23 (s, 3H), 3.08 (m, 2H), 3.03 (m, 2H), 2.91 (t, 2H), 2.61 (t, 2H), 2.17 (m, 1H) , 1.80 (m, 1H), 1.67 (m, 2H). MS (EI): 530 (MH +). N-2-,? -2-dimethyl-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) glycinamide: NMR1! (400MHz, d6-DMSO): 9.98 (s, 1H), 9.39 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.83 (d, 2H), 7.68 (d, 2H), 7.28 (d, 1H), 6.93 (d, 2H), 3.74 (ra, 4H), 3.11 (s, 2H), 3.05 (m, 4H), 2.29 (s, 6H). MS (EI): 433 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-ylphenyl) prolinamide: R ^ H (400MHz, d6-DMSO): 10.18 (s, 1H), 9.38 ( s, 1H), 8.43 (d, 1H), 8.13 (d, 2H), 7.83 (d, 2H), 7.67 (d, 2H), 7.27 (d, 1H), 6.93 (d, 2H), 3.74 (m , 4H), 3.71 (m, 1H), 3.04 (m, 4H), 2.90 (t, 2H), 2.05 (m, 1H), 1.66 (m, 2H). MS (EI): 445 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -3-phenyl-propanamide: NMR'H (400MHZ, d6-DMSO): 10.12 (s, 1H), 9.31 (s, 1H), 8.37 (d, 1H), 8.05 (d, 2H), 7.67 (d, 2H), 7.60 (d, 2H), 7.21 (ra, 5H), 7.12 (m, 1H), 6.83 (d, 2H), 3.67 (ra, 4H), 2.98 (m, 4H), 2.86 (t, 2H) ), 2.61 (t, 2H). MS (EI): 480 (MH +). N- (4 - {2 - [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -2-phenyl-acetamide: RM ^ H (400MHz, d6-DMSO): 10.44 (s, 1H), 9.38 (S, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.77 (d, 2H), 7.67 (d, 2H), 7.34 (m, 4H), 7.26 ( m, 2H), 6.93 (d, 2H), 3.75 (m, 4H), 3.69 (m, 2H), 3.04 (m, 4H). MS (EI): 466 (MH +). N- [3- ( { 4- [4- (acetylaraino) phenyl] pyrimidin-2-yl} amino) propyl] -2-fluoro-6-iodobenzaraide: NMR1! (400MHz, d6-DMSO): 10.16 ppm (s, 1H), 8.64 ppm (t, 1H), 8.30 ppm (d, 1H), 8.06 ppm (d, 2H), 7.70 ppm (m, 3H), 7.30 ppm (m, 1H), 7.20 ppm (m, 1H), 7.13ppm (ra, 1H), 7.07ppra (m, 1H), 3.34ppra (m, 4H), 2.08ppm (s, 3H), 1.83ppm (m 2H); MS (EI) C 22 H 21 FIN 502: 533.9 (MH +). N- [3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) phenyl] -2,6-difluoro-benzamide: RM ^ H (400MHz, d6-DMSO) : 10.78 ppm (s, 1H), 10.12 ppm (s, 1H), 9.70 ppm (s, 1H), 8.50 ppm (d, 1H), 8.39 ppm (s, 1H), 8.12 ppm (d, 2H), 7.73 ppm (d, 2H), 7.61 ppm (m, 1H), 7.47 ppm (m, 1H), 7.40 ppm (m, 1H), 7.27 ppm (m, 4H), 2.09 ppm (s, 3H); MS (El) C25H19F2Ns02: 460 (MH +). N- [3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) phenyl] -2,4,5-trifluoro-benzamide: RMIS ^ H (400MHz, d6- DMSO): 10.52 ppm (s, 1H), 10.29 ppm (s, 1H), 9.71 ppm (s, 1H), 8.50 ppm (d, 1H), 8.36 ppm (s, 1H), 8.20 ppm (d, 2H) , 7.87 ppm (m, 1H), 7.75 ppm (d, 3H), 7.51 ppm (m, 1H), 7.37 ppm (d, 1H), 7.28 ppm (m, 2H), 2.09 ppm (s, 3H); MS (El) C 25 H 18 F 3 N 502: 478 (MH +).

N- [3- ( { 4- [4- (acetylamino) phenyl] irimidin-2-yl} amino) phenyl] benzamide: R H (400MHz, d6-DMSO): 10.27 ppm (s, 1H ), 10.21 ppm (s, 1H), 9.67 ppm (s, 1H), 8.51 ppm (d, 1H), 8.47 ppm (s, 1H), 8.13 ppm (d, 2H), 8.00 ppm (m, 2H), 7.75 ppm (m, 2H), 7.58 ppm (m, 3H), 7.48 ppm (m, 1H), 7.37 ppm (d, 1H), 7.29 ppm (m, 2H), 2.09 ppm (s, 3H); MS (El) C 25 H 21 N 502: 424 (MH +). N- [3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) phenyl] -3,5-difluoro-benzamide: RM ^ H (400MHz, d6-DMSO) : 10.37 ppm (s, 1H), 10.20 ppm (s, 1H), 9.70 ppm (s, 1H), 8.51 ppm (d, 1H), 8.41 ppm (s, 1H), 8.21 ppm (d, 2H), 7.73 ppm (m, 4H), 7.55 ppm (m, 2H), 7.37 ppm (d, 1H), 7.29 ppm (m, 2H), 2.08 ppm (s, 3H); MS (El) C2SH19F2N502: 468.0 (MH +). N- [3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) phenyl] -2-chloro-6-fluoro-4-methylbenzamide: NMRH (400MHz, ds- DMSO): 10.72 ppm (s, 1H), 10.20 ppm (s, 1H), 9.69 ppm (s, 1H), 8.50 ppm (d, 1H), 8.41 ppm (s, 1H), 8.21 ppm (d, 2H) , 7.74 ppm (s, 2H), 7.50 ppm (m, 2H), 7.37 ppm (d, 1H), 7.28 ppm (m, 8H), 2.38 ppm (s, 3H), 2.08 ppm (s, 3H); MS (El) C 26 H 21 ClFN 502: 490.0 (MH +). N- (4- {2 - [(3- {[[2,6-dimethylphenyl) methyl] amino} phenyl) amino] irimidin-4-yl} -phenyl) acetamide: NMR: H (400MHz, d6-DMSO): 10.20 ppm (s, 1H), 9.36 ppm (s, 1H), 8.47 ppm (d, 1H), 8.16 ppm (d, 2H), 7.72 ppm (d, 2H), 7.35 ppm (s, 1H), 7.31 ppm (d, 1H), 7.12 ppm (m, 1H), 7.07 ppm (m, 2H), 6.99 ppm (m, 3H), 6.38 ppm (d, 1H), 5.46 ppm (t, 1H), 4.14 ppm (d, 2H), 2.36 ppm (s, 6H), 2.08 ppm (s, 3H); MS (EI) C27H27N50: 438.1 (MH +). N- (3- {2- [(3-aminophenyl) amino] pyrimidin-4-yl} phenyl) thiophene-2-carboxamide: NMR (400MHz, d6-DMSO): 10.66 ppm (s, 1H), 10.28 ppm (s, br, 2H), 10.10 ppm (s, 1H), 8.74 ppm (s, 1H), 8.63 ppm (d, 1H), 8.25 ppm (m, 2H), 7.94 ppm (m, 3H), 7.75 ppm (t, 1H), 7.55 ppm (t, 1H), 7.45 ppm (m, 2H), 7.26 ppm (m, 1H), 6.97 ppm (m, 1H); MS (EI) C 21 H 17 N 502 S: 388.0 (MH +). N- [3- ( { 4- [4- (acetylamino) phenyl] pyriraidin-2-yl.}. Amino) phenyl] -l-methylpiperidine-4-carboxamide: RMI ^ H (400MHz, dS-DMSO) : 10.21 ppm (s, 1H), 9.84 ppm (s, 1H), 9.60 ppm (s, 1H), 8.49 ppm (d, 1H), 8.29 ppm (s, 1H), 8.20 ppm (d, 2H), 7.74 ppm (d, 2H), 7.36 ppm (ra, 2H), 7.18ppm (m, 2H), 2.84ppm (m, 2H), 2.31ppm (m, 1H), 2.17ppm (s, 3H), 2.09ppm ( s, 3H), 1.87 ppm (m, 2H), 1.72 ppm (m, 4H); MS (EI) C 25 H 28 N 502: 445 (MH +). 4- (4-Aminophenyl) -N- [3- (morpholin-4-ylsulfonyl) phenyl] pyrimidin-2-amine: NMR'H (400MHZ, d6-DMSO): 9.94 ppm (s, 1H), 8.76 ppm ( s, 1H), 8.42 ppm (d, 1H), 7.98 ppm (d, dH), 7.90 ppm (m, 1H), 7.57 ppm (t, 1H), 7.28 ppm (m, 2H), 6.65 ppm (d, 2H), 5.81 ppm (s, 2H), 3.64 ppm (m, 4H), 2.90 ppm (m, 4H); MS (EI) C20H21N5O3S 412 (MH +). N- (4- {2 - [(3- {[[(2-fluoro-phenyl) amino]} phenyl) amino] pyrimidin-4-yl) phenyl) acetamide: RI ^ H (400MHz, ds-DMSO): 10.22 ppm (s, 1H), 9.35 ppm (s, 1H), 8.45 ppm (d, 1H), 8.12 ppm ( d, 2H), 7.74 ppm (d, 2H), 7.43 ppm (m, 2H), 7.29 ppm (m, 2H), 7.16 ppm (m, 3H), 6.99 ppm (m, 2H), 6.21 ppm (m, 2H), 4.33 ppm (d, 2H), 2.09 ppm (s, 3H); MS (El) C 25 H 22 FN 50: 428 (MH +). N- (4- { 2- [(3-aminophenyl) amino] pyrimidin-4-yl.} Phenyl) acetamide: NMR'H (400MHZ, d6-DMSO): 10.21 ppm (s, 1H), 9.31 ppm (s, 1H), 8.46ppm (d, 1H), 8.13ppm (d, 2H), 7.75ppm (d, 2H), 7.30ppm (d, 1H), 7.13ppm (s, 1H), 6.94ppm ( m, 2H), 6.20 ppm (d, 1H), 5.01 ppm (s, 2H), 2.10 ppm (s, 3H); MS (El) C18H17IN50: 320 (MH +). N- (4- {2- [(3-. {[[(4-fluoropheniDmethyl] amino.}. Phenyl) amino] pyrimidin-4-yl) -phenyl) acetamide: NMR! (400MHz, d6-DMSO): 10.26 ppm (s, 1H), 9.33 ppm (s, 1H), 8.45 ppm (d, 1H), 8.13 ppm (d, 2H), 7.75 ppm (d, 2H), 7.37 ppm (m, 2H), 7.31 ppm (m, 3H), 7.21 ppm (m, 2H), 6.97 ppm (m, 2H), 6.23 ppm (m, 2H), 4.48 ppm (d, 2H), 2.09 ppm (s) , 3H); MS (El) C25H23N50: 410 (MH +). N- (4- { 2- [(3-. {[[(3-fluorophenyl) methyl] amino.}. Phenyl) amino] pyrimidin-4-yl}. Phenyl) acetamide: RMIS ^ H ( 400MHz, d6-DMSO): 10.36 ppm (s, 1H), 9.35 ppm (s, 1H), 8.45 ppm (d, 1H), 8.12 ppm (d, 2H), 7.76 ppm (d, 2H), 7.33ppm ( m, 2H), 7.19 ppm (m, 3H), 6.99 ppm (m, 3H), 6.32 ppm (t, 1H), 6.20 ppm (m, 2H), 4.30 ppm (s, 2H), 2.09 ppm (s, 3H); MS (The) C25H22FN50: 428 (MH +). N- (4- {2 - [(3-. {[[(4-FluorophenyDmethyl) amino] phenyl) amino] pyrimidin-4-yl}. Phenyl) acetamide: NMRH (400MHz, d6- DMSO): 10.20 ppm (s, 1H), 9.33 ppm (s, 1H), 8.45 ppm (d, 1H), 8.12 ppm (d, 2H), 7.74 ppm (d, 2H), 7.39 ppm (m, 2H) , 7.30 ppm (d, 1H), 7.21 ppm (s, 1H), 7.13 ppm (t, 2H), 6.96 ppm (m, 2H), 6.22 ppm (m, 2H), 2.09 ppm (s, 3H); (El) C 25 H 22 FN 50: 428 (MH +). 4- [4- (. {4- [4- (Butanoylamino) phenyl] pyrimidin-2-yl} amino) phenyl] -N-ethyl-piperazine-1 carboxamide: NMR1 !! (400MHz, d6-DMSO): 10.21 ppm (s, 1H), 9.39 ppm (s, 1H), 8.44 ppm (d, 1H), 8.11 ppm (d, 2H), 7.77 ppm (d, 2H), 7.68 ppm (d, 2H), 7.28 ppm (d, 1H), 6.96 ppm (d, 2H), 6.59 ppm (t, 1H), 3.43 ppm (t, 4H), 3.07 ppm (m, 2H) , 3.02 ppm (t, 4H), 2.34 ppm (t, 2H), 1.63 ppm (m, 2H), 1.02 ppm (t, 3H), 0.98 ppm (t, 3H); MS (El) C27H33N702: 488 (MH + N- { 4- [2- ( { 4- [4- (2-piperazin-l-ylacetyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} butanamide : RMN1 !! (400MHz, d6-DMSO): 10.18 ppm (s, 1H), 9.40 ppm (s, 1H), 8.44 ppm (d, 1H), 8.11 ppm (d, 2H), 7.77 ppm (d, 2H), 7.68 ppm (d, 2H), 7.28 ppm (d, 1H), 6.97 ppm (d, 2H), 3.72 ppm (m, 2H), 3.59 ppm (m, 2H), 3.13 ppm (m, 4H), 3.01 ppm (m , 2H), 2.67 ppm (m, 4H), 2.33 ppm (m, 4H), 1.63 ppm (m, 2H), 0.93 ppm (t, 3H); MS (El) C30H38N802: 543 (MH +). N- [4- (2- { [4- (4-L-alanylpiperazin-1-yl) phenyl] amino}. pyrimidin-4-yl) phenyl] -butanamide: NMR'H (400MHZ, d6-DMSO): 10.15 ppm (s, 1H), 9.40 ppm (s, 1H), 8.44 ppm (d, 1H), 8.11 ppm (d , 2H), 7.76 ppm (d, 2H), 7.69 ppm (d, 2H), 7.28 ppm (d, 1H), 6.97 ppm (d, 2H), 3.79 ppm (m, 1H), 3.62 ppm (m, 4H) ), 3.06 ppm (m, 4H), 2.33 ppm (t, 2H), 1.91 ppm (br. S, 2H), 1.63 ppm (m, 2H), 1.09 ppm (d, 3H), 0.93 ppm (t, 3H) ); MS (EI) C 27 H 33 N 702: 488 (MH +). N- [4- (2- {[4- (4-L-prolylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] -butanamide: NMR! (400MHz, d6-DMSO): 10.21 ppm (s, 1H), 9.41 ppm (s, 1H), 8.44 ppm (d, 1H), 8.11 ppm (d, 2H), 7.77 ppm (d, 2H), 7.69 ppm (d, 2H), 7.28 ppm (d, 1H), 6.97 ppm (d, 2H), 3.85 ppm (m, 1H), 3.62 ppm (m, 4H), 3.04 ppm (m, 5H), 2.62 ppm (m , 1H), 2.34 ppm (t, 2H), 2.00 ppm (m, 1H), 1.62 ppm (m, 6H), 0.93 ppm (t, 3H); MS (EI) C 29 H 35 N 702: 514 (MH +). (3R) -1- (2-hydroxyethyl) -N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) pyrrolidine-3-carboxamide: RM ^ H (400MHz, d6-DMSO): 10.22 ppm (s, 1H), 9.38 ppm (s, 1H), 8.44 ppm (d, 1H), 8.11 ppm (d, 2H), 7.76 ppm (d, 2H) , 7.67 ppm (d, 2H), 7.28 ppm (d, 1H), 6.94 ppm (d, 2H), 4.50 ppm (m, 1H), 3.75 ppm (m, 4H), 3.49 ppm (m, 2H), 3.05 ppm (m, 6H), 2.91 ppm (t, 1H), 2.67 ppm (m, 1H), 2.56 ppm (m, 3H), 1.98 ppm (m, 2H); MS (EI) C27H32N603: 489 (MH +). N- (4- {2- [(3-fluoro-4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -L-prolinamide: RMIS ^ H (400MHz, d6-DMSO ): . 21 ppm (s, 1H), 9.69 ppm (s, 1H), 8.51 ppm (d, 1H), 8.13 ppm (d, 2H), 7.85 ppm (d, 2H), 7.79 ppm (m, 1H), 7.52 ppm (m, 1H), 7.37 ppm (d, 1H), 7.03 ppm (t, 1H), 3.74 ppm (ra, 5H), 3.14 ppm (br, s, 1H), 2.95 ppm (m, 4H), 2.91 ppm (m, 2H), 2.06 ppm (m, 1H), 1.80 ppm (m, 1H), 1.66 ppm (m, 2H); MS (EI) C 25 H 27 FN 602: 463 (MH +). N- (4- {2- [(3-fluoro-4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -D-alaninamide: RN ^ (400MHz, d6-DMSO) : 9.69 ppm (s, 1H), 8.51 ppm (d, 1H), 8.13 ppm (d, 2H), 7.84 ppm (d, 2H), 7.79 ppm (m, 1H), 7.54 ppm (m, 1H), 7.37 ppm (m, 1H), 7.37 ppm (m, 1H), 7.03ppm (t, 1H), 3.74ppm (m, 4H), 3.47ppm (m, 1H), 2.95ppm (m, 4H), 1.23ppm ( d, 3H); MS (EI) C23H25FNs02: 437 (MH +). N- (4- { 2- [(3-methyl-4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -D-prolinamide: NMRH (400MHz, d6-DMSO): . 22 ppm (s, 1H), 9.45 ppm (s, 1H), 8.46 ppm (d, 1H), 8.14 ppm (d, 2H), 7.85 ppm (d, 2H), 7.63 ppm (d, 2H), 7.32 ppm (d, 1H), 7.32 ppm (d, 1H), 3.73 ppm (m, 5H), 3.08 ppm (br. s., 1H), 2.90 ppm (t, 2H), 2.80 ppm (m, 4H), 2.27 ppm (s, 3H), 2.06 ppm (m, 1H), 1.80 ppm (m, 1H), 1.66 ppm (m, 2H); MS (EI) C 26 H 30 N 602: 459 (MH +). N- (4- { 2- [(3-methyl-4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl] phenyl) -L-alaninamide: RM ^ H (400MHz, d6-DMSO): 9.44 ppm (s, 1H), 8.47 ppm (d, 1H), 8.14 ppm (d, 2H), 7.83 ppm (d, 2H), 7.64 ppm (ra, 2H), 7.32 ppm (d, 1H), 7.02 ppra (m, 1H), 3.73 ppm (m, 4H), 3.46 ppm (ra, 1H), 2.80 ppm (m, 4H), 2.28ppra (m, 4H), 1.23ppm (d, 3H); MS (EI) C 24 H 28 N 602: 433 (MH +). 1-hydroxy-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -cyclopropanecarboxamide: R N1 !. (400MHz, d6-DMSO): 10.14 ppm (s, 1H), 9.39 ppm (s, 1H), 8.44ppra (d, 1H), 8.11ppm (d, 2H), 7.94ppra (d, 2H), 7.68ppm (d, 2H), 7.29 ppm (d, 1H), 6.94 ppm (d, 2H), 6.81 ppm (s, 1H), 3.74 ppm (m, 4H), 3.05 ppm (m, 4H), 1.18 ppm (m , 2H), 1.00ppm (m, 2H); MS (EI) C 24 H 25 N 503: 432 (MH +). N- (4- (2- (4- (4- (4-chloro-2,6 -dimethylphenylsulfonyl) piperazin-1-yl) phenyl-araino) pyrimidin-4-yl) phenyl) acetamide: RM ^ H (400MHz , d6-DMSO): 10.20 (s, 1H), 9.42 (s, 1H), 8.41 (m, 1H), 8.08 (d, 2H), 7.77 (s, 1H), 7.71 (d, 2H), 7.64 ( m, 2H), 7.57 (s, 1H), 7.27 (ra, 1H), 6.93 (m, 2H), 3.41 (m, 4H), 3.15 (ra, 4H), 2.53 (s, 3H), 2.37 (s) , 3H), 2.06 (s, 3H). MS (El): 591 (MH +). N- (4- (2- (4- (4- (2- (piperazin-1-yl) acetyl) piperazin-1-yl) phenylamine) pyrimidin-4-yl) phenyl) tetrahydrofuran-3-carboxamide: NMR ' H (400MHZ, d6-DMSO): 10.31 (s, 1H), 9.41 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.77 (d, 2H), 7.68 (d, 2H) , 7.28 (d, 1H), 6.96 (d, 2H), 3.96 (t, 1H), 3.75 (m, 5H), 3.60 (m, 2H), 3.32 (m, 1H), 3.19 (m, 1H), 3.12 (s, 2H), 3.10 (m, 2H), 3.01 (m, 2H), 2.68 (m, 4H), 2.32 (m, 4H), 2.10 (m, 2H). MS (El): 571 (MH +).

N- (4- (2- (4- (4-pivaloylpiperazin-1-yl) phenylamine) pyrimidin-4-yl) phenyl) -tetrahydrofuran-3-carboxamide: NMR! (400MHz, d6-DMSO): 10.30 (s, 1H), 9.41 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.77 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.95 (d, 2H), 3.96 (t, 1H), 3.74 (m, 6H), 3.19 (m, 2H), 3.05 (m, 4H), 2.10 (q, 2H), 1.23 (s, 9H). MS (EI): 529 (MH +). l-Ethyl-3- (4- (5-methyl-2- (4-morpholinophenylamino) pyrimidin-4-yl) phenylDurea: NMR'H (400MHz, d6-DMSO): 9.24 (s, 1H), 8.87 (s) , 1H), 8.29 (s, 1H), 7.64 (d, 2H), 7.59 (m, 2H), 7.53 (m, 2H), 6.88 (d, 2H), 6.41 (m, 1H), 3.73 (m, 4H), 3.12 (m, 2H), 3.02 (ra, 4H), 2.23 (s, 3H), 1.06 (t, 3H), MS (EI): 433 (MH +). 3-methoxy-N- (4- (5-methyl-2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) propanamide: RM ^ H (400MHz, d6-DMSO): 10.17 (s, 1H), 9.30 (s, 1H), 8.31 (s) , 1H), 7.74 (m, 2H), 7.66 (m, 4H), 6.90 (m, 2H), 3.74 (m, 4H), 3.64 (t, 2H), 3.26 (s, 3H), 3.03 ( m, 4H), 2.59 (m, 2H), 2.22 (s, 3H), MS (EI): 448 (MH +), N- (4- (2- (4- (4- (ethylsulfonyl) piperazine-1-) il) phenylamine) pyrimidin-4-yl) phenyl) acetamide: NMRH (400MHz, d6-DMSO): 10.21 (s, 1H), 9.38 (s, 1H), 8.42 (d, 1H), 8.08 (d, 2H) , 7.72 (d, 2H), 7.66 (d, 2H), 7.26 (d, 1H), 6.95 (d, 2H), 3.36 (m, 4H), 3.12 (m, 4H), 2.48 (m, 2H), 2.07 (s, 3H), 1.22 (t, 3H), MS (EI): 481 (MH +). 4- (4- (4- (4-aceta midphenyl) pyrimidin-2-ylamino) phenyl) -N-ethylpiperazine-l-carboxamide: RI ^ H (400MHz, d6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.41 (d, 1H), 8.08 (d, 2H), 7.72 (d, 2H), 7.64 (d, 2H), 7.25 (d, 1H), 6.94 (d, 2H), 6.57 (d, 1H), 3.50 (m, 2H), 3.39 (m, 4H), 2.99 (m, 4H), 2.07 (s, 3H), 1.00 (t, 3H). MS (EI): 460 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) morpholine-2-carboxamide: NMRH (400MHz, d6-DMSO): 9.87 (s) , 1H), 9.37 (s, 1H), 8.43 (s, 1H), 8.04-8.16 (d, 2H), 7.81-7.93 (d, 2H), 7-60-7.72 (d, 2H), 7.27 (s) , 1H), 6.85-6.99 (d, 2H), 4.08-4.69 (s, br, 1H), 4.00-4.07 (d, 1H), 3.85-3.94 (d, 1H), 3.72 (s, 3H), 3.51 -3.63 (d, 1H), 2.58-2.80 (m, 3H), 1.86 (s, 6H). MS (EI): 461 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-ylphenyl) -beta-alaninamide: NMR'H (400MHz, d6-DMSO): 9.38 (s, 1H) , 10.65 (d, 1H), 8.07-8.16 (d, 2H), 7.72-7.81 (d, 2H), 7.62-7.72 (d, 2H), 7.28 (s, 1H), 6.89-6.98 (d, 2H) . MS (EI): 419 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-ylphenyl) phenylalaninamide: NMR'H (400MHz, d6-DMSO): 9.39 (s, 1H), 8 .42 -8, .46 (d, 1H), 8. .09 -8. 14 (d, 2H), 7. .75 -7 .81 (d, 2H), 7 .64 -7. .70 (d, 2H), 7. .23 -7. 32 (m, 6H), 7. .16 -7 .22 (m, 2H), 6 .90 -6. .97 (d, 2H), 3, .71 -3. 78 (m, 4H), 3. .57 -3 .63 (m, 1H), 3 .02 -3, .08 (m, 4H), 2, .98 -3. 02 (m, 1H), 2, .71 -2 .79 (m, (EI): 495 (MH +). N2-methyl-N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -glycinamide: NMRH (400MHz, d6-DMSO): 9.39 (s, 1H), 8.45 (s, 1H), 8.09-8.17 (d, 2H), 7.78-7.86 (d, 2H, 7.65-7.73 (d , 2H), 7.29 (s, 1H), 6.90-7.00 (d, 2H), 3.74 (s, 4H), 3.05 (s, 4H), 2.33 (s, 3H), 1.92 (s, 1H), MS ( EI): 419 (MH +) 2-cyclopentyl-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyriraidin-4-yl.} Phenyl) acetamide: NMR1 *! 400MHz, d6-DMSO): 10.13 (s, 1H), 9.37 (s, 1H), 8.42-8.45 (d, 1H), 8.07-8.14 (d, 2H), 7.73-7.79 (d, 2H), 7.65- 7.71 (d, 2H), 7.25-7.28 (d, 1H), .6.90-6.97 (d, 2H), 3.71-3.77 (m, 4H), 3.02-3.07 (m, 4H), 2.33-2.37 (d, 2H), 2.20-2.30 (m, 1H), 1.71-1.82 (m, 2H), 1.48-1.66 (m, 4H), 1.14-1.25 (m, 2H), MS (EI): 458 (MH +). - (methyloxy) -N- (4- {2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} - phenyl) pyridine-3-carboxamide: NMR1 (400MHz, d6-DMSO): 10.50 (s, 1H), 9.44 (s, 1H), 8.80-8.83 (d, 1H), 8.44-8.49 (d, 1H), 8.24-8.28 (m, 1H), 8.15-8.21 ( d, 2H), 7. 92-97 (d, 2H), 7.67-7.72 (d, 2H), 7.30-7.34 (d, 1H), 6. 93-7.02 (m, 3H), 3.94-3.96 (s, 3H), 3.72-3.79 (m, 4H), 3.04-3.11 (m, 4H). MS (EI): 483 (MH +). N, -dimethyl- '- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl) phenyl) butanediamide: RMIS ^ H (400MHz, d6-DMSO): 10.22 ( s, 1H), 9.36 (s, 1H), 8.43 (s, 1H), 8.05-8.17 (d, 2H), 7.71-7.79 (d, 2H), 7.61-7.71 (d, 2H), 7.26-7.31 ( d, 1H), 6.89-7.00 (d, 2H), 3.68-3.79 (m, 4H), 3.02-3.08 (ra, 4H), 3.00 (s, 3?), 2.82 (s, 3?), 2.56-2.66 (ra, 4?). MS (El): 475 (MH +). N- [4- (2- { [4-morpholin-4-yl-3- (trifluoromethyl) phenyl] amino} pyrimidin-4-yl) -phenyl] -D-prolinamide: NMR! (400MHz, d6-DMSO): 10.31 (s, 1H), 9.94 (s, 1H), 8.53-8.57 (d, 1H), 8.48 (s, 1H), 8.14-8.21 (d, 2H), 7.93-7.98 (m, 1H), 7.82-7.88 (d, 2H), 7.56-7.61 (d, 1H), 7.42-7.46 (d, 1H), 3.79-3.86 (m, 1H), 3.67-3.75 (m, 4H) , 2.93-3.00 (m, 2H), 2.79-2.86 (m, 4H), 2.05-2.17 (m, 1H), 1.79-1.89 (m, 1H), 1.65-1.75 (m, 2H). MS (El): 513 (MH +). 3- (methyloxy) -N- [4- (2 { [4-morpholin-4-yl-3- (trifluoromethyl) phenyl] amino} - pyrimidin-4-yl) phenyl] propanamide: RM ^ H (400MHz, d6-DMSO): 10.24 (s, 1H), 9.94 (s, 1H), 8.53-8.56 (d, 1H), 8.47 (s, 1H), 8.13-8.19 (d, 2H), 7.94- 8.00 (d, 1H), 7.76-7.81 (d, 1H), 7.56-7.62 (d, 1H), 7.41-7.45 (d, 1H), 3.67-3.74 (m, 4H), 3.60-3.67 (m, 2H) ), 3.35 (s, 3H), 2.80-2.86 (d, 4H), 2.57-2.63 (m, 2H). MS (El): 502 (MH +). N- (4- { 2- [(4- { 4- [3- (dimethylamino) -2,2-dimethylpropyl] piperazin-1-yl}. Phenyl) -amino] pyrimidin-4-yl ) phenyl) -5-oxo-L-prolinamide: NMR1H (400MHz, d6-DMSO): 10.34 (S, 1H), 9.37 (s, 1H), 8.43-8.46 (d, 1H), 8.12-8.16 (d, 2H), 7.94 (s, 1H), 7.77-7.81 (d, 2H), 7.62-7.67 (d, 2H), 7.26-7.30 (d, 1H), 6.88-6.94 (d, 2H), 4.20-4.26 ( m, 1H), 3.02-3.08 (m, 4H), 2.57-2.64 (m, 4H), 2.21 (s, 6H), 2.17 (s, 2H), 2. 10 (s, 2H), 1.89 (s, 4H), 0.84 (s, 6H). MS (El): 571 (MH +). (2R) -N- (4- {2 - [(4- {4- [3- (methyloxy) propanoyl] piperazin-1-yl} phenyl) amino] -pyrimidin-4-yl} phenyl) tetrahydrofuran-2-carboxamide: NMR! (400MHz, d6-DMSO): 9.94 (s, 1H), 9.41 (s, 1H), 8.43-8.46 (d, 1H), 8.09-8.15 (d, 2H), 7.85-7.90 (d, 2H), 7.65 -7.71 (d, 1H), 6.92-6.98 (d, 2H), 4.39-4.48 (m, 1H), 3.95-4.05 (m, 1H), 3.79-3.89 (m, 1H), 3.52-3.64 (m, 6H), 3.32 (s, 1H), 3.23 (s, 2H), 2.98-3.11 (m, 4H), 2.58-2.65 (m, 2H), 2.15-2.25 (m, 1H), 1.96-2.07 (m, 1H), 1.83-1.93 (m, 2H). MS (EI): 531 (MH +). (2S) -N- (4- { 2- [(4- { 4- [3- (methyloxy) propanoyl] piperazin-1-yl}. Phenyl) amino] -pyrimidin-4-yl. phenyl) tetrahydrofuran-2-carboxamide: RM ^ H (400MHz, d6-DMSO): 9.94 (s, 1H), 9.41 (s, 1H), 8.42-8.47 (d, 1H), 8.09-8.16 (d, 2H), 7. 84-7.91 (d, 2H), 7.64-7.72 (d, 1H), 7.27-7.37 (d, 1H), 6.93-6.99 (d, 2H), 4.40-4.47 (m, 1H), 3.95-4.05 (m , 1H), 3.80-3.89 (m, 1H), 3.53-3.65 (m, 6H), 3.32 (s, 1H), 3.23 (s, 2H), 2.98-3.10 (m, 4H), 2.59-2.65 (m , 2H), 2.15-2.27 (m, 1H), 1.95-2.07 (m, 1H), 1.83-1.93 (m, 2H). MS (El): 531 (MH +). (2R, 4S) -4-hydroxy-N- (4- (2- (4- (4- (3-methoxypropanoyl) piperazin-1-yl) phenylamino) pyrimidin-4-yl) phenyl) pyrrolidine-2 -carboxamide: RMN1 !! (400MHz, d6-DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.42-8.46 (d, 1H), 8.09-8.15 (d, 2H), 7.80-7.86 (d, 2H), 7.65-7.71 (d, 2H), 7.27-7.31 (d, 1H), 6.93-6.98 (d, 1H), 4.20-4.26 (m, 1H) , 3.88-3.94 (m, 1H), 3.53-3.64 (m, 6H), 3.17 (s, 1H), 2.99-3.10 (m, 4H), 2.89-2.93 (m, 1H), 2.77-2.84 (m, 1H), 2.58-2.64 (m, 3H), 1.99-2.07 (m, 2H), 1.73-1.83 (m, 2H). MS (EI): 546 (MH +). N- (4- { 2- [(3-Fluoro-4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -D-prolinamide: NMR1 *. (400MHz, d6-DMSO): 11.07 (s, 1H), 9.89 (s, 1H), 8.46-8.56 (d, 1H), 8.08-8.21 (d, 2H), 7.74-7.91 (m, 3H), 7.47 -7.57 (d, 1H), 7.35-7.41 (d, 1H), 6.98-7.08 (m, 1H), 3.70-3.82 (m, 5H), 2.87-3.03 (m, 5H), 2.01-2.16 (m, 1H), 1.92 (s, 2H), 1.75-1.87 (m, 1H), 1.61-1.74 (m, 2H). MS (EI): 463 (MH +). N- (4- { 2- [(4- { 4- [3- (methyloxy) propanoyl] piperazin-1-yl}. Phenyl) amino] pyrimidin-4-yl}. Phenyl) tetrahydrofuran -3-carboxamide: R N'H (400MHz, d6-DMSO): 10.30 (s, 1H), 9.40 (s, 1H), 8.42-8.47 (d, 1H), 8.09-8.15 (d, 2H), 7.74 -7.80 (d, 2H), 7.64-7.71 (d, 2H), 7.27-7.30 (d, 1H), 6.92-7.00 (d, 2H), 3.92-3.99 (m, 1H), 3.68-3.84 (m, 4H), 3.53-3.64 (m, 5H), 3.32 (s, 1H), 3.23 (s, 2H), 3.16-3.22 (m, 1H), 2.98-3.10 (m, 4H), 2.59-2.65 (m, 1H), 2.06-2.15 (m, 2H). MS (EI): 531 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] irimidin-4-yl}. Phenyl) -3-pyridin-3-ylpropanamide: RM ^ H (400MHz, d6-DMSO ): 10.21 (s, 1H), 9.37 (s, 1H), 8.39-8.51 (m, 3H), 8.08-8.13 (d, 2H), 7.64-7.76 (m, 5H), 7.25-7.35 (m, 2H) ), 6.91-6.98 (d, 2H), 3.72-3.77 (m, 4?), 3.01-3.08 (m, 4?), 2.91-2.98 (m, 2?), 2.65-2.75 (m, 2?). MS (El): 481 (MH +). N- (3- (4- (4-acetamidophenyl) pyrimidin-2-ylamino) phenyl) -2-chlorobenzamide: NMR1 ?. (400MHz, d6-DMSO): 10,497 (s, 1H), 10,201 (s, 1H), 9,668 (s, 1H), 8,505 (d, 1H), 8,505 (d, 1H), 8,427 (s, 1H), 8.223 (d, 2H), 7.748 (d, 2H), 7.59 (m, 2H), 7.477 (m, 3H), 7.374 (d, 1H), 7.253 (m, 2H), 2.083 (s, 3H). MS (El): 458 (MH +). N- (3- (4- (4-acetamidophenyl) pyrimidin-2-ylamino) phenyl) -2-methylbenzamide: NMRH (400MHz, d6-DMSO): 10,284 (d, 2H), 9,622 (s, 1H), 8,487 (m, 2H), 8.235 (d, 2H), 7.749 (d, 2H), 7.352 (m, 8H), 2.084 (s, 3H). MS (El): 438 (MH +). N- (3- (4- (4-acetamidophenyl) pyrimidin-2-ylamino) phenyl) -2,4-dichlorobenzamide: NMRH (400MHZ, d6-DMSO): 10.533 (s, 1H), 10198 (s, 1H) , 9,687 (s, 1H), 8,506 (d, 1H), 8,406 (s, br, 1H), 8,220 (d, 2H), 7,787 (d, 1H), 7,747 (d, 2H), 7,659 (d, 1H) ), 7.591 (d, 1H), 7.464 (d, 1H), 7.377 (d, 1H), 7.247 (m, 2H), 2.085 (s, 3H). MS (El): 492 (MH +). N- (3- (4- (4-acetamidophenyl) pyrimidin-2-ylamino) phenyl) -2,5-dichlorobenzamide: R ^ H (400MHz, d6-DMSO): 10,510 (s, 1H), 10,198 (S, 1H), 9,696 (s, 1H), 8,507 (s, 1H), 8,389 (s, 1H), 8,220 (d, 2H), 7,744 (m, 3H), 7,617 (m, 2H), 7,487 (d, 1H) ), 7.379 (d, 1H), 7.282 (m, 2H), 2.081 (s, 3H). MS (El): 492 (MH +).

N- (3- (4- (4 -acetaraylphenyl) irimidin-2-ylamino) phenyl) -2-chloro-6-fluoro-3-methoxybenzamide: RM ^ H (400MHz, d6-DMSO): 10.726 (s, 1H ), 10,204 (s, 1H), 9,709 (s, 1H), 8,509 (d, 1H), 8,402 (s, 1H), 8,217 (d, 2H), 7,743 (d, 2H), 7,488 (d, 1H) , 7.386 (m, 2H), 7.282 (m, 2H), 7.221 (d, 1H), 3.904 (s, 3H), 2.082 (s, 3H). MS (El): 506 (MH +). N- (3- (4- (4-acetamidophenyl) pyrimidin-2-ylamino) phenyl) -2, 3-dichlorobenzamide: NMRH (400MHz, d6-DMSO): 10.6 (s, 1H), 10.2 (s, 1H) , 9.7 (s, 1H), 8.5 (d, 1H), 8.4 (s, 1H), 8.2 (d, 2H), 7.8 (m, 3H), 7.6 (d, 1H), 7.5 (ra, 2H), 7.4 (d, 1H), 7.2 (m, 2H), 2.081 (s, 3H). MS (El): 492 (MH +). (R) -N- (4- (2- (4- (4- (pyrrolidine-2-carbonyl) piperazin-1-yl) phenylamine) -pyrimidin-4-yl) phenyl) cyclopropanecarboxamide: NMRH (400MHz, d6- DMSO): 10,476 (s, 1H), 9,406 (s, 1H), 8,448 (d, 1H), 8,124 (d, 2H), 7,767 (ra, 4H), 7,287 (d, 1H), 6,977 (d, 2H) ), 3.85 (m, 1H), 3.65 (m, 4H), 3.0 (ra, 4H), 2.95 (m, 1H), 2.6 (ra, 1H), 2.0 (m, 1H), 1.8 (m, 1H) , 1613 (m, 3H), 0.84 (m, 4H). MS (El): 512 (MH +). N- (4- (2- (4- (4- (2- (piperazin-1-yl) acetyl) piperazin-1-yl) phenylamine) pyrimidin-4-yl) phenyl) cyclopropanecarboxamide: NMR1! (400MHz, d6-DMSO): 10,480 (s, 1H), 9,399 (s, 1H), 8,447 (d, 1H), 8,124 (d, 2H), 7,769 (d, 2H), 7,692 (d, 2H), 7.285 (d, 1H), 6.975 (d, 2H), 3.170 (m, 2H), 3.592 (m, 2H), 3.134 (s, 2H), 3.099 (m, 2H), 3.028 (m, 2H), 2,694 (m, 4?), 2,331 (m, 4?), 0.842 (m, 4?). MS (El): 541 (MH +). 4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) benzamide: RM 'H (400MHZ, d6-DMSO): 9.5 (s, 1H), 8.5 (d, 1H), 8.2 (d, 2H), 8.15 (s, 1H), 8 (d, 2H), 7.7 (d, 1H), 7.5 (s, 1H), 7.4 (d, 1H), 6.9 (d, 1H), 4.8 (m, 4H), 3.0 (m, 4H). MS (EI): 376 (MH +). (R) -N- (4- (2- (4- (4- (pyrrolidine-2-carbonyl) piperazin-1-yl) phenylamine) pyrimidin-4-yl) phenyl) cyclopropanecarboxamide: RMK ^ H (400MHz, d6 -ODO): 8,355 (d, 1H), 8,114 (d, 2H), 7,177 (d, 2H), 7,639 (d, 2H), 7,217 (d, 1H), 7,028 (d, 2H), 4,394 (m, 1H), 3.797 (m, 2H), 3.692 (m, 2H), 3.137 (m, 4H), 3.1 (m, 1H), 2.410 (m, 1H), 1.992 (m, 2H), 1.827 (m, 2H) ), 0.981 (m, 2H), 0.85 (m, 2H). MS (EI): 512 (MH +). (S) -N- (4- (2- (4- (4- (2-Aminopropanoyl) piperazin-1-yl) phenylamine) pyrimidin-4-yl) phenyl) cyclopropanecarboxamide: RMI ^ H (400MHz, d6-MeOD ): 8.357 (d, 1H), 8.116 (d, 2H), 7.718 (d, 2H), 7.642 (d, 2H), 7.221 (d, 1H), 7.033 (d, 2H), 4.1 (m, 1H) , 3.85 (m, 1H), 3.7 (m, 4H), 3.2 (m, 4H), 1.8 (m, 1H), 1.4 (d, 3H), 0.9 (m, 2H), 0.85 (m, 2H). MS (EI): 486 (MH +). (R) -N- (4- (2- (4- (4- (2-Aminopropanoyl) piperazin-1-yl) phenylamine) pyrimidin-4-yl) phenyl) cyclopropanecarboxamide: NMRH (400MHz, d6-MeOD): 8.4 (d, 1H), 8.15 (d, 2H), 7.8 (d, 2H0, 7.6 (d, 2H), 7.2 (d, 1H), 7.0 (d, 2H), 4.0 (m, 1H), 3.7 (m, 4H), 3.2 (m, 4H), 1.8 (m, 1H) , 1.3 (d, 3H), 0.9 (m, 2H), 0.85 (m, 2H). MS (EI): 486 (MH +). (R) -N- (4- (2- (4- (4-acetylpiperazin-1-yl) phenylamine) pyrimidin-4-yl) phenyl) -pyrrolidine-2-carboxamide: RMIS ^ H (400MHz, d6-DMSO ): 10,193 (s, 1H), 9,411 (s, 1H), 8,452-8,439 (d, 1H), 8,136-8,144 (d, 2H), 7,849-7,828 (d, 2H), 7,690-7,688 (d, 2H) ), 7.302-7.289 (d, 1H), 6.971-6.948 (d, 2H), 3.743 (m, 1H), 3.588 (m, 4H), 3.085-3.015 (m, 4H), 2.905 (t, 2H), 2.046 (s, 3H), 1808 (m, 1H), 1663 (m, 2H). MS (EI): 486 (MH +). (R) -N- (4- (2- (4- (4- (2-methoxyacetyl) piperazin-1-yl) phenylamine) pyrimidin-4-yl) phenyl) pyrrolidine-2-carboxamide: NMRH (400MHZ, d6 -DMSO): 10,198 (s, 1H), 9,414 (s, 1H), 8,452 (d, 1H), 8,136 (d, 2H), 7,850 (d, 2H), 7,691 (d, 2H), 7,302 (d, 1H), 6,970 (d, 2H), 4,136 (s, 2H), 3,744 (m, 1H), 3,599-3,535 (m, 4H), 3,302 (s, 3H), 3,078 (m, 4H), 2,905 (t , 2H), 2.079 (m, 1H), 1791 (m, 1H), 1646 (m, 2H). MS (EI): 516 (MH +). N-. { l- [4- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} araino) phenyl] pyrrolidin-3-yl} acetamide: RMNXH (400MHz, d6-DMSO): 10.20 (s, 1H), 9.20 (s, 1H), 8.60 (s, 1H), 8.15-8.20 (m, 3H), 7.79-7.86 (m, 4H), 7.20 (s, 1H), 6.58 (d, 2H), 4.39 (m, 1H), 3.43 (m, 1H), 3.23 (m, 1H), 3.10 (m, 1H), 2.18 (m, 1H), 2.07 (s, 3H), 1.85 (m, 1H), 1.80 (s, 3H). MS (EI): 431 (MH +). N- [4- (2- {[4- (3-oxopiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] acetamide: NMR! (400MHz, d6-DMSO): 10.22 (s, 1H), 9.40 (s, 1H), 8.41 (s, 1H), 8.06 (d, 2H), 8.02 (s, 1H), 7.65-7.80 (m, 4H) ), 7.25 (s, 1H), 6.97 (d, 2H), 3.64 (s, 2H), 3.35-3.40 (m, 4H), 2.05 (s, 3H). (MS (EI): 403 (MH +). N- [4- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) phenyl] -N-methylglycinate ethyl: MS (EI): 420 (MH +). 1- [4- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) phenyl] piperidine-3-ethylcarboxylate: NMR ( 400MHz, d6-DMSO): 10.40 (s, 1H), 10.00 (s, 2H), 8.65 (d, 1H), 8.14 (d, 2H), 7.78 (d, 2H), 7.50-7.62 (m, 4H) 7.40 (d, 1H), 2.09 (s, 3H), 2.00 (s, 3H), MS (El): 362 (MH +). 1- [4- ( { 4- [4- (acetylamino) phenyl) ] pyrimidin-2-yl.}. amino) phenyl] piperidine-3-carboxylic acid ethyl ester: MS (El): 460 (MH +). N- (4 - { 2 - [(4-. {bis] 2- (methyloxy) ethyl] amino.}. Phenyl) amino] pyrimidin-4-yl.} Phenyl) acetamide: MS (El) for C 24 H 2 g Ns 0 3: 436 (MH +). N- [4- (2-. [4- (morpholin-4-ylsulfonyl) phenyl] amino} pyrimidin-4-yl) phenyl] -acetamide: MS (El) for C22H23N504S 454 (MH +). 3-hydroxy-3-methyl-N- [4] - (2- {[[3- (methyloxy) -4-morpholin-4-ylphenyl] amino} - pyrimidin-4-yl) phenyl] butanamide: NMR (400MHz, d6-DMSO): 10.04 (s, 1H), 9.46 (s, 1H), 8.45 (d, 1H), 8.11 (d, 2H), 7.75 (d, 2H), 7.65 (s, 1H) , 7.29 (d, 1H), 6.91 (d, 1H), 3.79 (s, 3H), 3.68 (m, 4H), 2.89 (m, 4H), 2.44 (s, 2H), 1.23 (s, 6H). MS (El) for C 26 H 31 N 504: 478 (MH +). 1-methyl-N- [4- (2- { [3- (methyloxy) -4-morpholin-4-ylphenyl] amino} pyrimidin-4-yl) phenyl] -D-prolinamide: NMR (400MHz) , d6-DMSO): 10.0 (s, 1H), 9.44 (s, 1H), 8.42 (d, 1H), 8.18 (s, 2H), 7.82 (d, 2H), 7.62 (s, 1H), 7.30 ( m, 2H), 6.81 (d, 1H), 3.80 (s, 3H), 3.68 (m, 4H), 2.85-3.10 (m, 6H), 2.37-2.48 (m, 5H), 2.20 (m, 1H) , 1.80 (m, 2H). MS (El) for C27H32N603: 489 (MH +). N- [4- (2- { [3- (methyloxy) -4-morpholin-4-ylphenyl] amino} pyrimidin-4-yl) phenyl] -D-alaninamide: NMR (400MHz, d6-DMSO ): 11.40 (s, 1H), 10.10 (s, 1H), 8.57 (d, 1H), 8.45 (d, 2H), 8.02 (d, 2H), 7.87 (m, 3H), 7.47 (m, 2H) , 4.15 (m, 1H), 3.95-4.10 (m, 7H), 3.58 (m, 4H), 1.48 (d, 3H). MS (El) for C24H28N603: 449 (MH +). N- [4- (2- {[[3- (methyloxy) -4-morpholin-4-ylphenyl] amino} pyrimidin-4-yl) phenyl] cyclopropanecarboxamide: NMR (400MHz, d6-DMSO): 10.45 (s, 1H), 9.43 (s, 1H), 8.42 (d, 1H), 8.17 (d, 2H), 7.75 (d, 2H), 7.64 (s, 1H), 7.15 (m, 2H), 6.84 ( d, 1H), 3.80 (s, 3H), 3.75 (m, 4H), 2.96 (m, 4H), 2.52 (m, 2H), 0.80 (m, 2H). MS (El) for C25H27N503: 446 (MH +). N- [4- (2- { [3- (methyloxy) -4-morpholin-4-ylphenyl] amino} pyrimidin-4-yl) phenyl] butanamide: NMR (400MHz, d6-DMSO): 10.18 (s, 1H), 9.43 (s, 1H), 8.44 (d, 1H), 8.17 (m, 2H), 7.75 (d, 2H), 7.64 (s, 1H), 7.25 (m, 2H), 6.84 ( d, 1H), 3.80 (s, 3H), 3.75 (m, 4H), 2.96 (m, 4H), 2.35 (q, 2H), 1.62 (m, 2H), 0.92 (q, 3H). MS (El) for C25H29Ns03: 448 (MH +). N- (4- {2 - [(4- {4- [3- (methyloxy) propanoyl] piperazin-1-yl} phenyl) amino] -pyrimidin-4-yl}. Phenyl) butanamide: RM (400MHz, d6-DMSO): 10.18 (s, 1H), 9.40 (s, 1H), 8.41 (d, 1H), 8.17 (d, 2H), 7.78 (d, 2H), 7.68 (d, 2H), 7.24 (s, 1H), 6.94 (d, 2H), 3.60 (m, 6H), 3.21 (s, 3H), 3.0-3.09 (m, 4H), 2.60 (q, 2H), 2.35 (m , 2H), 1.60 (m, 2H), 0.95 (q, 3H). MS (El) for C28H34N503: 503 (MH +). O-methyl-N- [4- (2. {[[3- (methyloxy) -morpholin-4-ylphenyl] amino} pyrimidin-4-yl) phenyl] -L-serinamide: NMR (400MHz, d6-DMSO): 11.60 (s, 1H), 10.1 (s, 1H), 8.60 (s, 1H), 8.55 (m, 2H), 8.20 (m, 2H), 7.98 (s, 1H), 7.90 (d , 2H), 7.80 (s, 1H), 7.48 (m, 2H), 4.35 (m, 1H), 4.04 (m, 5H), 3.98 (s, 3H), 3.85 (m, 4H), 3.60 (m, 4H). MS (El) for C 25 H 30 N 6 O 4: 479 (MH +). N- [4- (2- { [3- (methyloxy) -4-morpholin-4-ylphenyl] amino} pyrimidin-4-yl) phenyl] -D-prolinamide: NMR (400MHz, d6-DMSO ): 11.57 (s, 1H), 10.25 (br, 1H), 10.06 (s, 1H), 8.76 (br, 1H), 8.60 (d, 1H), 8.22 (d, 2H), 8.05 (s, 1H) , 7.87 (m, 3H), 7.50 (ra, 2H), 4.18-4.52 (m, 5H), 4.08 (m, 2H), 3.99 (s, 3H), 3.62 (m, 4H), 3.30 (m, 2H) ), 1.95 (m, 2H). MS (El) for C 26 H 30 N 6 O 3: 475 (MH +).

N- (4- { 2- [(4- { 4- [3- (methyloxy) propanoyl] piperazin-1-yl}. Phenyl) amino] -pyrimidin-4-yl}. Phenyl) Cyclopropanecarboxamide: NMR (400MHz, d6-DMS0): 10.45 (s, 1H), 9.40 (s, 1H), 8.41 (s, 1H), 8.12 (d, 2H), 7.75 (d, 2H), 7.68 (d, 2H), 7.28 (d, 1H), 6.98 (d, 2H), 3.60 (m, 6H), 3.22 (s, 3H), 3.0-3.11 (m, 4H), 6.62 (q, 2H), 0.82 (m , 4H). MS (El) for C28H32N603: 501 (MH +). N-. { 4- [2- (. {4- [4- (piperidin-4-ylcarbonyl) piperazin-1-yl] phenyl} amino) -pyrimidin-4-yl] phenyl} -D-prolinamide: RMN1 !. (400MHz, d6-DMSO): 11.40 (s, 1H), 10.0 (m, 1H), 9.96 (s, 1H), 9. 11 (br d, 1H), 8.7-8.8 (m, 2H), 8.55 (d, 1H), 7.87 (m, 4H), 7.59 (br s, 2H), 7.45 (d, 1H), 4.48 (m, 1H), 3.4-3.5 (m, 4H), 3.25-3.30 (m, 4H), 3.0-3.1 (m, 1H), 2.9-3.0 (ra, 2H), 2.4-2.5 (m, 1H), 1.9- 2.0 (m, 3H), 1.7-1.9 (m, 4H); MS (El) C 31 H 38 N 802: 555 (MH +). 3- (methyloxy) -N-. { 4 - [2- ( { 4- [4- (piperidin-4-ylcarbonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} propanamide: NMR'H (400MHz, d6-DMSO): 10.49 (s, 1H), 9.93 (s, 1H), 9.07 (m, 1H), 8.72 (m, 1H), 8.50 (d, 1H), 8.13 ( d, 2H), 7.85 (d, 2H), 7.79 (d, 2H), 7.56 (br s, 2H), 7.42 (d, 1H), 3.61 (t, 2H), 3.3-3.5 (m, 4H), 3.2-3.30 (m, 5H), 3.0-3.1 (m, 1H), 2.85-3.0 (m, 2H), 2.59 (t, 2H), 1.7-1.9 (m, 4H); MS (El) C 30 H 37 N 7 O 3: 544 (MH +). l-ethyl-3-. { 4- [2- (. {4- [4- (piperidin-4-ylcarbonyl) piperazin-1-yl] phenyl} amino) -pyrimidin-4-yl] phenyl} urea: RM ^ H (400MHz, d6-DMSO): 9.96 (s, 1H), 9.20 (s, 1H), 8.93 (m, 1H), 8.65 (m, 1H), 8.46 (d, 1H), 8.09 (d, 2H), 7.79 (m, 2H), 7.58 (d, 2H), 7.41 (m, 3H), 6.51 (br s, 1H), 3.2-3.4 (m, 6H), 3.13 (q, 2H), 3.0-3.1 (m , 1H), 2.9-3.0 (m, 2H), 1.7-1.9 (m, 4H), 1.06 (t, 3H); MS (EI) C 29 H 36 N 802: 529 (MH +). N- (4- {2 - [(4. {4- [3- (dimethylamino) -2,2-dimethylpropanoyl] piperazin-1-yl} phenyl) amino] pyrimidin-4-yl. phenyl) acetamide: RMNXH (400MHz, d6-DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.28 (d, 1H), 6.96 (d, 2H), 6.57 (br s, 1H), 3.70 (m, 4H), 3.07 (m, 4H), 2.60 (br s, 2H) , 2.28 (br s, 6H), 2.09 (s, 3H), 1.23 (s, 6H); MS (EI) C 29 H 37 N 702: 516 (MH +). 2- (methyloxy) -N- (4- [2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -ethanesulfonamide: NMRH (400MHz, d6-DMSO): 9.39 ( s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.67 (d, 2H), 7.31 (d, 2H), 7.26 (d, 1H), 6.94 (d , 2H), 3.74 (m, 4H), 3.67 (t, 2H), 3.43 (t, 2H), 3.18 (s, 3H), 3.05 (m, 4H); MS (EI) C 23 H 27 N 504 S: 470 (MH +). 3- (methyloxy-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) propane-1-sulfonamide: MS (EI) C 24 H 29 N 504 S: 484 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl}. Amino-N- (tetrahydrofuran-2-ylmethyl) benzamide: RM ^ H (400MHz, d6-DMSO): 10.23 ( s, 1H), 9.77 (s, 1H), 8.52 (d, 1H), 8.45 (d, 1H), 8.43 (d, 1H), 8.19 (d, 1H), 8.17 (d, 1H), 7.88-7.86 (m, 1H), 7.76 (s, 1H), 7.74 (s, 1H), 7.43-7.38 (m, 3H), 4.01-3.98 (m, 1H), 3.81-3.76 (m, 2H), 3.65-3.62 (m, 2H), 2.09 (s, 3H), 1.85-1.80 (m, 3H), 1.64-1.61 (m, 1H). MS (EI): 432.5 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] irimidin-2-yl} amino) -N- [3- (2-oxopyrrolidin-1-yl) propyl] benzamide: NMR! (400MHz, d6-DMSO): 10.23 (s, 1H), 9.78 (s, 1H), 8.52 (d, 1H), 8.49 (s, 1H), 8.41 (t, 1H), 8.19 (dd, 2H), 7.87-7.84 (m, 1H), 7.76 (S, 1H), 7.74 (s, 1H), 7.40-7.38 (m, 3H), 3.27-3.23 (m, 6H), 2.22 (t, 2H), 2.09 ( s, 3H), 1.96-1.88 (m, 2H), 1.73-1.70 (m, 2H). MS (EI): 473.5 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) -N - [(3S, 5s, 7s) -trotre- [3.3.1.1-3,7-] dec-l-yl] benzamide: RM ^ H (400MHz, d6-DMSO): 10.21 (s, 1H), 9.73 (s, 1H), 8.52 (d, 1H), 8.35 (s, 1H), 8.16 (d , 2H), 7.84-7.81 (m, 1H), 7.76 (d, 2H), 7.55 (s, 1H), 7.39-7.31 (m, 3H), 2.09 (s, 3H), 1.67 (m, 15H). MS (EI): 482.6 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) -N- [2- (methyloxy) ethyl] -benzamide: NMRH (400MHz, d6-DMSO): 10.23 (s, 1H), 9.77 (s, 1H), 8.52 (d, 1H), 8.46 (d, 2H), 8.19 (d, 1H), 8.18 (d, 1H), 7.88-7.85 (m, 1H), 7.77 (s, 1H), 7.75 (s, 1H), 7.43-7.39 (m, 3H), 3.48-3.41 (m, 4H), 3.29-3.27 (m, 3H), 2.09 (s, 3H). MS (EI): 406.3 (MH +). N- [4- (2- {[3- (1, 3-thiazolidin-3-ylcarbonyl) phenyl] amino} pyrimidin-4-yl) phenyl] -acetamide: NMR! (400MHz, d6- D SO): 10.23 (s, 1H), 9.84 (s, 1H), 8.52 (d, 1H), 8.19-8.12 (m, 3H), 7.90-7.87 (m, 1H), 7.77-7.75 (m, 2H) ), 7.43-7.38 (m, 2H), 7.11 (d, 1H), 4.64 (m, 2H), 3.77 (m, 2H), 3.06 (m, 2H), 2.09 (s, 3H). MS (EI): 420.6 (MH +). N-. { 4- [2- ( { 3- [(4-pyridin-2-ylpiperazin-1-yl) carbonyl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: RMNXH (400MHz, d6-DMSO): 10.20 (s, 1H), 9.83 (s, 1H), 8.53 (d, 1H), 8.14-8.11 (m, 3H), 8.04 (t, 1H), 7.89- 7.86 (m, 1H), 7.73 (d, 2H), 7.57-7.53 (m, 1H), 7.43-7.39 (m, 2H), 7.03-7.01 (m, 1H), 6.83 (d, 1H), 6.69- 6.66 (m, 1H), 3.74 (m, 4H), 3.49 (m, 4H), 2.08 (s, 3H). MS (EI): 494.5 (MH +). 3- (. {4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) -N-. { [2- (methyloxy) phenyl] -methyl} Benzamide: RM ^ H (400MHz, d6-DMSO): 10.22 (s, 1H), 9.79 (s, 1H), 8.80 (d, 1H), 8.53-8.49 (m, 2H), 8.19 (dd, 2H), 7.94-7.91 (m, 1H), 7.74 (d, 2H), 7. 52-7.49 (m, 1H), 7.44-7.39 (m, 1H), 7.26-7.29 (ra, 2H), 6.99 (dd, 1H), 6.93-6.89 (m, 1H), 4.46 (d, 2H), 3.84 (s, 3H), 2.09 (s, 3H). MS (EI): 468.5 (MH +). 3- (. {4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) -N-. { [3- (methyloxy) phenyl] -methyl} Benzamide: RM ^ (400MHz, d6-DMSO): 10.22 (s, 1H), 9.79 (s, 1H), 8.97 (t, 1H), 8.53-8.49 (m, 2H), 8.20-8.18 (m, 2H) , 7.93-7.90 (m, 1H), 7.75 (d, 2H), 7.48-7.46 (m, 1H), 7.43-7.39 (m, 1H), 7.27-7.23 (m, 1H), 6.92-6.90 (m, 2H), 6.83-6.80 (m, 1H), 4.47 (d, 2H), 3.71 (s, 3H), 2.09 (S, 3H). MS (EI): 468.4 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] irimidin-2-yl} amino) -N- [(2-fluorophenyl) methyl] -benzamide: NMR'H (400MHZ, d6-DMS0) : . 22 (s, 1H), 9.79 (s, 1H), 8.97 (t, 1H), 8.53-8.49 (m, 2H), 8.19-8.17 (m, 2H), 7.93-7.90 (m, 1H), 7.75 ( d, 2H), 7.50-7.47 (m, 1H), 7.43-7.37 (m, 2H), 7.32-7.29 (m, 1H), 7.22-7.16 (m, 2H), 4.40 (d, 2H), 2.09 ( s, 3H). MS (El): 456.4 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] irimidin-2-yl} amino) -N- [(4-fluorophenyl) methyl] benzamide: RM ^ H (400MHz, d6-DMSO): 10.22 (s, 1H), 9.79 (s, 1H), 9.00 (t, 1H), 8.53-8.50 (m, 2H), 8.19-8.17 (m, 2H), 7.90-7.88 (m, 1H), 7.75 ( d, 2H), 7.47-7.36 (m, 4H), 7.19-7.13 (m, 2H), 4.47 (d, 2H), 2.09 (s, 3H). MS (El): 456.5 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl}. Amino) -N- (3,3-dimethylbutyl) -benzamide: NMR! (400MHz, d6-DMSO): 10.21 (s, 1H), 9.76 (s, 1H), 8.53-8.51 (d, 1H), 8.41 (s, 1H), 8.33 (t, 1H), 8.18-8.17 (m , 2H), 7.88-7.85 (m, 1H), 7.75 (d, 2H), 7.39-7.37 (m, 2H), 3.30-3.26 (m, 2H), 2.08 (s, 3H), 1.48-1.44 (m , 2H), 0.94 (s, 9H). MS (El): 432.4 (MH +). N- [4- (2- {[[3- (thiomorpholin-4-ylcarbonyl) phenyl] amino} pyrimidin-4-yl) phenyl] -acetamide: NMR'H (400MHz, d6-DMSO): . 23 (s, 1H), 9.82 (s, 1H), 8.53 (d, 1H), 8.15-8.20 (m, 2H), 7.99 (t, 1H), 7.85-7.82 (m, 1H), 7.76 (d, 2H), 7.41-7.37 (m, 2H), 6.98-6.96 (m, 1H), 3.88 (m, 4H), 3.60 (m, 4H), 2.09 (S, 3H). MS (El): 434.5 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) -N- (2-thienylmethyl) benzamide: NMR'H (400MHZ, d6-DMS0): 10.22 (s) , 1H), 9.79 (s, 1H), 9.09 (t, 1H), 8.53-8.50 (m, 2H), 8.18 (d, 2H), 7.89-7.86 (m, 1H), 7.75 (d, 2H), 7.44-7.38 (m, 3H), 7.03 (m, 1H), 6.98-6.96 (m, 1H), 4.64 (d, 2H), 2.09 (s, 3H). MS (El): 444.4 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl.}. Amino) -N- [3- (dimethylamino) -propyl] benzamide: R Ix ^ H (400MHz, d6-DMSO ): 10.22 (s, 1H), 9.79 (s, 1H), 8.74 (m, 1H), 8.55-8.50 (m, 2H), 8.21-8.18 (m, 2H), 7.95-7.87 (m, 1H), 7.75 (d, 2H), 7. 45-7.40 (m, 2H), 3.05 (s, 2H), 2.75 (s, 6H), 2.55-2.54 (m, 2H), 2.09 (s, 3H), 1.25-1.21 (m, 2H). MS (El): 433.4 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl}. Amino) -N- [2- (2-chlorophenyl) -ethyl] benzamide: NMR'H (400MHZ, d6- DMSO): 10.21 (s, 1H), 9.77 (s, 1H), 8.54-8.51 (m, 2H), 8.44 (m, 1H), 8.18 (d, 2H), 7.88-7.86 (m, 1H), 7.75 (d, 2H), 7.45-7.36 (m, 4H), 7.28-7.25 (m, 2H), 3.55-3.50 (m, 2H), 3.01-2.98 (m, 2H), 2.08 (s, 3H). MS (El): 486.8 (MH +). 3- (. {4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) -N-. { [2- (trifluoromethyl) -phenyl] methyl} Benzamide: NMR1H (400MHz, d6-DMSO): 10.21 (s, 1H), 9.81 (s, 1H), 9.07 (t, 1H), 8.53-8.49 (m, 2H), 8.19-8.17 (m, 2H), 7.96-7.94 (m, 1H), 7.75-7.72 (m, 2H), 7.55-7.39 (m, 6H), 4.68 (d, 2H), 2.08 (s, 3H). MS (El): 506.5 (MH +). 3- (. {4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) - N- ([3- (trifluoromethyl) -phenyl] methyl.} Benzamide: NMR! (400MHz, d6-DMSO): 10.21 (s, 1H), 9.80 (s, 1H), 9.10 (t, 1H), 8.53-8.49 (m, 2H), 8.19-8.17 (m, 2H), 7.94-7.91 (m, 1H), 7.74 (d, 2H), 7.68-7.58 (m, 3H), 7.48-7.39 (m, 3H) ), 4.58 (d, 2H), 2.09 (s, 3H), MS (El): 506.4 (MH +). 3- (. {4- [4- (acetylamino) phenyl] -irimidin-2-yl}. amino) -N- { [4- (trifluoromethyl) -phenyl] methyl.} benzamide: R IS ^ H (400MHz, d6-DMSO): 10.21 (s, 1H), 9.80 (s, 1H), 9.10 (t, 1H), 8.52 (m, 2H), 8.18 (d, 2H), 7.91-7.89 (m, 1H), 7.75-7.69 (m, 4H), 7.55 (d, 2H), 7.49-7.38 (m , 3H), 4.58 (d, 2H), 2.08 (s, 3H), MS (El): 506.5 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] irimidin-2-yl} amino) -N- [(2,4-difluorophenyl) -methyl] benzamide: NMR1 !! (400MHz, d6-DMSO): 10.21 (s, 1H), 9.79 (s, 1H), 8.98 (t, 1H ), 8.52 (m, 2H), 8.18 (d, 2H), 7.91-7.89 (m, 1H), 7.54 (d, 2H), 7.47-7.38 (m, 4H), 7.27-7.22 (m, 1H), 7.09-7.04 (m, 1H), 4.48 (d, 2H), 2.09 (s, 3H), MS (The ): 474.4 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] irimidin-2-yl}. Amino) -N-ethyl-N-methylbenzamide: NMRH (400MHz, d6-DMSO): 10.23 (s, 1H) , 9.80 (s, 1H), 8.53 (d, 1H), 8.13 (d, 2H), 7.76-7.74 (m, 2H), 7.40-7.32 (m, 3H), 6.94 (m, 2H), 3.28-3.24 (m, 2H), 2.94 (m, 3H), 2.09 (s, 3H), 1.15-1.08 (m, 3H). MS (El): 390.4 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) -N- (. {4- [(trifluoromethyl) -oxy] phenyl} methyl) benzamide: RMN1 !. (400MHz, d6-DMSO): 10.21 (s, 1H), 9.79 (s, 1H), 9.04 (t, 1H), 8.52 (m, 2H), 8.18 (d, 2H), 7.91-7.88 (m, 1H) ), 7.75 (d, 2H), 7.48-7.39 (m, 4H), 7.34-7.32 (m, 2H), 4.51 (d, 2H), 2.09 (S, 3H). MS (EI): 522.5 (MH +). N-. { 4- [2- ( { 3- [(4-Acetylpiperazin-1-yl) carbonyl] phenyl} araino) pyrimidin-4-yl] -phenyl} acetamide: RJYUS ^ H (400MHz, d6-DMSO): 10.22 (s, 1H), 9.82 (s, 1H), 8.53 (t, 1H), 8.19 (d, 2H), 8.14-8.12 (m, 2H), 7.84-7.84 (m, 1H), 7.75 (d, 2H), 7.40-7.38 (ra, 2H), 3.53-3.44 (m, 8H), 2.09 (s, 6H). MS (EI): 459.5 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl}. Amino) -N- (cyclopropylmethyl) -benzamide: R ^ H (400MHz, d6-DMSO): 10.22 (s, 1H), 9.77 (s, 1H), 8.53-8.50 (m, 2H), 8.48 (d, 1H), 8.19 (d, 2H), 7.86-7.84 (m, 1H), 7.75 (d, 2H), 7.41 -7.38 (m, 2H), 3.17-3.14 (m, 2H), 2.09 (s, 3H), 1.06 (m, 1H), 0.45-0.42 (m, 2H), 0.25-0.23 (m, 2H). MS (EI): 402.5 (MH +). 3- . { (4- [4- (acetylamino) phenyl] pyrimidin-2-yl.}. Amino) -N- [2- (2-fluorophenyl) -ethyl] benzamide: NMR'H (400MHZ, d6-DMSO): 10.21 ( s, 1H), 9.77 (s, 1H), 8.54-8.51 (m, 2H), 8.44 (m, 1H), 8.20-8.17 (m, 2H), 7.88-7.86 (m, 1H), 7.75 (d, 2H), 7.40-7.26 (m, 4H), 7.18-7.13 (m, 2H), 3.52-3.49 (m, 2H), 2.92-3.88 (m, 2H), 2.09 (s, 3H). MS (EI): 470.4 (MH +). N- [4- (2- {[[3- (pyrrolidin-1-ylcarbonyl) phenyl] amino} pyrimidin-4-yl) phenyl] -acetamide: NMR'H (400MHz, d6-DMSO): 10.22 (s, 1H), 9.78 (s, 1H), 8.53 (d, 1H), 8.20-8.12 (m, 4H), 7.83 (d, 1?), 7.76-7.73 (ra, 2H), 7.39-7.35 (m, 2H), 3.50-3.40 (m, 4H), 2.09 (s, 3H), 1.95-1.80 (ra , 4H). MS (El): 402.5 (MH +). N-. { 4 - [2- ( { 3- [(4-pyrimidin-2-ylpiperazin-1-yl) carbonyl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: RMN1 !. (400MHz, d6-DMSO): 10.20 (s, 1H), 9.83 (s, 1H), 8.53 (d, 2H), 8.39 (d, 1H), 8.14-8.12 (m, 2H), 8.04 (t, 1H) ), 7.89-7.87 (m, 1H), 7.74 (d, 1H), 7.43-7.38 (m, 2H), 7.03-7.01 (ra, 1H), 6.67 (t, 2H), 3.81 (ra, 4H), 3.73 (m, 4H), 2.08 (s, 3H). MS (El): 495.6 (MH +). N-. { 4- [2- ( { 4- [4- (9H-Fluoren-2-ylmethyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: RMIS ^ H (400MHz, d6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.87 (t, 2H), 7.73 ( d, 2H), 7.65 (d, 2H), 7.59-7.56 (m, 2H), 7.37-7.25 (m, 4H), 6.92 (d, 2H), 3.92 (s, 2H), 3.60 (s, 2H), 3.10 (m, 4H), 2.56 (m, 4H), 2.08 (s, 3H) .. MS (El): 567.7 (MH +). N- (4- { 2- [(4- {4- [(3-methyl-2-thienyl) methyl] piperazin-1-yl} phenyl) amino] pyrimidin-4-yl} phenyl) acetamide: RMN1 !. (400MHz, d6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.73 (d, 2H), 7.65 (d, 2H), 7.33 (d, 1H), 7.26 (d, 1H), 6.92 (d, 2H), 6.85 (d, 1H) ), 3.63 (s, 2H), 3.07 (m, 4H), 2.56 (m, 4H), 2.17 (s, 3H), 2.08 (s, 3H). MS (El): 499.5 (MH +). N- (4- {2 - [(4- { 4- [(5-Ethylfuran-2-yl) methyl] piperazine- 1-il} phenyl) amino] -pyrimidin-4-yl} phenyl) acetamide: RMIS ^ H (400MHz, d6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.73 (d, 2H), 7.64 (d, 2H) 7.26 (d, 1H), 6.92 (d, 2H), 6.18 (d, 1H), 6.01 (d, 1H), 3.48 (s, 2H), 3.07 (m, 4H), 2.62- 2.56 (m, 6H), 2.09 (s, 3H), 1.16 (t, 3H). MS (EI): 497.6 (MH +). N- (4- {2 - [(4- { 4 - [(3- {[[4- (1, 1-dimethylethyl) phenyl] oxy} phenyl) methyl] iperazin-1- phenyl) amino] irimidin-4-yl] phenyl) acetamide: NMR'H (400MHZ, d6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H ), 8.11 (d, 2H), 7.74 (d, 2H), 7.64 (d, 2H), 7.42-7.38 (m, 2H), 7.33 (t, 1H), 7.26 (d, 1H), 7.08 (d, 1H), 6.97-6.86 (m, 6H), 3.52 (s, 2H), 3.06 (m, 4H), 2.52 (m, 4H), 2.09 (S, 3H), 1.27 (s, 9H). MS (EI): 627.7 (MH +). N-. { 4 - [2- ( { 4 - [4- (3-thienylmethyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] -phenyl} acetamide: RMI ^ H (400MHz, d6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.73 (d, 2H), 7.64 ( d, 2H), 7.51-7.45 (m, 1H), 7.35 (d, 1H), 7.29-7.25 (m, 1H), 7.08-7.04 (m, 1H), 6.91 (d, 2H), 3.53 (s, 2H), 3.07 (m, 4H), 2.52 (m, 4H), 2.09 (s, 3H). MS (EI): 485.6 (MH +). 4 - ( { 4 - [4 - ( { 4 - [4 - (acetylamino) phenyl] pyrimidin-2-yl.}. Amino) -phenyl] piperazin-1-yl.} Methyl) benzoate methyl: NMR'H (400MHz, d6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.94 (d, 2H), 7.73 ( d, 2H), 7.65 (d, 2H), 7.50 (d, 2H), 7.26 (d, 1H), 6.92 (d, 2H), 3.85 (s, 3H), 3. 61 (s, 2H), 3.09 (m, 4H), 2.54 (m, 4H), 2.09 (s, 3H). MS (El): 537.7 (MH +). N- (4- {2 - [(4- { 4- [3- (Reththylthio) rovyl] piperazin-1-yl} phenyl) amino] pyriraidin-4-yl} phenyl) acetamide : RMIS ^ H (400MHz, d6-DMSO): 10.21 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.65 (d , 2H), 7.26 (d, 1H), 6.92 (d, 2H), 3.34 (m, 4H), 3.07 (m, 4H), 2.39 (m, 4H), 2.09 (s, 3H), 2.03 (m, 3H), 1.75-1.68 (m, 2H). MS (EI): 477.5 (MH +). N- (4- {2 - [(4. {4 - [(4. {[[3- (dimethylamino) propyl] oxy} phenyl) methyl] piperazin-1-yl}. phenyl) amino] pyrimidin-4-yl.} phenyl) acetamide: NMR'H (400MHz, d6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.11 ( d, 2H), 7.73 (d, 2H), 7.64 (d, 2H), 7.26-7.21 (m, 3H), 6.92-6.87 (m, 4H), 3.97 (t, 2H), 3.44 (m, 6H) , 3.06 (m, 4H), 2.37 (t, 2H), 2.16 (s, 6H), 2.09 (s, 3H), 1.87-1.82 (m, 2H). MS (EI): 580.7 (MH +). N- [4- (2- { [4- (4- { 2- [(phenylmethyl) oxyl] ethyl} piperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] acetamide: NMR'H (400MHz, d6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.65 (d, 2H), 7.38-7.26 (m, 6H), 6.92 (d, 2H), 4.50 (s, 2H), 3.59 (m, 3H), 3.07 (m, 3H), 2.58 (m, 6H) 2.09 (s, 3H). MS (EI): 523.5 (MH +). N- (4- { 2- [(4- { 4- [(2-chloroquinolin-3-yl) methyl] piperazin-1-yl}. Phenyl) amino] -pyrimidin-4-yl. phenyl) acetamide: Riyi 'H (400MHz, d6-DMSO): 10.20 (s, 1H), 9.37 (s, 1H), 8.49 (s, 1H), 8.44 (d, 1H), 8.13-8.09 (m , 3H), 7.96 (d, 1H), 7. 83-7.79 (m, 1H), 7.74 (d, 1H), 7.69-7.65 (m, 3H), 7.26 (d, 2H), 6.95 (d, 2H), 3.78 (s, 2H), 3.15 (m, 4H), 2.69 (m, 4H), 2.09 (s, 3H). MS (EI): 565.1 (MH +). N-. { 4- [2- ( { 4- [4- (2,2 · -bitien-5-ylmethyl) iperazin-1-yl] phenyl} araino) -pyrimidin-4-yl] phenyl} acetamide: RMIS ^ H (400MHz, d6-DMSO): 10.20 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.65 ( d, 2H), 7.49 (dd, 1H), 7.27-7.25 (m, 2H), 7.15 (d, 1H), 7.09-7.07 (m, 1H), 6.96-6.92 (m, 3H), 3.73 (s, 2H), 3.10 (m, 4H), 2.59 (m, 4H), 2.09 (S, 3H). MS (EI): 567.6 (MH +). N- [4- (2- { [4- (4-. {[[4- (2-thienyl) phenyl] methyl.}. Piperazin-1-yl) phenyl] amino.} - pyrimidin-4 -yl) phenyl] acetamide: NMR'H (400MHz, d6-DMSO): 10.20 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.73 (d, 2H), 7.66-7.62 (m, 4H), 7.54-7.50 (m, 2H), 7.38 (d, 2H), 7.26 (d, 1H), 7.15-7.13 (m, 1H), 6.92 (d, 2H) , 3.54 (s, 2H), 3.09 (m, 4H), 2.55-2.52 (m, 4H), 2.09 (s, 3H). MS (EI): 561.6 (MH +). N- (4- {2 - [(4- {4- [(4-cyanophenyl) methyl] piperazin-1-yl} phenyl) amino] -pyrimidin-4-yl}. Phenyl) acetamide: RMI ^ H (400MHz, d6-DMSO): 10.20 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.82 (d, 2H), 7.73 (d, 2H), 7.65 (d, 2H), 7.56 (d, 2H), 7.26 (d, 1H), 6.92 (d, 2H) ), 3.63 (s, 2H), 3.10-3.08 (m, 4H), 2.54-2.52 (m, 4H), 2.09 (s, 3H). MS (EI): 504.5 (MH +). N- [4- (2- { [4- (4-. {[2,5-bis (methyloxy) phenyl] methyl.}. piperazin-1-yl) phenyl] -amino} pyrimidin-4-yl) phenyl] acetamide: R N'H (400MHZ, d6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.65 (d, 2H), 7.26 (d, 1H), 6.95-6.90 (m, 4H), 6.81-6.78 (m, 1H), 3.74 (s, 3H), 3.70 (s, 3H), 3.50 (s, 2H), 3.09 (m, 4H), 2.55 (m, 4H), 2.09 (s, 3H). MS (EI): 539.7 (MH +). N-. { 4- [2- (. {4- [4- (2,2-diphenylethyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: R IS ^ H (400MHz, d6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.82 (d, 2H), 7.65 -7.59 (m, 6H), 7.50-7.46 (m, 4H), 7. 26 (d, 1H), 7.21 (d, 2H), 6.92 (d, 2H), 4.45 (t, 1H), 3.61 (t, 2H), 3.09 (m, 4H), 2.54 (m, 4H), 2.09 (s, 3H). MS (EI): 569.6 (MH +). N-. { 4- [2- (. {4- [4- (lH-pyrrol-2-ylmethyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: NMR1H (400MHz, d6-DMSO): 10.71 (s, 1H), 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.73 (d, 2H), 7.64 (d, 2H), 7.26 (d, 1H), 6.91 (d, 2H), 6.65-6.63 (m, 1H), 5.94-5.90 (m, 2H), 3.44 (s, 2H), 3.06 (m, 4H), 2.48 (m, 4H), 2.09 (s, 3H). MS (EI): 468.6 (MH +). N- [4- (2- { [4- (4-propylpiperazin-1-yl) phenyl] amino.} Pyrimidin-4-yl) phenyl] -acetamide: RMIS ^ H (400MHz, d6-DMSO) : 10.22 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.73 (d, 2H), 7.65 (d, 2H), 7.26 (d, 1H), 6.92 (d, 2H), 3.06 (m, 4H), 2.27 (m, 4H), 2.08 (s, 3H), 1.80 (s, 2H), 1.48 (m, 2H), 0.88 (t, 3?). MS (El): 431.6 (MH +). N- [4- (2- {[4- (4-butylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] acetamide: NMR'H (400MHZ, d6-DMSO): 10.22 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.12 (d, 2H), 7.74 (d, 2H), 7.64 (d, 2H), 7.25 (d, 1H), 6.92 (d, 2H), 3.07 (m, 4H), 2.31 (m, 4H), 2.09 (s, 3H), 1.87 (m, 2H), 1.44 (m, 2H), 1.30 (m, 2H), 0.90 ( t, 3H). MS (El): 445.6 (MH +). N-. { 4- [2- (. {4- [4- (cyclopropylmethyl) iperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: RMN1 !! (400MHz, d6-DMSO): 10.22 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.73 (d, 2H), 7.65 (d, 2H), 7.25 (d, 1H), 6.92 (d, 2H), 3.08 (m, 4H), 2.58 (m, 4H), 2.22 (d, 2H), 2.09 (s, 3H), 1.86 (s, 1H), 0.49 (m, 2H), 0.09 (m, 2H). MS (El): 443.6 (MH +). N- [4- (2- {[[4- (4-pentanoylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] -acetamide: RMIN ^ H (400MHz, d6-DMSO) : 10.22 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.68 (d, 2H), 7.28 (d, 1H), 6.96 (d, 2H), 3.60 (m, 4H), 3.07 (m, 2H), 3.02 (m, 2H), 2.35 (t, 2H), 2.09 (s, 3H), 1.49 (m, 2H), 1.31 (m, 2H), 0.89 (t, 3H). MS (El): 473. 6 (MH +). N-. { 4 - [2- ( { 4 - [4- (pyridin-2-ylcarbonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: RMIN H (400MHz, d6-DMSO): 10.22 (s, 1H), 9.41 (s, 1H), 8.62 (d, 1H), 8.44 (d, 1H), 8.10 (d, 2H), 7.95 (t , 1H), 7.74 (d, 2H), 7.69 (d, 2H), 7.61 (d, 1?), 7.27 (d, 1H), 6.97 (d, 2H), 3.82 (t, 2H), 3.57 (t, 2H), 3.18 (t, 2H), 3.06 (t, 2H), 2.09 (s, 3H). MS (EI): 494.6 (MH +). N-. { 4- [2- ( { 4- [4- (pyridin-3-ylcarbonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: RM ^ H (400MHz, d6-DMSO): 10.22 (s, 1H), 9.41 (s, 1H), 8.68 (m, 2H), 8.44 (d, 1H), 8.10 (d, 2H), 7.89 ( d, 1H), 7.74 (d, 2H), 7.69 (d, 2H), 7.51 (m, 1H), 7.28 (d, 2H), 3.80 (m, 2H), 3.49 (m, 2H), 3.18 (m , 2H), 3.09 (m, 2H), 2.09 (s, 3H). MS (EI): 494.6 (MH +). N-. { 4- [2- ( { 4- [4- (pyridin-4-ylcarbonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: RMIx ^ H (400MHz, d6-DMSO): 10.22 (s, 1H), 9.41 (s, 1H), 8.69 (d, 2H), 8.44 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.44 (d, 2H), 7.28 (d, 1H), 6.96 (d, 2H), 3.79 (d. m, 2H), 3.41 (m, 2H), 3.18 (m, 2H), 3.07 (m, 2H), 2.09 (s, 3H). MS (EI): 494.6 (MH +). N-. { 4- [2- (. {4- [4- (lH-pyrazol-4-ylcarbonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: RMN1 !! (400MHz, d6-DMSO): 10.22 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.10 (d, 2H), 7.75-7.68 (m, 4H), 7.28 (d, 2H) ), 6.97 (d, 3H), 3.75 (m, 4H), 3.11 (m, 4H), 2.09 (s, 3H). MS (EI): 483.5 (MH +). N- (4- {2 - [(4- {4- [(l-acetylpiperidin-4-yl) carbonyl] piperazin-1-yl} phenyl) amino] -pyrimidin-4-yl} phenyl) acetamide: RM 'H (400MHZ, d6-DMSO): 10.21 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.26 (d, 1H), 6.97 (d, 2H), 3.65 (m, 4H), 3.02 (m, 8H), 2.62 (m, 1H), 2.09 (s, 3H), 1.99 (s, 3H) ), 1.66 (ra, 2H), 1.56 (m, 2H). MS (El): 542.7 (MH +). N- (4- (2- (4- (4- (2-cyclopropylacetyl) iperazin-1-yl) phenylamine) pyrimidin-4-yl) phenyl) acetamide: NMRH (400MHz, d6-DMSO): 10.22 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.10 (d, 2H), 7.54 (d, 2H), 7.68 (d, 2H), 7.28 (d, 1H), 6.96 (d, 2H) ), 3.59 (m, 4H), 3.04 (m, 4H), 2.30 (d, 2H), 2.09 (s, 3H), 0.97 (m, 1H), 0.45 (m, 2H), 0.14 (m, 2H) . MS (El): 471.6 (MH +). N- (4- { 2- [(4- { 4- [3- (methyloxy) propanoyl] piperazin-1-yl}. Phenyl) amino] pyrimidin-4-yl} phenyl) acetamide : RMI ^ H (400MHz, d6-DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.68 (d , 2H), 7.27 (d, 1H), 6.95 (d, 2H), 3.58 (m, 6H), 3.23 (s, 3H), 3.08 (m, 2H), 3.02 (m, 2H), 2.62 (t, 2H), 2.09 (s, 3H). MS (El): 475.6 (MH +). N-. { 4- [2- ( { 4- [4- (2-. {[[2- (methyloxy) ethyl] oxy} acetyl) piperazin-1-yl] phenyl} amino) -pyrimidin-4 - il] phenyl} acetamide: NMR1H (400MHz, d6-DMSO): 10.23 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.68 (d, 1H), 7.27 (d, 1H), 6.96 (d, 2H), 4.20 (s, 2H), 3.58 (m, 6H), 3.47 (m, 2H), 3.25 (s, 3H), 3.06 (m, 4H) ), 2.09 (s, 3H). MS (El): 505.6 (MH +). N- (4- (2- (4- (4- (2- (pyridin-3-yl) acetyl) piperazine- 1 - il) phenylamine) pyrimidin-4-yl) phenyl) acetamide: NMR1! (400MHz, d6-DMSO): 10.22 (s, 1H), 9.41 (s, 1H), 8.44 (m, 3H), 8.10 (d, 2H), 7.75 (d, 2H), 7.68 (d, 2H), 7.64 (m, 1H), 7.34 (m, 1H), 7.28 (d, 1H), 6.96 (d, 1H), 3.83 (s, 2H), 3.70 (m, 2H), 3.63 (m, 2H), 3.05 (m, 4H), 2.09 (s, 3H). MS (El): 508.6 (MH +). (2R, 4S) -4-hydroxy-N- (4- (2- (4- (4- (3-methoxypropanoyl) piperazin-1-yl) phenylamino) pyrimidin-4-yl) phenyl) pyrrolidine-2 -carboxamide: RM ^ H (400MHz, d6-DMSO): 10.22 (s, 1H), 9.40 (s, 1H), 8.48 (d, 1H), 8.44 (d, 1H), 8.39 (dd, 1H), 8.11 (d, 1H), 7.74 (d, 2H), 7.69 (m, 3H), 7.28 (m, 3H), 6.94 (d, 2H), 3.59 (m, 4H), 3.01 (m, 4H), 2.86 (t, 2H), 2.73 (t, 2H), 2.09 (s, 3H). MS (El): 522.6 (MH +). N-. { 4 - [2 - ( { 3 - [4- (1, 3-thiazol-2-ylmethyl) piperazin-1-yl] phenyl} amino) -pyrimidin-4-yl] phenyl} acetamide: RMN1 !! (400MHz, d6-DMSO): 10.19 (s, 1H), 9.45 (s, 1H), 8.47 (d, 1H), 8.11 (d, 2H), 7.73 (d, 2H), 7.66 (d, 1H), 7.60 (s, 1H), 7.31 (d, 1H), 7.21 (d, 1H), 7.12 (t, 1H), 6.55 (d, 1H), 3.90 (s, 1H), 3.17 (m, 4H), 2.66 (m, 4H), 2.07 (s, 3H). MS (El): 486.6 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-ylphenyl) -5-oxo-L-prolinamide: NMRH (400MHz, d6-DMSO): 10.33 (s, 1H), 9.40 (s, 1H), 8.45 (d, 1H), 8.14 (d, 2H), 7.93 (s, 1H), 7.79 (d, 2H), 7.67 (d, 2H), 7.29 (s, d, 1H), 6.93 (d, 2H), 4.23 (dd, 1H), 3.75 (m, 4H), 3.06 (m, 4H), 2.35 (m, 1H), 2. 21 (m, 2H), 2.02 (m, 1H). MS (EI): 459.5 (MH +). (3S) -N- (4- {2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) pyrrolidine-3-carboxamide: RMI ^ H (400MHz, d6- DMSO): 10.75 (s, 1H), 9.84 (s, 1H), 9.34 (m, 1H), 9.14 (m, 1H), 8.51 (d, 1H), 8.16 (d, 2H), 7.82 (d, 3H) ), 7.41 (d, 2H), 3.93 (m, 4H), 3.82 (m, 6H), 3.36 (m, 2H), 3.24 (m, 1H), 2.33-2.24 (m, 1H), 2.11-2.04 ( m, 2H). MS (EI): 445.5 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -L-threoninamide: NMRH (400MHz, d6-DMSO): 11.53 (s, 1H), 10.11 (s, 1H), 8.51 (d, 1H), 8.31 (d, 2H), 8.15 (d, 2H), 7.86 (t, 3H), 7.73 (d, 2H), 7.44 (d, 2H) ), 4.01 (m, 6H), 3.48 (m, 4H), 1.18 (s, 3H). MS (EI): 449.5 (MH +). N-. { 4- [2- ( { 4- [4- (N, N-diethyl-beta-alanyl) piperazin-1-yl] phenyl-1.}. Amino) -pyrimidin-4-yl] phenyl} acetamide: RMIS ^ H (400MHz, d6-DMSO): 10.20 (s, 1H), 9.38 (s, 1H), 8.42 (d, 1H), 8.09 (d, 2H), 7.73 (d, 2H), 7.67 ( d, 2H), 7.25 (d, 1H), 6.95 (d, 2H), 3.58 (ra, 4H), 3.05 (m, 4H), 2.81 (t, 2H), 2.66-2.55 (m, 6H), 1.93 (s, 3H), 0.99 (t, 6H). MS (EI): 516.7 (MH +). N1- (4- {2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-ylphenyl) -D-glutamamide: NMR'H (400MHZ, d6-DMSO): 9.36 (s, 1H) , 8.42 (d, 2?), 8.11 (d, 3H), 7.80 (d, 2H), 7.66 (d, 2H), 7.26 (d, 2H), 6.92 (d, 3H), 3.72 (m, 4H) , 3.32 (m, 1H), 3.02 (m, 4H), 1.93 (s, 2H), 1.82 (s, 2H). MS (EI): 476.6 (MH +).

(S) -1-ethyl-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) pyrrolidine-3-carboxamide: NMRH (400MHz, d6-DMSO): 10.19 (s, 1H) , 9.38 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.77 (d, 2H), 7.68 (d, 2H), 7.28 (d, 1H), 6.94 (d, 2H), 3.04 (m, 4H), 2.90 (m, 2H), 2.65 (m, 2H), 2.43 (m, 3H), 1.98 (m, 6H), 1.03 (t, 3H). MS (EI): 473.6 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-ylphenyl) -D-norvalinemide: RM 'H (400MHZ, d6-DMSO): 11.50 (s, 1H) , 10.15 (s, 1H), 8.56 (m, 3H), 8.24 (d, 2H), 7.94 (d, 2H), 7.76 (m, 3H), 7.51 (d, 2H), 4.08 (m, 4H), 3.67 (d, 1H), 1.97 (m, 4H), 1.43 (m, 2H), 1.19 (m, 2H), 0.94 (m, 3H). MS (EI): 447.6 (MH +). N- (4-. {2- [4-morpholin-4-ylphenyl) amino] pyrimidin-4-ylphenyl) -D-norleucinamide: RM ^ H (400MHz, d6-DMSO): 11.55 (s, 1H), 10.19 (s, 1H), 8.57 (d, 2H), 8.26 (d, 1H), 8.01 (m, 4H), 7.80 (m, 3H), 7.53 (d, 2H), 4.05 (m, 4H), 3.68 (d, 1H), 1.92 (m, 4H), 1.36 (m, 4H), 1.19 (m, 2H) ), 0.99 (d, 3H). MS (EI): 461.6 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl-L-alloisoleucinamide: RMI ^ H (400MHz, d6-DMSO): 11.32 (s) , 1H), 10.01 (s, 1H), 8.56 (d, 2H), 8.44 (d, 3H), 8.21 (d, 2H), 7.89 (m, 3H), 7.46 (d, 2H), 4.02 (m, 4H), 3.56 (d, 1H), 1.99 (m, 4H), 1.63 (m, 1H), 1.17 (m, 2H), 1.00 (d, 3H), 0.91 (d, 3H), MS (EI): 461.6 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4- il-phenyl) -L-leucinamide: NMR'H (400MHZ, ds-DMSO): 11.32 (s, 1H), 9.97 (s, 1H), 8.56 (d, 2H), 8.45 (d, 3H), 8.21 (d, 2H), 7.89 (m, 3H), 7.46 (d, 2H), 4.02 (m, 4H), 3.57 (d, 1H), 1.99 (m, 4H), 1.91 (m, 1H), 1.71 (t, 2H) ), 1.17 (t, 3H), 0.95 (t, 3H). MS (EI): 461.6 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] irimidin-2-yl.}. Amino) -N- (2-ethylphenyl) benzamide: R ^ H (400MHz, d6-DMSO): 10.21 (s) , 1H), 9.85 (d, 2H), 8.59 (s, 1H), 8.53 (d, 1H), 8.18 (d, 2H), 7.93 (m, 1H), 7.73 (d, 2H), 7.57 (d, 1H), 7.46 (t, 1H), 7.40 (d, 1H), 7.30-7.34 (m, 2H), 7.24-7.27 (m, 2H), 2.62-2.67 (m, 2H), 2.08 (s, 3H) , 1.13-1.7 (t, 3H). MS (El) for C27H25N502: 452.58 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) -N- (phenylmethyl) -benzamide: RM ^ H (400MHz, d6-DMSO): 10.22 (s), 1H), 8.98-9.10 (t, 1H), 8.52 (d, 1H), 8.50 (s, 1H), 8.18 (d, 2H), 7.9 (dd, 1H), 7.76 (s, 1H), 7.74 ( s, 1H), 7.47 (d, 1H), 7.39-7.43 (m, 2H), 7.43 (s, 2H), 7.34 (d, 2H), 7.23-7.25 (m, 1H), 4.50 (d, 2H) 2.09 (s, 3H). MS (El) for C2SH23N502: 438.48 (MH +). N-. { 4- [2- ( { 3- [(4-cyclopentyl-piperazin-1-yl) -carbonyl] -phenyl} -amino) -pyrimidin-4-yl] -phenyl} acetamide: NMR'H (400MHz, d6-DMSO): 10.23 (s, 1H), 9.82 (s, 1H), 8.53 (d, 1H), 8.12 (s, 2H), 8.05 (s, 1H), 7.81 ( dd, 1H), 7.76 (d, 2H), 7.38 (t, 2H), 6.95 (d, 1H), 2.89 (s, 2H), 2.73 (s, 2H), 2.34-2.45 (m, 5H), 2.09 (s, 3H), 2.73-2.75 (m, 2H), 1.52- 1. 59 (m, 2H), 1.46-1.50 (m, 2H), 1.27-1.33 (m, 2H): MS (El) for C28H32N602: 485.8 (MH +). N-. { 4- [2- ( { 3- [(4-pyrazin-2-ylpiperazin-1-yl) carbonyl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: RMIN H (400MHz, d6-DMSO): 10.17 (s, 1H), 9.84 (s, 1H), 8.54 (d, 1H), 8. 43 (d, 1H), 8.11 (d, 2H), 8.06-8.10 (m, 2H), 7.86-7.88 (m, 2H), 7.73 (d, 2H), 7.42 (d, 1H), 7.39 (d, 1H), 7.02-7.04 (m, 1H), 3.69 (m, 4H), 3.57 (m, 4H), 2.08 (s, 3H). MS (El) for C27H26N802: 495.7 (MH +). N- (4- {2 - [(3- {[4- (3-chlorophenyl) piperazin-1-yl] carbonyl} phenyl) amino] pyrimidin-4-yl} phenyl) acetamide : RMK ^ H (400MHz, d6-DMSO): 10.20 (s, 1H), 9.84 (s, 1H), 8.53 (d, 1H), 8.13 (dd, 2H), 8.064 (t, 1H), 7.85-7.87 (m, 1H), 7.74 (d, 2H), 7.39-7.43 (m, 2H), 7.22 (t, 1H), 7.01-7.03 (m, 1H), 6.96 (t, 1H), 6.90 (dd, 1H) ), 6.81 (dd, 1H), 3.76 (m, 4H), 3.52 (m, 4H), 2.08 (s, 3H). MS (El) for C29H27CIN602: 528.1 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl}. Amino) -N- [(1-methyl-1H-benzimidazol-2-yl) methyl] benzamide: RMIS ^ H (400MHz, d6-DMSO): 10.23 (s, 1H), 9.80 (s, 1H), 8.52 (t, 2H), 8. 17-8.19 (m, 2H), 7.91-7.93 (m, 1H), 7.75 (d, 2H), 7.50-7.59 (m, 3H), 7.39-7.43 (m, 2H), 7.16-7.26 (m, 2H) ), 4.80 (d, 2H), 3.86 (s, 3H), 2.10 (s, 3H). MS (El) for C28H25N702: 492.4 (MH +). 3- (. {4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) - N-propylbenzamide: NMR'H (400MHZ, d6-DMSO): 10.22 (1H), 9.77 (s, 1H), 8.52 (d, 1H), 8.46 (s, 1H), 8.40 (t, 1H), 8.18 (d, 2H), 7.83-7.86 (m, 1H), 7.75 (d, 2H), 7.38-7.40 (m, 3H), 3.21-3.26 (m, 2H), 2.09 (s, 3H), 1.52- 1.58 (m, 2H), 0.89-0.93 (t, 3H). MS (El) for C22H23N502: 390.7 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl}. Amino) -N-cyclopropylbenzamide: NMRH (400MHz, d6-DMSO): 10.24 (s, 1H), 9.77 (s) , 1H), 8.52 (d, 1H), 8.47 (s, 1H), 8.40 (d, 1H), 8.18 (d, 2H), 7.82-7.85 (m, 1H), 7.76 (d, 2H), 7.39 ( d, 1H), 7.36-7.37 (m, 2H), 2.84-2.89 (m, 1H), 2.09 (s, 3H), 0.69-0.73 (m, 2H), 0.56-0.60 (m, 2H). MS (El) for C22H21N502: 388.7 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) -N- [(3-fluorophenyl) -methyl] benzamide: NMR'H (400MHZ, d6-DMSO) : 10.22 (s, 1H), 9.80 (s, 1H), 9.04 (t, 1H), 8.53 (d, 1H), 8.50 (s, 1H), 8.17-8.20 (m, 2H), 7.90-7.93 (m , 1H), 7.74 (d, 2H), 7.46-7.50 (m, 1H), 7.36-7.43 (m, 3H), 7.08-7.19 (m, 3H), 4.51 (d, 2H), 2.09 (s, 3H) ). MS (El) for C 26 H 22 FN 502: 456.5 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) - N- (naphthalen-1-ylmethyl) -benzamide: R NXH (400MHz, d6-DMSO): 10.21 (s, 1H), 9.79 (s, 1H), 9.03 (t, 1H), 8.52 (d, 2H), 8.15-8.23 (m, 3H), 7.95-7.97 (m, 1H), 7.90-7.93 (m , 1H), 7.85-7.87 (dd, 1H), 7.75 (d, 2H), 7.55-7.60 (m, 2H), 7.48-7.50 (m, 3H), 7.38-7.42 (m, 2H), 4.97 (d , 2H), 2.08 (s, 3H).

MS (El) for C 30 H 25 N 6 O 2: 488.6 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl}. Amino) -N- [2- (dimethylamino) ethyl] -N-methylbenzamide: RMIN ^ H (400MHz, d6- DMSO): 10.23 (s, 1H), 9.80 (s, 1H), 8.53 (d, 1H), 8.13 (d, 2H), 8.00 (d, 1H), 7.82 (s, 1H), 7.75 (d, 2H) ), 7.35-7.39 (m, 2H), 6.93 (d, 1H), 3.39-3.419 (m, 2H), 2.94 (s, 3H), 2.21 (m, 2H), 2.09 (s, 6H), 1.95 ( s, 3H). MS (El) for C24H28N602: 433.7 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl.}. Amino) -N- [(2-methylphenyl) -methyl] benzamide: RMI ^ H (400MHz, d6-DMSO) : 10.22 (s, 1H), 9.79 (s, 1H), 8.56 (t, 1H), 8.52 (d, 1H), 8.50 (s, 1H), 8.17-8.19 (m, 2H), 7.90-7.90 (m , 1H), 7.75 (d, 2H), 7.45-7.50 (s, 1H), 7.39-7.43 (m, 2H), 7.25-7.27 (1H), 7.14-7.18 (m, 3H), 4.47 (d, 2H) ), 2.34 (s, 3H), 2.09 (s, 3H). MS (El) for C27H25N502: 452.6 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) -N- [(3-chlorophenyl) methyl] benzamide: NMR'H (400MHz, d6-DMSO): 10.25 (S, 1H), 9.80 (s, 1H), 9.05 (t, 1H), 8.53 (d, 1H), 8.50 (s, 1H), 8.17-8.20 (m, 2H), 7.91-7.94 (m, 1H), 7.60 (s, 1H), 7.40 (s, 1H), 7.46-7.48 (m, 1H), 7.43 (d, 1H), 7.36-7.40 (m, 3H), 7.30-7.32 (m, 2H) , 4.95 (d, 2H), 2.09 (s, 3H). MS (El) for C26H22CIN502: 472.8 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl}. Amino) -N- (2-phenylethyl) -benzamide: NMR'H (400MHz, d6-DMSO): 10.22 ( s, 1H), 9.78 (s, 1H), 8.51-8.53 (m, 2H), 8.46 (s, 1H), 8.19 (d, 2H), 7.85-7.88 (m, 1?), 7.76 (d, 2H), 7.37-7.38 (m, 3H), 7.27-7.32 (m, 4H), 7.19-7.23 (m, 1H), 3.47-3.52 (m, 2H), 2.84-2.88 (m, 2H), 2.08 (s, 3H). MS (El) for C27H25N502: 452.6 (MH +). N-. { 4- [2- ( { 3- [(4-Methylpiperazin-1-yl) carbonyl] phenyl} amino) pyrimidin-4-yl] -phenyl} acetamide: RMN1 !. (400MHz, d6-DMSO): 10.24 (s, 1H), 9.82 (s, 1H), 8.53 (d, 1H), 8.2-8.15 (m, 2H), 8.04 (s, 1H), 7.80- 7.82 (m, 1H), 7.76 (d, 2H), 7.36-7.40 (m, 2H), 6.94-6.96 (m, 1H), 2.94 (s, 2H), 2.78 (s, 2H), 2.37 (s, 2H), 2.27 (s, 2H), 2.18 (s, 3H), 2.09 (s, 3H). MS (El) for C 24 H 26 N 602: 431.6 (MH +). N- (4- {2 - [(3- {[4- (2-fluorophenyl) piperazin-1-yl] carbonyl} phenyl) amino] -pyrimidin-4-yl} phenyl) Acetamide: R N1 !! (400MHz, ds-DMSO): 10.22 (s, 1H), 9.84 (s, 1H), 8.53 (d, 1H), 8.14 (d, 2H), 8.08 (m, 1H), 7.85 (d, 1H), 7.77 (d, 2H), 7.39-7.43 (m, 2H), 7.05-7.17 (m, 2H), 6.99-7.05 (m, 4H), 3.81 (s, 2H), 3.55 (s, 2H), 3.09 ( s, 2H), 2.98 (s, 2H), 2.09 (s, 3H). MS (El) for C29H27FN602: 511.7 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) -N- [2- (phenyloxy) ethyl] -benzamide: NMRH (400MHz, d6-DMSO): 10.22 (s, 1H), 9.79 (s, 1H), 8.65 (t, 1H), 8.2 (d, 2H), 8.50 (s br, 1H), 8.9 (d, 2H), 7.88-7.90 (m, 1H) , 7.76 (d, 2H), 7.38-7.45 (m, 3H), 7.27-7.30 (m, 2H), 6.91-6.98 (m, 3H), 4.11-4.14 (m, 2H), 3.63-3.78 (m, 2H), 2.09 (s, 3H). MS (EI) for C27H25NS03: 468.4 (MH +). l-. { [3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) phenyl] carbonyl} -piperidine-4-methyl carboxylate: RMN'H (400MHZ, d6-DMS0): 10.23 (s, 1H), 9.82 (s, 1H), 8.53 (d, 1H), 8.14 (d, 2H) |, 7.97 (t, 1H), 7.86-7.88 (m, 1H), 7.75 (d, 2H), 7.36-7.70 (m, 2H), 6.94-6.96 (m, 1H), 3.61 (s, 3H), 3.30-3.36 (m, 2H). MS (El) for C26H27N504: 474.6 (MH +). N- [4- (2- { [3- ( { 4- [3 - (methyloxy) phenyl] piperazin-1-yl}. Carbonyl) phenyl] amino.} - pyrimidin-4-yl ) phenyl] acetamide: RMNXH (400MHz, d6-DMSO): 10.21 (s, 1H), 9.83 (s, 1H), 8.53 (d, 1H), 8.14 (d, 2H), 8.04 (m, 1H), 7.86 -7.89 (m, 1H), 7.75 (d, 2H), 7.39-7.43 (m, 2H), 7.12 (t, 1H), 7.00-7.03 (m, 1H), 6.53 (dd, 1H), 6.47 (t , 1H), 6.40 (dd, 1H), 3.78-3.80 (m, 2H), 3.71 (s, 3H), 3.20-3.24 (m, 2H), 3.12-3.19 (m, 2H), 2.09 (s, 3H ). MS (El) for C30H30N6O3: 523.5 (MH +). 3- (. {4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) -N-. { 2- [2- (methyloxy) phenyl] -ethyl} benzamide: NMR'H (400MHz, d6-DMSO): 10.22 (s, 1H), 9.78 (s, 1H), 8.52-8.53 (m, 1H), 8.45 (s, 2H), 8.19 (d, 2H), 7.88 (s, 1H), 7.75 (s, 1H), 7.38-7.39 (m, 3H), 7.17-7.23 (m, 2H), 6.97 (d, 1H), 6.87 (t, 1H), 3.78 (s, 3H), 3.45-3.47 (m, 2H), 2.84-2.87 (m, 2H), 2.09 (s, 3H).

MS (El) for C28H27N503: 482.7 (MH +). N- [4- (2- {[[3- (1, 3-dihydro-2H-isoindol-2-ylcarbonyl) phenyl] amino} pyrimidin-4-yl) -phenyl] acetamide: NMR1H (400MHz, d6-DMSO): 10.21 (s, .lH), 9.82 (s, 1H), 8.53 (d, 1H), 8.16 (s, 1H), 8.12-8.14 (m, 2H), 7.94-7.97 (m, 1H ), 7.74 (s, 1H), 7. 72 (s, 1H), 7.39-7.45 (m, 3H),? .2? -? 32 (m, 1H), 7.26 (d, 2H), 7.19-7.21 (m, 1H), 7.89 (s, 2H), 4.82 (s, 2H), 2.09 (s, 3H). MS (El) for C27H23N502: 450.7 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] irimidin-2-yl} amino) -N- (biphenyl-4-ylmethyl) -benzamide: NMRH (400MHZ, d6-DMSO): 10.23 ( s, 1H), 9.80 (s, 1H), 9.04 (s br, 1H), 8.53 (d, 2H), 8.19 (d, 2H), 7.89 (d, 1H), 7.76 (d, 2H), 7.64 (s) m, 4H), 7.35-7.50 (m, 8H), 4.55 (s, 2H), 2.08 (s, 3H). MS (El) for C32H27N502: 514.8 (MH +). N- (4- { 2- [(3- {[[4- (phenylcarbonyl) piperazin-1-yl] carbonyl} phenyl) amino] pyrimidin-4-yl} phenyl) acetamide: NMRH (400MHz, d6-DMSO): 10.25 (s, 1H), 9.83 (s, 1H), 8.53 (d, 1H), 8.14 (d, 2H), 8.04 (s, 1H), 7.86 (d, 1H), 7.76 (d, 2H), 7.44 (m, 5H), 7.39 (d, 2H), 7.00 (d, 1H), 3.56 (m, 8H), 2.09 (s, 3H). MS (El) for C30H28N6O3: 521.6 (MH +). N- [4 - (2. {[[3- ( { 4- [4- (methyloxy) phenyl] piperazin-1-yl}. Carbonyl) phenyl] amino.} - pyrimidin-4-yl ) phenyl] acetamide: NMR1.-. (400MHz, d6-DMSO): 10.21 (s, 1H), 9.83 (s, 1H), 8.53 (d, 1H), 8.13 (m, 2H), 8.05 (m, 1H), 7.86 (m, 1H), 7.75 (d, 2H), 7.37-7.43 (m, 2H), 7.01 (m, 1H), 6.90 (m, 2H), 6.82 (m, 2H), 3.77 (m, 2H), 3.68 (s, 3H) , 3.53 (m, 2H), 3.08 (m, 2H), 2.97 (m, 2H), 2.09 (s, 3H). MS (El) for C30H30NsO3: 523.7 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) -N-methyl-N-. { [2- (methyloxy) -phenyl] methyl} Benzamide: RM ^ H (400MHz, d6-DMSO): 10.23 (s, 1H), 9.80 (s, 1H), 8.37 (m, 1H), 8. 14 (d, 2H), 7.76 (m, 3H), 7.39 (d, 2H), 7.25-7.32 (m "2H), 7.14-7.18 (m, 1H), 7.04 (ra, 1H), 6.95 (d, 2H), 4.57 (d, 2H), 3.76 (d, 3H), 2.88 (s, 3H), 2.09 (s, 3H). MS (El) for C28H27N503: 482.7 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyriraidin-2-yl.}. Amino) - N - [(2-fluorophenyl) methyl] -N-methylbenzamide: RM ^ H (400MHz, d6- DMSO): 10.23 (s, 1H), 9.08 (s, 1H), 8.52 (m, 1H), 8.14 (d, 2H), 8.01 (m, 1H), 7.89 (m, 1H), 7.75 (d, 2H) ), 7.38 (m, 4H), 7.21 (m, 2H), 7.01 (m, 1H), 4.67 (d, 2H), 2.91 (s, 3H), 2.09 (S, 3H), MS (El) for C27H24FN502 : 470.6 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl}. Amino) -N- (2-pyridin-2-ylethyl) -benzamide: RM ^ H (400MHz, d6-DMSO ): 10.22 (s, 1H), 9.78 (s, 1H), 8.51-8.54 (m, 3H), 8.46 (s, 1H), 8.18 (d, 2H), 7.86-7.88 (m, 1H), 7.76 ( d, 2H), 7.69-7.73 (m, 1H), 7.37-7.40 (m, 3H), 7.31 (m, 1H), 7.21-7.24 (m, 1H), 3.61-3.66 (m, 2H), 3.02 ( m, 2H), 2.09 (s, 3H). MS (EI) for C2SH24N602: 453.6 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl}. Amino) -N- (pyridin-2-ylmethyl) -benzamide: RM 'H (400MHZ, d6-DMSO): 10.22 (s, 1H), 9.81 (s, 1H), 9.06 (m, 1H), 8.52 (m, 2H), 8.19 (d, 2H), 7.91 (m, 1H), 7.73-7.79 (m, 3H) , 7.51 (d, 1H), 7.40 (m, 2H), 7.30 (d, 1H), 7.25-7.27 (m, 1H), 4.59 (d, 2H), 2.09 (s, 3H). MS (El) for C25H22N602: 439.8 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl}. Pyrimidin-2-yl} amino) -N- (pyridin-3-ylmethyl) -benzamide: RM ^ H (400MHz, d6-DMSO): 10.22 (s, 1H), 9.78 (s, 1H), 8.52 (d, 1H), 8. 45 (s br, 1H), 8.25 (d, 1H), 7.18 (d, 3H), 7.82-7.85 (m, 1H), 7.76 (d, 3H), 7.35-7.41 (ra, 4H), 4.25 (ra , 2H), 2.09 (s, 3H). MS (El) for C25H22N602: 438.6 (MH +) - 3- (. {4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) -N- (pyridin-4-ylmethyl) -benzamide : RM XH (400MHz, d6-DMSO): . 22 (s, 1H), 9.80 (s, 1H), 9.08 (t, 1H), 8.50-8.54 (m, 4H), 8.18 (d, 2H), 7.92 (d, 1H), 7.74 (d, 2H) , 7.49 (d, 1H), 7.42 (t, 1H), 7.40 (d, 1H), 7.31 (d, 2H), 4.51 (d, 2H), 2.09 (s, 3H). MS (El) for C25H22N602: 438.5 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) -N-methyl-N- (phenylmethyl) -benzamide: RMIS ^ H (400MHz, d6-DMSO): . 23 (s, 1H), 9.81 (s, 1H), 8.53 (s br, 1H), 8.14 (d, 2H), 7. 46 (d, 2H), 7.23-7.46 (m, 8H), 7.21 (s br, 1H), 7.02 (s br, 1H), 4.56 (d, 2H), 2.95 (s, 3H), 2.09 (s, 3H). MS (EI) for C27H25N502: 452.7 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) -N-cyclopentylbenzamide: NMR'H (400MHz, d6-DMSO): 10.22 (s, 1H), 9.75 (s, 1H), 8.52 (d, 1H), 8.45 (s br, 1H), 8.25 (d, 1H), 8.17 (d, 2H), 7.84 (d, 1H), 7.75 (d, 2H), 7.35 -7.42 (m, 3H), 4.22-4.27 (m, 1H), 2.09 (s, 3H), 1.88-1.93 (m, 2H), 1.70 (m, 2H), 1.49-1.59 (m, 4H). MS (El) for C 24 H 25 N 502: 416.8 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl}. Amino) -N- [(2-chlorophenyl) methyl] -benzamide: NMR'H (400MHZ, d6-DMSO) : . 21 (s, 1H), 9.80 (s, 1H), 9.00 (t, 1H), 8.53 (d, 1H), 8.50 (s br, 1H), 8.18 (d, 2H), 7.93 (d, 1H), 7.63 (d, 2H), 7.52 (d 1H), 7.28-7.48 (m, 6H), 4.56 (d, 2H), 2.09 (s, 3H). MS (El) for C26H22CIN502: 473.0 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl.}. Amino) - N - [(4-chlorophenyl) methyl] -benzamide: NMR'H (400MHZ, d6-DMSO) : . 22 (S, 1H), 9.79 (s, 1H), 9.02 (t, 1H), 8.52 (d, 1H), 8.50 (s br, 1H), 8.18 (d, 2H), 7.90 (d, 1H), 7.74 (d, 2H), 7.46 (d, 1H), 7.41 (m, 2H), 7.38 (s, 2H), 7.36 (m, 2H), 4.48 (d, 2H), 2.09 (s, 3H). MS (El) for C26H22CIN502: 473.1 (MH +). 3- ( { 4- [4- (acetylaraine) phenyl] pyrimidin-2-yl}. Amino) -N- (furan-2-ylmethyl) -benzamide: NMRH (400MHZ, d6-DMSO): 10.22 ( s, 1H) 9.78 (s, 1H), 8.91 (t, 1H), 8.52 (d, 1H), 8.48 (s, br, 1H), 8.17 (d, 2H), 7.88 (d, 1H), 7.76 (d , 2H), 7.58 (m, 1H), 7.44 (d, 1H), 7.37-7.41 (m, 2H), 6.41 (m, 1H), 6.28 (dd, 1H), 4.48 (d, 2H), 2.09 ( s, 3H). MS (El) for C 24 H 21 N 503: 428.6 (MH +). 3- (. {4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) -N-. { [4- (methyloxy) phenyl] -methyl} Benzamide: NMRH (400MHz, ds-DMSO): 10.22 (s, 1H), 9.77 (s, 1H), 8.92 (t, 1H), 8.52 (d, 1H), 8.49 (s br, 1H), 8.19 (d , 2H), 7.88 (d, 1H), 7.76 (d, 2H), 7.45 (d, 1H), 7.37-7.41 (m, 2H), 7.27 (d, 2H), 6.89 (d, 2H), 4.42 ( d, 2H), 3.72 (s, 3H), 2.08 (s, 3H). MS (El) for C27H25N503: 468.4 (MH +). N- [4- (2- { [3- ( { 4- [2- (methyloxy) phenyl] piperazin-1-yl}. carbonyl) phenyl] amino} -pyrimidin-4-yl) phenyl] acetamide: RM ^ H (400MHz, d6-DMSO): 10.22 (s, 1H), 9.82 (s, 1H), 8.53 (d, 1H), 8.14 (d, 2H), 8.06 (s, 1H), 7.86 (d, 1H), 7.76 (d, 2H), 7.40 (m, 2H), 7.01 (d, 1H), 6.59 (m, 2H), 6.88 (s, 2H), 3.78 (s, 3H), 3.55 (m, 2H), 3.03 (m, 2H), 2.94 (s, 2H), 2.79 (s, 2H), 2.09 (s, 3H). MS (El) for C30H30N6O3: 523.5 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl}. Amino) -N- [3- (methyloxy) propyl] -benzamide: RMIS ^ H (400MHz, d6-DMSO) : 10.22 (s, 1H), 9.76 (s, 1H), 8.52 (d, 1H), 8.46 (s br, 1H), 8.40 (t, 1H), 8.18 (d, 2H), 7.85-7.88 (m, 1H), 7.75 (d, 2H), 7.38-7.40 (m, 3H), 3.40 (m, 2H), 3.30 (m, 2H), 3.24 (s, 3H), 2.09 (s, 3H), 1.74-1.80 (m, 2H). MS (El) for C23H2SN503: 420.5 (MH +). N- (4-. {2- [(3- {[[2R, 6S) -2,6-dimethylmorpholin-4-yl] carbonyl} phenyl) amino] -pyrimidin-4-yl} phenyl) acetamide: RMI ^ H (400MHz, d6-DMSO): 10.23 (s, 1H), 9.81 (s, 1H), 8.53 (d, 1H), 8.13 (d, 2H), 7.99 (m, 1H), 7.86 (d, 1H), 7.76 (d, 2H), 7.37-7.41 (m, 2H), 6.98 (d, 1H), 2.94 (s, 2H), 2.79 (s, 2H), 2.09 (s, 3H), 1.96 (s, 1H) , 1.16 (m, 3H), 0.99 (m, 3H). MS (El) for C25H27N503: 445.5 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) -N- [(6-chloropyridin-3-yl) methyl] benzamide: NMRH (400MHz, d6-DMSO ): 10.22 (s, 1H), 9.79 (s, 1H), 9.06 (t, 1H), 8.52 (d, 1H), 8.49 (s, 1H), 8.40 (d, 1H), 8.18 (d, 2H) , 7.91 (m, 2H), 7.81 (dd, 1H), 7.74 (d, 2H), 7.49 (d, 1H), 7.41-7.46 (m, 2H), 7.39 (d, 1?), 4.50 (d, 2H), 2.09 (s, 3H). MS (El) for C25H21CIN602: 474.1 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) -N-butylbenzamide: NMR'H (400MHZ, d6-DMSO): 10.24 (s, 1H), 9.80 (s, 1H), 8.53 (d, 1H), 8.13 (d, 2H), 8.02 (s br, 1H), 7.78 (ra, 1H), 7.75 (d, 2H), 7.39 (d, 1H), 7.35 (d, 1H), 6.91 (d, 2H), 3.26 (m, 2H), 2.09 (s, 3H), 1.62 (m, 2H), 1.32 (m, 2H), 1.08 (m, 3H). MS (El) for C23H25N502: 404.5 (MH +). N- (4- {2 - [(3- {[4- (2-chlorophenyl) piperazin-1-yl] carbonyl} phenyl) amino] -pyrimidin-4-yl}. Phenyl) acetamide: R ^ H (400MHz, d6-DMSO): 10.22 (s, 1H), 9.83 (s, 1H), 8.53 (d, 1H), 8.14 (d, 2H), 7.90 (s br, 1H), 7.85 (d, 1H), 7.76 (d, 2H), 7.38-7.43 (m, 3H), 7.28 (m, 1H), 7.13 (dd, 1H), 7.07 (dd, 1H), 7.03 (m, 1H), 3.81 (m, 4H), 3.58 (m, 4H), 2.09 (s, 3H). MS (El) for C29H27CIN602: 528.1 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) -N-ethyl-N- [2- (methyloxy) -ethyl] benzamide: NMRH (400MHz, d6- DMSO): 10.22 (s, 1H), 9.80 (s, 1H), 8.53 (d, 1H), 8.13 (d, 2H), 7.99 (m, 2H), 7.82 (m, 1H), 7.76 (d, 2H) ), 7.39 (d, 2H), 7.36 (d, 2H), 6.92 (d, 1H), 3.57 (m, 2H), 3.12 (m, 2H), 2.94 (s, 3H), 2.09 (s, 3H) , 1.10 (m, 3H). MS (El) for C24H27Ns03: 434.4 (MH +). N-. { 4- [2- (. {4- [4 (phenylmethyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] -phenyl} Acetamide: R N1 !! (400MHz, d6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2?), 7.65 (d, 2?), 7.35 (d, 4?), 7.27 (d, 2?), 6.92 (d, 2?), 3.54 (s, 2?) , 3.9 (m, 4?), 2.53 (m, 4?), 2.09 (s, 3?). MS (El) for C29H30N6O: 479.7 (MH +). N- (4- {2 - [(4- {4- [(5-methyl-3-phenylisoxazol-4-yl) methyl] piperazin-1-yl} phenyl) -amino] irimidin- 4-yl. Phenyl) acetamide: NMR'H (400MHZ, d6-DMSO): 10.20 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.93 -7.96 (m, 2H), 7.74 (d, 2H), 7.66 (d, 2H), 7.50-7.53 (m, 3H), 7.26 (d, 1H), 6.93 (d, 1H), 3.43 (s, 2H) ), 3.09 (m, 4H), 2.56 (m, 4H), 2.48 (s, 3H), 2.09 (s, 3H). MS (El) for C33H33N-O.,: 560.4 (MH +). N- (4- {2 - [(4- { 4- [(5-methyl-l-phenyl-lH-pyrazol-4-yl) methyl] iperazin-l-yl}. -phenyl) amino] pyrimidin-4-yl.} phenyl) acetamide: NMR'H (400MHZ, d6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.65 (d, 2H), 7.56 (s, 1H), 7.53 (d, 4H), 7.40-7.45 (m, 1H), 7.26 (d, 1H), 6.92 (d , 2H), 3.43 (s, 2H), 3.09 (m, 4H), 2.56 (m, 4H), 2.31 (s, 3H), 2.09 (s, 3H). MS (El) for C33H34N80: 559.7 (MH +). N- (4- {2 - [(4- {4- [(2-phenyl-1,3-thiazol-4-yl) methyl] piperazin-1-yl} phenyl) amino] - pyrimidin-4-yl.} phenyl) acetamide: R ^ H (400MHz, d6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H) , 7.94 (d, 2H), 7.74 (d, 2H), 7.65 (d, 2H), 7.57 (s, 1H), 7.48-7.53 (m, 3H), 7.26 (d, 1H), 6.93 (d, 1H) ), 3.73 (s, 2H), 3.11 (m, 4H), 2.65 (m, 4H), 2.09 (s, 3H). MS (El) for C32H31N7OS: 562.5 (MH +). N- [4- (2- { [4- (4- { [6- (phenyloxy) pyridin-3-yl] methyl.}. piperazin-1-yl) phenyl] amino} -pyrimidin-4-yl) phenyl] acetamide: NMR'H (400MHZ, d6-DMSO): 10.23 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 8.07 (d, 1H), 7.81 (dd, 1H), 7.74 (d, 2H), 7.65 (d, 2H), 7.43 (t, 2H), 7.26 (d, 1H), 7.19-7.23 (m, 1H) , 7.14 (d, 2H), 7.01 (d, 1H), 6.92 (d, 2H), 3.21 (s, 2H), 3.08 (m, 4H), 2.48 (m, 4H), 2.09 (s, 3H). MS (El) for C34H33 702: 572.4 (MH +). N-. { 4- [2- (. {4- [4- (cyclohexylmethyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] -phenyl} acetamide: RMI ^ H (400MHz, d6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.65 ( d, 2H), 7.26 (d, 1H), 6.92 (d, 2H), 3.06 (m, 4H), 2.47 (m, 4H), 213. (d, 2H), 2.09 (s, 3H), 1.76 ( d, 2H), 1.65 (m, 3H), 1.49-1.54 (m, 1H), 1.12-1.17 (m, 3H), 0.80-0.89 (m, 2H). MS (El) for C29H36N60: 485.8 (MH +). N- (4- { 2- [(4- { 4- [(1S, 4S) -cyclohex [2.2.1] hept-5-en-2-ylmethyl] piperazin-1-yl}. phenyl) -amino] pyrimidin-4-yl.} phenyl) acetamide: RMIS ^ H (400MHz, d6-DMSO): 10.21 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.65 (d, 2H), 7.26 (d, 1H), 6.92 (d, 2H), 6.14-6.16 (m, 1H), 5.95-5.97 (m, 1H) ), 3.07 (m, 4H), 2.79 (d, 2H), 2.45 (m, 4H), 2.32-2.39 (m, 2H), 2.09 (s, 3H), 1.95-1.99 (m, 1H), 1.81- 1.87 (m, 1H), 1.31 (m, 1H), 1.23 (m, 1H), 0.51 (m, 1H). MS (El) for C30H34N6O: 495.7 (MH +). N- [4- (2- { [4- (4-Pentylpiperazin-1-yl) phenyl] amino.} Pyrimidin-4-yl) phenyl] acetamide: NMRH (400MHz, d6-DMSO): . 21 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.65 (d, 2H), 7.26 (d, 1H), 6.92 (d, 2H), 3.07 (m, 4H), 2.55 (m, 4H), 2.307 (t, 2H), 2.09 (s, 3H), 1.43-1.49 (m, 2H), 1.22-1.34 (m, 4H) ), 0.88 (t, 3H). MS (El) for C27H34N60: 459.7 (MH +). N- (4- {2 - [(4- {4- [(2-chlorophenyl) methyl] piperazin-1-yl} phenyl) amino] pyrimidin-4-yl} phenyl) acetamide : RMN1 !! (400MHz, d6-DMSO): 10.21 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.66 (d, 2H), 7.54 (dd, 1H), 7.45 (dd, 1H), 7.29-7.39 (m, 2H), 7.26 (d, 1H), 6.93 (d, 2H), 3.64 (s, 2H), 3.10 (m, 4H) , 2.60 (m, 4H), 2.09 (s, 3H). MS (El) for C29H29CIN60: 514.1 (MH +). N- [4- (2-. {[[4- (4-. {[[3,5-bis (methyloxy) phenyl] methyl] piperazin-1-yl) phenyl] amino}. Pyrimidin- 4-yl) phenyl] acetamide: NMR'H (400MHz, d6-DMSO): 10.21 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.74 (d , 2H), 7.65 (d, 2H), 7.26 (d, 1H), 6.93 (d, 2H), 6.51 (d, 2H), 6.39 (t, 1H), 3.75 (s, 6H), 3.46 (s, 2H), 3.09 (m, 4H), 2.61 (m, 4H), 2.09 (s, 3H). MS (El) for C 31 H 34 N 603: 539.8 (MH +). N- (4- { 2- [(4- { 4- [(4-fluorophenyl) methyl] piperazin-1-yl}. Phenyl) amino] pyrimidin-4-yl} phenyl) acetamide : RMN1 !! (400MHz, ds-DMSO): 10.21 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.65 (d, 2H), 7.36-7.39 (m, 2H), 7.26 (d, 1H), 7.16 (t, 2H), 6.92 (d, 2H), 3.51 (S, 2H), 3.08 (m, 4H), 2.28 (m, 4H) 2.09 (s, 3H). MS (El) for C29H29FN60: 497.8 (MH +). N- (4- {2 - [(4- {4- [(1-methyl-1H-pyrrol-2-yl) methyl] piperazin-1-yl} phenyl) amino] -pyrimidine- 4-yl.} Phenyl) acetamide: R N'H (400MHZ, d6-DMSO): 10.21 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.65 (d, 2H), 7.26 (d, 1H), 6.92 (d, 2H), 6.68 (t, 1H), 5.88-5.91 (m, 2H), 3.61 (s, 2H) , 3.4 (s, 3H), 3.06 (m, 4H), 2.58 (m, 4H), 2.09 (s, 3H). MS (El) for C28H31N70: 482.8 (MH +). N- [4- (2- {[4- (4-. {[[5- (3-chlorophenyl) furan-2-yl] methyl} piperazin-1-yl) phenyl] -amino} pyrimidin-4-yl) phenyl] acetamide: NMR'H (400MHz, d6-DMSO): 10.20 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.72-7.76 (m, 3H), 7.63- 7.66 (m, 3H), 7.45 (t, 1H), 7.33 (d, 1H), 7.26 (d, 1H), 7.06 (d, 1H), 6.92 (d, 2H), 6.48 (d, 1H), 3.64 (s, 2H), 3.10 (m, 4H), 2.60 (m, 4H), 20.9 (s, 3H). MS (El) for C33H31CIN60: 580.3 (MH +). N- [4- (2- { [4-fluoro-2- (trifluoromethyl) phenyl] methyl.}. Piperazin-1-yl) phenyl] -amino} pyrimidin-4-yl) phenyl] acetamide: NMR'H (400MHz, d6-DMSO): 10.21 (s, 1H), 9.37 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.84 -7.88 (m, 1H), 7.74 (d, 2H), 7.66 (d, 2H), 7.54-7.72 (m, 2H), 7.26 (d, 1H), 6.93 (d, 2H), 3.66 (s, 2H), 3.10 (m, 4H), 2.56 (m, 4H), 2.09 (s, 3H). MS (EI) for C 30 H 28 F 4 N 6 O: 565.3 (MH +). N- [4 - (2- {[4- (4-. {[[4- (lH-imidazol-1-yl) phenyl] methyl] piperazin-1-yl) phenyl] amino}. -pyrimidin-4-yl) phenyl] acetamide: RMNXH (400MHz, d6-DMSO): 10.21 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.25 (t, 1H), 7.11 (d, 2H), 7.74 (d, 3H), 7.61-7.67 (m, 4H), 7.48 (d, 2H), 7.26 (d, 1H), 7.11 (t, 1H), 6.93 (d, 2H), 3.58 (s, 2H), 3.10 (m, 4H), 2.55 (m, 4H), 20.9 (s, 3H). MS (El) for C 32 H 32 N 80: 545.8 (MH +). N- [4- (2-. {[[4- (4-. {[[2,5-bis (trifluororaethyl) phenyl] methyl] piperazin-1-yl) phenyl] -amino} pyrimidine- 4-yl) phenyl] acetamide: RM ^ H (400MHz, d6-DMSO): 10.20 (s, 1H), 9.37 (s, 1H), 8.43 (d, 1H), 8.17 (s, 1H), 8.10 (d , 2H), 8.00 (d, 1H), 7.89 (d, 1H), 7.74 (d, 2H), 7.67 (d, 2H), 7.26 (d, 1H), 6.94 (d, 2H), 3.79 (s, 2H), 3.12 (m, 4H), 2.60 (ra, 4H), 2.09 (s, 3H). MS (El) for C 31 H 28 F 6 N 60: 615.7 (MH +). N- (4- {2 - [(4. {4 - [(2,6-dimethylphenyl) methyl] piperazin-1-yl} phenyl) amino] -pyrimidin-4-yl}. phenyl) acetamide: RMN1 !. (400MHz, d6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.24 (d, 2H), 7.64 (d, 2H), 7.26 (d, 1H), 7. 00-7.08 (m, 3H), 6.90 (d, 2H), 3.50 (s, 2H), 3.02 (m, 4H), 2.54 (m, 4H), 2.37 (s, 6H), 2.09 (s, 3H) . MS (El) for C 31 H 34 N 60: 507.7 (MH +). N- (4- {2 - [(4. {4 - [(2,3-dimylphenyl) methyl] piperazin-1-yl} phenyl) amino] -pyrimidin-4-yl}. phenyl) acetamide: NMR1.! (400MHz, d6-DMSO): 10.21 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.65 (d, 2H), 7.26 (d, 1H), 7. 01- 7.09 (m, 3H), 6.91 (d, 2H), 3.45 (s, 2H), 3.05 (m, 4H), 2.53 (m, 4H), 2.24 (d, 6H), 2.09 (s, 3H) . MS (El) for C 31 H 34 N 60: 507.8 (MH +).

N- [4- (2- { [4- (4-. {[2,4- bis (ethyloxy) phenyl] methyl] piperazin-1-yl) phenyl] amino} pyrimidin-4 -yl) phenyl] acetamide: R N'H (400MHZ, d6-DMSO): 10.21 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.64 (d, 2H), 7.26 (d, 1H), 7.19 (d, 1H), 6.91 (d, 2H), 6.47- 6.51 (m, 2H), 3.97-4.04 (m, 4H), 3.46 (s, 2H), 3.06 (m, 4H), 2.52 (m, 4H), 2.09 (S, 3H), 1.30-1.35 (m, 6H). MS (El) for C33H38N603: 567.8 (MH +). N- [4- (2- {[4- (4-. {[[3- (ethyloxy) phenyl] methyl} piperazin-1-yl) phenyl] amino} -pyrimidin-4-yl ) phenyl] acetamide: NMRH (400MHz, d6-DMSO): 10.21 (s, 1H), 9.36 (s, 1H), 8.45 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.24 (t, 1H), 7.11-7.19 (m, 3H), 7.02-7.09 (m, 3H), 6.91 (d, 2H), 3.96-4.00 (m, 2H), 3.40 (s, 2H), 3.07 (m , 4H), 2.59 (m, 4H), 2.09 (s, 3H), 1.32-1.38 (m, 3H). MS (El) for C31H24N602: 523.8 (MH +). N-. { 4- [2- (. {4- [4- (3-methylbutanoyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: RMIS ^ H (400MHz, d6-DMSO): 10.23 (s, 1H), 9.04 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 ( d, 2H), 7.27 (d, 1H), 6.96 (d, 2H), 3.67 (m, 4H), 3.06 (m, 2H), 3.02 (m, 2H), 2.24 (d, 2H), 2.09 (s) , 3H), 1.97-2.09 (m, 1H), 0.92 (d, 6H). MS (El) for C27H32N602: 473.8 (MH +). N-. { 4- [2- ( { 4- [4- (Cyclobutylcarbonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: RMNXH (400MHz, ds-DMSO): 10.22 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2?), 7.69 (d, 2?), 7.27 (d, 1?), 6.95 (d, 2H), 3.59 (m, 2H), 3.46 (m, 2H), 3.39 ( t, 1H), 3.02 (m, 4H), 2.11-2.23 (m, 4H), 2.09 (s, 3H), 1.89-1.92 (m, 1H), 1.72-1.78 (m, 1H). MS (El) for C27H30N6O2: 470.7 (MH +). N-. { 4- [2- (. {4- [4- (Cyclopentylcarbonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: RMIS ^ H (400MHz, d6-DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 ( d, 2H), 7.27 (d, 1H), 6.96 (d, 2H), 3.63 (m, 4H), 3.04 (m, 4H), 2.98 (m, 1H), 2.09 (s, 3H), 1.74-2.09 (m, 2H), 1.51-1.72 (m, 6H). MS (El) for C28H32N602: 485.5 (MH +). N- [4- (2- { [4- (4- { [2- (methyloxy) phenyl] carbonyl}. Piperazin-1-yl] amino.} - pyrimidin-4-yl) phenyl ] acetamide: RMIS ^ H (400MHz, d6-DMSO): 10.22 (s, 1H), 9.40 (s), 1H), 8.44 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.68 (d, 2H), 7.42 (m, 1H), 7.27 (d, 1H), 7.22 (dd, 1H), 7.10 (d, 1H), 7.02 (m, 1H), 6.96 (d, 2H), 3.81 (s, 3H), 3.77 (m, 2H), 3.27 (m, 2H), 3.12 (m, 2H) ), 3.01 (ra, 2H), 2.09 (s, 3H). MS (El) for C30H30N6O3: 523.7 (MH +). N- (4 - {2 - [(4 - { 4 - [(2-methylphenyl) carbonyl] piperazin-1-yl}. Phenyl) amino] pyrimidin-4-yl}. Phenyl) acetamide : NMR1H (400MHz, d6-DMSO): 10.22 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H) ), 7.30-7.36 (m, 2H), 7.28 (d, 2H), 7.19-7.24 (m, 1H), 6.96 (d, 2H), 3.82 (m, 2H), 3.28 (m, 2H), 3.16 ( m, 2H), 3.00 (m, 2H), 2.25 (s, 3H), 2.09 (S, 3H). MS (El) for C30H30N6O2: 507.8 (MH +). N- [4- (2- { [3- (4- { [2- (methyloxy) phenyl] methyl.}. Piperizan-l-yl) phenyl] amino.} - pyrimidin-4-yl ) Femyl] Acetamide: NMR'H (400MHZ, d6-DMSO): 11.21 (s, 1H), 9.46 (s, 1H), 8.49 (d, 1H), 8.12 (d, 2H), 7.73 (d, 2H) , 7.63 (s, 1H), 7.36 (d, 1H), 7.32 (d, 1H), 7.21 (m, 2H), 7.10 (t, 1H), 6.98 (m, 2H), 6.55 (d, 1H), 3.80 (s, 3H), 3.54 (s, 2H), 3.16 (m, 4H), 2.57 (m, 4H), 2.09 (s, 3H). MS (El) for C 30 H 32 N 6 O 2: 509.6 (MH +). N-. { 4- [2- ( { 4- [(2R, 6S) -2,6-dimethylmorpholin-4-yl] phenyl} amino) pyrimidin-4-yl] phenyl} -D-prolinamide: RMNXH (400MHz, d6-DMSO): 11.44 (s, 1H), 10.07 (s, 1H), 8.74 (s, 1H), 8.57 (d, 1H), 8.21 (s, 2H), 7.90 (m, 4H), 7.73 (s, 2H), 7.48 (d, 1H), 4.49 (m, 1H), 4.24 (m, 2H), 4.02 (m, 1H), 3.57 (m, 3H), 3.29 ( m, 2H), 1.99 (m, 4H), 1.18 (m, 7H). MS (EI for C27H32NS02: 473.5 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -5-oxo-D- prolinamide) RMNXH (400MHz, d6-DMSO): 10.33 (s, 1H), 9.39 (s, 1H), 8.45 (d, 1H), 8.14 (d, 2H), 7.93 (s, 1H), 7.79 (d, 2H), 7.67 (d, 2H), 7.28 (d, 1H), 6.93 (d, 2H), 4.23 (m, 1H), 3.75 (m, 4H), 3.05 (m, 4H), 2.35 (m, 1H) ), 2.21 (m, 2H), 2.03 (m, 1H). MS (El) for C 25 H 26 N 603: 459.5 (MH +). N1- (4- {2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -D-aspartamide: NMRH (400MHz, d6-DMSO): 11.71 (s, 1H), 10.09 (s, 1H), 8.94 (s, 3H), 8.58 (d, 1H), 8.23 (d, 2H), 7.91 (m, 4H), 7.73 (s br, 2H), 7.49 (d, 1H), 4.52 (m, 4H), 4.05 (m, 5?), 3.33 (d, 1?), 3.29 (d, 1H). MS (El) for C24H27N703: 462.5 (MH +). N1- (4- {2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-ylphenyl) -L-glutamamide: NMR ^ (400MHz, d6-DMSO): 9.39 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.83 (d, 2H), 7.67 (d, 2H), 7.35 (s, 1H), 7.29 (d, 1H), 6.93 (d, 2H), 6.77 (s, 1H), 3.75 (m, 4H), 3.37 (t, 1H), 3.05 (m, 4H), 1.88 (m, 2H), 1.70 (m, 1H). MS (El) for C 25 H 29 N 703: 476.5 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) araino] pyrimidin-4-ylphenyl) -D-threoninamide: R N'H (400MHZ, d6-DMSO): 11.26 (s, 1H ), 9.89 (s, 1H), 8.54 (d, 1H), 8.31 (s, 2H), 8.19 (d, 2H), 7.86 (d, 3H), 7.44 (m, 3H), 4.11 (m, 2H) , 3.96 (m, 4H), 3.39 (m, 4H), 1.23 (d, 3H). MS (El) for C24H28N603: 449.5 (MH +). N- (4-. {2- [(3-chloro-4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl] phenyl) -L-prolinamide: NMR1! (400MHz, d6-DMSO): 11.43 (s, 1H), 9.99 (s, 1H), 8.55 (d, 1H), 8.20 (d, 2H), 8.03 (s, 1H), 7.89 (2H), 7.71 ( dd, 1H), 7.46 (d, 2H), 7.20 (d, 1H), 4.49 (m, 1H), 3.76 (m, 4H), 3.28 (m, 2H), 2.96 (m, 4H), 1.97 (m , 4H). MS (El) for C25H27CIN602: 479.9 (MH +). N- (4- { 2- [(3-chloro-4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -D-prolinamide: NMR ^ (400MHz, d6-DMSO) : 11.55 (S, 1H), 10.15 (s, 1H), 8.56 (d, 1H), 8.21 (d, 2H), 8.01 (s, 1H), 7.89 (d, 2H), 7.71 (dd, 1H), 7.49 (d, 2H), 7.23 (d, 1H), 4.51 (m, 1H), 3.76 (m, 4H), 3.29 (m, 2H), 2.97 (m, 2H), 1.97 (m, 4H). MS (El) for C25H27CIN602: 479.9 (MH +).

N- (4- { 2- [(4-morpholin-4-ylphenyl) araino] irimidin-4-ylphenyl) -D-leucinamide: NMR'H (400MHZ, d6-DMSO): 11.41 (s, 1H) , 10.05 (s, 1H), 8.56 (d, 1H), 8.60 (ra, 3H), 8.25 (d, 2H), 7.96 (m, 3H), 7.69 (m, 2H), 7.47 (d, 1H), 4.14 (m, 1H), 4.04 (ra, 4H), 3.57 (m, 4H), 1.71 (m, 2H), 1.19 (m, 1H), 1.00 (s, 6H). MS (El) for C 26 H 32 N 602: 461.5 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-ylphenyl) -D-isoleucinamide: NMR'H (400MHz, d6-DMSO): 11.41 (s, 1H) , 10.10 (S, 1H), 8.56 (d, 1H), 8.47 (m, 2H), 8.20 (d, 2H), 7.92 (m, 3H), 7.73 (m, 2H), 7.47 (d, 1H), 4.12 (ra, 4H), 3.57 (m, 4H), 1.65 (m, 2H), 1.18 (m, 2H), 1.00 (d, 3H), 0.89 (t, 3H). MS (El) for C 26 H 32 N 602: 461.5 (MH +). (2R) -2-amino-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -butanamide: RM 'H (400MHz, d6 -DMSO): 11.57 (s, 1H), 10.20 (s, 1H), 8.56 (m, 3H), 8.24 (m, 2H), 7.97 (m, 4H), 7.82 (s, 1H), 7.54 (s, 1H), 4.05 (m, 5H), 1.96 (m, 4H), 1.10 (ra, 5H). MS (El) for C24H28N602: 433.5 (MH +). N- (4- { 2- [(3-Aminophenyl) amino] pyrimidin-4-yl}. Phenyl) thiophene-2-carboxamide: NMR'H (400MHz, d6-DMSO): 10.5 (s, 1H ), 9.40 (br s, 1H), 8.55 (d, 1H), 8.23 (d, 2H), 8.09 (dd, 1H), 7.96-7.91 (m, 5H), 7.53 (m, 1H), 7.45 (d) , 1H), 7.32-7.25 (m, 3H), 6.74 (br s, 1H). MS (EI): 388.0 (MH +). N- (3- { [4- (4-Aminophenyl) pyrimidin-2-yl] amino.} Phenyl) -2,6-dichlorobenzamide: NMRH (400MHz, dG-DMSO): 10.7 (s, 1H) , 9.67 (s, 1H), 8.37-8.35 (m, 2H), 8.01 (d, 2H), 7. 61-7.58 (m, 2H), 7.51-7.49 (m, 1H), 7.44 (dt, 1H), 7.31-7.22 (m, 3H), 6.69 (d, 2H), 5.95 (br, 2H); MS (EI): 450.0 (MH +). 4- . { [2-chloro-4- (methyloxy) phenyl] oxy} -N- (4-morpholin-4-ylphenyl) pyrimidin-2-amine: RMI ^ H (400MHz, d6-DMSO): 9.37 (s, 1H), 8.31 (d, 1H), 7.33-7.23 (m 4H) , 7.02 (dd, 1H), 7.00 (br d, 2H), 6.41 (d, 1H), 3.83 (s, 3H), 3.73-3.71 (m, 4H), 2.98-2.96 (m, 4H). MS (El): 412.8 (MH +). N- [4- ( { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Oxy) phenyl] acetamide: NMRH (400MHz, d6-DMSO): 10.2 (s, 1H), 9.92 (br s, 1H), 8.33 (d, 1H), 7.66 (d, 2H), 7.42 (br s, 2H), 7.17 (d, 2H), 7.10 (br s, 2H), 6.50 ( d, 1 H), 3.86 (br s, 4 H), 3.24 (br s, 4 H), 2.08 (s, 3 H); MS (El): 406.1 (MH +). N- [4- (2- {[4- (4-D-alanylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] -3- (methyloxy) propanamide: RMIS ^ H (400MHz., D6-DMSO): 10.3 (s, 1H), 9.61 (br s, 1H), 8.46 (d, 1H), 8.16-8.12 (m, 4H), 7.78 (d, 2H), 7.72 (d , 2H), 7.34 (d, 1H), 7.12 (br s, 2H), 4.47-4.44 (m, 1H), 3.80 (br s, 4H), 3.64 (t, 2H), 3.64 (s, 3H), 3.07 (br s, 4H), 2.60 (t, 2H), 1.34 (d, 3H); MS (El): 504.2 (MH +). 3- (methyloxy) -N- [4- (2 { [4- (4-L-prolylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] propanamide: NMRH (400MHz, d6-DMSO): 10.3 (s, 1H), 9.51 (s, 1H), 8.54 (m, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.77 (d, 2H), 7.71 (d, 2H), 7.31 (d, 1H), 7.04 (br d, 2H), 4.68 (m, 1H), 4.07 (br s, 4H), 3.64 (t, 2H), 3.25 (s, 3H), 3.17 (br s, 4H) , 2.60 (t, 2H), 2.43-2.39 (m, 2H), 1.94-1.81 (m, 4H); MS (EI): 530.2 (MH +). N-. { 4- [2- (. {4- [4- (cyclobutylcarbonyl) iperazin-1-yl] phenyl} araino) pyrimidin-4-yl] phenyl} cyclopropanecarboxamide: NMR'H (400MHz, d6-DMSO): 10.5 (s, 1H), 9.60 (br s, 1H), 8.46 (d, 1H), 8.12 (d, 2H), 7.78-7.76 (m, 4H) , 7.34 (m, 1H), 7.13 (br s, 2H), 3.70 (m, 1H), 3.54 (br s, 4H), 3.41 (m, 1H), 3.16 (br s, 4H), 2.23-2.08 ( m, 3H), 1.95-1.74 (m, 3H), 0.84-0.83 (m, 4H); MS (EI): 497.2 (MH +). N-. { 4- [2- (. {4- [4- (2-methylpropanoyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] -phenyl} Cyclopropanecarboxamide: RMIS ^ H (400MHz, ds-DMSO): 10.5 (s, 1H), 9.69 (br s, 1H), 8.47 (d, 1H), 8.13 (d, 2H), 7.77 (d, 4H), 7.36 (d, 2H), 7.23 (br s, 1H), 3.76 (br s, 4H), 3.25 (br s, 4H), 2.94 (septet, 1H), 1.84 (p, 1H), 1.03 (d, 6H) , 0.84-0.83 (m, 4H). MS (EI): 485.1 (MH +). 2, 6-dichloro-N-. { 3- . { (4- { 4- [(cyclopropylcarbonyl) amino] phenyl} pyrimidin-2-yl) -amino] phenyl} Benzamide: RMIS ^ H (400MHz, d6-DMSO): 10.7 (s, 1H), 10.5 (s, 1H), 9.74 (s, 1H), 8. 50 (d, 1H), 8.40 (s, 1H), 8.21 (d, 2H), 7.76 (d, 2H), 7.61-7.59 (m, 2H), 7.53-7.49 (m, 1H), 7.47-7.45 ( m, 1H), 7.39 (d, 1H), 7.31-7.22 (m, 2H), 1.83 (p, 1H), 0.83-0.81 (m, 4H); MS (EI): 518.1 (MH +). 2, 6-dichloro-N- (3 { [4- (lH-indol-5-yl) pyrimidin-2- il] amino} phenyl) benzamide: NMR'H (400MHZ, d6-DMSO): 11.3 (s, 1H), 10.7 (s, 1H), 9.56 (s, 1H), 8.45 (s, 1H), 8.39 (d, 1H), 8.31 (s, 1H), 7.96 (dd, 1H), 7.54-7.52 (m, 2H), 7.46-7.41 (m, 3H), 7.37-7.34 (m, 2H), 7.21 (d, 2H), 6.48- 6.48 (m, 1H). MS (El): 474.0 (MH +). N- (4- { 2- [(3-aminophenyl) amino] irimidin-4-yl}. Phenyl) -2-morpholin-4-ylacetamide: RM 'H (400MHZ, d6-DMSO): 11.0 ( s, 1H), 10.4 (br, 2H), 9.89 (s, 1H), 8.56 (d, 1H), 8.23 (d, 2H), 7.82-7.79 (m, 3H), 7.62 (br, 1H), 7.44 (d, 1H), 7.34 (br, 1H), 6.8 (br, 1H), 4.24 (s, 2H), 3.96-3.84 (m 8H); MS (El): 405.3 (MH +). N- (4-phenylpyrimidin-2-yl) benzene-1,3-diamine: NMR1 ^. (400MHz, d6-DMSO)): 9.37 (s, 1H), 8.51 (d, 1H), 8.19-8.16 (m, 2H), 7.57-7.53 (m, 3H), 7.37-7.36 (d, 1H), 7.10 (t, 1H), 7.00-6.91 (m, 2H), 6.22-6.20 (m, 1H), 5.00 (s, 2H). MS (El): 263.3 (MH +). N- [3- ( { 4- [4- (acetylamino) -2-chlorophenyl] pyrimidin-2-yl} amino) phenyl] -2,6-dichlorobenzamide: RMIS ^ H (400MHz, d6-DMSO ): 10.7 (s, 1H), 10.3 (s, 1H), 9.78 (s, 1H), 8.52 (d, 1H), 8.13-8.12 (m, 1H), 7.93 (s, 1H), 7.71 (d, 1H), 7.30-7.21 (m, 5H), 7.30-7.21 (m, 2H), 7.11 (d, 1H), 2.07 (s, 3H). MS (El): 527.9 (MH +). 2, 6-dichloro-N-. { 3- [(4-phenylpyridin-2-yl) amino] phenyl} benzamide: NMR'H (400MHZ, d6-DMSO): 10.7 (s, 1H), 9.76 (s, 1H), 8.56 (d, 1H), 8.39 (s, 1H), 8.26-8.23 (m, 2H), 7. 61-7.59 (m, 2H), 7.55-7.48 (m, 5H), 7.44 (d, 1H), 7.31-7.24 (m, 2H); MS (EI): 437.0 (MH +). 4- (2,4-dichlorophenyl) -N- (4-morpholin-4-ylphenyl) pyrimidin-2-amine: NMR'H (400MHZ, d6-DMS0): 9.59 (s, 1H), 8.52 (d, 1H ), 7.80 (d, 1H), 7.66 (d, 1H), 7.63-7.58 (m, 3H), 7.00 (d, 1H), 6.88 (d, 2H), 3.74-3.72 (m, 4H), 3.04- 3.01 (m, 4H); MS (EI): 401.0 (MH +). 4- (2,4-dichlorophenyl) -N-. { 3 - [(4-ethylpiperazin-1-yl) carbonyl] phenyl} pyrimidin-2-amino: RMNXH (400MHz, d6-DMSO): 10.0 (s, 1H), 8.62 (d, 1H), 7.92 (s, 1H), 7.82 (d, 1H), 7.76 (dd, 1H), 7.70-7.68 (m, 1H), 7.62-7.59 (ra, 1H), 7.34 (t, 1H), 7.13 (d, 1H), 6.96-6.94 (m, 1H), 3.59 (brs, 2H), 3.32 (br s, 2H), 2.37 (br s, 2H), 2.30 (q, 2H), 2.22 (br s, 2H), 0.99 (t, 3H); MS (EI): 456.0 (MH +). 2, 6-dichloro-N- (3 - { [4- (2,4-dichlorophenyl) pyrimidin-2-yl] amino.}. Phenyl) benzamide: RM ^ H (400MHz, d6-DMSO): 10.7 (s, 1H), 9.89 (s, 1H), 8.59 (d, 1H), 8.14-8.13 (m, 1H), 7.80 (d, 1H), 7.77 (d, 1H), 7.59-7.48 (m, 5H) ), 7.32-7.23 (m, 2H), 7.14 (d, 1H); MS (EI): 504.9 (MH +). N- (2- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-ylphenyl) acetamide: NMR'H (400MHZ, d6-DMSO): 11.3 (s, 1H), 9.61 ( s, 1H), 8.53 (d, 1H), 8.19 (d, 1H), 7.79 (d, 1H), 7.50 (d, 2H), 7.48-7.44 (m, 1H), 7.22 (td, 1H), 7.14 (d, 1H), 6.94 (d, 2H), 3.75-3.73 (m, 4H), 3.06-3.03 (m, 4H), 1.69 (s, 3H). MS (EI): 390.1 (MH +). 4- [3- (methyloxy) phenyl] -N- (4-morpholin-4-ylphenyl) pyrimidine-2-amino: RMNXH (400MHz, d6-DMSO): 9.45 (s, 1H), 8.49 (d, 1H) , 7.73-7.66 (m, 4H), 7.45 (t, 1H), 7.34 (d, 1H), 7.13-7.10 (m, 1H), 6.92 (d, 2H), 3.86 (s, 3H), 3.75-3.35 (m, 4H), 2.51-2.50 (m, 4H). MS (EI): 363.1 (H +). 4- (2,3-dihydro-l, 4-benzodioxin-6-yl) -N- (4-morpholin-4-ylphenyl) pyrimidin-2-amine: R t ^ H (400MHz, d6-DMSO): 9.36 (s, 1H), 8.41 (d, 1H), 7.69-7.64 (m, 4H), 7.25 (d, 1H), 6.99 (d, 1H), 6.92 (d, 2H), 4.33-4.30 (m, 4H) ), 3.75-3.73 (m, 4H), 3.06-3.03 (m, 4H); MS (EI): 391.1 (MH +). 3- (methyloxy) -N-. { 4- [2- (. {4- [4- (piperazin-1-ylacetyl) piperazin-1-yl] phenyl) amino-pyrimidin-4-yl] phenyl} propanamide: RMNXH (400MHz, d6-DMSO): 10.2 (s, 1H), 9.43 (s, 1H), 8.79 (br, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.77 (d, 2H), 7.69 (d, 2H), 7.29 (d, 1H), 6.98 (d, 2H), 3.64 (t, 2H), 3.59 (br s, 2H), 3.25 (s, 3H), 3.22 (br m , 8H), 3.13 (br m, 4H), 3.07 (br m, 4H), 2.60 (t, 2H). MS (EI): 559.3 (MH +). N2, N2-dimethyl-N- [4- (2- {[4- (4-L-prolylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] glycinamide-1.3 AcOH: NMR'H (400MHz, d6-DMSO): 10.00 (s, 1H), 9.42 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.84 (d, 2H), 7.69 (d, 2H), 7.29 (d, 1H), 6.97 (d, 2H), 3.90 (m, 1H), 3.64 (m, 4H), 3.11 (s, 2H), 3.10-2.98 (m, 5H), 2.66 (m , 1H), 2.29 (s, 6H), 2.07-1.99 (m, 1H), 1.89 (S, 4H), 1.73-1.54 (m, 3H); MS (EI) C 29 H 36 N 802: 529.2 (MH +).

N2, N2-dimethyl-N- [4- (2 { [4- (4-D-prolylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] glycinamide-1.4 AcOH: NMR'H (400MHZ, d6-DMSO): 10.00 (s, 1H), 9.42 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.84 (d, 2H), 7.69 (d, 2H), 7.29 (d, 1H), 6.97 (d, 2H), 3.97 (m, 1H), 3.64 (m, 4H), 3.12 (s, 2H), 3.11-3.0 (m, 5H), 2.70 (m , 1H), 2.29 (s, 6H), 2.07-1.99 (m, 1H), 1.90 (s, 4H), 1.75-1.55 (m, 3H); MS (EI) C 29 H 36 N 802: 529.2 (MH +). 2- (dimethylamino) -N- (4- (2- (4- (4- (2- (piperazin-1-yl) acetyl) piperazin-1-yl) phenylamino) pyrimidin-4-yl) phenyl) acetamide- 3 AcOH: NMR'H (400MHz, d6-DMSO): 10.01 (s, 1H), 9.41 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.84 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.96 (d, 1H), 3.71 (m, 2H), 3.59 (m, 2H), 3.15 (s, 2H), 3.12 (s, 2H), 3.10 ( m, 2H), 3.02 (m, 2H), 2.71 (m, 4H), 2.35 (m, 4H), 2.29 (s, 6H), 1.84 (s, 9H); MS (EI) C 30 H 39 N 902: 558.5 (MH +). 1, 1-dimethylethyl [(4- {2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} -phenyl) methyl] carabamate: RMIS ^ H (400MHz, CDC13): 8.20-8.22 (b, 1H), 8.05 (d, 2H), 7.65 (d, 1H), 7.50 (d, 2H), 7.25 (s, 1H), 7.23 (d, 2H), 7.05 (d, 2H), 5.01 (d, 1H), 4.40-4.44 (b, 2H), 3.90 (t, 4H), 3.20 (t, 4H), 1.50 (s, 9H); MS (El) for C 26 H 31 N 503: 462 (MH +). 4- (4- (aminomethyl) phenyl) -N- (4-morpholinophenyl) pyrimidine-2-amino: NMR'H (400MHz, CD3CN): 10.10-10.20 (b, 1H), 8.40 (d, 1H), 8.20 (d, 2H), 7.80 (d, 2H), 7.60 (d, 2H),7. 50 (d, 2H), 7.45 (d, 1H), 7.20-7.22 (b, 2H), 4.40-4.44 (b, 2H), 3.90 (t, 4H), 3.20 (t, 4H); MS (El) for C21H23N50: 362 (MH +). 4- . { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} Methyl benzoate: NMR'H (400MHZ, CDC13): 8.45 (s, 1H), 8.20-8.30 (m, 4H), 7.65 (d, 1H), 7.25 (d, 2H), 7.15 (d, 2H), 6.85 (d, 1H), 4.01 (S, 3H), 3.90 (t, 4H), 3.20 (t, 4H); MS (El) for C22H22N403: 391 (MH +). l-. { 4 - [2- ( { 4- [4- (2, 2-dimethylpropanoyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-ylphenyl} -3-ethylurea: RMIN ^ H (400MHz, d6-DMSO): 9.50-9.45 (b, 1H), 8.80 (s, 1H), 8.40 (s, 1H), 8.05 (d, 2H), 7.75-7.70 ( m, 4H), 7.30 (d, 1H), 7.05 (d, 2H), 6.01 (d, 1H), 4.01 (q, 2H), 3.90 (m, 2H), 3.20 (m, 6H), 1.20 (s) , 9H), 1.10 (t, 3H); MS (El) for C28H35N702: 502 (MH +). 1- . { 4- [2- ( { 4- [4- (Cyclobutylcarbonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} -3-ethylurea: RMIS ^ H (400MHz, d6-DMSO): 9.45 (s, 1H), 8.80 (s, 1H), 8.40 (s, 1H), 8.05 (d, 2H), 7.75-7.70 (m, 4H), 7.30 (d, 1H), 7.05 (d, 2H), 6.01 (d, 1H), 3.80 (m, 4H), 3.50 (q, 2H), 3.40 (m, 4H), 3.30 (m, 1H) ), 3.20 (m, 6H), 1.10 (t, 3H); MS (El) for C28H33N702: 500 (MH +). l-ethyl-3-. { 4- [2- ( { 4- [2- ( { 4- [4- (2-methylpropanoyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl}. urea: NMR1 !! (400MHz, d6-DMSO): 9.45 (s, 1H), 8.80 (s, 1H), 8.40 (s, 1H), 8.05 (d, 2H), 7.75-7.70 (m, 4H), 7.30 (d, 1H), 7.05 (d, 2H), 6.01 (d, 1H), 3.80 (m, 4H), 3.30 (q, 2H), 3.20 (m, 4H), 3.10 (m, 1H), 1.20 (m, 6H), 1.10 (t, 3H); MS (El) for C27H33N702: 488 (MH +). N-ethyl-4- (4- { [4- (4- { [Ethylamino) carbomyl] amino} phenyl) pyriraidin-2-yl] amino} phenyl) piperazine-1-carboxamide: NMR'H (400MHZ, d6-DMS0): 9.45 (s, 1H), 8.80 (s, 1H), 8.40 (m, 1H), 8.05 (d, 2H), 7.75- 7.70 (m, 4H), 7.30 (d, 1H), 7.05 (d, 2H), 6.50 (s, 1H), 6.20 (d, 1H), 3.40-3.50 (m, 4H), 3.00-3.15 (m, 8H), 1.10-1.20 (m, 6H); MS (El) for C 26 H 32 N 802: 489 (MH +). l-Ethyl-3- [4- (2. {[[4- (4-L-prolylpiperazin-1-yl) phenyl] amino] pyrimidin-4-yl) phenyl] -urea: NMR1! (400MHz, d6-DMSO): 10.20-10.25 (b, 1H), 9.45 (s, 1H), 8.40 (m, 1H), 8.05 (d, 2H), 7.75-7.60 (m, 6H), 7.30 (d , 1H), 7.00-6.90 (m, 2H), 3.80-3.81 (m, 1H), 3.70-3.65 (m, 4H), 3.20-3.25 (m, 2H), 3.15-3.10 (m, 4H), 1.60 -1.50 (m, 6H), 1.10-1.20 (ra, 3H); MS (El) for C28H34N802: 515 (MH +). 1- [4- (2- { [4- (4-L-alanylpiperazin-1-yl) phenyl] amino} pyrimidin-4-ylphenyl] -3-ethyl-urea: NMRH (400MHz, d6- DMSO): 9.70-9.65 (b, 1H), 9.25 (s, 1H), 8.40 (m, 1H), 8.05 (d, 2H), 7.75-7.60 (m, 4H), 7.30 (d, 1H), 7.00 -6.90 (m, 2H), 6.80-6.75 (m, 1H), 3.80-3.81 (m, 1H), 3.70-3.65 (ra, 4H), 3.60-3.55 (b, 2H), 3.25-3.20 (m, 6H), 1.10-1.20 (m, 6H); MS (EI) for C26H32N802: 849 (MH +). L-ethyl-3- { 4- [2- ( { 4- [4- (piperazin- l-ylacetyl) piperazin-l-yl] phenyl.}. amino) pyrimidin-4-yl] phenyl.} urea: NMRH (400MHz, d4-MeOH): 8.40 (m, 1H), 8.05 (d, 2H), 7.75-7.60 (m, 4H), 7.30 (d, 1H), 7.00-6.90 (m, 2H), 3.80-3.81 (m, 4H), 3.30-3.10 (m, 16H), 2.80-2.90 (m, 4H), 1.20 (t, 3H); MS (EI) for C29H37N902: 544 (MH +). l-ethyl-3- [4- (2 { [4- (4-D-prolipiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] -urea: RMI ^ H ( 400MHz, d6-DMSO): 10.20-10.25 (b, 1H), 9.40-9.35 (b, 1H), 9.20 (s, 1H), 8.40 (m, 1H), 8.05 (d, 2H), 7.75-7.60 ( m, 4H), 7.30 (d, 1H), 7.00-6.90 (ra, 2H), 6.80-6.75 (b, 1H), 3.80-3.81 (m, 1H), 3.70-3.65 (m, 4H), 3.20- 3.25 (m, 2H), 3.15-3.10 (ra, 4H), 1.60-1.50 (m, 6H), 1.10-1.20 (m, 3H); MS (El) for C28H34N802: 515 (MH +). 1- [4- (2- { [4- (4-D-alanylpiperazin-1-yl] amino.}. Pyrimidin-4-yl) phenyl] -3-ethyl-urea: RM ^ H (400MHz, d6-DMSO): 11.00-10.90 (b, 1H), 9.25 (s, 1H), 8.40 (m, 1H), 8.05 (d, 2H), 7.75-7.60 (m, 4H), 7.30 (d, 1H) , 7.00-6.90 (m, 2H), 6.80-6.75 (m, 1H), 3.80-3.81 (m, 1H), 3.70-3.65 (m, 4H), 3.60-3.55 (b, 2H), 3.25-3.20 ( m, 6H), 1.10-1.20 (m, 6H); MS (El) for C 26 H 32 N 802: 489 (MH +). (R) -N- (4- (2- (4- (4- (2-ethoxyacetyl) piperazine 1-yl) phenylamino) pyriraidin-4-yl) -phenyl) irrolidine-2-carboxamide: NMR'H (400MHZ, d6-DMSO): 10.20-10.25 (b, 1H), 9.40 (s, 1H), 8.50 (d, 1H), 8.05 (d, 2H), 7.75-7.60 (m, 4H), 7.30 (d, 1H), 7.00-6.90 (m, 2H), 4.20 (s, 2H), 3.80-3.81 (m , 2H), 3.70-3.65 (m, 1H), 3.20-3.25 (m, 2H), 3.25-2.85 (m, 6H), 2.20 (m, 1H), 1.80-1.60 (m, 6H), 1.20 (t, 3H); MS (El) for C29H35N703: 530 (MH +). N- [4- (2- { [4- (4-Forraylpiperazin-1-yl) phenyl] araino} pyrimidin-4-yl) phenyl] -D-prolinamide: R N1 !. (400MHz, CDC13) 10.10-10.00 (b, 1H), 8.30 (d, 2H), 8.05 (s, 1H), 8.00 (d, 2H), 7.75-7.60 (m, 4H), 7.30 (d, 1H) , 7.00-6.90 (m, 2H), 6.10-6.00 (b, 1H), 4.20 (m, 1H), 3.80-3.60 (m, 4H), 3.20-3.25 (m, 6H), 2.20 (m, 2H) 1.90-1.80 (m, 2H); MS (El) for C 26 H 29 N 702: 472 (MH +). N- (4- { 2- [(4- { 4- [4- (dimethylamino) butanoyl] piperazin-1-yl}. Phenyl) amino] pyrimidin-4-yl}. Phenyl) - D-prolinamide: RMNXH (400MHz, d6-DMSO): 10.20-10.25 (b, 1H), 9.40 (s, 1H), 8.50 (d, 1H), 8.05 (d, 2H), 7.75-7.60 (m, 4H) ), 7.30 (d, 1H), 7.00-6.90 (m, 2H), 4.20 (m, 1H), 3.80-3.60 (m, 4H), 3.20-3.25 (m, 6H), 2.90-2.85 (m, 4H) ), 2.40 (s, 3H), 2.30-2.22 (m, 2H), 2.20 (m, 3H), 2.05 (s, 3H), 1.90-1.80 (m, 2H); MS (El) for C 31 H 40 N 8 O 2: 557 (MH +). N- (4- (2- (3-aminophenylamino) pyrimidin-4-yl) phenyl) -2-phenoxyacetamide: NMR ^ (400MHz, d6-DMSO): 10.41 (s, 1H), 12.4 (s, br, 1H ), 8.56 (s, 1H), 8.19 (s, 1H), 7.97-7.82 (m 3H), 7.61-7.26 (m, 5H), 7.07-7.02 (m, 3H), 6.98 (m, 1H), 4.79 (s, 2H). MS (EI): 412 (MH +). N- (4- (2- (4- (4-acetylpiperazin-1-yl) phenylamino) pyrimidin-4-yl) phenyl) acetamide: NMRH (400MHz, d6-MeOH): 10.22 (s, 1H), 9.41 ( m, 1H), 8.12 (m, 2H), 7.75 (m, 2H), 7. 68 (ra, 2H), 7.27 (m, 1H), 3.72 (m, 4H), 6.94 (m, 2H), 3.58 (m, 4H), 3.09 (ra, 2H), 3.02 (m, 2H), 2.09 (s, 3H), 2.03 (s, 3H). MS (El): 4.31 (MH +). N- (4- (2- (3-amino-2, 4,5,6-tetrafluorophenylamino) pyrimidin-4-yl) acetamide: NMRH (400MHz, d4-MeOH): 8.26 (m, 1H), 8.07 (m , 2H), 7.82 (m, 2H), 7.41 (m, 1H), 2.18 (s, 3H), MS (El): 392 (MH +), N- (4- (2- (4- (piperazin-1) -yl) phenylamino) pyrimidin-4-yl) phenyl) acetamide: MS (El) for C 22 H 24 N 60: 389 (MH +). 1-amino-N- (4- (2- (4-morpholinophenylamino) pyrmidine-4-yl) phenyl) cyclopropane-carboxamide: NMR1 !! (400MHz, d6-DMSO): 10.27 (s, 1H), 10.19 (s, 1H), 9.23 (m, 3H), 8.60 (ra, 1H), 8.09 (ra, 2H) ), 7.95 (m, 3H), 7.79 (m, 2H), 7.54 (m, 1H), 4.11 (ra, 4H), 3.65 (ra, 4H), 1.71 (m, 2H), 1.42 (m, 2H) MS (El): 431 (MH +). (S) -N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) indolino-2-carboxamide: NMR'H (400MHz, d6- DMSO): 10.18 (s, 1H), 9.50 (m, 1H), 8.43 (m, 1H), 8.08 (m, 2H), 7.92 (m, 2H), 7.84 (m, 2H), 7.31 (m, 1H) ), 7.10-6.88 (m, 4H), 6.61 (m, 2H), 6.07 (m, 1H), 4.42 (m, 1H), 3.75 (m, 4H), 3.18-2.99 (m, 6H), MS ( El): 493 (MH +). N- (4- (2 - (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) tetrahydrofuran-3-carboxamide: NMR1! (400MHz, ds-DMSO): 10.34 (s, 1H), 9.39 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.77 (d, 2H), 7.67 (d, 2H), 7.28 (d, 1H), 6.93 (d, 2H), 3. 95 (t, 1H), 3.82-3.69 (m, 7H), 3.25-3.16 (m, 1H), 3.05 (t, 4H), 2.13-2.06 (m, 2H). MS (EI): 446 (MH +). N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) -2- (pyridin-3-yl) -acetamide: NMRH (400MHz, d6-DMSO): 10.53 (s, 1H), 9.34 (s, 1H), 8.54 (s, 1H), 8.47 (d, 1H), 8.33 (d, 1H), 8.12 (d, 2H), 7.76 (d, 3H), 7.67 (d, 2H), 7.37 (m, 1H), 7.28 (d, 1H), 6.93 (d, 2H), 3.76-3.73 (m, 6H), 3.06-3.03 (m, 4H). MS (EI): 467 (MH +). l- (4- (2- (4- (4- (3- (dimethylamino) -2, 2 -dimethylpropyl) piperazin-1-yl) phenylamino) pyrimidin-4-yl) phenyl) -3-ethylurea: NMR'H (400MHz, d6-DMSO): 9.33 (s, 1H), 9.00 (s, 1H), 8.40 (d, 2H), 7.66 (d, 2H), 7.55 (d, 2H), 7.23 (d, 1H), 6.93 (d, 2H), 6.39 (t, 1H), 3.17-3.08 (m, 10H), 2.85 (s, 4H), 1.08-1.04 (m, 9H). MS (EI): 531 (MH +). (R) -N- (4- (2- (4- (4- (3- (dimethylamino) -2,2-dimethylpropyl) piperazin-1-yl) phenylamine) pyrimidin-4-yl) phenyl) pyrrolidine-2 -carboxamide: NMR1H (400MHz, d6-DMSO): 12.64 (s, 1H), 9.35 (s, 1H), 8.42 (d, 1H), 8.10 (d, 2H), 7.69-7.63 (m, 4H), 7.28 (d, 1H), 6.89 (d, 2H), 3.30-3.23 (m, 1H), 3.15 (d, 2H), 3.10-3.04 (m, 4H), 2.62-2.58 (m, 4H), 2.34-2.28 (m, 1H), 2.21 (s, 6H), 2.18 (s, 2H), 1.82-1.64 (m, 4H), 0.84 (S, 6H). MS (EI): 557 (MH +). (R) -2-amino-N- (4- (2- (4- (4- (3- (dimethylamino) -2,2-dimethylpropyl) piperazin-1-yl) phenylamino) pyrimidin-4-yl) phenyl propanamide: RMNXH (400MHZ, d6-DMSO): 9.35 (s, 1H), 8. 42 (d, 1H), 8.10 (d, 2H), 7.80 (d, 2H), 7.63 (d, 2H), 7.27 (d, 1H), 6.89 (d, 2H), 3.49-3.43 (m, 1H) , 3.05-3.01 (m, 4H), 2.62-2.58 (m, 4H), 2.19 (s, 6H), 2.15 (s, 2H), 2.07 (s, 2H), 1.21 (d, 3H), 0.82 (s) , 6H). MS (EI): 531 (MH +). N- (4- (2- (4- (4- (3- (dimethylamino) -2, 2-dimethylpropyl) piperazin-1-yl) phenylamine) pyrimidin-4-yl) phenyl) -3-methoxypropanamide: RMIS ^ H (400MHz, d6-DMSO): 10.31 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.78 (d, 2H), 7.66 (d, 2H) , 7.27 (d, 1H), 6.93 (d, 2H), 3.63 (t, 2H), 3.34 (s, 4H), 3.25 (s, 3H), 3.13 (s, 4H), 2.84 (s, 6H), 2.74 (s, 4H), 2.60 (t, 2H), 1.05 (S, 6H). MS (El): 546 (MH +). 2- (dimethylamino) -N- (4- (2- (4- (4- (3- (dimethylamino) -2, 2-dimethylpropyl) piperazin-1-yl) phenylamine) pyrimidin-4-yl) phenyl) acetamide : RMNXH (400MHz, d6-DMSO): 9.98 (s, 1H), 9.33 (s, 1H), 8.41 (d, 1H), 8.08 (d, 2H), 7.81 (d, 2H), 7.62 (d, 2H), 7.24 (d, 1H), 6.88 (d, 2H), 3.09 (s, 2H), 3.05-3.02 (m, 4H), 2.60-2.45 (m, 4H), 2.27 (s, 6H), 2.20 (s, 6H), 2.15 (s, 2H), 2.09 (s, 2H), 0.82 (s, 6H). MS (El): 545 (MH +). N- (4- (2- (4- (4- (3- (dimethylamino) -2, 2-dimethylpropyl) piperazin-1-yl) phenylamine) pyrimidin-4-yl) phenyl) butyramide: NMR'H (400MHz, d6-DMSO): 10.18 (s, 1H), 9.36 (s, 1H), 8.41 (d, 1H), 8.08 (d, 2H), 7.75 (d, 2H), 7.64 (d, 2H), 7.26 (d, 1H), 6.92 (d, 2H), 3.12 (s, 4H), 3.07 (s, 4H), 2.84 (s, 6H), 2.73 (s, 4H), 2.31 (t, 2H) ), 1.66-1.58 (m, 2H), 1.03 (s, 6H), 0.91 (t, 3H). MS (El): 530 (MH +). (3S, 7S) -7- (hydroxymethyl) -N- (4- (2- (4-raorpholinophenylamino) irimidin-4-yl) phenyl) quinuclidine-3-carboxamide: RM 'H (400MHZ, d6-DMS0): 10.25 (s, 1H), 9.39 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.77 (d, 2H), 7.68 (d, 2H), 7.27 (d (1H), 6.93 (d, 2H), 3.74 (t, 4H), 3.65-3.58 (m, 2H), 3.45-3.37 (m, 3H), 3.05 (t, 4H), 2.94-2.88 (m, 3H), 2.71-2.67 (m, 1H), 2.17 (s, 1H), 1.68-1.63 (m, 2H), 1.50-1.46 (m, 1H), 1.27-1.21 (m, 1H), MS (EI): 515 (MH +). (R) -N- (4- (2- (3-ethoxy-4-raorpholinophenylamino) pyrimidin-4-yl) phenyl) -pyrrolidine-2-carboxamide: RMI H (400MHz, d6-DMSO): 11.45 (s, 1H), 10.04 (s, 1H), 8.59 (d, 1H), 8.21 (d, 2H), 7.87 (d, 2H), 7.49 (d, 1H), 7.44-7.41 (m, 2H), 7.32 (s) , 1H), 7.19 (s, 1H), 4.51-4.45 (m, 2H), 4.28-4.25 (m, 4H), 4.09-4.01 (m, 4H), 3.68-3.52 (m, 3H), 3.33-3.23 (m, 2H), 2.49-2.42 (m, 1H), 2.03-1.91 (m, 3H), 1.49 (t, 3H), MS (EI): 489 (MH +), N- { 4- [2 - ( { 4-morpholin-4-yl-3- [(phenylmethyl) oxy] phenyl.} Amino) p irimidin-4-yl] -phenyl} -D-prolinamide: RMNXH (400MHz, d6-DMSO): 11.57 (s, 1H), 10.17 (s, 1H), 8.59 (d, 1H), 8.23 (d, 2H), 8.09 (s, 1H), 7.90 (m, 3H), 7.59 (m, 2H), 7.48 (m, 5H), 5.34 (s, 2H), 4.51 (m, 4H), 4.06 (m, 5H), 3.29 (m, 3H), 1.98 ( m, 3H). MS (El) for C 32 H 34 N 603: 551.7 (MH +). 4-methyl-N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -piperazine-l-carboxamide: NMRH (400MHz, d6-DMSO ): 9.35"(s, 1H), 8.41 (d, 1H), 8.15 (s, 1H), 8. 06 (d, 1H), 7.66 (m, 3H), 7.25 (d, 1H), 6.93 (d, 2H), 3.74 (m, 4H), 3.53 (m, 8H), 3.04 (m, 4H), 3.32 (m, 3H). MS (EI) for C 26 H 31 N 702: 474.6 (MH +). 1- [3- (dimethylaraine) propyl] -3- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl.} Phenyl) urea: RMIS ^ H (400MHz , d6-DMSO): 9.34 (s, 1H), 9.22 (s, 1H), 8.40 (d, 1H), 8.05 (d, 2H), 7.67 (d, 2H), 7.57 (d, 2H), 7.24 ( d, 1H), 6.93 (d, 2H), 6.66 (t, 1H), 3.74 (m, 4H), 3.17 (m, 2H), 3.05 (m, 4H), 2.90 (t, 2H), 2.62 (s) , 6H), 1.78 (m, 2H). MS (El) for C 26 H 33 N 702: 476.6 (MH +). 1- [3- (methyloxy) propyl] -3- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl.} Phenyl) urea: NMR1! (400MHz, d6-DMSO): 9.3 (s, 1H), 8.87 (s, 1H), 8.40 (d, 1H), 8.05 (d, 2H), 7.67 (d, 2H), 7.55 (d, 2H), 7.24 (d, 1H), 6.93 (d, 2H), 6.37 (t, 1H), 3.74 (m, 4H), 3.38 (d, 2H), 3.25 (s, 3H), 3.15 (m, 2H), 3.04 (m, 4H), 1.68 (m, 2H). MS (El) for C 25 H 30 N 6 O 3: 463.6 (MH +). 1- (2-morpholin-4-ylethyl) -3- (4-. {-2- [(4-morpholin-4-yl} phenyl) amino] pyrimidin-4-yl} phenyl) urea: NMR (400MHz, d6-DMSO): 9.34 (s, 1H), 9.00 (s, 1H), 8.40 (d, 1H), 8.17 (s, 1H), 8.05 (d, 2H), 7.68 (d, 2H) , 7.55 (d, 2H), 7.24 (d, 1H), 6.93 (d, 2H), 6.25 (t, 1H), 3.74 (m, 4H), 3.60 (m, 4H), 3.22 (m, 2H), 3.04 (m, 4H), 2.40 (m, 5H). MS (El) for C27H33N703: 504.5 (MH +). 1- [2- (dimethylamino) ethyl] -3- (4-. {2- 2- [(4-morpholin-4 - ilphenyl) amino] pyrimidin-4-yl} phenyl) urea: RM ^ H (400MHz, d6-DMSO): 9.33 (s, 1H), 9.06 (s, 1H), 8.40 (d, 1H), 8.21 (s, 1H), 8.04 (d, 2H), 7.67 (d, 2H), 7.55 (d, 2H), 7.23 (d, 1H), 6.93 (d, 2H), 6.33 (t, 1H), 3.74 (d, 4H), 3.21 (m, 2H), 3.05 (m, 1H), 2.38 (t, 2H), 2.12 (s, 6H). MS (El) for C 25 H 31 N 702: 462.5 (MH +). 1-Ethyl-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -L-prolinamide: NMR1! (400MHz, d6-DMSO): 9.53 (s, 1H), 9.40 (s, 1H), 8.45 (d, 1H), 8.14 (d, 2H), 7.85 (d, 2H), 7.67 (d, 2H), 7.29 (d, 1H), 6.93 (d, 1H), 3.75 (m, 4H), 3.21 (m, 1H), 3.09 (m, 4H), 2.65 (m, 1H), 2.54 (m, 2H), 2.35 (m, 1H), 2.14 (m, 1H), 1.79 (m, 3H), 1.08 (t, 3H). MS (El) for C27H32N602: 473.6 (MH +). 1- (2-hydroxyethyl) -N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl.} - phenyl) -D-prolinamide: NMR1! (400MHz, ds-DMSO): 10.31 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.81 (d, 2H), 7.67 (d, 2H), 7.30 (d, 1H), 6.93 (d, 1H), 5.05 (s, br, 1H), 3.75 (m, 4H), 3.05 (m, 4H), 2.75 (ra, 2H), 2.63 (m, 1H) , 2.40 (m, 2H), 2.18 (m, 2H), 1.80 (m, 3H). MS (El) for C27H32N603: 489.5 (MH +). N- (4- {2 - [(4. {4- [3- (dimethylamino) -2,2-dimethylpropyl] piperazin-1-yl} phenyl) -amino] pyrimidin-4-yl .}. phenyl) tetrahydrofuran-3-carboxamide: RMN1 !. (400MHz, d6-DMSO): 10.39 (s, 1H), 9.39 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.79 (d, 2H), 7.66 (d, 2H), 7.28 (d, 1H), 6.93 (d, 2H), 3.94 (t, 1H), 3.75 (m, 4H), 3.15 (m, 8H), 2.80 (m, 9H), 2.09 (m, 2H), 1.03 (s, 7H). MS (El) for C 32 H 43 N 702: 558.7 (MH +). (2R) -N- (4- { 2- [(4- { 4- [3- (dimethylamino) -2,2-dimethylpropyl] piperazin-1-yl}. Phenyl) amino] irimidin -4-yl.} Phenyl) tetrahydrofuran-2-carboxamide: RMIS ^ H (400MHz, d6-DMSO): 10.88 (s, 1H), 9.34 (s, 1H), 8.52 (s, 1H), 8.38 (s) , 1H), 8.00 (s, 1H), 7.56 (m, 2H), 7.22 (d, 1H), 6.96 (d, 2H), 4.43 (m, 1H), 4.00 (ra, 1H), 3.86 (m, 1H), 3.05 (m, 7H), 2.60 (m, 7H), 2.20 (ra, 10H), 0.85 (s, 6H). C32H43N702. MS (El) for C 32 H 43 N 702: 558.7 (MH +). N- (4- {2 - [(4- {4- [3- (dimethylamino) -2,2-dimethylpropyl] piperazin-1-yl} phenyl) -amino] pyrimidin-4-yl phenyl) cyclopropanecarboxaraide: R ^ H (400MHz, d6-DMSO): 10.47 (s, 1H), 9.36 (s, 1H), 8.42 (d, 1H), 8.10 (d, 2H), 7.75 (d, 2H), 7.64 (d, 2H), 7.26 (d, 1H), 6.90 (d, 2H), 3.05 (ra, 4H), 2.61 (m, 4H), 2.21 (s, 6H), 2.17 (s, 2H) ), 2.10 (s, 2H), 1.90 (s, 1H), 1.82 (m, 1H), 0.84 (m, 9H). MS (El) for C 31 H 41 N 70: 528.6 (MH +). (S) -N- (4- (2- (4- (4- (3- (dimethylamino) -2,2-dimethylpropyl) piperazin-1-yl) phenyl-amino) irimidin-4-yl) phenyl) tetrahydrofuran - 2 -carboxamide: RMIN H (400MHz, d6-DMSO): 9.95 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.88 (d, 2H), 7.67 (d, 2H), 7.29 (d, 1H), 6.93 (d, 2H), 4.44 (t, 1H), 4.01 (m, 1H), 3.85 (m, 1H), 3.14 (m, 6H), 2.86 (s, 6H), 2.77 (m, 4H), 2.21 (m, 2H), 2.01 (m, 2H), 1.90 (m, 2H), 1.05 (s, 6H). MS (El) for C 32 H 43 N 702: 558.7 (MH +). N- (4- (2- (4- (4- (piperidine-4-carbonyl) piperazin-1-yl) phenylamine) pyrimidin-4-yl) -phenyl) tetrahydrofuran-3-carboxamide: NMR'H (400MHZ, d6-DMSO): 10.35 (s, 1H), 9.41 (s, 1H), 8.44 (s, 1H), 8.14 (d, 2H), 7.78 (d, 2H), 7.68 (d, 2H), 7.28 (d , 1H), 6.96 (d, 2H), 3.96 (m, 1H), 3.73 (m, 3H), 3.62 (m, 4H), 3.20 (m, 1H), 3.04 (m, 5H), 2.79 (m, 1H), 2.62 (t, 2H), 2.11 (m, 2H), 2.79 (m, 3H), 1.55 (m, 3H). MS (El) for C 31 H 37 703: 556.6 (MH +). 1- (1-Methylethyl) -N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -D-prolinamide: NMR1! (400MHz, d6-DMSO): 9.98 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.84 (d, 2H), 7.67 (d, 2H), 7.29 (d, 1H), 6.93 (d, 2H), 3.74 (m, 4H), 3.14 (m, 1H), 3.05 (m, 4H), 2.81 (1H), 2.54 (m, 2H), 2.08 (ra , 1H), 1.77 (m, 1H), 1.75 (m, 2H), 1.05 (m, 6H). MS (El) for C28H34N602: 487.6 (MH +). 1-Ethyl-N- (4- {2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -D-prolinamide: NMRH (400MHz, d6-DMSO): 9.95 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.85 (d, 2H), 7.67 (d, 2H), 7.29 (d, 1H), 6.95 (d, 2H), 3.74 (m, 4H), 3.20 (m, 1H), 3.07 (m, 5H), 2.64 (m, 1H), 2.54 (m, 1H), 2.35 (m, 1H), 2.14 ( m, 1H), 1.79 (m, 3H), 1.08 (t, 3H). MS (El) for C27H32N602: 473.5 (MH +). 2- (2-fluorophenyl) -N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) acetamide: RMIS H (400MHz, d6- DMSO): 10.50 (s, 1H), 9.32 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.76 (d, 2H), 7.67 (d, 1H), 7.41 (m, 1H) ), 7.34 (m, 1H), 7.28 (d, 1H), 7.18 (m, 2H), 6.93 (d, 2H), 3.79 (s, 2H), 3.74 (m, 4H), 3.05 (m, 4H) . MS (El) for C28H26FN502: 484.5 (MH +). N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) araino] pyrimidin-4-yl} phenyl) pyridine-4-carboxamide: NMR! (400MHz, d6-DMSO): 10.76 (S, 1H), 9.42 (s, 1H), 8.82 (d, 2H), 8.47 (d, 1H), 8.20 (d, 2H), 7.96 (s, 2H), 7.89 (d, 2H), 7.68 (d, 2H), 7.32 (d, 1H), 6.95 (d, 2H), 3.75 (m, 4H), 3.07 (m, 4H). MS (EI) for C 26 H 24 N 602: 453.5 (MH +). (R) -N- (4- (5-methyl-2- (4- (4- ((l-methyl-lH-imidazol-2-yl) methyl) piperazin-l-yl) -phenylamino) pyrimidin-4 -yl) phenyl) pyrrolidine-2-carboxamide: NMR ^ (400MHz, d6-DMSO): 10.19 (s, br, 1H), 9.25 (s, br, 1H), 8.31 (s, 1H), 7.81-7.58 ( m, 6H), 7.09-6.76 (br, m, 3H), 3.79 (m, 3H), 3.66 (s, 3H), 3.02-2.92 (m, 4H), 2.20 (m, 4H), 2.09 (m, 2H), 2.00 (m, 1H), 1.82 (m, 1H), 1.70 (m, 1H), 1.70 (m, 1H), 12.4 (s, 3H). MS (EI): 552 (MH +). (R) -2-amino-N- (4- (5-methyl-2- (4- (4- ((1-methyl-lH-imidazol-2-yl) methyl) piperazin-1-yl) phenylamine) pyrimidin-4-iD-propanamide: RMN'H (400MHz, d6-DMSO): 10.20 (s, br, 1H), 9.24 (s, br, 1H), 8.31 (s, 1H), 7.80 (d, 2H), 7.66 -7.69 (m, 4H), 7.09 (s, 1H), 6.85 (m, 2H), 6.76 (s, 1H), 3.80 (m, 3H), 3.66 (m, 3H), 3.00 (m, 4H), 2.22 (s, 3H), 1.24 (s, 3H), MS (EI): 526 (MH +).

(S) -2-amino-N- (4- (5-methyl-2- (4- (4- ((1-methyl-1H-imidazol-2-yl) methyl) iperazin-1-yl) phenylamino) pyrimidin-4-yl) phenyDpropanamide: NMR'H (400MHz, d6-DMSO): 10.20 (s, br, 1H), 9.24 (s, br, 1H), 8.31 (s, 1H), 7.79 (d, 2H) , 7.67-7.58 (m, 4H), 7.09 (s, 1H), 6.86 (m, 2H), 6.76 (s, 1H), 3.80 (m, 3H), 3.66 (m, 3H), 3.01 (m, 4H) ), 2.95 (m, 4H), 2.22 (s, 3H), 1.23 (s, 3H), MS (El) for C29H35N90: 526 (MH +). N- [3- ( { 2 - [(4-) morpholin-4-ylphenyl) amino] -7H-pyrrolo [2,3-d] pyrimidin-4-yl}. amino) phenyl] acetamide: RMI H (400MHz, DMSO): 11.14 (s, 1H), 9.87 ( s, 1H), 9.15 (s, 1H), 8.47 (s, 1H), 8.04 (s, 1H), 7.80-7.73 (m, 1H), 7.70-7.63 (m, 2H), 7.25-7.18 (m, 2H), 6.89-6.81 (m, 3H), 6.67-6.64 (m, 1H), 3.77-3.71 (m, 4H), 3.04-2.98 (m, 4H), 2.06 (s, 3H), MS (EI) for C 24 H 25 N 702: 444 (MH +). N- (4- { 2- [(2-methyl-4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. phenyl) -acetamide: RM ^ H (400MHz, DMSO): (br s, 1H), 9.51 (br s, 1H), 8.34 (d, 1H), 8.08 (d, 2H), 7.74 (d, 2H), 7.39 (d, 2H), 7.05 (br, d, 2H), 3.80 (s, 4H), 3.22 (s, 4H), 2.21 (s, 3H), 2.07 (s, 3H). MS (El): (MH +). N- (4- { 2- [(4-pyrrolidin-1-ylphenyl) amino] pyrimidin-4-yl.} Phenyl) acetamide: NMRH (400MHz, DMSO): 10.33 (br s, 9.72 (br s) , 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.77 (d, 2H), 7.69 (br, 2H), 7.34 (d, 1H), 3.37 (m, 4H), 2.10 (s) , 3H), 2.03 (s, 4H) .MS (EI): 374 (MH +). N- [4- (2- { [4-diethylamino) phenyl] amino.}. Pyrimidin-4- il) phenyl] acetamide: NMR'H (400MHZ, DMSO): 10.34 (br s), 9.99 (br s, 1 H), 8.56 (d, 1 H), 8.12 (d, 2 H), 8.06 (d, 2 H), 7.79 (d, 2H), 7.72 (d, 2H), 7.44 (d, 1H), 3.49 (q, 4H), 2.10 (s, 3H), 1.05 (dt, 6H). MS (El): 376 (MH +). N- [4-. { 2- [(4-azepan-l-ylphenyl) amino] pyrimidin-4-yl} phenyl) acetamide: NMR'H (400MHZ, DMSO): 10.34 (br s), 9.99 (br s, 1 H), 8.56 (d, 1 H), 8.12 (d, 2 H), 8.06 (d, 2 H), 7.79 ( d, 2H), 7.72 (d, 2H), 7.44 (d, 1H), 3.54 (m, 4H), 2.09 (s, 3H), 1.91 (m, 2H), 1.70 (m, 2H), 1.64 (m , 4H), 1.44 (m, 2H), 1.37 (m, 2H). MS (El): 402 (MH +). N-. { 4- [2- ( { 4- [methyl- (2-phenyl) amino] phenyl} amino) pyrimidin-4-yl] phenyl] acetamide: NMR'H (400MHZ, DMSO): 10.34 (br s) , 1H), 9.95 (br s, 1H), 8.54 (d, 1H), 8.15 (d, 2H), 7.98 (m, 1H), 7.79 (d, 2H), 7.43 (d, 1H), 7.31 (m , 3H), 7.23 (m, 4H), 3.71 (m, 2H), 3.13 (m, 2H), 2.10 (s, 1H), 1.99 (s, 3H). MS (El): 438 (MH +). N- [4- (2- { [1,4-Dioxa-8-azaspiro [4.5] dec-8-yl) phenyl] amino} pyrimidin-4-yl) phenyl] acetamide: RM ^ H (400MHz, DMSO): 10.34 (br S), 9.99 (br, 1H), 8.56 (d, 1H), 8.12 (d, 2H), 8.06 (d , 2H), 7.79 (d, 2H), 7.72 (d, 2H), 7.44 (d, 1H), 3.90 (s, 4H), 2.70 (t, 4H), 2.10 (s, 3H), 1.76 (t, 4H). MS (El): 446 (MH +). N- [4- (2- { [4- (2-oxopiperidin-1-yl) phenyl] amino.} Pyrimidin-4-yl) phenyl] acetamide: RMIN H (400MHz, DMSO): 10.32 (br s, 1H), 9.86 (br s 1H), 8.51 (d, 1H), 8.14 (d, 2H), 7.85 (t, 4H), 7.40 (d, 1H), 7.22 (d, 2H), 3.59 (m, 2H), 2.38 (t, 2H), 2.09 (s, 3H), 1.85 (m, 4H). MS (EI): 402 (MH +). N- [4- (2- { [4- (2-methylpiperidin-1-yl) phenyl] amino.} Pyrimidin-4-yl) phenyl] -acetamide: NMR'H (400MHz, DMSO): 10.21 (br s, 1H), 9.36 (br s, 1H), 8.43 (s, 1H), 8.27 (s, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.65 (d, 2H), 7.26 (s, 1H), 6.92 (d, 2H), 2.09 (s, 3H), 3.41 (m, 3H), 1.60 (m, 6H), 0.88 (d, 3H). MS (EI): 402 (MH +). N- (4 - { 2- [(4-Rhorpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -D-valinaraide: NMR'H (400MHZ, DMSO): 11.51 (br s) , 1H), 10.16 (br s, 1H), 8.57 (s, 1H), 8.48 (m, 2H), 8.20 (m, 2H), 7.93 (m, 3H), 7.78 (m, 1H), 7.50 (s) , 1H), 5.45 (br s, 4H), 4.07 (s, 4H), 3.53 (s, 4H), 3.35 (m, 1H), 2.25 (m, 1H), 1.03 (m, 6H). MS (EI): 447 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -D-valinamide: NMRH (400 MHz, d6-DMSO): 11.51 (br s, 1H), 10.16 (br s, 1H), 8.57 (s, 1H), 8.48 (m, 2H), 8.20 (m, 2H), 7.93 (m, 3H), 7.78 (m, 1H), 7.50 ( s, 1H), 5.45 (br s, 4H), 4.07 (s, 4H), 3.53 (s, 4H), 3.35 (m, 1H), 2.25 (m, 1H), 1.03 (m, 6H). MS (EI): 447 (MH +). 2-methyl-N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -alaninaraide: NMRH (400MHz, DMSO): 10.68 (br s) , 1H), 10.02 (br s, 1H), 8.53 (m, 2H), 8.18 (d, 2H), 7.95 (d, 2H), 7.89 (d, 2H), 7.66 (m, 1H), 7.47 (d , 1H), 5.20 (br s, 4H), 4.01 (s, 4H), 3.44 (s, 4H), 1.66 (6H). MS (El): 433 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-ylphenyl) tryptophanamide: RM 'H (400MHZ, DMSO): 11.37 (s, 1H), 10.07 (s, 1H), 10.03 (s, 1H), 8.56 (d, 1H), 8.42 (d, 2H), 8.19 (d, 2H), 7.91 (d, 2H), (d, 2H), 7.73 (d, 1H) , 7.66 (1H, 7.46 (d, 1H), 7.35 (d, 1H), 7.28 (d, 1H), 7.07 (t, 1H), 6.95 (t, 1H), 4.70 (br s, 4H), 4.34 ( m, 1H), 4.03 (s, 4H), 3.49 (S, 4H), 3.36 (dq, 2H), MS (El): 534 (MH +), N- (4 - {2 - [(4-) morpholin-4-ylphenyl) amino] pyrimidin-4-yl.} phenyl) -L-prolinamide: RMIN ^ H (400MHz, DMSO): 11.43 (br s, 1H), 10.97 (br s, 2H), 8.73 ( d, 1H), 8.57 (d, 1H), 8.21 (d, 2H), 7.91 (d, 2H), 7.98 (d, 2H), 7.71 (br s, 2H), 7.48 (d, 1H), 4.48 ( m, 1H), 4.08 (s, 4H), 3.74 (m, 4H), 3.42 (m, 1H), 3.36 (m, 1H), 3.04 (m, 4H), 2.22 (m, 1H), 1.90 (m , 2H), 1.82 (m, 2H), MS (El): 445 (MH +). N- (4 - {2 - [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl.} phenyl) -1,2,3,4-tetrahydro-isoquinoline-1-carboxamide: NMR'H (400MHZ, DMSO): 11. 30 (br d, 1H), 10.04 (br s, 1H), 8.56 (d, 1H), 8.39 (s, 3H), 8.20 (d, 2H), 7.90 (m, 2H), 7.87 (m, 2H) , 7.67 (m, 3H), 7.47 (d, 1H), 5.00 (br s, 3H), 4.65 (s, 1H), 4.20 (m, 2H), 4.03 (s, 4H), 3.97 (m, 1H), 3.94 (m, 2H), 3.80 (m, 1H), 3.49 (s, 4H). MS (El): 507 (MH +). O- (1,1-dimethylethyl) -N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -L-serinamide: NMRH (400MHz , DMSO): 12.11 (br s, 1H), 10.65 (br s, 1H), 10.12 (s, 1H), 9.60 (s, 1H), 8.58 (d, 1H), 8.23 (d, 2H), 7.95 (d, 2H), 7.79 (s, 1H), 7.56 (d, 1H), 7.49 ( d, 1H), 7.31 (s, 2H), 5.14 (br s, 4H), 4.06 (s, 4H), 3.79 (m, 1H), 3.54 (s, 4H), 3.45 (m, 1H), 3.15 ( q, 1H), 1.21 (s, 9H). MS (EI): 491 (MH +). 3-amino-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) tetrahydro-furan-3-carboxamide: RMIN ^ H (400MHz, DMSO): 10.89 (br s, 1H), 9.92 (br s, 1H), 8.83 (s, 2H), 8.55 (d, 1H), 8.21 (d, 2H), 7.94 (d, 2H), 7.87 (d, 1H), 7.53 (s, 1H), 7.43 (d, 1H), 4.30 (br s, 4H), 4.21 (d, 1H), 4.07 (d, 1H), 4.05 (m, 1H), 4.02 (m, 1H), 3.97 (s, 4H), 3.42 (s, 4H), 2.79 (m, 1H), 2.28 (m, 1H). MS (EI): 461 (MH +). bis (1,1-dimethylethyl) (2R) -2-. { [(4-morpholin-4-morpholin-4-ylphenyl) amino] irimidin-4-yl} phenyl) amino] carbonyl} piperazine-1, 4-dicarboxylate: RMIS ^ H (400MHz, DMSO): 10.41 (br s, 1H), 9.35 (s, 1H), 8.42 (d, 1H), 8.14 (d, 2H), 8.76 (d, 2H), 7.67 (d, 2H), 7.28 (d, 1H), 6.93 (d, 2H), 4.51 (m, 1H), 3.90 (m, 2H), 3.74 (m, 4H), 3.66 (t, 4H), 3.04 (t, 4H), 1.41 (s, 3H), 1.33 (s, 9H), 1.17 ( s, 6H). MS (EI): 660 (MH +). N- (4- {2 - [(4- {4- [2- (2-fluorophenyl) acetyl] iperazin-1-yl} phenyl) amino] pyrimidin-4-yl}. ) acetamide: RMIS ^ H (400MHz, DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.75 (d, 2H), 7.70 (d) , 2H), 7.29 (m, 3H), 7.16 (m, 2H), 6.98 (d, 2H), 3.80 (s, 2H), 3.69 (m, 2H), 3.63 (ra, 2H), 3.09 (m, 2?), 3.04 (m, 2?), 2.09 (s, 3?). MS (El): 525.5 (MH +). N- (4- {2 - [(4- { 4- [2- (2-methylphenyl) acetyl] piperazin-1-yl) phenyl) amino] pyrimidin-4-yl} phenyl) acetamide: RMIN H (400MHz, DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.45 (d, 1H), 8. 12 (d, 2H), 7.75 (d, 2H), 7.69 (d, 2H), 7.28 (d, 1H), 7.12 (m, 4H), 6.97 (d, 2H), 3.74 (s, 2H), 3.65 (m, 4H), 3.05 (m, 4H), 2.20 (s, 3H), 2.09 (s, 3H). MS (El): 521.6 (MH +). N- (4- {2 - [(4- {4- [2- (3-fluorophenyl) acetyl] piperazin-1-yl} phenyl) amino] pyrimidin-4-yl}. ) acetamide: RMIx ^ H (400MHz, DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.75 (d, 2H), 7.69 (d , 2H), 7.35 (m, 1H), 7.28 (d, 1H), 7.08 (m, 3H), 6.96 (d, 2H), 3.81 (s, 2H), 3.64 (m, 4H), 3.02 (m, 4H), 2.09 (s, 3H). MS (El): 525.4 (MH +). N-. { 4- [2- (. {4- [4- (3-thienylcarbonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] -phenyl} acetamide: NMR1H (400MHz, DMSO): 10.21 (s, 1H); 9.40 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.83 (m, 1H), 7.75 (d, 2H), 7.70 (d, 2H), 7.64 (m, 1H), 7.25 (m, 2H), 6.98 (d, 2H), 3.68 (m, 4H), 3.11 (m, 4H), 2.09 (s, 3H). MS (El) 499.4 (MH +). N- (4- {2 - [(4- {4- [(6-chloropyridin-3-yl) carbonyl] piperazin-1-yl) phenyl) amino] -pyrimidin-4-yl} phenyl) acetamide: NMR'H (400MHz, DMSO): 10.21 (s, 1H), 9.41 (s, 1H), 8.53 (m, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.98 ( dd, 1H), 7.75 (d, 2H), 7.70 (d, 2H), 7.65 (d, 1H), 7.28 (d, 1H), 6.98 (d, 2H), 3. 78 (m, 2H), 3.48 (ra, 2H), 3.17 (m, 2H), 3.08 (m, 2H), 2.09 (S, 3H). MS (El): 529.1 (MH +). N- (4- {2 - [(4- { 4- [(3-Rethylfuran-2-yl) carbonyl] piperazin-1-yl}. Phenyl) amino] -pyrimidin-4-yl. phenyl) acetamide: NMR'H (400MHz, DMSO): 10.21 (s, 1H), 9.41 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.75-7.68 (m, 5H) ), 7.28 (d, 1H), 6.98 (d, 2H), 6.52 (d, 1H), 3.73 (m, 4H), 3.11 (m, 4H), 2.17 (s, 3H), 2.09 (s, 3H) . MS (El): 497.6 (MH +). N- (4- { 2- [(4- { 4- [(3-fluoro-2-methylphenyl) carbonyl] piperazin-1-yl}. Phenyl) amino] pyrimidin-4-yl. phenyl) acetamide: MS (El) for C 30 H 29 FN 6 O 2: 525.5 (MH +). N- (4- { 2- [(4- { 4- [(imidazol-4-yl) carbonyl] piperazin-1-yl}. Phenyl) amino] pyrimidin-4-yl}. Phenyl Acetamide: MS (El) for C26H26H802: 483.5 (MH +). N- (4- {2 - [(4- {4- [(2-methoxypyridin-3-yl) carbonyl] piperazin-1-yl} phenyl) amino] -pyrimidin-4-yl. phenyl) acetamide: NMR'H (400MHz, DMSO): 10.21 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.26 (dd, 1H), 8.12 (d, 2H), 7.75-7.67 (m, 5H), 7.28 (d, 1H), 7.09 (dd, 1H), 6.97 (d, 2H), 3.90 (s, 3H), 3.77 (m, 2H), 3.29 (m, 2H) , 3.14 (m, 2H), 3.04 (m, 2H), 2.09 (s, 3H). MS (El): 524.6 (MH +). N- (4- {2 - [(4- {4- [(4-fluoro-3-methylphenyl) carbonyl] piperazin-1-yl} phenyl) amino] irimidin-4-yl} phenyl) acetamide: MS (El) for C 30 H 29 FN 6 O 2: 525.5 (MH +). N-. { 4- [2- ( { 4- [4- (naphthalen-2-ylsulfonyl) piperazin-1- il] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: RMIS ^ H (400MHz, DMSO): 10.20 (s, 1H), 9.37 (s, 1H), 8.50 (d, 1H), 8.42 (d, 1H), 8.22 (dd, 2H), 8.09 (dd, 3H), 7.82-7.71 (m, 5H), 7.64 (d, 2H), 7.26 (d, 1H), 6.89 (d, 2H), 3.14 (ra, 4H), 3.11 (m, 4H), 2.08 (s, 3H). MS (El): 579.6 (MH +). N-. { 4- [2- ( { 4- [4- (quinolin-8-ylsulfonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: RMN1 !. (400MHz, DMSO): 10.20 (s, 1H), 9.37 (s, 1H), 9.10 (dd, 1H), 8.56 (dd, 1H), 8.42 (ra, 2H), 8.34 (dd, 1H), 8.10 ( d, 2H), 7.79 (m, 1H), 7.73 (m, 3H), 7.65 (d, 2H), 7.27 (d, 1H), 6.90 (d, 2H), 3.45 (m, 4H), 3.08 (m , 4H), 2.09 (s, 3H). MS (El): 580.8 (MH +). N- [4- (2- { [4- (4-. {[[4- (1, 1-dimethylethyl) phenyl] sulfonyl.] Piperazin-1-yl) phenyl] amino.} - pyrimidine -4-yl) phenyl] acetamide: RM ^ H (400MHz, DMSO): 10.20 (s, 1H), 9.38 (s, 1H), 8. 43 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.70 (m, 4H), 7.66 (d, 2H), 7.27 (d, 1H), 6.91 (d, 2H), 3.16 (m, 4H), 3.01 (m, 4H), 2.08 (s, 3H), 1.32 (s, 9H). MS (El): 585.5 (MH +). N- [4- (2- { [4- (4- { [5-bromo-2- (methyloxy) phenyl] sulfonyl}. Piperazin-1-yl) phenyl] -amino. pyrimidin-4-yl) phenyl] acetamide: NMR'H (400MHz, DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8. 44 (d, 1H), 8.09 (dd, 2H), 7.84 (d, 2H), 7.74 (d, 2H), 7.68 (d, 2H), 7.28 (d, 2H), 6.94 (d, 2H), 3.92 (s, 3H), 3.27 (m, 4H), 3.11 (m, 4H), 2.09 (s, 3H). MS (El) for C29H29BrN604S: 638.6 (MH +).

N- (4- {2 - [(4- { 4- [(phenylmethyl) sulfonyl] piperazin-1-yl}. Phenyl) amino] pyrimidin-4-yl}. Phenyl) acetamide: RMIN ^ H (400MHz, DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.75 (d, 2H), 7.69 (d, 2H), 7.42 (m, 5H), 7.28 (d, 1H), 6.96 (d, 2H), 4.50 (s, 2H), 3.20 (m, 4H), 3.06 (m, 4H), 2.08 (s, 3H). MS (EI): 543.6 (MH +). N - [4- (2- { [4- (4- { [3- (trifluoromethyl) phenyl] sulfonyl}. Piperazin-1-yl) phenyl] amino.} - pyrimidin-4-yl ) phenyl] acetamide: NMR'H (400MHZ, DMSO): 10.21 (s, 1H), 9.39 (s, 1H), 8.44 (d, 1H), 8.18-8.08 (m, 4H), 8.02 (s, 1H) , 7.97 (d, 1H), 7.724 (d, 2H), 7.67 (d, 2H), 7.27 (d, 1H), 6.92 (d, 2H), 3.15 (m, 4H), 3.10 (m, 4H), 2.09 (s, 3H). MS (El): 597.7 (MH +). N - (4- { 2- [(4- { 4- [(2-methylphenyl) sulfonyl] piperazin-1-yl}. Phenyl) amino] pyrimidin-4-yl} phenyl) acetamide : RMIN H (400MHz, DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.43 (d, 1H), 8. 09 (dd, 2H), 7.85 (dd, 1H), 7.74 (d, 2H), 7.67-7.59 (m, 3H), 7.47 (m, 2H), 7.27 (d, 1H), 6.94 (d, 2H) , 3.17 (m, 4H), 3.13 (m, 4H), 2.61 (s, 3H), 2.09 (s, 3H). MS (El): 543.7 (MH +). N - (4- { 2- [(4- { 4- [(3-fluorophenyl) sulfonyl] piperazin-1-yl}. Phenyl) amino] pyrimidin-4-yl} phenyl) acetamide : RMIS ^ H (400MHz, DMSO): 10.21 (s, 1H), 9.39 (s, 1H), 8.43 (d, 1H), 8. 10 (dd, 2H), 7.73 (m, 3H), 7.67-7.62 (m, 5H), 7.27 (d, 1H), 6.92 (d, 2H), 3.14 (m, 4H), 3.08 (m, 4H) 2.09 (s, 3H). MS (El): 547.7 (MH +).

N- (4- {2 - [(4- {4- [(2,4-difluorophenyl) sulfonyl] piperazin-1-yl} phenyl) amino] -pyrimidin-4-yl}. phenyl) acetamide: MS (El) for C28H26F2N603S: 565.6 (MH +). N-. { 4- [2- ( { 3- [4- ( { 4- [(trifluoromethyl) oxy] phenyl} methyl) piperazin-1-yl}. Phenyl} -amino) pyrimidin-4 -il] phenyl} acetamide: NMR'H (400MHZ, DMSO): 10.21 (s, 1H), 9.47 (s, 1H), 8. 49 (d, 1H), 8.14 (dd, 2H), 7.75 (d, 2H), 7.64 (s, 1H), 7.48 (d, 2H), 7.33 (m, 3H), 7.22 (m, 1H), 7.13 (m, 1H), 6.56 (dd, 1H), 3.57 (s, 2H), 3.16 (m, 4H), 2.54 (m, 4H), 2.09 (s, 3H). MS (El): 563.6 (MH +). N- (4- {2 - [(3- { 4- [(1-methyl-1H-imidazol-2-yl) methyl] piperazin-1-yl}. Phenyl) amino] -pyrimidine- 4-yl. Phenyl) acetamide: NMR'H (400MHZ, d6-DMSO): 10.22 (s, 1H), 9.45 (s, 1H), 8.49 (d, 1H), 8.13 (dd, 2H), 7.75 (d, 2H), 7.58 (s, 1H), 7.33 (d, 1H), 7.25 (dd, 1H), 7.15-7.09 (m, 2H), 6.77 (d, 1H), 6.56 (dd, 1H), 3.68 (s, 3H), 3.58 (s, 2H), 3.12 (m, 4H), 2.54 (m, 4H), 2.09 (s, 3H). MS (El): 483.5 (MH +). N-. { 4- [2- ( { 3- [4- ( { 2- [(trifluoromethyl) oxy] phenyl} methyl) piperazin-1-yl] phenyl} -amino) pyrimidin-4-yl ] phenyl } acetamide: NMR'H (400MHZ, DMSO): 10.21 (s, 1H), 9.47 (s, 1H), 8. 50 (d, 1H), 8.13 (dd, 2H), 7.75 (d, 2H), 7.64-7.62 (m, 2H), 7.44-7.36 (m, 4H), 7.23 (dd, 1H), 7.14 (m, 1H), 6.55 (dd, 1H), 3.62 (s, 2H), 3.16 (m, 4H), 2.57 (m, 4H), 2.09 (s, 3H). MS (El): 563.6 (MH +). N- (4- {2 - [(3- { 4- [(3-chlorophenyl) methyl] piperazin-1- il} phenyl) amino] pyrimidin-4-yl} phenyl) acetamide: R NXH (400MHz, DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 9.40 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.75 (d , 2H), 7.69 (d, 2H), 7.44-7.38 (m, 4H), 7.28 (d, 1H), 6.96 (d, 2H), 4.48 (s, 2H), 3.27 (m, 4H), 3.09 ( m, 4H), 2.09 (s, 3H). MS (EI): 514.1 (MH +). N-. { 4- [2- (. {3- [4- (2, 3-dihydroxypropyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: RM ^ H (400MHz, DMSO): 10.23 (s, 1H), 9.46 (s, 1H), 8.49 (d, 1H), 8.14 (d, 2H), 7.75 (d, 2H), 7.63 (s, 1H), 7.33 (d, 1H), 7.22 (d, 1H), 7.13 (m, 1H), 6.56 (dd 1H), 3.67 (s, 2H), 3.14 (m, 5H), 2.60 (m, 4H), 2.45 (m, 1H), 2.30 (m, 1H), 2.09 (s, 3H). MS (EI): 463.6 (MH +). N-. { 4- [2- ( { 3- [4- (1, 3-benzodioxol-5-ylmethyl) piperazin-1-yl] phenyl} amino) irimidin-4-yl] phenyl} acetamide: NMR'H (400 MHZ, d6-DMS): 10.21 (s, 1H), 9.46 (s, 1H), 8.49 (s, 1H), 8.12 (m 2H), 7.75 (d, 2H), 7.62 ( s, 1H), 7.33 (d, 1H), 7.23 (dd, 1H), 7.12 (t, 1H), 6.90-6.85 (m, 2H), 6.79 (m, 1H), 6.55 (dd, 1H), 5.99 (s, 2H), 3.44 (s, 2H), 3.15 (m, 4H), 2.52 (m, 4H), 2.09 (s, 3H). MS (EI): 523.5 (MH +). N-. { 4- [2- ( { 3- [4- (pyrimidin-2-ylmethyl) iperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: RMNXH (400MHZ, d6-DMSO): 10.21 (s, 1H), 9.47 (s, 1H), 8.52-8.49 (m, 2H), 8.13 (m, 2H), 7.81-7.72 (m, 3H), 7.63 (s, 1H), 7.50 (d, 1H), 7.33 (d, 1H), 7.30-7.21 (ra, 2H), 7.13 (t, 1H), 6.57 (dd, 1H), 3.67 (s, 2H) , 3.17 (m, 4H), 2.60 (m, 4H), 2.09 (s, 3H).

MS (El): 480.6 (MH +). N-. { 4- [2- ( { 3- [4- (pyrimidin-3-ylmethyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} acetaraide: R NXH (400 MHZ, d6-DMSO): 10.22 (s, 1H), 9.47 (s, 1H), 8.54 (d, 1H), 8.49 (d, 2H), 8.12 (m, 2H), 7.78- 7.73 (m, 3H), 7.63 (s, 1H), 7.40-7.37 (m, 1H), 7.33 (d, 1H), 7.23 (d, 1H), 7.13 (t, 1H), 6.55 (dd, 1H) , 3.58 (s, 2H), 3.16 (m, 4H) 2.55 (m, 4H), 2.10 (s, 3H). MS (EI): 480.5 (MH +). N-. { 4- [2- ( { 3- [4- (pyridin-4-yl-ethyl) piperazin-1-yl] phenyljamino) pyrimidin-4-yl] -phenyl} acetamide: RM ^ H (400MHz, DMSO): 10.21 (s, 1H), 9.47 (s, 1H), 8.53 (dd, 2H), 8.49 (d, 1H), 8.14 (d, 2H) 7.75 (d, 2H) ), 7.64 (s, 1H), 7.38 (dd, 2H), 7.33 (d, 1H), 7.23 (d, 1H), 7.13 (t, 1H), 6.56 (dd, 1H), 3.59 (s, 2H) , 3.18 (m, 4H), 4.56 (m, 4H), 2.09 (s, 3H). MS (EI): 480.7 (MH +). N-. { 4- [2- ( { 3- [4- (lH-pyrrol-2-ylmethyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: R N1 !. (400MHz, DMSO): 10.21 (s, 1H), 9.45 (s, 1H), 8.49 (d, 1H), 8.12 (m, 2H), 7.75 (d, 2H), 7.61 (s, 1H), 7.33 ( d, 1H), 7.21 (d, 1H), 7.12 (t, 1H), 6.64 (m, 1H), 6.55 (dd, 1H), 5.92 (m, 2H), 3.46 (s, 2H), 3.14 (m , 4H), 2.09 (s, 3H). MS (EI): 468.6 (MH +). 4- [4- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) phenyl] -N- (phenylmethyl) -piperazine-l-carboxamide: RM ^ H (400MHz, DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.62 (s, 1H), 8. 45 (d, 1H), 8.12 (d, 2H), 7.75 (d, 2H), 7.70 (d, 2H), 7.48 (dd, 2H), 7.28-7.21 (m, 3H), 7.00 (d, 2H) , 6.94 (t, 1H), 4.41 (s, 2H), 3.60 (m, 4H), 310 (m, 4H), 2.09 (s, 3H). MS (EI): 522.4 (MH +). N- [4- (2- { [3- (4- { [2- (methyloxy) phenyl] carbonyl}. Piperazin-1-yl) phenyl] amino.} - pyrimidin-4-yl phenyl] acetamide: RMIN ^ H (400MHz, DMSO): 10.22 (s, 1H); 9.50 (s, 1H); 8.50 (d, 1H), 8.13 (d, 2H), 7.74 (d, 2H), 7.64 (s, 1H), 7.41 (m, 1H), 7.34 (d, 1H), 7.29 (d, 1H), 7.23 (dd, 1H), 7.16 (t, 1H), 7.10 (d, 1H), 7.01 (t, 1H), 6.59 (d, 1H), 3.79 (s, 3H), 3.21 (m, 4H), 3.07 ( m, 4H), 2.09 (s, 3H). MS (EI): 523.5 (MH +). N-. { 4- [2- (. {3- [4- (lH-pyrazol-4-ylcarbonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: NMR1 (400MHz, DMSO): 13.22 (s, 1H), 10.22 (s, 1H), 9.51 (s, 1H), 8.50 (d, 1H), 8.14 (d, 3H), 7.76 (d, 3H) , 7.66 (s, 1H), 7.34 (d, 1H), 7.29 (d, 1H) 7.17 (t, 1H), 6.59 (d, 1H), 3.78 (m, 4H), 3.20 (m, 4H), 2.09 (s, 3H). MS (EI): 483.5 (MH +). N-. { 4- [2- ( { 3- [4- (3-pyridin-3-ylpropanoyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: NMR1 (400MHz, DMSO): 10.24 (s, 1H), 9.50 (s, 1H), 8.50 (d, 2H), 8.39 (dd, 1H), 8.14 (d, 2H), 7.79 (d, 2H) , 7.69 (dd, 2H), 7.34-7.24 (m, 3H), 7.15 (t, 1H), 6.58 (dd, 1H), 3.61 (m, 4H), 3.10 (m, 4H), 2.86 (t, 2H) ), 2.74 (t, 2H), 2.09 (s, 3H). MS (EI): 522.7 (MH +).

N- (4- { 2- [(3- { 4- [3- (methyloxy) propanoyl] piperazin-1-yl}. Phenyl) amino] pyrimidin-4-yl} phenyl) acetamide : NMR1 (400MHz, DMSO): 10.22 (s, 1H), 9.50 (s, 1H), 8.50 (d, 1H), 8.14 (d, 2H), 7.76 (d, 2H), 7.66 (s, 1H), 7.34 (d, 1H), 7.27 (d, 1H), 7.16 (t, 1H), 6.59 (dd, 1H), 3.63 (m, 4H), 3.58 (t, 2H), 3.23 (s, 3H), 3.12 (ra, 4H), 2.63 (t, 2H), 2.09 (s, 3H). MS (El): 475.6 (MH +). N- [4- (2- { [3- (4- { 2- [(4-fluorophenyl) oxy] acetyl}. Piperazin-1-yl) phenyl] amino.} - pyrimidin-4 -yl) phenyl] acetamide: RMNXH (400MHz, DMSO) ': 10.23 (s, 1H) 9.51 (s, 1H), 8.50 (d, 1H), 8.14 (d, 2H), 7.76 (d, 2H), 7.66 (s, 1H), 7.34 (d, 1H), 7.29 (d, 1H), 7.19-7.10 (ra, 3H), 6.96 (m, 2H), 6.60 (dd, 1H), 4.88 (s, 2H), 3.64 (m, 4H), 3.17 (m, 4H), 2.09 (s, 3H). MS (El): 541.5 (MH +). N-. { 4- [2- ( { 3- [4- (Cyclobutylcarbonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] -phenyl} acetamide: RMIs ^ H (400MHz, DMSO): 10.24 (s, 1H), 9.50 (s, 1H), 8.50 (d, 1H), 8.14 (d, 2H), 7.76 (d, 2H), 7.69 (s, 1H), 7.34 (d, 1H), 7.24 (d, 1H), 7.15 (t, 1H), 6.58 (dd, 1H), 3.61 (m, 2H), 3.48 (m, 2H), 3.41 (t, 1H) ), 3.10 (m, 4H), 2.18 (m, 2H), 2.09 (s, 3H), 1.92 (m, 2H), 1.75 (m, 2H). MS (El): 471.4 (MH +). N-. { 4- [2- ( { 3- [4- (pyrimidin-4-ylcarbonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] -phenyl} acetamide: NMR1 (400MHz, DMSO): 10.22 (s, 1H), 9.51 (s, 1H), 8.69 (dd, 2H), 8.50 (d, 1H), 8.14 (d, 2H), 7.74 (d, 2H) 7.66 (s, 1H), 7.45 (dd, 2H), 7.34 (d, 1H), 7.28 (d, 1H), 7.16 (t ('lH), 6.60 (d, 1H), 3.81 (m, 2H), 3.43 (m, 2H), 3.27 (m, 2H), 3.14 (m, 2H), 2.10 (s, 3H), MS (EI): 494.6 (MH +), N- { 4- [2- ( { 3- [4- ( pyridin-2-ylcarbonyl) piperazin-1-yl] phenyl.} amino) pyrimidin-4-yl] phenyl.} acetamide: R N1 (400MHz, DMSO): 10.21 (s, 1H) 9.50 (s, 1H) , 8.61 (d, 1H), 8.50 (d, 1H), 8.14 (d, 2H), 7.95 (t, 1H), 7.74 (d, 2H), 7.66 (d, 2H), 7.50 (t, 1H), 7.34 (d, 1H), 7.29 (d, 1H), 7.16 (t, 1H), 6.60 (d, 1H), 3.84 (m, 2H), 3.59 (m, 2H), 3.26 (m, 2H), 3.14 (m, 2H), 2.09 (s, 3H) .MS (EI): 496.6 (MH +). N- (4- {2 - [(3- { 4- [(2-Rethylphenyl) carbonyl] piperazin-1-yl}. phenyl) araino] pyrimidin-4-yl}. phenyl) acetamide: NMR1 (400MHz, DMSO): 10.23 (s, 1H), 9.49 (s, 1H), 8.49 (d, 1H ), 8.13 (d, 2H), 7.74 (d, 2H), 7.63 (s, 1H), 7.34-7.16 (m, 7H), 6.59 (d, 1H), 3.84 (m, 2H), 3.28 (m, 2H), 3.25 (m, 2H), 3.06 (ra, 2H), 2.24 (s, 3H), 2.09 (s, 3H), MS (EI): 507.6 (MH +), N- { - [2- (. { 3- [4- (2, 2-dimethylpropanoyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: RM ^ H (400MHz, DMSO): 10.21 (s, 1H), 9.51 (s, 1H), 8.50 (dd, 1H), 8.14 (d, 2H), 7.76 (d, 2H), 7.68 (s, 1H), 7.34 (d, 1H), 7.26 (d, 1H), 7.16 (t, 1H), 6.59 (d, 1H), 3.72 (m, 4H), 3.13 (m, 4H), 2.09 (s, 3H) ), 1.23 (s, 9H). MS (EI): 473.5 (MH +). N-. { 4- [2- ( { 3- [4- (pyridin-3-ylcarbonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] -phenyl} acetamide: NMR1 (400MHz, DMSO): 10.23 (s, 1H), 9.51 (s, 1H), 8.67 (m, 2H), 8.50 (d, 1H), 8.13 (m, 2H), 7.90 (m, 1H), 7.75 (d, 2H), 7.66 (s, 1H), 7.50 (m, 1H), 7.34 (d, 1H), 7.29 (dd, 1H) ), 7.17 (t, 1H), 6.60 (dd, 1H), 3.82 (m, 2H), 3.50 (ra, 2H), 3.29 (m, 2H), 3.16 (m, 2H), 2.09 (s, 3H) . MS (EI): 494.7 (MH +). N-. { 4- [2- (. {3- [4- (2-methylpropanoyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] -phenyl} acetamide: NMR1 (400MHz, DMSO): 10.24 (s, 1H), 9.51 (s, 1H), 8.50 (d, 1H), 8.14 (dd, 2H), 7.76 (d, 2H), 7.69 (s, 1H) , 7.34 (d, 1H), 7.26 (dd, 1H), 7.16 (t, 1H), 6.60 (dd, 1H), 3.66 (m, 4H), 3.11 (m, 4H), 2.90 (m, 1H), 2.09 (s, 3H), 1.03 (s, 6H). MS 459.6 (MH +). N- [4- (2- { [3- (methyloxy) -4-morpholin-4-ylphenyl] amino} pyrimidin-4-yl) phenyl] tetrahydrofuran-3-carboxamide: NMR1 (400MHz, DMSO) : 10.32 (s, 1H), 9.48 (s, 1H), 8.48 (d, 1H), 8.16 (d, 2H), 7.78 (d, 2H), 7.67 (s, 1H), 7.32 (d, 1H), 7.29 (dd, 1H), 6.87 (d, 1H), 3.95 (t, 2H), 3.81 (s, 3H), 3.78 (ra, 2H), 3.71 (m, 4H), 3.29-3.17 (m, 1H) , 2.91 (m, 4H), 2.13-2.07 (m, 2H). MS (El): 476.5 (MH +). (2R) -N- [4- (2-. {[[3- (methyloxy) -4-morpholin-4-ylphenyl] amino} pyrimidin-4-yl) -phenyl] tetrahydrofuran-2-carboxamide: NMR1 (400MHz, DMSO): 9.94 (s, 1H), 9.48 (s, 1H), 8.48 (d, 1H), 8.16 (d, 2H), 7.89 (d, 2H), 7.66 (s, 1H), 7.33 ( d, 1H), 7.30 (dd, 1H), 6.87 (d, 1H), 4.43 (dd, 1H), 4.01 (m, 1H), 3.86 (m, 1H), 3.81 (s, 3H), 3.72 (m , 4H), 2.91 (m, 4H), 2.22-2.19 (m, 1H), 2.03-1.89 (m, 1H), 1.89 (m, 2H). MS (El): 476. 4 (MH +). (2S) -N- [4- (2- { [3- (methyloxy) -4-morpholin-4-ylphenyl] amino} pyrimidin-4-yl) -phenyl] tetrahydrofuran-2-carboxamide: NMR1 (400MHz, DMSO): 9.94 (s, 1H), 9.48 (s, 1H), 8.48 (d, 1H), 8.16 (d, 2H), 7.89 (d, 2H), 7.66 (s, 1H), 7.33 ( d, 1H), 7.30 (dd, 1H), 6.87 (d, 1H), 4.43 (dd, 1H), 4.01 (ra, 1H), 3.86 (m, 1H), 3.81 (s, 3H), 3.72 (m , 4H), 2.91 (m, 4H), 2.24-2.19 (m, 1H), 2.03-1.98 (ra, 1H), 1.89 (m, 2H). MS (El): 476. 5 (MH +). N- (4- { 2- [(4- { 4- [(2-fluorophenyl) sulfonyl] piperazin-1-yl}. Phenyl) araino] irimidin-4-yl}. Phenyl) acetamide : NMR1 (400MHz, ds-DSMO): 10.21 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.85-7.77 (m, 2H), 7.74 (d , 2H), 7.68 (d, 2H), 7.56-7.46 (ra, 2H), 7.28 (d, 1H), 6.93 (d, 2H), 3.18-3.16 (m, 8H), 2.09 (s, 3H). MS (El): 547.7 (MH +). N- (4- {2 - [(3- { 4 - [(3,5-dichlorophenyl) carbonyl] piperazin-1-yl) phenyl) amino] -pyrimidin-4-yl} phenyl) acetamide: NMR1 (400MHz, d6-DSMO): 10.24 (s, 1H), 9.51 (s, 1H), 8.50 (d, 1H), 8.14 (d, 2H), 7.73 (m, 3H), 7.64 ( s, 1H), 7.54 (d, 2H), 7.34 (d, 1H), 7.29 (d, 1H), 7.16 (t, 1H), 6.60 (dd, 1H), 3.79 (m, 2H), 3.46 (m , 2H), 3.26 (m, 2H), 3.26 (m, 2H), 2.15 (m, 2H), 2.09 (s, 3H). MS (El): 562.5 (MH +). Ethyl 3- (4- (2- (4-morpholinophenylamino (pyrimidin-4-yl) phenylamino) -3-oxopropanoate: RM ^ H (400MHz, d6-DMSO): 10.46 (s, 1H), 9.35 (s, 1H), 8.42 (d, 1H), 8.11 (d, 2H), 7.71 (d, 2?), 7.64 (d, 2?), 7.26 (d, 1?), 6.92 (d, 2H), 4.11 (q, 2H), 3.72 (m, 2H), 3.37 ( m, 4H), 3.02 (m, 4H), 1.19 (t, 3H). MS (El): 462 (MH +). N- (4- (2- (4- (4-isobutyrylpiperazin-1-yl) penylamino) pyrimidin-4-yl) phenyl) -tetrahydrofuran-3-carboxamide: RMIS H (400MHz, d6-DMSO): 10.30 (s) , 1H), 9.43 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.77 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.97 (m, 2H), 3.96 (t, 1H), 3.76 (m, 2H), 3.63 (m, 4H), 3.19 (m, 2H), 3.06 (m, 4H), 2.93 (m, 1H), 2.10 (m, 2H) ), 1.02 (d, 6H). MS (EI): 515 (MH +). N- (4- (2- (4- (4- (cyclobutanecarbonyl) piperazin-1-yl) phenylamino) pyrimidin-4-yl) phenyl) tetrahydrofuran-3-carboxamide: RM ^ H (400MHz, d6-DMSO): 10.30 (s, 1H), 9.42 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.77 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.96 (d, 2H), 3.96 (t, 1H), 3.76 (m, 3H), 3.59 (m, 2H), 3.41 (m, 3H), 3.19 (m, 1H), 3.03 (m, 4H), 2.41 ( m, 6H), 1.90 (m, 1H), 1.75 (m, 1H). MS (EI): 527 (MH +). N-ethyl-4- (4- (4- (4-tetrahydrofuran-3-carboxamido) phenyl) pyrimidin-2-yl-amino (phenyl) piperazine-l-carboxamide: NMR'H (400MHz, d6-DMSO): 10.30 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.77 (d, 2H), 7.67 (d, 2H), 7.28 (d, 1H), 6.96 (d, 2H), 6.59 (t, 1H), 3.96 (t, 1H), 3.75 (m, 3H), 3.42 (m, 4H), 3.19 (m, 1H), 3.05 (m, 6H), 2.10 ( q, 2H), 1.02 (t, 3H) MS (EI): 516 (MH +) N- (4- (2- (4- (4- ((R) -2-aminopropanoyl) iperazin-1- il) phenylamino) pyrimidin-4-yl) phenyl) tetrahydrofuran-3-carboxamide: NMR'H (400MHZ, d6-DMSO): 10.31 (s, 1H), 9.42 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.77 (d, 2H), 7.69 (d, 2H), 7.29 (d, 1H), 6.97 (d, 2H), 3.96 (dd, 1H), 3.89 (m, 1H), 3.76 (m, 4H), 3.63 (m, 4H), 3.18 (m, 2H), 3.07 (m, 4H), 2.09 (m, 2H), 1.13 (d, 3H). MS (El): 5.16 (MH +). N- (4- (2- (4- (4- ((S) -2-aminopropanoyl) piperazin-1-yl) phenylamino) pyrimidin-4-yl) phenyl) tetrahydrofuran-3-carboxamide: NMR'H (400MHZ , d6-DMSO): 10.31 (s, 1H), 9.42 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.77 (d, 2H), 7.68 (d, 2H), 7.29 ( d, 1H), 6.97 (d, 2H), 3.96 (t, 1H), 3.85 (q, 1H), 3.76 (m, 3H), 3.63 (m, 4H), 3.19 (m, 1H), 3.07 (m , 4H), 2.10 (m, 2H), 1.11 (d, 3H). MS (El): 516 (MH +). N- (4- (2- (4- (4- ((R) -pyrrolidine-2-carbonyl) piperazin-1-yl) phenylamino) pyrimidin-4-yl) phenyl) tetrahydrofuran-3-carboxamide: RMIS ^ H (400MHz d6-DMSO): 10.31 (s, 1H), 9.42 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.77 (d, 2H), 7.69 (d, 2H), 7.29 (d, 1H), 6.97 (d, 2H), 3.97 (m, 2H), 3.76 (m, 3H), 3.64 (m, 4H), 3.19 (m, 1H), 3.06 (m, 6H), 2.73 ( m, 1H), 2.90 (m, 2H), 1.67 (m, 4H). MS (El): 542 (MH +). N- (4- (2- (4- (4- ((S) -pyrrolidine-2-carbonyl) piperazin-1-yl) phenylamino) pyrimidin-4-yl) phenyl) tetrahydrofuran-3-carboxamide: NMRH (400MHz , d6-DMSO): 10.31 (s, 1H), 9.42 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.77 (d, 2H), 7.69 (d, 2H), 7.29 ( d, 1H), 6.97 (d, 2H), 3.96 (t, 1H), 3. 86 (m, 1H), 3.76 (m, 3H), 3.64 (m, 4H), 3.18 (m, 1H), 3.05 (m, 6H), 2.64 (m, 1H), 2.10 (m, 1H), 2.00 (m, 1H), 1.62 (ra, 4H). MS (EI): 542 (MH +). N-. { 4- [2- (lH-benzimidazol-6-ylamino) -5-methylpyrimidin-4-yl] phenyl} acetamide: RMN1 !! (400MHz, d6-DMSO): 10.25 (s, 1H), 8.97 (s, 1H), 8.78 (s, 1H), 8.21 (d, 2H), 7.86 (d, 2H), 7.80 (d, 2H), 6.96 (s, 1H), 6.78 (dd, 2H), 2.44 (s, 3H), 2.11 (s, 3H); MS (EI) C 20 H 18 N 60: 359.3 (M + H) +. 4- (4-furan-2-ylphenyl) -N- (4-morpholin-4-ylphenyl) pyrimidin-2-amine: RM 'H (400MHZ, d6-DMSO): 9.46 (s, 1H), 8.49 (d , 1H), 8.22 (d, 2H), 7.87 (d, 2H), 7.84 (dd, 1H), 7.68 (d, 2H), 7.37 (d, 1H), 7.12 (t, 1H), 6.94 (d, 2H), 6.66 (dd, 1H), 3.75 (t, 4H), 3.05 (t, 4H); MS (EI) C 24 H 22 N 402: 399.3 (M + H) +. N- (4-morpholin-4-ylphenyl) -4- [4- (pyrimidin-2-ylamino) phenyl] pyrimidin-2 -amine: RMNXH (400MHz, d6-DMSO): 10.01 (s, 1H), 9.35 ( s, 1H), 8.56 (d, 2H), 8.42 (d, 1H), 8.11 (dd, 2H), 7.95 (d, 2H), 7.69 (d, 2H), 7.27 (d, 1H), 6.96-6.92 (m, 3H), 3.75 (t, 4H), 3.06 (t, 4H); MS (EI) C 24 H 23 N 70: 426.3 (M + H) +. N- [4- (2- {[[4- (4-ethylpiperazin-1-yl) phenyl] amino]} - 5-methylpyrimidin-4-yl) phenyl] -cyclopropanecarboxamide: RMI H (400MHz, dGDMSO) : 10.40 (s, 1H), 9.41 (bs, 1H), 9.30 (s, 1H), 8.30 (s, 1H), 7.23-7.70 (m, 2H), 7.65-7.62 (m, 3H), 6.91 (d , 2H), 3.70-3.50 (bs, 2H), 3.21-2.87 (m, 8H), 2.20 (s, 3H), 1. 80 (p, 1H), 1.18 (bs, 3H), 0.81 (d, 4H); MS (EI) C 24 H 23 N 70: 457.4 (M + H) +. N- [4- (2- {[4- (4-ethylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] cyclopropanecarboxamide: RMI ^ H (400MHz), d6-DMSO) : 10.48 (s, 1H), 9.37 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.76 (d, 2H), 7.65 (d, 2H), 7.27 (d, 1H), 6.93 (d, 2H), 3.09 (bs, 4H), 2.60-2.35 (m, 6H), 1.83 (p, 1H), 1.06 (t, 3H), 0.84-0.82 (m, 4H); MS (EI) C 26 H 30 N 60: 443.4 (M + H) +. N- (4- {2- [(3,5-dimorpholin-4-ylphenyl) amino] -5-methylpyrimidin-4-yl) phenyl) -N2, N2-dimethylglycinamide: RMIS ^ H (400MHz, d6- DMSO): 10.04 (s, 1H), 9.25 (s, 1H), 8.37 (s, 1H), 7. 81 (d, 2H), 7.74 (d, 2H), 7.12 (s, 2H), 6.11 (s, 1H), 3.73 (t, 8H), 3.20 (bs, 2H), 3.06 (t, 8H), 2.34 (s, 6H), 2.28 (s, 3H); MS (EI) C 29 H 37 N 703: 532.4 (M + H) +. N2, N2-dimethyl-N- (4-. {5-methyl-2- [(4-morpholin-4-phenyl) amino] irimidin-4-yl) -phenyl) glycinamide: RMI ^ H (400MHz, ds -DMSO): 10.43 (s, 1H), 9.28 (s, 1H), 8.33 (s, 1H), 7.77 (d, 2H), 7.69 (d, 2H), 7.63 (d, 2H), 6.88 (d, 2H), 3.73 (t, 4H), 3.35 (br, 2H), 3.01 (t, 4H), 2.65 (s, 6H), 2.21 (s, 3H); MS (EI) C 25 H 30 N 602: 447.4 (M + H) +. N- (4-. {5-methyl-2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -D-prolinamide: RMI ^ H (400MHz, d6-DMSO ): 10.15 (s, 1H), 9.28 (s, 1H), 8.32 (s, 1H), 7.82-7.79 (m 2H), 7.64 (t, 4H), 6.88 (d, 2H), 3.75-3.72 (t , 5H), 3.01 (t, 4H), 2.91 (t, 2H), 2.22 (s, 3H), 2.11-2.02 (m, 1H >, 1.84-7.75 (m, 1H), 1.70-1.63 (m, 2H); MS (El) C 26 H 30 N 602: 459.4 (M + H) +. N-. { 4- [2- (. {4- [4- (2-methylpropanoyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] -phenyl} -D-Prolinamide: RMNXH (400MHz, d6-DMSO): 10.25 (s, 1H), 9.41 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.83 (d, 2H), 7.68 (d, 2H), 7.30 (d, 1H), 6.96 (d, 2H), 3.80-3.77 (m, 1H), 3.65-3.41 (m, 4H), 3.08-3.02 (m, 4H), 2.96-2.89 (m, 3H), 2.13-2.08 (m, 1H), 1.84-1.78 (m, 1H), 1.73-1.68 (m, 2H), 1.02 (d, 6H); MS (EI) C 29 H 35 N 702: 514.4 (M + H) +. N-. { 4- [2- ( { 4- [4- (2, 2-dimethylpropanoyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} -D-prolinamide: RMIS ^ H (400MHz, d6-DMSO): 10.85 (s, 1H), 9.41 (s, 1H), 8.47 (d, 1H), 8.18 (d, 2H), 7.78 (d, 2H), 7.68 (d, 2H), 7.31 (d, 1H), 6.96 (d, 2H), 4.40-4.34 (m, 1H), 3.70 (t, 4H), 3.32-3.25 (m, 2H), 3.05 (t, 4H), 2.44-2.38 (m, 1H), 2.05-1.94 (m, 3H), 1.23 (s, 9H); MS (EI) C 30 H 37 N 702: 528.4 (M + H) +. N-. { 4- [2- (. {4- [4- (Cyclobutylcarbonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] -phenyl} -D-prolinamide: RMN1H (400MHz, d6-DMSO): 10.19 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.84 (d, 2H), 7.67 (d, 2H), 7.30 (d, 1H), 6.95 (d, 2H), 3.74-3.70 (m, 1H), 3.60-3.46 (m, 4H), 3.04-3.00 (m, 4H), 2.91 (t, 2H), 2.22-2.02 (m, 6H), 1.95 -1.87 (m, 1H), 1.82-1.73 (m, 2H), 1.70-1.64 (m, 2H); MS (EI) C30H35N702: 526.2 (M + H) +. N-ethyl-4- [4- ( { 4- [4- (D-prolylamino) phenyl] pyrimidine- 2-il} amino) phenyl] -piperazine-l-carboxamide: RMI ^ H (400MHz, ds-DMSO): 10.19 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.84 (d, 2H), 7.67 (d, 2H), 7.29 (d, 1H), 6.96 (d, 2H), 6.59 (t, 1H), 3.74-3.71 (m, 1H), 3.42 (t, 4H) , 3.10-3.05 (m, 2H), 3.01 (t, 4H), 2.91 (t, 2H), 2.22 (s, 3H), 2.09-2.02 (m, 1H), 1.84-1.76 (m, 1H), 1.70 -1.63 (m, 2H), 1.02 (t, 3H); MS (EI) C 28 H 34 N 802: 515.5 (M + H) +. N- [4- (2- { [4- (4-D-prolylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] -D-prolinamide: RJVDN ^ H (400MHz, d6-DMSO): 10.20 (s, 1H), 9.42 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.84 (d, 2H), 7.68 (d, 2H), 7.30 (d , 1H), 6.97 (d, 2H), 3.92-3.89 (m, 1H), 3.75-3.71 (m, 1H), 3.65-3.59 (m, 4H), 3.09-2.98 (m, 5H), 2.91 (t , 2H), 2.69-2.63 (m, 1H), 2.09-2.02 (m, 2H), 1.84-1.76 (m, 1H), 1.70-1.54 (m, 5H); MS (EI) C 30 H 36 N 802: 541.4 (M + H) +. N- [4- (2- { [4- (4-L-prolylpiperazin-1-yl) phenyl] amino.} Pyrimidin-4-yl) phenyl] -D-prolinamide: NMRH (400MHz, d6- DMSO): 10.20 (s, 1H), 9.41 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.84 (d, 2H), 7.68 (d, 2H), 7.30 (d, 1H) ), 6.96 (d, 2H), 3.92-3.89 (m, 1H), 3.75-3.71 (m, 1H), 3.65-3.59 (m, 4H), 3.09-2.98 (m, 5H), 2.91 (t, 2H) ), 2.69-2.63 (m, 1H), 2.09-2.02 (m, 2H), 1.84-1.76 (m, 1H), 1.70-1.56 (m, 5H); MS (EI) C 30 H 36 N 802: 541.4 (M + H) +. 1-Methyl-N- (4- {2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -L-prolinamide: NMR'H (400MHZ, d6-DMSO ): 9. 93 (s, 1H), 9.39 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.87 (d, 2H), 7.67 (d, 2H), 7.29 (d, 1H), 6.93 (d, 2H), 3.74 (m, 4H), 3.12 (m, 1H), 3.05 (m, 4H), 2.95 (m, 1H), 2.36 (m, 4H) 2.17 (m, 1H), 1.80 (m , 3H); MS (El) for C 26 H 30 N 6 O 2: 459 (MH +). 1-Methyl-N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl) phenyl) piperidine-2-carboxamide: RMIS ^ H (400MHz, d6-DMSO) : 9.97 (s, 1H), 9.39 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.85 (d, 2H), 7.67 (d, 2H), 7.28 (d, 1H), 6.93 (d, 2H), 3.74 (m, 4H), 3.05 (m, 4H), 2.92 (m, 1H), 2.60 (dd, 1H), 2.16 (s, 3H) 2.03 (m, 1H), 1.76 ( m, 2H), 1.60 (m, 3H), 1.25 (m, 1H); MS (El) for C27H32N602: 473 (MH +). N-. { 4- [2- (. {4- [4- (Piperidin-4-ylcarbonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl} phenyl } acetamide: RMN1 !! (400MHz, d6-DMSO): 10.25 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.36 (s, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.28 (d, 1H), 6.97 (d, 2H), 3.64 (m, 4H), 3.17 (m, 2H), 3.06 (m, 4H), 2.93 (m, 1H), 2.81 (m, 2H), 2.09 (s, 3H), 1.60-1.75 (m, 4H); MS (El) for C28H33N702: 500 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-ylphenyl) -2-pyridin-4-ylacetamide: NMR'H (400MHz, d6-DMSO): 10.53 ( s, 1H), 9.38 (s, 1H), 8.53 (d, 2H), 8.44 (d, 1H), 8.12 (d, 2H), 7.95 (d, 1H), 7.76 (d, 2H), 7.67 (d , 2H), 7.35 (d, 1H), 6.92 (d, 2H), 3.75 (m, 6H), 3.04 (m, 4H). MS (EI): 467 (MH +). 2- (3-fluorophenyl) -N- (4-. {2- 2- [(4-morpholin-1-ylphenyl)) amino] pyrimidin-4-yl} phenyl) acetamide: NMRH (400MHz, d6-DMSO): 10.44 (s, 1H), 9.36 (s, 1H), 8.42 (m, 1H), 8.09 (d, 2H), 7.74 (d, 2H), 7.64 (d, 2H), 7.35 (m, 1H), 7.24 (m, 1H), 7.15 (d, 2H), 7.07 (m, 1H), 6.90 (d, 2H), 3.71 (m, 6H), 3.04 (m, 4H). MS (EI): 484 (MH +). 3- (4-chlorophenyl) -N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] irimidin-4-yl}. -phenyl) propanamide: NMRH (400MHz, d6-DMSO ): 10.19 (s, 1H), 9.38 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.73 (d, 2H), 7.68 (d, 2H), 7.35 (d, 2H) , 7.26 (m, 3H), 6.93 (d, 2H), 3.74 (m, 4H), 3.04 (m, 4H), 2.92 (t, 2H), 2.67 (t, 2H). MS (EI): 515 (MH +). 2- (3-chlorophenyl) -N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl.} - phenyl) acetamide: NMRH (400MHz, d6-DMSO ): 10.47 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.75 (d, 2H), 7.66 (d, 2H), 7.43 (s, 1H) , 7.32 (m, 4H), 6.93 (d, 2H), 3.74 (m, 6H), 3.04 (m, 4H). MS (EI): 500 (MH +). 2-Methyl-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -3-phenyl-propanamide: NMR1. (400MHz, d6-DMSO): 10.12 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.09 (d, 2H), 7.72 (d, 2H), 7.67 (d, 2H), 7.25 (m, 4H), 7.17 (m, 2H), 6.93 (d, 2H), 3.74 (m, 4H), 3.06 (m, 4H), 2.99 (m, 1H), 2.81 (m, 1H), 2.64 (m, 1H), 1.12 (d, 3H). MS (EI): 494 (MH +). trans-N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. phenyl) -2-phenyl-cyclopropanecarboxamide: NMR (400MHz, d6-DMSO): 10.53 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.77 (d, 2H), 7.67 (d, 2H), 7.28 (m, 3H), 7.21 (m, 3H), 6.93 (d, 2H), 3.74 (m, 4H), 3.04 (m, 4H), 2.39 (m, 1H), 2.11 (m, 1H), 1.53 (m, 1H), 1.42 (m, 1H). MS (EI): 492 (MH +). 2- [4-fluorophenyl) -N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) acetamide: RM ^ H (400MHz, ds) -DMSO): 10.44 (s, 1H), 9.38 (s, 1H), 8.43 (d, 1H), 8.12 (d, 2H), 7.75 (d, 2H), 7.65 (d, 2H), 7.38 (m, 2H), 7.27 (d, 1H), 7.18 (dd, 2H), 6.93 (d, 2H), 3.71 (m, 4H), 3.69 (s, 2H), 3.04 (m, 4H). MS (EI): 484 (MH +). 3- (2-chlorophenyl) -N- [4-. { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) propanamide: R ^ H (400MHz, d6-DMSO): 10.23 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.75 (d, 2H) , 7.67 (d, 2H), 7.45 (dd, 1H), 7.40 (dd, 1H), 7.25 (ra, 3H), 6.93 (d, 2H), 3.74 (m, 4H), 3.04 (m, 6H) 2.70 (t, 2H). MS (EI): 515 (MH +). 3- (3-chlorophenyl) -N- (4- { 2- [(4-raorpholin-4-ylphenyl) amino] pyrimidin-4-yl] -phenyl) propanamide: NMR1! (400MHz, d6-DMSO): 10.19 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.75 (d, 2H), 7.67 (d, 2H), 7.27 (m, 5H), 6.93 (d, 2H), 3.74 (m, 4H), 3.04 (m, 4H), 2.94 (t, 2H), 2.69 (t, 2H). MS (EI): 515 (MH +). 3- (2-fluorophenyl) -N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) ropanamide: NMRH (400MHz, d6- DMSO): 10.21 (s, 1H), 9.38 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.73 (d, 2H), 7.67 (d, 2H), 7.35 (t, 1H) ), 7.26 (d, 2H), 7.11 (m, 2H), 6.93 (d, 2H), 3.74 (m, 4H), 3.04 (m, 4H), 2.95 (t, 2H), 2.68 (t, 2H) . MS (EI): 498 (MH +). Nalpha, Nalpha-dimethyl-N- (4- { 2- [(4-morpholin-4-phenyl) amino] -pyrimidin-4-yl}. Phenyl) -L-phenylalaninamide: NMR'H (400MHz, d6-DMSO): 10.04 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.09 (d, 2H), 7.74 (d, 2H), 7.67 (d, 2H), 7.24 (m , 5H), 7.17 (m, 1H), 6.93 (d, 2H), 3.74 (m, 4H), 3.48 (dd, 1H), 3.06 (m, 5H), 2.86 (dd, 1H), 2.49 (s, 6H). MS (EI): 523 (MH +). 2- (2-chlorophenyl) -N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl) -phenyl) acetamide: NMR1! (400MHz, d6-DMSO): 10.54 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.76 (d, 1H), 7.67 (d, 2H), 7.46 (m, 2H), 7.33 (m, 2H), 7.29 (d, 1H), 6.93 (d, 2H), 3.89 (s, 2H), 3.75 (m, 4H), 3.04 (m, 4H). MS (EI): 500 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) araino] pyrimidin-4-yl}. Phenyl-2-pyridin-2-yl-acetamide: NMR'H (400MHz, d6- DMSO): 10.51 (s, 1H),, 9.35 (s, 1H), 8.49 (d, 1H), 8.41 (d, 1H), 8.10 (d, 2H), 7.77 (m, 3H), 7.64 (d, 2H), 7.39 (d, 1H), 7.26 (m, 2H), 6.92 (d, 2H), 3.87 (s, 2H), 3.71 (m, 4H), 3.02 (m, 4H), MS (EI): 467 (MH +) 2- (4-chlorophenyl) -N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) -amino] pyrimidin-4-yl} - phenyl) acetamide: NMR1 !! (400MHz, d6- DMSO): 10.47 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.75 (d, 2H), 7.66 (d, 2H), 7.39 (m, 4H) ), 7.26 (m, 1H), 6.93 (d, 2H), 3.74 (m, 4H), 3.70 (s, 2H), 3.04 (m, 4H). MS (EI): 500 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -2-. { 4- [(trifluoromethyl) oxy] phenyl} acetamide: R Ix ^ H (400MHz, ds-DMSO): 10.50 (s, 1H), 9.38 (s, 1H), 8.43 (d, 1H), 8.12 (d, 2H), 7.75 (d, 2H), 7.66 (d, 2H), 7.47 (d, 2H), 7.35 (d, 2H), 7.27 (d, 1H), 6.93 (d, 2H), 3.74 (m, 6H), 3.04 (m, 4H). MS (EI): 550 (MH +). 2- [2- (methyloxy) phenyl] -N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) acetamide: RMIS ^ H ( 400MHz, ds-DMSO): 10.34 (s, 1H), 9.38 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.76 (d, 2H), 7.67 (d, 2H), 7.26 (m, 3H), 7.00 (d, 1H), 6.91 (m, 3H), 3.77 (s, 3H), 3.74 (m, 4H), 3.67 (s, 2H), 3.04 (m, 4H). MS (EI): 496 (MH +). 2- [3- (methyloxy) phenyl] -N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) acetamide: RMIS ^ H (400MHz , ds-DMSO): 10.44 (s, 1H), 9.38 (s, lH), 8.43 (d, 1H), 8.11 (d, 2H), 7.76 (d, 2H), 7.67 (d, 2H), 7.26 ( m, 2H), 6.93 (m, 4H), 6.82 (dd, 1H), 3.74 (m, 7H), 3.55 (s, 2H), 3.04 (ra, 4H). MS (El): 496 (MH +). 2- [4- (methyloxy) phenyl] -N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) acetamide: NMRH (400MHz, d6 -DMSO): 10.38 (s, 1H), 9.38 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.75 (d, 2?), 7.67 (d, 2?), 7.26 (m, 3?), 6.93 (m, 4?), 3.74 (m, 7?), 3.60 (s, 2?) , 3.04 (m, 4?). MS (El): 496 (MH +). N- [4- (2- { [4- (4-ethylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl-D-alaninamide: NMRH (400MHz, d6-DMSO): 9.35 (s, 1H), 8.43 (d, 1H), 8.13 (d, 2H), 7.82 (d, 2H), 7.63 (d, 2H), 7.28 (d, 1H), 6.92 (d, 2H), 3.48 (m, 1H), 2.35 (q, 2H), 1.86 (br s, 8H), 1.24 (d, 3H), 1.03 (t, 3H). MS (EI): 446 (MH +). N-. { 4- [2- ( { 4- [4- (N, N-dimethylglycyl) piperazin-1-yl] phenyl} amino) pyriraidin-4-yl] -phenyl} acetamide: RM ^ H (400MHz, d6-DMSO): 10.21 (s, 1H), 9.39 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.75 (d, 2H), 7.67 ' (d, 2H), 7.28 (d, 1H), 6.96 (d, 2H), 3.68 (m, 4H), 3.10 (s, 2H), 3.07 (m, 4H), 2.18 (s, 6H), 2.09 ( S, 2H). MS (EI): 474 (MH +). N- [4- (2- { [4- (4-ethylpiperazin-1-yl) phenyl] amino} pyridin-4-yl) phenyl] -3- (methyloxy) propanamide: NMR1! (400MHz, d6-DMSO): 10.23 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.75 (d, 2H), 7.65 (d, 2H), 7.25 (d, 1H), 6.92 (d, 2H), 3.63 (t, 2H), 3.25 (s, 3H), 3.09 (m, 4H), 2.60 (t, 2H), 2.58 (m, 6H), 1.05 (t, 3H). MS (EI): 461 (MH +). (2R) -2-amino-N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -2-phenylethanamide: RM ^ H (400MHz , d6-DMSO): 9.37 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.80 (d, 2H), 7.66 (d, 2H), 7.49 (d, 2H), 7.34 ( t, 2H), 7.26 (m, 2H), 6. 92 (d, 2H), 4.56 (s, 1H), 3.75 (m, 4H), 3.04 (m, 4H). MS (EI): 481 (MH +). ? '2,?' 2 '-dimethyl-N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl.} - phenyl) -D-alanininamide: R N1 !. (400MHz, d6-DMSO): 10.02 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.84 (d, 2H), 7.66 (d, 2H), 7.28 (d, 1H), 6.92 (d, 2H), 3.75 (ra, 4H), 3.21 (q, 1H), 3.04 (m, 4H), 2.25 (s, 6H), 1.19 (d, 3H). MS (EI): 447 (MH +). 1-methyl-N- (4- {2. {(4 (morpholin-4-ylphenyl) amino} pyrimidin-4-yl} phenyl) -D-prolinamide: NMR! (400MHz, d6-DMSO): 9.94 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.87 (d, 2H), 7.30 (d, 1H), 6.94 (d, 2H), 3.76 (m 4H), 3.12 (m, 1H), 3.05 (ra, 4H), 2.95 (m, 1H), 2.36 (s, 3H), 2.30 (m, 1H), 2.18 ( m, 1H), 1.78 (m, 3H). MS (EI) 459 (MH +). ? '2,?' 2 '-dimethyl-N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl.} - phenyl) -L-alaninamide: NMR1 !! (400MHz, d6-DMSO): 10.03 (s, 1H), 9.39 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.84 (d, 2H), 7.67 (d, 2H), 7.28 (d, 1H), 6.92 (d, 2H), 3.75 (m 4H), 3.21 (q, 1H), 3.05 (ra, 4H), 2.25 (s, 6H), 1.19 (d, 3H). MS (EI): 447 (MH +). N- (4 - {2 - [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -1-phenyl-cyclopropanecarboxamide: NMR! (400MHz, d6-DMSO): 9.38 (s, 1H), 8.43 (d, 1H), 8.09 (d, 2H), 7.72 (d, 2H), 7.65 (d, 2H), 7.40 (m, 4H), 7.28 (m, 2H), 6.92 (d, 2H), 3.74 (m, 4H), 3.04 (m, 4H), 1.74 (dd, 2H), 1.15 (dd, 2H). MS (El): 492 (MH +). 2-Methyl-N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -butanamide: RM ^ H (400MHz, d6-DMSO): 10.12 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.78 (d, 2H), 7.67 (d, 2H), 7.27 (d, 1H), 6.93 (d, 2H), 3.75 (m, 4H), 3.04 (m, 4H), 2.46 (q, 1H), 1.65 (m, 1H), 1.41 (m, 1H), 1.10 (d, 3H), 0.87 ( t, 3H). MS (El): 432 (MH +). (2S) -1-methyl-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) acetidine-2-carboxamide: RI ^ H ( 400MHz, d6-DMSO): 9.88 (s, 1H), 9.39 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.89 (d, 2H), 7.67 (d, 2H), 7.29 (d, 1H), 6.93 (d, 2H), 3.74 (m, 4H), 3.56 (t, 1H), 3.36 (m, 1H), 3.04 (m, 4H), 2.93 (q, 1H), 2.33 ( s, 3H), 2.30 (m, 1H), 2.12 (m, 1H). MS (El): 445 (MH +). 2,4,6-trichloro-N- (3- {[4- (4-methyl-2-thienyl) pyrimidine-2-yl] amino} propyl) -benzamide: NMR1! (400MHz, d6-DMSO): 8.68 (br s, 1H), 8.24 (d, 1H), 7.72-7.70 (m, 3H), 7.29 (s, 1H), 7.17 (t, 1H), 6.98 (d, 1H), 3.37-3.35 (m, 2H), 3.28-3.27 (m, 2H), 2.22 (s, 3H), 1.77 (br t, 2H). MS (El) 457.0 (MH +). N-. { 4- [2- ( { 4- [4- (2, 2-dimethylpropanoyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} Cyclopropanecarboxamide: MS (El) C29H34N602: 499 (MH +). 4- . { 4- [(4- { 4- [(cyclopropylcarbonyl) amino] phenyl} pyrimidin-2-yl) amino] phenyl} -N-ethylpiperazine-l-carboxamide: MS (El) C27H31N702: 486 (MH +). N- [3- ( { 4- [3,4-bis (methyloxy) phenyl] pyrimidine-2-yl} amino) propyl] -2,6-dichloro-benzamide: NMR! (400MHz, d6-DMSO): 8.67 (br s, 1H), 8.26 (d, 1H), 7.69-7.67 (m, 2H), 7.49-7.35 (m, 3H), 7.14-7.09 (m, 2H), 7.03 (d, 1H), 3.82 (s, 3H), 3.80 (s, 3H), 3.42 (m, 2H), 3.32 (m, 2H), 1.80 (m, 2H). MS (EI): 461.2 (MH +). 2, 6-dichloro-N- [3- (. {4- [(4-morpholino-4-ylphenyl) amino] irimidin-2-yl} amino) -propyl] benzamide: RM ^ H (400MHz, de-DMSO): 8.85 (br s, 1H), 8.63 (t, 1H), 7.69 (d, 1H), 7.48 (d, 2H), 7.44 (d, 1H), 7.42 (s, 1H), 7.37- 7.33 (m, 1H), 6.81 (d, 2H), 6.59 (br s, 1H), 5.83 (d, 1H), 3.67-3.65 (m, 4H), 3.23-3.20 (m, 4H), 2.97-2.94 (m, 4H), 1.70 (t, 2H). (MS) (EI): 501.2 (MH +). 2,6-dichloro-N- (3- {[4- (2,3-dihydro-l, 4-benzodioxin-6-yl) -5-fluoropyrimidin-2-yl] amino} propyl) benzamide : RM ^ H (400MHz, d6-DMSO): 8.62 (t, 1H), 8.29 (d, 1H), 7.49-7.42 (m, 4H), 7.37-7.33 (m, 1H), 7.15 (t, 1H) , 6.94-6.92 (m 1 H), 4.27-4.21 (m, 4H), 3.33-3.22 (m, 4H), 1.74 (t, 2H); MS (EI): 477.1 (MH +). 2, 6-dichloro-N-. { 3- [(4- { 3- [(dimethylamino) methyl] phenyl} pyrimidin-2-yl) amino] propyl} benzamide: RMN1 !. (400MHz, d6-DMSO): 8.68 (t, 1H), 8.31 (d, 1H), 8.01-7.95 (m, 2H), 7.49-7.38 (m, 5H), 7.23 (br s, 1H), 7.10 ( d, 1H), 3.43 (m, 2H), 3.33-3.29 (m, 4H), 2.14 (s, 6H), 1.82 (t, 2H); MS (EI): 460. 2 (MH +). 2, 6-dichloro-N- [3- (. {4- [3- (1-methylethyl) phenyl] piperidin-2-yl} amino) -propyl-benzaraide: RM ^ H (400MHz, d6- DMSO): 8.66 (t, 1H), 8.31 (d, 1H), 7.95-7.88 (m, 2H), 7.55 (br s, 1H), 7.45-7.43 (m, 2H), 7.40-7.34 (m, 3H) ), 7.20 (br s, 1 H), 3.30 (br s, 2 H), 3.29-3.25 (m, 2 H), 2.92 (septet, 1 H), 1.78 (m, 2 H), 1.18 (d, 6 H); MS (El): 443.0 (MH +). 2, 6-dichloro-N-. { 3- [(4- { 4- [(1-Methylethyl) oxy] phenyl} pyrimidin-2-yl) amino] propyl} Benzamide: RM ^ H (400MHz, d6-DMSO): 8.68 (t, 1H), 8.25 (d, 1H), 8.03 (d, 2H), 7.49-7.47 (ra, 2H), 7.42-7.38 (m, 1H ), 7.10 (t, 1H), 7.03 (d, 1H), 6.98 (d, 2H), 4.69 (septet, 1H), 3.42 (m, 2H), 3.30 (m, 2H), 1.80 (t, 2H) , 1.27 (d, 6H); MS (El): 459.0 (MH +). N- [3- ( { 4- [3- (acetylamino) phenyl] pyrimidin-2-yl} amino) propyl] -2,6-dichloro-benzamide: NMR! (400MHz, d6-DMSO): 10.1 (s, 1H), 8.70 (t, 1H), 8.70 (t, 1H), 8.33-8.27 (m 2H), 7.70 (m, 2H), 7.49-7.46 (m, 2H), 7.42-7.37 (m, 2H), 7.37 (br S, 1H), 7.01 (d, 1H), 3.43 (m, 4H), 2.02 (s, 3H), 1.97 (m, 2H). MS (El): 458.2 (MH +). 2, 6-dichloro-N- [3- (. {4- [(E) -2-phenylethenyl] pyrimidin-2-yl} amino) propyl] -benzamide: NMRH (400MHz, d6-DMSO): 8.71 (t, 1H), 8.27 (d, 1H), 7.76 (d, 1H), 7.67-7.65 (m, 2H), 7.51-7.49 (m, 2H), 7.44-7.34 (m, 4H), 7.12- 7.06 (m, 2H), 6.72 (d, 1H), 3.36 (m, 2H), 3.33 (m, 2H), 1.81 (t, 2H). MS (El): 427.0 (MH +). (4- {2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl) phenyl) carbamate phenyl: NMR! (400MHz, d6-DMSO): 8.59 (d, 1H), 7.90 (d, 2H) 7.69 (d, 1H), 7.44.7.40 (m, 2H), 7.28-7.20 (m, 5H), 6.97 (d, 2H), 6.62 (d, 2H), 5.90 (s, 2H), 3.74-3.72 (m, 4H), 3.13-3.11 (m, 4H). MS (EI): 468.1 (MH +). 4- [2-. { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -phenylmethyl carbamate: NMR'H (400MHz, d6-DMSO): 8.55 (d, 1H), 7.85 (d, 2H), 7.64 (d, 1H), 7.33-7.30 (m, 5H), 7.13 ( d, 2H), 6.92 (d, 2H), 6.62 (d, 2H), 5.88 (s, 2H), 5.88 (s, 2H), 3.74-3.71 (m, 4H), 3.11-3.09 (m, 4H) . MS (EI): 428. 3 (MH +). N-. { 4- [2- ( { 4- [4- (2, 2-dimethylpropanoyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} -3 - (methyloxy) propanamide: RMN1 !. (400MHz, d6-DMSO): 10.2 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.77 (d, 2H), 7.68 (d, 2H), 7.68 (d, 2H), 7.28 (d, 1H), 6.95 (d, 2H), 3.71-3.69 (m, 4H), 3.65 (t, 2H), 3.25 (s, 3H), 3.06-3.03 (m, 4H), 2.59 (t, 2H), 1.23 (S, 9H). MS (EI): 517.4 (MH +). N-. { 4- [2- (. {4- [4-cyclobutylcarbonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} -3- (methyloxy) propanamide: NMR'H (400MHZ, d6-DMSO): 10.2 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.77 (d , 2H), 7.68 (d, 2H), 7.28 (d, 1H), 6.96 (d, 2H), 3.65-3.60 (m, 4H), 3.47-3.37 (m, 4H), 3.25 (s, 3H), 3.03-302 (m, 3H), 2.60 (t, 2H), 2.21-2.07 (m, 4H), 1.94-1.87 (m, 1H), 1.78.1.73 (m, 1H). MS (EI): 515. 2 (MH +). 3- (methyloxy) -N-. { 4 - [2- ( { 4- [4- (2-methylpropanoyl) piperazin-2-yl] phenyl} amino) -pyrimidin-4-yl] phenyl} propanamide: RM ^ H (400MHz, d6-DMSO): 10.2 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.76 (d, 2H), 7.68 ( d, 2H), 7.28 (d, 1H), 6.96 (d, 2H), 2.65-3.62 (m, 6H), 3.25 (s, 3H), 3.08-3.02 (m, 4H), 2.92 (m, 1H) , 2.59 (t, 2H), 1.02 (d, 6H). MS (EI): 503.4 (MH +). N-ethyl-4- (4- { [4- (4-. {[[3- (methyloxy) propanoyl] amino} phenyl) pyrimidin-2-yl] -amino} phenyl) piperazine- l-carboxamide: NMR'H (400MHZ, d6-DMSO): 10.2 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.77 (d, 2H), 7.68 (d, 2H), 7.28 (d, 1H), 6.97 (d, 2H), 6.59 (t, 1H), 3.64 (t, 2H), 3.43 (m, 4H), 3.25 (s, 3H), 3.10-3.03 (m , 6H), 2.61 (t, 2H), 1.02 (t, 3H). MS (El): 504.4 (MH +). N- (4- (2- (4- (4-ethylpiperazin-1-yl) phenylamino) pyrimidin-4-yl) phenyl) -2-phenyl-acetamide: NMRH (400MHz, d6-DMSO): 10.4 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.12 (d, 2H), 7.76 (d, 2H), 7.64 (d, 2H), 7.38-7.33 (m, 3H), 7.27 (d , 1H), 6.92 (d, 2H), 3.69 (s, 2H), 3.10-3.04 (m, 4H), 2.35 (q, 3H), 1.89 (S, 2H), 1.03 (t, 2H); MS (El): 493.1 (MH +). 1- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) pyrrolidin-2-one: RMNXH (400MHz, d6-DMSO): 8.26 (d, 1H), 8.14 (d, 2H), 7.77 (d, 2H), 7.65 (d, 2H), 7.36 (d, 1H), 7.25 (d, 2H), 3.92-3.84 (m, 5H), 3.82-3.74 (m, 1H), 3.74- 3. 60 (m, 1H), 3.42-3.30 (m, 4H), 3.06-3.02 (ra, 1H), 2.16-2.06 (m, 2H); MS (EI): 416.1 (MH +). (R) -2-amino-N- (4- (2- (4- (4- (cyclobutanecarbonyl) piperazin-1-yl) phenylamino) pyrimidin-4-yl) phenyl) propanamide: NMR'H (400MHz, d6 -DMS0): 9.41 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.82 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.95 (d, 2H), 3.63-3.56 (m, 2H), 3.43-3.37 (m 3H), 3.18 (d, 1H), 3.07-2.98 (m, 4H), 2.25-2.02 (ra, 4H), 1.98-1.83 (m , 1H), 1.82-1.70 (m, 1H), 1.23 (d, 3H); MS (EI): 500.2 (MH +). (R) -2-amino-N- (4- (2- (4- (4-pivaloylpiperazin-1-yl) phenylamino) pyrimidin-4-yl) phenyl) propanamide: RMIS ^ H (400MHz, d6-DMSO) : 9.41 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.82 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.95 (d, 2H), 3.73-3.67 (m, 4H), 3.52-4.42 (ra, 1H), 3.08-3.02 (m, 4H), 1.25 (s, 3H), 1.23 (d, 3H); MS (EI): 502.4 (MH +). (S) -2-hydroxy-3-methyl-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) butanamide: RMIS ^ H (400 ???, d6-DMSO): 9.90 (s, 1H), 9.39 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.90 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.94 ( d, 2H), 5.76 (d, 1H), 3.86 (dd, 1H), 3.78-3.73 (m, 4H), 3. 08-3.02 (m, 4H), 0.96 (d, 3H), 0.87 (d, 3H); MS (EI): 448.3 (MH +). (R) -2-hydroxy-3-methyl-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) butanamide: NMRH (400MHz, d6-DMSO): 9.90 (s, 1H) , 9.39 (s, 1H), 8.45 (d, 1H), 8. 12 (d, 2H), 7.90 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.94 (d, 2H), 5.76 (d, 1H), 3.86 (dd, 1H), 3.78 -3.73 (m, 4H), 3.08-3.02 (m, 4H), 0.96 (d, 3H), 0.87 (d, 3H); MS (EI): 448.3 (MH +). N-. { 4- [2- ( { 4- [4-cyclopropylcarbonyl) pyrazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} -D-alaninamide: RMIS ^ H (400MHz, d6-DMSO): 11.17 (s, 1H), 10.4 (s, 1H), 8.58 (s, 1H), 8.40 (s, 2H), 8.11-8.09 (m, 2H), 7.96-7.82 (m, 3H), 7.76-7.65 (m, 1H), 7.45 (d, 1H), 4.05 (t, 4H), 3.75-3.70 (m, 1H), 3.50 (t, 4H) , 2.10-200 (m, 1H), 1.45 (d, 3H), 0.82-0.72 (m, 4H). MS (EI): 486 (MH +). (2S) -2-amino-N- (4-. {2- 2- [(4-morphol-4-ylphenyl) amino] primidin-4-yl} phenyl) -2-phenylethanamide: (400MHz, d6-DMSO): 11.73 (s, 1H), 10.08 (s, 1H), 8.99 (s, br, 1H), 8.58 (s, 1H), 8.19 (d, 2H), 7.96-7.83 (m , 3H), 7.76-7.65 (m, 3H), 7. 45-7.40 (m, 3H), 5.40 (s, br, 1H), 3.85 (s, br, 4H), 3.50 (S, br, 4H). MS (EI): 481 (MH +). 2-amino-2- (4-chlorophenyl) -N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) acetamide: RMIS ^ H ( 400MHz, d6-DMSO): 11.80 (s, 1H), 10.00 (s, 1H), 9.00 (s, 2H), 8.57 (d, 1H), 8.20 (d, 2H), 7.95-7.83 (m, 4H) , 7.80-7.60 (m, 3H), 7.58 (d, 2H), 7.43 (d, 1H), 5.50 (s, 1H), 4.00 (t, 4H), 3.50 (t, 4H). MS (EI): 515 (MH +). N- (4 - {2 - [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) morpholine-3-carboxamide: RMI ^ H (400MHz, d6-DMSO): 11. 60 (s, 1H), 10.20 (s, 1H), 10.00 (s, 1H), 9.40 (s, br, 1H), 8.58 (d, 1H), 8.20 (d, 2H), 7.95-7.88 (m, 3H), 7.60-7.20 (m, 4H), 4.42-4.30 (m, 2H), 4.05-3.90 (m, 2H), 3.85-3.70 (m, 4H), 3.60-3.45 (m, 4H), 3.25- 3.10 (m, 3H). MS (EI): 461 (MH +). l-Ethyl-3- [4- (2- {[4- (4-ethylpiperazin-1-yl) -3- (methyloxy) phenyl] amino} pyrimidin-4-yl) phenyl] urea: NMRH (400MHz, d6-DMSO): 9.40 (s, 1H), 8.90 (s, 1H), 8.42 (d, 1H), 8.20 (s, 1H), 8.05 (d, 2H), 7.56 (d, 2H), 7.28 (d, 2H), 6.83 (d, 1H), 6.36 (t, 1H), 3.80 (s, 3H), 3.12 (q, 2H), 2.98 (s, br, 4H), 2.58 (s, br, 4H), 2.42 (q, 2H), 1.08-1.00 (m, 6H). MS (EI): 476 (MH +). N- [4- (2- { [4- (4-ethylpiperazin-1-yl) -3- (methyloxy) phenyl] amino} pyrimidin-4-yl) -phenyl] -D-prolinamide: RMI ^ H (400MHz, d6-DMSO): 11.23 (s, 1H), 11.05 (s, 1H), 10.18 (s, br, 1H), 10.00 (s, 1H), 8.75 (s, br, 1H), 8.57 (d, 1H), 8.21 (d, 2H), 7.85 (d, 2H), 7.63 (s, 1H), 7.44 (d, 1H), 7.33 (dd, 1H), 7.33 (dd, 1H), 7.03 ( d, 1H), 4.55-4.50 (m, 1H), 3.82 (s, 3H), 3.80-3.60 (m, 4H), 3.35-3.05 (m, 7H), 2.50-2.45 (m, 2H), 2.02- 1.95 (m, 3H), 1.30 (t, 3H). MS (EI): 502 (MH +). N- [4- (2- { [4- (4-ethylpiperazin-1-yl) -3-methyloxy) phenyl] amino} pyrimidin-4-yl) -phenyl] acetamide: NMRH (400MHz, d6-DMSO): 10.22 (s, 1H), 9.40 (s, 1H), 8.44 (s, 1H), 8.15 (d, 2H), 7.80- 7.60 (m, 3H), 7.33 (d, 2H), 6.85 (d, 1H), 3.80 (s, 3H), 2.90 (s, br, 4H), 2.35 (q, 2H), 2.05 (s, 4H) , 1.95 (s, 3H), 1.00 (S, 3?). MS (El): 447 (MH +). 1- (2,6-dichlorophenyl) -3- (3- {[[4- (4-methyl-2-thienyl) pyrimidin-2-yl] amino} propyl) -urea: NMR! (400MHz, d6-DMSO): 8.26 (d, 1H), 8.02 (br, 1H), 7.71 (s, 1H), 7.48 (d, 2H), 7.31 (s, 1H), 7.26 (t, 1H), 7.16 (t, 1H), 6.99 (d, 1H), 6.39 (t, 1H), 3.38 (t, 2H), 3.15 (t, 2H), 2.21 (s, 3H), 1.65 (m, 2H). MS (El) for C19H19C12N50S: 436 (MH +). 1- [2-fluoro-5- (trifluoromethyl) phenyl] -3- (3- {[[4- (4-methyl-2-thienyl) pyrimidin-2-yl] amino) propyl) urea: RMIS ^ H (400MHz, d6-DMSO): 8.65 (d, 2H), 8.23 (s, 1H), 7.7 (s, 1H), 7. 4 (t, 1H), 7.38-7.15 (m, 3H), 7.0 (s, 1H), 6.8 (t, 1H), 3.38 (t, 2H), 3.2 (t, 2H), 2.21 (s, 3H) , 1.75 (m, 2H). MS (El) for C20H19F4N5OS: 454 (MH +). 2, 6-dichloro-N- [3- (. {4- [4- (diraethylamino) phenyl] pyrimidin-2-yl} amino) propyl} -benzenesulfonamide: NMRH (400MHz, d6-DMSO): 8.16 (d, 1H), 8.12 (t, 1H), 7.94 (d, 2H), 7.58 (d, 2H), 7.48 (t, 1H), 6.97 (d , 1H), 6.92 (t, 6.76 (d, 2H) 3.28 (m, 2H), 3.02-2.96 (m, 8H), 1.68 (m, 2H), MS (El) for C21H23C12N502S: 480 (MH +). - [3- ( { 4- [4- (dimethylamino) phenol] pyrimidin-2-yl} amino) propyl] -2,6-difluoro-benzenesulfonamide: NMRH (400MHz, d6-DMSO): 8.25 ( T, 1H), 8.16 (d, 1H), 7.94 (d, 2H), 7.66 (m, 1H), 7.24 (t, 2H), 6.98 (d, 1H), 6.95 (t, 1H), 6.76 (d , 2H), 3.33 (t, 2H), 3.0 (t, 2H), 2.98 (s, 6H), 1.68 (m, 2H), MS (El) for C21H23F2N502S: 448 (MH +).

N- [3- ( { 4- [4- (diraethylamino) phenyl] irimidin-2-yl} amino) propyl] naphthalene-2-sulfonamide: NMR1! (400MHz, d6-DMSO): 8.42 (br, 1H), 8.15-8.06 (m, 3H), 8.02 (d, 1H), 7.94 (d, 2H), 7.8 (dd, 1H), 7.74-7.62 (m , 3H), 6.96 (d, 1H), 6.92 (t, 1H), 6.74 (d, 2H), 3.3 (t, 2H), 2.98 (s, 6H), 2.83 (t, 2H), 1.63 (m, 2H). MS (El) for C25H27N502S: 462 (MH +) N- [3- (. {4- [4- (dimethylamino) phenyl] pyrimidin-2-yl} amino) propyl] -3,4-bis (methyloxy) ) benzenesulfonamide: RMN1 !. (400MHz, d6-DMSO): 8.17 (d, 1H), 7.94 (d, 2H), 7.46 (t, 1H), 7.34 (dd, 1H), 7.27 (d, 1H), 7.06 (d, 1H), 6.97 (d, 1H), 6.93 (t, 1H), 6.76 (d, 2H), 3.8 (s, 6H), 3.3 (t, 2H), 2.98 (s, 6H), 2.8 (t, 2H), 1.65 (m, 2H). MS (El) for C 23 H 29 N 504 S: 472 (M + H) 3-chloro-N- [3- (. {4- [4- (dimethylamino) phenyl] pyrimidin-2-yl] amino) propyl] propane l-sulfonamide: RMN1 !! (400MHz, d6-DMSO): 8.2 (s, 1H), 7.98 (d, 2H), 7.2 (t, 1H), 7.0 (t, 2H), 6.8-6.7 (m, 2H), 3.7 (t, 2H) ), 3.1-2.9 (m, 10H), 2.05 (t, 2H), 1.7 (m, 2H), 1.2 (m, 2H). MS (El) for C18H26C1N502S: 412 (MH +) N- [3- (. {4- [4- (dimethylamino) phenyl] pyrimidin-2-yl} amino) propyl] propane-1-sulfonamide: 1H NMR ( 400MHz, d6-DMSO): 8.2 (d, 1H), 7.96 (d, 2H), 7.0-6.95 (m, 3H), 6.76 (d, 2H), 3.38 (t, 2H), 3.0-2.9 (m, 10H), 1.75 (t, 2H), 1.6 (q, 2H), 0.95 (t, 3H). MS (El) for C18H27N502S: 378 (MH +). (3 - { [4 - (2,4-dichlorophenyl) pyrimidin-2-yl] amino.}. propyl) methyl carbamate: NMR'H (400MHZ, d6-DMSO): 8.4 (d, 1H), 7.75 (s, 1H), 7.63-7.55 (m, 2H), 7.35 (t, 1H), 7.12 (t , 1H), 6.8 (d, 1H), 3.5 (s, 3H), 3.28 (t, 2H), 3.03 (t, 2H), 1.65 (m, 2H). MS (El) for C15H16C12N402: 355 (MH +). (3- {[[4- (2, 4-dichlorophenyl) pyrimidin-2-yl] amino} propyl) -carbamic acid 1-methylethyl ester: RI ^ H (400MHz, d6-DMSO): 8.38 (d, 1H), 7.75 (s, 1H), 7.63-7.55 (m, 2H), 7.35 (t, 1H), 7.0 (t, 1H), 6.8 (d, 1H), 4.72 (m, 1H), 3.28 (q , 2H), 3.0 (q, 2H), 1.65 (p, 2H), 1.12 (d, 6H). MS (E) for C 17 H 20 Cl 2 N 4 O 2: 383 (MH +). (3 - { [4- (2, 4-dichlorophenyl) pyrimidin-2-yl] amino.}. Propyl) phenylmethyl carbamate: NMR1! (400MHz, d6-DMSO): 8.46 (d, 1H), 8.2 (br, 1H), 7.8 (d, 1H), 7.66 (br, 1H), 7.6 (dd, 1H), 7.4-7.28 (m, 5H) ), 7.04 (br, 1H), 5.0 (s, 2H), 3.4 (t, 2H), 3.1 (t, 2H), 1.7 (m, 2H). MS (E) for C 21 H 20 Cl 2 N 4 O 2: 431 (MH +). N-. { 4- [2- ( { [3- (3-chlorophenyl) isoxazol-5-yl] methyl} amino) pyrimidin-4-yl] -henyl} acetamide: RMN1 !! (400MHz, d6-DMSO): 10.18 (s, 1H), 8.37 (d, 1H), 8.06 (d, 2H), 7.92 (t, 1H), 7.88-7.82 (m, 2H), 7.7 (d, 2H) ), 7.56-7.48 (m, 2H), 7.2 (d, 1H), 7.0 (s, 1H), 4.7 (s, 2H), 2.05 (s, 3H). MS (El) for C22H18C1NS02: 420 (MH +). 4- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) piperidine-1-ethyl carboxylate: RMNXH (400MHz, d6-DMSO): 10.18 (s, 1H), 8.3 (d, 1H), 8.04 (d, 2H), 7.7 (d, 2H), 7.13 (d, 1H), 7.06 (d, 1H), 4.05 (q, 3H), 3.95 (br, 2H), 2.96 (br, 2H), 2.08 (s, 3H), 1.9 (br, 2H), 1.4 ( q, 2H), 1.2 (t, 3H). MS (El) for C20H25N5O3: 384 (MH +). 4- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) piperidine-l-carboxylic acid 1,1-dimethylethyl ester: RMIS ^ H (400MHz, d6-DMSO): 10.18 (s, 1H), 8.3 (d, 1H), 8.05 (d, 2H), 7.7 (d, 2H), 7.2 (br, 1H), 7.1 (d, 1H), 3.92 (br, 3H), 2.9 ( br, 2H), 2.08 (s, 3H), 1.87 (br, 2H), 1.46-1.36 (m, 11H). MS (EI) for C22H29N503: 412 (MH +). N-. { 4- [2- (3, 5-diamino-lH-l, 2,4-triazol-1-yl) pyriraidin-4-yl] phenyl} acetamide: RMIS ^ H (400MHz, d6-DMSO): 10.28 (s, 1H), 8.7 (d, 1H), 8.16 (d, 2H), 7.78 (d, 2H), 7.7 (d, 1H), 7.58 ( s, 2H), 2.03 (s, 3H). MS (El) for C 14 H 14 N 80: 311 (MH +). N-. { 4- [2- ( { 5- [(4-ethylpiperazin-1-yl) carbonyl] pyridin-2-yl} amino) pyrimidin-4-yl] -henyl} acetamide: RMNXH (400MHz, d6-DMS0): 10.26 (s, 1H), 0.12 (s, 1H), 8.6 (d, 1H), 8.46 (d, 1H), 8.36 (d, 1H), 8.18 (d, 2H), 7.9 (dd, 1H), 7.77 (d, 2H), 7.54 (d, 1H), 2.46-2.32 (m, 6H), 2.1 (s, 3H), 1.0 (t, 3H). MS (El) for C24H27N702: 446 (MH +). N- (4- { 2- [(4-cyanophenyl) amino] pyrimidin-4-yl}. Phenyl) acetamide: NMR'H (400MHz, d6-DMSO): 10.24 (d, 2H), 8.6 ( d, 1H), 8.17 (d, 2H), 8.06 (d, 2H), 7.78 (d, 4H), 7.5 (d, 1H), 2.05 (s, 3H). MS (El) for C19H15N50: 330 (MH +). N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyridin-4-yl}. phenyl) acetamide: NMR'H (400MHZ, d6-DMSO): 10.14 (s, 1H), 8.82 (s, 1H), 8.12 (d, 1H), 7.72 (d, 2H), 7.62 (d, 2H), 7.53 (d, 2H), 6.97-6.92 (m, 2H), 6.9 (d, 2H), 3.74 (t, 4H), 3.02 (t, 4H), 2.07 (s, 3H). MS (El) for C 23 H 24 N 402: 389 (MH +). N- [4- (2- { [4- (4-ethylpiperazin-1-yl) phenyl] amino.} - 5-methylpyrimidin-4-yl) phenyl] -3- (methyloxy) propanamide: RM ^ H (400MHz, d6-DMSO): 10.18 (s, 1H), 9.25 (s, 1H), 8.3 (s, 1H), 7.75 (d, 2H), 7.63 (d, 2H), 7.61 (d, 2H), 6.86 (d, 2H), 3.64 (t, 2H), 3.25 (s, 3H), 3.03 (t, 4H), 2.6 (t, 2H), 2.38 (br, 2H), 2.2 (s, 3H), 1.03 (t, 3H). MS (El) for C72H34N602: 475 (MH +). 1- (4- (4- (4-Acetamidophenyl) pyrimidin-2-ylamino) phenyl) piperidin-4-ylcarbamate tert-butyl: RMNXH (400MHz, d6-DMSO): 10.21 (s, 1H), 9.38 (s) , br, 1H), 8.43 (s, 1H), 8.08 (m, 2H), 7.74 (m, 2H), 7.62 (m, 2H), 7.23 (m, 1H), 6.98 (m, 3H), 3.77 ( m, 2H), 3.63 (m, 2H), 2.09 (s, 3H), 1.80 (m, 2H), 1.49 (m, 2H), 1.30 (s, 9H). MS (El) for C28H34N603: 503 (MH +). 4- (4-aminophenyl) -N- (4- (4-aminopiperidin-1-yl) phenyl) pyrimidin-2-amine: NMR'H (400MHz, d6-DMSO): 9.19 (s, 1H), 8.3 ( m, 1H), 7.87 (m, 2H), 7.63 (m, 2H), 7.14 (m, 1H), 6.92 (m, 2H), 6.62 (m, 2H), 5.74 (m, 2H), 3.57 (m , 2H), 2.67 (m, 2H), 1.81 (m, 2H), 1.38 (ra, 2H). MS (El) for C21H24N6: 361 (MH +). N- (1- (4- (4- (4-acetamidophenyl) pyrimidin-2-ylamino) phenyl) piperidin-4-yl) -acetamide: RMNXH (400MHz, d6-DMSO): 10.26 (s, 1H), 9.34 (s, 1H), 8.43 (d, 1H), 8.1 (d, 2H), 7.85 ( d, 1H), 7.75 (d, 2H), 7.64 (d, 2H), 7.27 (d, 1H), 6.94 (d, 2H), 3.67 (ra, 1H), 3.55 (ra, 2H), 2.72 (t , 2H), 2.09 (s, 3H), 1.88-1.76 (m, 5H), 1.48 (m, 2H). MS (El) for C25H28N602: 445 (MH +). N- (4- (2- (4- (4- (cyclopropanecarbonyl) piperazin-1-yl) phenylamino) pyrimidin-4-yl) -phenyl) cyclopropanecarboxamide: NMR'H (400MHZ, d6-DMSO): 10.51 (s) , 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.87 (d, 2H), 7.69 (d, 2H), 7.28 (d, 1H), 6.97 (d, 2H), 3.82 (m, 2H), 3.61 (m, 2H), 3.25-2.99 (m, 4H), 2.04 (m, 1H), 1.83 (m, 1H), 0.89-0.68 (ra, 8H). MS (El) for C28H30N6O2: 483 (MH +). N- (4- (2- (4- (4-isobutyrylpiperazin-1-yl) phenylamine) pyrimidin-4-yl) phenyl) -tetrahydrofuran-2 -carboxamide: RMIS ^ H (400MHz, d6-DMSO): 9.94 ( s, 1H), 9.42 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.87 (d, 2H), 7.68 (d, 2H), 7.31 (d, 1H), 6.96 (d , 2H), 4.42 (m, 1H), 3.99 (m, 1H), 3.85 (m, 1H), 3.62 (m, 4H), 3.08 (ra, 2H), 3.02 (m, 2H), 2.92 (ra, 1H), 2.21 (m, 1H), 2.01 (m, 1H), 2.73 (m, 2H), 1.03 (d, 6H). MS (El) for C 29 H 34 N 603: 515 (MH +). N- (4- (2- (4- (4- (cyclobutanecarbonyl) piperazin-1-yl) phenylamine) pyrimidin-4-yl) phenyl) tetrahydrofuran-2-carboxamide: NMR'H (400MHZ, d6-DMSO): 9.94 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.87 (d, 2H), 7.68 (d, 2H), 7. 30 (d, 1H), 6.95 (d, 2H), 4.43 (m, 1H), 3.99 (m, 1H), 3.84 (m, 1H), 3.59 (m, 2H), 3.43 (m, 2H), 3.01 (m, 4H), 2.28-1.69 (m, 10H). MS (El) for C 30 H 34 N 6 O 3: 527 (MH +). N- (4- (2- (4- (4-pivaloylpiperazin-1-yl) phenylamine) pyrimidin-4-yl) phenyl) -tetrahydrofuran-2-carboxamide: NMR1! (400MHz, d6-DMSO): 9.95 (s, 1H), 9.42 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.88 (d, 2H), 7.69 (d, 2H), 7.30 (d, 1H), 6.95 (d, 2H), 4.43 (m, 1H), 4.0 (m, 1H), 3.84 (m, 1H), 3.7 (m, 4H), 3.04 (m, 4H), 2.22 (m, 1H), 2.02 ( m, 1H), 1.86 (m, 2H), 1.23 (s, 9H). MS (El) for C 30 H 36 N 6 O 3: 529 (MH +). N-cyclopropyl-4 - (2- (4-morpholinophenylamino) pyrimidin-4-yl) benzamide: NMRH (400MHz, d6-DMSO): 9.51 (s, br, 1H), 8.58 (s, br, 1H), 8.52 (d, 1H), 8.21 (d, 2H), 7.96 (d, 2H), 7.67 (d, 2H), 7.39 (d, 1H), 6.93 (d, 2H), 3.76 (m, 4H), 3.05 (m, 4H), 2.89 (m, 1H), 0.71 ( m, 2H), 0.60 (m, 2H). MS (EI): 416 (MH +). N- (2-methoxyethyl) -4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) benzamide: NMR'H (400MHZ, d6-DMSO): 9.51 (s, br, 1H), 8.68 (s, br, 1H), 8.52 (d, 1H), 8.23 (d, 2H), 8.00 (d, 2H), 7.67 (d, 2H), 7.40 (d, 1H), 6.94 (d, 2H), 3.75 (m, 4H), 3.47 (m, 4H), 3.28 (2, 3H), 3.05 ( m, 4H). MS (El): 434 (MH +). 2, 6-dichloro-n-. { 3- [(4-pyridin-3-ylpyrimidin-2-yl) amino] propyl} -benzamide: RMNXH (400MHz, d6-DMSO): 9.25 (br s, 1H), 8.68-8.66 (m, 2H), 8.37 (m, 2H), 7.49-7.47 (m, 3H), 7. 42-7.38 (m, 1H), 7.32 (m, 1H), 7.21-7.20 (m, 1H), 3.44 (m, 2H), 3.29 (m, 2H), 1.82 (m, 2H). MS (EI): 402.0 (MH +). 2,6-dichloro-n- (3 { [4- (4-methyl-3,4-dihydro-2h-l, 4-benzoxazin-7-yl) pyrimidin-2-yl] amino}. propyl) benzamide: RMIS ^ H (400MHz, d6-DMSO): 8.69 (t, 1H), 8.18 (d, 1H), 7.58 (dd, 1H), 7. 51-7.40 (m, 4H), 7.02-6.97 (m, 2H), 6.73 (d, 1H), 4.25-4.23 (m, 2H), 3.41 (m, 2H), 3.32-3.29 (m, 4H), 2.91 (s, 3H), 1.81 (t, 2H). MS (EI): 472.3 (MH +). 2,6-dichloro-n- (3 - { [4- (2, 3-dihydro-l, 4-benzodioxin-6-yl) -6-methyl-pyrimidin-2-yl] amino.}. Propyl ) benzamide: RMNXH (400MHz, ds-DMSO): 8.68 (t, 1H), 7.62-7.59 (m, 2H), 7.51-7.49 (m, 2H), 7.44-7.40 (m, 1H), 7.02 (t, 1H), 6.97-6.92 (m, 2H), 4.30-4.28 (m, 4H), 3.44-3.43 (m, 2H), 3.32-3.29 (m, 2H), 2.27 (s, 3H), 1.80 (t, 2H). MS (EI): 473.3 (MH +). N- (4- {2- [(3- {[[2,6-dichlorophenyl) carbonyl] amino} propyl) -amino] pyrimidin-4-yl} phenyl} morpholine- 4 - carboxamide: NMR'H (400MHz, d6-DMSO): 8.69 (m, 2H), 8.33 (d, 1H), 8.18 (m, 1H), 7.60 (m, 2H), 7.51-7.49 (m, 2H), 7.44-7.34 (m, 2H), 7.20 (m, 1H), 7.01 (d, 1H), 3.62-3.61 (m, 4H), 3.43 (m, 6H), 3.32 (m, 2H), 1.83 (m, 2H). MS (El): 529.1 (MH +). 2, 6-dichloro-n-. { 3- [(4- { 4- [(cyclopropylcarbonyl) amino] -phenyl} - pyrimidin-2-yl) amino] propyl} Benzamide: RMI ^ H (400MHz, d6-DMSO): 10.4 (s, 1H), 8.72 (t, 1H), 8.36-8.33 (m, 2H), 7.73 (m, 2H), 7.51-7.39 (m, 4H ), 7.24 (m, 1H), 7.03 (d, 1H), 3.45 (m, 2H), 3.33 (m, 4H), 1.84-1.78 (m, 2H), 0.81- 0. 78 (m, 3H). MS (El): 484.0 (MH +). N- (4- {2- [(3- {[[2,6-dichlorophenyl) carbonyl] amino} propyl) -araino] pyrimidin-4-yl} phenyl) thiophen-2 - carboxamide: NMR'H (400MHz, d6-DMS0): 10.4 (s, 1H), 8.72 (t, 1H), 8.44 (t, 1H), 8.37 (d, 1H), 8.05 (s, 1H), 7.90- 7.81 (m, 3H), 7.50-7.39 (m, 4H), 7.25-7.23 (m, 2H), 7.07 (d, 1H), 3.47 (m, 2H), 3.34 (m, 2H), 1.85 (m, 2H). MS (EI): 526.0 (MH +). 2, 6-dichloro-n- (3 - { [4 - (4 - { [N- (2-morpholin-4-ylethyl) glycyl] -amino} phenyl) pyrimidin-2-yl] amino.}. propyl) benzaraide: NMR'H (400MHz, d6-DMSO): 10.0 (br s, 1H), 8.72 (t, 1H), 8.35-8.32 (m, 2H), 7.82-7.75 (m, 2H ), 7.51-7.40 (m, 4H), 7.22 (s, 1H), 7.05 (d, 1H), 3.56 (m, 4H), 3.45 (m, 2H), 3.30 (m, 3H), 2.64 (m, 2H), 2.41-2.35 (m, 8H), 1.84 (br s, 2H). MS (EI): 586.1 (MH +). 1- (4- {2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -ethanone: NMRH (400MHz, d6-DMSO): 8.50 (d, 1H) , 8.26-8.24 (ra, 2H), 8.12-8.10 (m, 2H), 7.30 (s, 1H), 7.64-7.62 (m, 2H), 7.31 (d, 1H), 7.00-6.98 (m, 2H) , 3.82-3.80 (m, 4H), 3.12-3.10 (m, 4H), 2.64 (s, 3H). MS (EI): 375.1 (MH +). (le) -l- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. phenyl) ethanone oxime: NMRH (400MHz, d6-DMSO): 11.4 ( s, 1H), 9.82 (br s, 1H), 8.55 (d, 1H), 8.20 (d, 2H), 7.85-7.82 (m, 4H), 7.45 (d, 1H), 7.36 (br s, 1H) , 4.69 (br, 1H), 3.91 (m, 4H), 3.34 (m, 4H), 2.21 (s, 3H). MS (EI): 388.1 (MH-).

N-. { 4- [2- ( { 4- [4- (Cyclopropylcarbonyl) piperazin-1-yl] phenyl} - amino) pyrimidin-4-yl] phenyl} -2-phenylacetamide: RMI H (400MHz, d6-DMSO): 10.4 (s, 1H), 9.43 (br s, 1H), 8.42 (d, 1H), 8.10 (d, 2H), 7.75 (d, 2H) , 7.67 (d, 2H), 7.33-7.20 (m, 2H), 7.07 (s, 2H), 6.97-6.95 (m, 4H), 3.82 (ra, 4H), 3.67 (s, 2H), 3.03 (m , 4H), 2.07 (m, 1H), 0.75-0.69 (m, 4H). MS (EI): 533.2 (MH +). N- [3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl.} Araino) propyl] -2-broraobenzamide: RMIS ^ H (400MHz, d6-DMSO): 10.14 ppm ( s, 1H), 8.42 ppm (t, 1H), 8.29 ppm (d, 1H), 8.06 ppm (d, 1H), 7.70 ppm (d, 2H), 7.65 ppm (m, 1H), 7.39 ppm (m, 3H), 7.12 ppm (t, 1H), 7.07 ppm (d, 1H), 3.33 ppm (br.m, 2H), 3.31 ppm (m, 2H), 2.07 ppm (s, 3H), 1.81 ppm (ra, 2H); MS (El) for C22H22BrN502: 468 (MH +). N- [3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) propyl] -2-fluorobenzamide: NMRH (400MHz, d6-DMSO): 10.17 ppm (s, 1H), 8.37 ppm (t, 1H), 8.30 ppm (d, 1H), 8.06 ppm (d, 2H), 7.70 ppm (d, 2H), 7.61 ppm (m, 1H), 7.50 ppm (m, 1H) , 7.26 ppm (m, 2H), 7.16 ppm (t, 1H), 7.08 ppm (d, 1H), 3.41 ppm (br., 2H), 3.33 ppm (m, 2H), 2.08 ppm (s, 3H) 1.81 ppm (br.m, 2H); MS (El) for C22H22FN502: 408 (MH +). N- [3- ( { 4- [- (acetylamino) phenyl] pyrimidin-2-yl} araino) propyl] -2-chlorobenzamide: NMR! (400MHz, d6-DMSO): 10.14 ppm (s, 1H), 8.45 ppm (t, 1H), 8.28 ppm (d, 1H), 8.04 ppm (d, 2H), 7.68 ppm (d, 2H), 7.68 ppm (d, 2H), 7.47 ppm (m, 1H), 7.41 ppm (ra, 2H), 7.35 ppm (ra, 1H), 7.13 ppm (t, 1H), 7.06 ppm (d, 1H), 3.42 ppm (br.m, 2H), 3.29 ppm (m, 2H), 2.05 ppm (s, 3H), 1.78 ppm (br, 2H); MS (El) for C22H22BrN502: 468 (MH +). N- [4- (2- {[3- (morpholin-4-ylsulfonyl) phenyl] amino} pyrimidin-4-yl) phenyl] -acetamide: NMR! (400MHz, d6-DMSO): 10.23 ppm (s, 1H), 10.12 ppm (s, 1H), 8.74 ppm (s, 1H), 8.58 ppm (d, 1H), 8.21 ppm (d, 2H), 7.93 ppm (m, 1H), 7.76 ppm (d, 2H), 7.60 ppm (t, 1H), 7.47 ppm (d, 1H), 7.30 ppm (m, 1H), 3.64 ppm (m, 4H), 2.90 ppm (m , 4H), 2.10 ppm (s, 3H); MS (El) for C22H23N504S: 454 (MH +). N-. { 4- [2- ( { 3- [(cyclohexylmethyl) amino] phenyl} amino) pyrimidin-4-yl] phenyl} -acetamide: NMR1H (400MHz, d6-DMSO): 10.43 ppm (s, 1H), 9.32 ppm (s, 1H), 8.46 ppm (d, 1H), 8.13 ppm (d, 2H), 7.77 ppm (d, 2H) ), 7.30 ppm (d, 2H), 7.17 ppm (s, 1H), 6.94 ppm (m, 2H), 6.22 ppm (m, 1H), 5.56 ppm (t, 1H), 2.87 ppm (t, 2H), 2.09 ppm (s, 3H), 1.85 ppm (br d, 2H), 1.69 ppm (br m, 2H), 1.64 ppm (br m, 1H), 1.19 ppm (m, 3H), 0.94 ppm (ra, 2H); MS (El) for C 25 H 29 N 50: 416 (MH +). N- (4- {2- [(3- {[[5-bromo-2-fluorophenyl) methyl] amino} phenyl) amino] pyrimidin-4-yl} phenyl) acetamide: NMR1 !! (400MHz, d6-DMSO): 10.21 ppm (s, 1H), 9.37ppra (s, 1H), 8.45ppm (d, 1H), 8.12ppm (d, 2H), 7.74ppm (d, 2H), 7.55ppm (m, 1H), 7.47 ppm (m, 1H), 7.31 ppm (d, 1H), 7.20 ppm (m, 1H), 7.05 ppm (m, 1H), 7.00 ppm (t, 1H), 6.28 ppm (t , 1H), 6.22 ppm (m, 1H), 4.32 ppm (d, 2H), 2.09 ppm (s, 3H); MS (El) for C25H21BrFN50: 507 (MH +) - N- (4-. {2- 2- [(3- {[[2,5-dimethylphenyl) methyl] amino} phenyl) amino] pyrimidin-4 -yl.}. phenyl) acetamide: NMR1! (400MHz, d6-DMSO): 10.20 ppm (s, 1H), 9.33 ppm (s, 1H), 8.45 ppm (d, 1H), 8.13 ppm (d, 2H), 7.73 ppm (d, 2H), 7.30 ppm (d, 1H), 7.16 ppm (m, 2H), 7.06 ppm (d, 1H), 6.97 ppm (m, 3H), 6.23 ppm (m, 1H), 5.99 ppm (t, 1H), 4.17 ppm (d) , 2H), 2.28 ppm (s, 3H), 2.21 ppm (s, 3H), 2.08 ppm (s, 3H); MS (EI) C27H27N50: 438 (MH +). N- (4- {2- [(3,4-dimorpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) acetamide: R IS ^ H (400MHz, d6-DMSO): 10.22 ppm (s, 1H), 9.43 ppm (s, 1H), 8.46 ppm (d, 1H), 8.14 ppm (d, 2H), 7.74 ppm (d, 2H), 7.65 ppm (s, 1H), 7.34 ppm (m , 2H), 7.29ppm (d, 2H), 6.88ppm (d, 1H), 3.75ppm (m, 8H), 3.15ppm (brs, 4H), 3.05ppm (brs, 4H), 2.09ppm (s) , 3H); MS (El) for C 26 H 30 N 603: 475 (MH +). N-. { 4- [2- ( { 4- [4- (pyridin-3-ylcarbonyl) piperazin-1-yl] phenyl} amino) pyriraidin-4-yl] phenyl J-cyclopropanecarboxamide: NMR'H (400MHz, d6- DMSO): 10.47 ppm (s, 1H), 9.41 ppm (s, 1H), 8.67 ppm (m, 2H), 8.44 ppm (d, 1H), 8.11 ppm (d, 2H), 7.89 ppm (m, 1H) , 7.76 ppm (d, 2H), 7.69 ppm (d, 2H), 7.51 ppm (m, 1H), 7.28 ppm (d, 1H), 6.97 ppm (d, 2H), 3.80 ppm (s, 2H), 3.49 ppm (s, 2H), 3.13 ppm (br d, 4H), 1.83 ppm (m, 1H), 0.84 ppm (m, 4H); MS (El) for C 30 H 29 N 7 O 2: 520 (MH +).

N-. { 4- [2- ( { 4- [4- (2-methylpropanoyl) iperazin-1-yl] phenyl} amino) pyrimidin-4-yl] -phenyl} butanamide: RMN1 !! (400MHz, d6-DMSO): 10.16 ppm (s, 1H), 9.41 ppm (s, 1H), 8.44 ppm (d, 1H), 8.11 ppm (d, 2H), 7.77 ppm (d, 2H), 7.68 ppm (d, 2H), 7.28 ppm (d, 1H), 6.96 ppm (d, 2H), 3.63 ppm (m, 4H), 3.05 ppm (m, 4H), 2.92 ppm (m, 1H), 2.33 ppm (t , 1H), 1.63 ppm (m, 2H), 1.02 ppm (d, 6H), 0.93 ppm (t, 3H); MS (El) for C28H34N602: 487 (MH +). N-. { 4- [2- ( { 4- [4- (2, 2-dimethylpropanoyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} butanamide: RMIS ^ H (400MHz, d6-DMSO): 10.15 ppm (s, 1H), 9.41 ppm (s, 1H), 8.44 ppm (d, 1H), 8.11 ppm (d, 2H), 7.77 ppm (d, 2H), 7.68 ppm (d, 2H), 7.28 ppm (d, 1H), 6.95 ppm (d, 2H), 3.70 ppm (m, 4H), 3.05 ppm (m, 4H), 2.33 ppm (t, 2H) , 1.63 ppm (m, 2H), 1.23 ppm (s, 9H), 0.93 ppm (t, 3H); MS (El) for C 29 H 36 N 602: 501 (MH +). N-. { 4- [2- ( { 4- [4- (Cyclobutylcarbonyl) iperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} butanamide: RMN1 !! (400MHz, d6-DMSO): 10.28 ppm (s, 1H), 9.41 ppm (s, 1H), 8.44 ppm (d, 1H), 8.11 ppm (d, 2H), 7.79 ppm (d, 2H), 7.68 ppm (d, 2H), 7.28 ppm (d, 1H), 6.95 ppm (d, 2H), 3.59 ppm (m, 2H), 3.46 ppm (m, 2H), 3.40 ppm (m, 1H), 3.02 ppm (m , 4H), 2.35ppm (t, 2H), 2.14ppm (m, 4H), 1.91ppm (m, 1H), 1.75ppm (m, 1H), 1.63ppm (m, 2H), 0.93ppm (t, 3H) ); MS (El) for C29H34N602: 499 (MH +).

N- (4 - {2 - [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) pyridine-2-carboxamide: NMRH (400MHz, d6-DMSO): 10.91 (s) , 1H), 9.41 (s, 1H), 8.78 (d, 1H), 8.47 (d, 2H), 8.17 (m, 4H), 7.69 (m, 2H), 7.33 (d, 1H), 6.95 (d, 2H), 6.80 (s, 2H), 3.75 (m, 4H), 3.06 (m, 4H). MS (El) for C 26 H 24 N 602: 453.5 (MH +). 2-hydroxy-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -benzamide: NMR! (400MHz, d6-DMSO): 10.39 (s, 1H), 9.51 (s, 1H), 8.47 (s, 1H) 8.16 (d, 2H), 7.91 (d, 2H), 7.17 (m, 3H), 7.53 (t, 1H), 7.34 (s, 2H), 7.20 (d, 1H), 7.07 (m, 3H), 3.91 (m, 4H), 3.12 (m, 4H). MS (El) for C27H25N503: 468.5 (MH +). 3- (methyloxy) -N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -benzamide: R ^ H (400MHz, d6-DMSO ): 10.49 (s, 2H), 8.19 (m, 3H), 7.97 (m, 3H), 7.55 (m, 2H), 7.50 (m, 3H), 7.20 (dd, 3H), 3.86 (m, 8H) 3.77 (s, 3H). MS (El) for C28H27N503: 482.6 (MH +). 4- (methyloxy) -N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -benzamide: RM ^ H (400MHz, d6-DMSO ): 10.35 (s, 1H), 9.40 (s, 1H), 8.45 (s, 1H), 8.16 (d, 2H), 7.98 (m, 4H), 7.68 (d, 2H), 7.31 (d, 1H) , 7.09 (d, 2H), 6.94 (d, 2H), 3.83 (s, 3H), 3.75 (m, 4H), 3.05 (m, 4H). MS (EI) for C28H27N503: 482.6 (MH +). 4-chloro-N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -benzamide: RM ^ H (400MHz, d6-DMSO): . 58 (s, 1H), 9.41 (s, 1H), 8.46 (s, 1H), 8.17 (d, 2H), 8.01 (d, 2H), 7.95 (d, 2H), 7.66 (m, 4H), 7.32 (d, 1H), 6.94 (d, 2H), 3.75 (m, 4H), 3.05 (m, 4H). MS (El) for C27H24CIN502: 487.0 (MH +). (2R) -N- [4- (2- { [4- (4-ethylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] -tetrahydrofuran-2-carboxamide: RMI ^ H (400MHz, d6-DMSO): 9.95 (s, 1H), 9.38 (s, 1H), 8.45 (s, 1H), 8.12 (d, 2H), 7.89 (d, 2H), 7.66 (d, 2H) , 7.29 (s, 1H), 6.92 (d, 2H), 4.44 (t, 2H), 4.00 (m, 2H), 3.85 (m, 2H), 2.41 (m, 4H), 2.20 (m, 2H), 2.02 (m, 2H), 1.88 (m, 2H), 1.05 (m, 4H). MS (El) for C27H32N602: 473.6 (MH +). (2S) -N- [4- (2- { [4- (4-Ethylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] -tetrahydrofuran-2-carboxamide: NMR ' H (400MHZ, d6-DMSO): 9.94 (s, 1H), 9.38 (s, 1H), 8.44 (s, 1H), 8.12 (d, 2H), 7.87 (d, 2H), 7.65 (d, 2H) , 7.29 (s, 1H), 6.99 (d, 2H), 4.43 (m, 2H), 3.99 (m, 2H), 3.86 (m, 2H), 2.43 (m, 2H), 2.22 (m, 2H), 2.02 (m, 2H), 1.88 (m, 3H), 1.05 (m, 5H). MS (El) for C27H32N602: 473.6 (MH +). 1- (2-hydroxyethyl) -N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] irimidin-4-yl}. -phenyl) -L-prolinamide: NMRH (400MHz, d6-DMSO): 10.31 (s, 1H), 9.39 (s, 1H), 8.44 (d, 1H), 8.14 (d, 2H), 7.81 (d, 2H), 7.67 (d, 2H), 7.29 (d , 1H), 6.95 (d, 2H), 5.05 (s, br, 1H), 3.74 (m, 4H), 3.59 (m, 1H), 3.49 (m, 1H), 3.23 (m, 2H), 3.05 ( m, 4H), 2.77 (m, 1H), 2.63 (m, 1H), 2.41 (m, 1H), 2.16 (m, 1H), 1.80 (m, 3H). MS (El) for C27H32N603: 489. 6 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-ylphenyl) thiophen-2-carboxamide: RM ^ H (400MHz, d6-DMSO): 10.47 (s, 1H ), 9.45 (s, 1H), 8.47 (s, 1H), 8.17 (d, 2H), 8.08 (s, 1H), 7.92 (m, 3H), 7.70 (s, 2H), 7.32 (s, 1H) , 7.26 (t, 1H), 6.99 (s, 2H), 3.76 (m, 4H), 3.09 (m, 4H). MS (El) for C25H23N502S: 458.6 (MH +). N- [4- (2- {[[4- (4-ethylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] -tetrahydrofuran-3-carboxamide: RMI ^ H (400MHz, d6-DMSO): 10.31 (s, 1H), 9.37 (s, 1H), 8.44 (s, 1H), 8. 14 (m, 2H), 7.79 (d, 2H), 7.65 (d, 2H), 7.27 (d, 1H), 6.92 (d, 2H), 3.96 (t, 1H), 3.76 (m, 3H), 3.19 (m, 1H), 3.09 (m, 4H), 2.55 (m, 4H), 2.42 (m, 2H), 2.10 (m, 2H), 1.05 (t, 3H). MS (El) for C27H32N602: 473.6 (MH +). N- (4- { 2- [4- (4-nicotinoylpiperazin-1-yl) phenylamine] pyrimidin-4-yl}. Phenyl) -2-phenylacetamide: RM ^ H (400MHz, d6-DMSO): 8.8 (d, 2H), 8.40 (s, 1H), 8.05 (d, 2H), 7.80 (d, 1H), 7.60-7.2 (m, 10H), 7.1-6.90 (m, 5H), 3.80-3.60 ( m, 4H), 3.7 (s, 2H), 3.20-3.25 (m, 4H); MS (El) for C34H31N702: 570 (MH +). 3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) -N- (diphenylmethyl) benzamide: NMR! (400MHz, d6-DMSO): 10.22 (s, 1H), 9.78 (s, 1H), 9.24 (d, 1H), 8.52 (d, 1H), 8.39 (s br, 1H), 8.16 (d, 2H) , 7.95 (d, 1H), 7.75 (d, 2H), 7.53 (dt, 1H), 7.39-7.43 (m, 3H), 7.38 (d, 3H), 7.32-7.36 (m, 4H), 7. 24-7.28 (m, 2H), 6.43 (d, 1H), 2.10 (s, 3H). MS (El) for C32H27N502: 514.3 (MH +). N- [4- (2- { [4- (4-Methylpiperazin-1-yl) phenyl] amino.}. Pyrimidin-4-yl) phenyl] -acetaraide: RM ^ H (400MHz, d6-DMSO) : 10.24 (s, 1H), 9.35 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.65 (d, 2H), 7.26 (d, 1H), 6.93 (d, 2H), 3.07 (m, 4H), 2.45 (m, 4H), 2.22 (s, 3H), 2.09 (s, 3H). MS (EI) for C23H26N60: 403.4 (MH +). N-. { 4- [2- ( { 4- [4- (phenylcarbonyl) piperazin-1-yl) phenyl} amino) pyrimidin-4-yl] -phenyl} acetaraide: RMN1 !! (400MHz, d6-DMSO): 10.22 (s, 1H), 9.41 (s, 1H), 8.45 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.73-7.79 (m, 5H), 7.28 (d, 1H), 6.98 (d, 2H), 3.78 (m, 2H), 3.48 (ra, 2H), 3.15 (m, 2H), 3.07 (m, 2H) 2.09 (s, 3H). MS (El) for C29H28N602: 493.4 (MH +). N-. { 4- [2- (. {4- [4- (2-Cyclopentylacetyl) piperazin-1-yl] phenyl} araino) pyrimidin-4-yl] phenyl} acetamide: RMNXH (400MHz, d6-DMSO): 10.22 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.68 (d, 2H), 7.27 (s, 1H), 6.96 (d, 2H), 3.60 (ra, 4H), 3.04 (ra, 4H), 2.37 (d, 2H), 2.15 (m, 1H), 2.09 (s, 3H) ), 1.61-1.78 (m, 2H), 1.53-1.59 (m, 2H), 1.46-1.52 (m, 2H), 1.09-1.77 (m, 2H). MS (El) for C29H34N602: 499.3 (MH +). N-. { 4- [2- (. {4- [4- (cyclohexylcarbonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: RMN1 !! (400MHz, d6-DMSO): 10.22 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2?), 7.68 (d, 2?), 7.27 (d, 1?), 6.96 (d, 2H), 3.61 (m, 4H), 3.04 (m, 4H), 2.09 ( s, 3H), 1.62-1.70 (m, 6H), 1.26-1.38 (m, 5H). MS (El) for C 29 H 34 N 60: 499.2 (MH +). N- (4- {2 - [(4- {4- [(2-chlorophenyl) carbonyl] piperazin-1-yl} phenyl) amino] pyrimidin-4-yl} phenyl) acetamide : RMIS ^ H (400MHz, d6-DMSO): 10.21 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8. 10 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.56 (d, 1H), 7.41-7.49 (m, 3H), 7.27 (d, 1H), 6.96 (d, 2H) , 3.81 (m, 2H), 3.28 (m, 2H), 3.16 (m, 2H), 3.05 (m, 2H), 2.09 (s, 3H). MS (El) for C29H27CIN602: 527.8 (MH +). N- (4- { 2- [(4- {4- [(3-fluorophenyl) carbonyl] piperazin-1-yl} phenyl) amino] pyrimidin-4-yl} phenyl) acetamide : RMNXH (400MHz, d6-DMSO): 10.21 (s, 1H), 9.41 (s; 1H), 8.44 (d, 1H), 8. 11 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.53 (m, 1H), 7.27-7.35 (m, 4H), 6.97 (d, 2H), 3.77 (m, 2H) , 3.46 (m, 2H), 3. 16 (m, 2H), 3.07 (m, 2H), 2.09 (s, 3H). MS (El) for C29H27FN602: 511.5 (MH +). N- (4- {2 - [(4- { 4- [(3-fluoro-4-methylphenyl) carbonyl] piperazin-1-yl) phenyl) araino] -pyrimidin-4-yl} phenyl) acetamide: NMR'H (400MHz, d6-DMSO): 10.21 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.38 (m, 1H), 7.28 (d, 1H), 7.25 (d, 1H), 7.18 (d, 1H), 6.56 (d, 2H), 3.75 (m, 2H), 3.49 (m, 2H), 3.14 (m, 2H), 3.07 (m, 2H), 2.28 (d, 3H), 2.09 (s, 3H). MS (El) for C 30 H 29 FN 6 O 2: 525.7 (MH +). N- (4- {2 - [(4- { 4- [(3,4-dichlorophenyl) carbonyl] piperazin-l-il} phenyl) amino] -pyrimidin-4-yl} phenyl) acetamide: R 'H (400MHZ, d6-DMSO): 10.22 (s, 1H), 9.41 (s, 1H), 8.45 (s, 1H), 8.11 (d, 2H), 7.75 (m, 3H), 7.69 (d, 2H), 7.45 (dd, 1H), 7.28 (d, 1H), 6.97 (d, 2H), 3.77 (m, 2H), 3.47 (m, 2H), 3.16 (m, 2H), 3.07 (m, 2H), 2.09 (s, 3H). MS (El) for C29H26C12N602: 562.3 (MH +). N- (4- {2 - [(4. {4 - [(3,5-dichlorophenyl) carbonyl] piperazin-1-yl} phenyl) amino] -pyrimidin-4-yl}. phenyl) acetamide: NMR'H (400MHz, d6-DMSO): 10.21 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.75 (d, 2H), 7.75 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.54 (d, 2H), 7.28 (d, 1H), 6.97 (d, 2H), 3.77 (m, 2H), 3.45 (m, 2H), 3.17 (m, 2H), 3.08 (m, 2H), 2.09 (S, 3H). MS (El) for C 29 H 26 C 12 N 602: 562.6 (MH +). N- [4- (2- { [4- (4-. {[[3- (methyloxy) phenyl] carbonyl}. Piperazin-1-yl) phenyl] amino.} - pyrimidin-4-yl ) phenyl] acetamide: NMR'H (400MHz, d6-DMSO): 10.21 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.38 (t, 1H), 7.28 (d, 1H), 7.04 (dd, 1H), 6.95-6.99 (m, 4H), 3.79 (s, 3H), 3.77 (m, 2H), 3.47 (m , 2H), 3.15 (m, 2H), 3.06 (m, 2H), 2.09 (s, 3H). MS (El) for C30H30N6O3: 523.5 (MH +). N- (4- { 2- [(4- { 4- [(4-chlorophenyl) carbonyl] piperazin-1-yl}. Phenyl) amino] pyrimidin-4-yl} phenyl) acetamide : NMR1H (400MHz, d6-DMSO): 10.22 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H) ), 7.53 (d, 2H), 7.49 (d, 2H), 7.27 (d, 1H), 6.97 (d, 2H), 3.77 (m, 2H), 3.47 (m, 2H), 3.15 (m, 2?), 3.06 (m, 2?), 2.09 (s, 3?). MS (El) for C29H27C1N602: 527.8 (MH +). N- (4- { 2- [(4- { 4- [(4-methylphenyl) carbonyl] piperazin-1-yl}. Phenyl) amino] pyrimidin-4-yl} phenyl) acetamide : RMNXH (400MHz, d6-DMSO): 10.22 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H) ), 7.34 (d, 2H), 7.27 (m, 3H), 6.97 (d, 2H), 3.75 (m, 2H), 3.51 (m, 2H), 3.10 (m, 4H), 2.36 (s, 3H) 2.09 (s, 3H). MS (El) for C30H30N6O2: 507.3 (MH +). N- (4- { 2- [(4- { 4- [(l-methyl-lH-pyrrol-2-yl) carbonyl] piperazin-1-yl}. Phenyl) amino] -pyrimidine- 4-yl.} Phenyl) acetamide: NMR'H (400MHz, d6-DMSO): 10.21 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.27 (d, 1H), 6.98 (d, 2H), 6.92 (t, 1H), 6.37 (dd, 1H), 6.05 (dd, 1H), 3.76 (d. m, 4H), 3.69 (s, 3H), 3.11 (m, 4H), 2.09 (s, 3H). MS (El) for C28H29N702: 496.4 (MH +). N-. { 4- [2- (. {4- [4- (furan-2-ylcarbonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] -phenyl} acetamide: RM ^ H (400MHz, d6-DMSO): 10.22 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.87 (d, 1H), - 7.74 (d, 2H), 7.69 (d, 2H), 7.28 (d, 1H), 7.04 (d, 1H), 6.98 (d, 2H), 6.66 (dd, 1H), 3.82 (m, 4H), 3.14 (d, m, 4H), 2.09 (s, 3H). MS (El) for C27H2eN603: 483.3 (MH +). N- [4- (2- { [4- (4- { 2- [(4-fluorophenyl) oxy] acetyl}. Piperazin-1-yl) phenyl] amino.} - pyrimidin-4 - il) phenyl] acetamide: R N'H (400MHZ, d6-DMSO): 10.22 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 (d , 2H), 7.27 (d, 1H), 7.12 (m, 2H), 6.94-6.99 (m, 4H), 4.87 (s, 2H), 3.61 (m, 4H), 3.13 (m, 2H), 3.06 ( ra, 2H), 2.09 (s, 3H). MS (El) for C 30 H 29 FN 6 O 3: 541.4 (MH +). N- (4- {2 - [(4- { 4- [(3-methylphenyl) sulfonyl] piperazin-1-yl} phenyl) amino] irimidin-4-yl} phenyl) acetamide : MS (El) for C29H30N6O3S: 543.5 (MH +). N-. { 4- [2- ( { 4- [4- (phenylsulfonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] -phenyl} acetamide: MK ^ H (400MHz, d6-DMSO): 10.21 (s, 1H), 9.39 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.80 (m, 1H), 7.78 ( d, 1H), 7.74-7.77 (m, 2H), 7.70-7.73 (m, 2H), 7.67-7.69 (m, 1H), 7.65 (d, 2H), 7.27 (d, 1H), 6.90 (d, 2H), 3.15 (m, 4H), 3.02 (m, 4H), 2.09 (s, 3H). MS (El) for C 26 H 26 N 603 S2: 529.4 (MH +). N-. { 4- [2- (. {4- [4- (2-thienylsulfonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] -phenyl} acetamide: RMN1 !. (400MHz, d6-DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.10 (m, 3H), 7.74 (d, 2H), 7.70 (dd, 1H), 7.66 (d, 2H), 7.33 (dd, 1H), 7.27 (d, 1H), 6.93 (d, 2H), 3.19 (m, 4H), 3.07 (m, 4H), 2.09 (s, 3H). MS (El) for C26H26N603S2: 535.6 (MH +). N- (4- { 2- [(4- { 4- [(4-fluorophenyl) sulfonyl] piperazin-1-yl}. Phenyl) amino] pyrimidin-4-yl} phenyl) acetamide : RMIS ^ H (400MHz, d6-DMSO): 10.21 (s, 1H), 9.40 (s, 1H) 8.44 (d, 1H), 8.10 (d, 2H), 7.87 (m, 2H), 7.74 (d, 2H), 7.66 (d, 2H), 7.53 (m, 2H), 7.27 (d, 1H), 6.91 (d, 2H), 3.15 (m, 4H), 3.04 (m, 4H), 2.09 (s, 3H). MS (El) for C28H27FN603S: 547.4 (MH +). N- [4- (2- { [4- (4-. {[[4- (methyloxy) phenyl] sulfonyl}. Piperazin-1-yl) phenyl] amino.} - pyrimidin-4-yl ) phenyl] acetamide: NMR'H (400MHZ, d6-DMSO): MS (El) for C29H30N6O4S: 559.9 (MH +). N- (4- { 2- [(4- { 4- [(4-chlorophenyl) sulfonyl] iperazin-1-yl}. Phenyl) amino] pyrimidin-4-yl} phenyl) acetamide : RMIS ^ H (400MHz, d6-DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.72-7.82 (d, 6H), 7.66 (d, 2H) ), 7.27 (d, 1H), 6.91 (d, 2H), 3.15 (m, 4H), 3.05 (m, 4H), 2.09 (s, 3H). MS (E) for C28H27C1N603S: 563.9 (MH +). N- (4- { 2- [(4- {4- [(3-chlorophenyl) sulfonyl] piperazin-1-yl} phenyl) amino] pyrimidin-4-yl} phenyl) acetamide : RMIS ^ H (400MHz, d6-DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.85 (m, 1H), 7.76-7.81 (m, 2H) ), 7.73 (d, 3H), 7.66 (d, 2H), 7.27 (d, 1H), 6.91 (d, 2H), 3.14 (m, 4H), 3.09 (m, 4H), 2.09 (s, 3H). MS (El) for C28H27C1N603S: 5640 (MH +). N-. { 4- [2- (. {4- [4- (Biphenyl-4-ylsulfonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: NMR1H (400MHz, d6-DMSO): 10.21 (s, 1H), 9.39 (s, 1H), 8.43 (d, 1H), 8.08 (d, 2H), 7.96 (d, 2H), 7.86 (d, 2H), 7.77 (d, 2H), 7.73 (d, 2H), 7.66 (d, 2H), 7.51-7.55 (m, 2H), 7.46 (m, 1H), 7.26 (d, 1H), 6.91 (d , 2H), 3.18 (m, 4H), 3.08 (m, 4H), 2.09 (s, 3H). MS (El) for C34H32N603S: 605.8 (MH +).

N-. { 4- [2- ( { 4- [4- (naphthalen-1-ylsulfonyl) iperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: RMN1 !! (400MHz, d6-DMSO): 10.21 (s, 1H), 9.38 (s, 1H), 8.72 (d, 1H), 8.42 (d, 1H), 8.33 (d, 1H), 8.20 (dd, 1H), 8.14 (d, 1H), 8.09 (d, 2H), 7.74-7.79 (m, 1H), 7.73 (d, 2H), 7.62-7.70 (m, 2H), 7.64 (d, 2H), 7.26 (d, 1H), 6.88 (d, 2H), 3.21 (m, 4H), 3.09 (m, 4H), 2.09 (S, 3H). MS (El) for C 32 H 30 N 6 O 3 S: 579.6 (MH +). N- (4- {2 - [(3- { 4- [(2-chlorophenyl) methyl] piperazin-1-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) acetamide: NMR1! (400MHz, d6-DMSO): 10.21 (s, 1H), 9.46 (s, 1H), 8.49 (d, 1H), 8.14 (d, 2H), 7.74 (d, 2H), 7.64 (s br, 1H) , 7.36 (dd, 1H), 7.33 (d, 1H), 7.20-7.27 (m, 2H), 7.13 (t, 1H), 6.92-7.00 (m, 2H), 6.55 (d, 1H), 3.54 (s) , 2H), 3.16 (m, 4H), 2.57 (m, 4H), 2.09 (s, 3H). MS (El) for C29H29C1N60: 513.8 (MH +). N- [4- (2- {[[3- (4- {[[3- (methyloxy) phenyl] methyl} piperazin-1-yl) phenyl] amino} -pyrimidin-4-yl ) phenyl] acetamide: NMR1 !. (400MHz, d6-DMSO): 10.21 (s, 1H), 9.46 (s, 1H), 8.48 (d, 1H), 8.13 (d, 2H), 7.74 (d, 2H), 7.62 (s, 1H), 7.33 (d, 1H), 7.22-7.27 (m, 2H), 7.13 (t, 1H), 6.19 (m, 2H), 6.83 (d, 1H), 6.55 (d, 1H), 3.74 (s, 3H) , 3.52 (s, 2H), 3.16 (m, 4H), 2.55 (m, 4H), 2.09 (s, 3H). MS (El) for C 30 H 32 N 6 O 2: 509.8 (MH +). N-. { 4- [2- ( { 3- [4- (3-methylbutyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] -phenyl Jacetamide: NMRH (400MHz, d6-DMSO): 10.22 (s, 1H), 9.47 (s, 1H), 8.49 (d, 1H), 8.14 (d, 2H), 7.75 (d, 2?), 7.68 (s, 1?), 7.33 (d, 1H), 7.19 (d, 1H), 7.13 (t, 1H), 6.55 (d, 1H), 3.15 (m , 4H), 2.54 (m, 4H), 2.34 (t, 2H), 2.09 (s, 3H), 1.57-1.62 (m, 1H), 1.34-1.40 (m, 2H), 0.90 (d, 6H). MS (El) for C27H34N60: 459.7 (MH +). N-. { 4- [2- ( { 3- [4- (2,3-dihydro-l, 4-benzodioxin-6-ylmethyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl } acetamide: RM 'H (400MHZ, d6-DMSO): MS (El) for C31H32N603: 537.5 (MH +). N-. { 4- [2- (. {3- [4- (Cyclopropylmethyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} Acetamide: R N1H (400MHz, d6-DMSO): 10.22 (s, 1H), 9.47 (s, 1H), 8.49 (d, 1H), 8.14 (d, 2H), 7.75 (d, 2H), 7.69 (s) , 1H), 7.33 (d, 1H), 7.19 (d, 1H), 7.13 (t, 1H), 6.56 (d, 1H), 3.17 (m, 4H), 2.60 (m, 4H), 2.24 (d, 2H), 2.09 (s, 3H), 0.88 (m, 1H), 0.47-0.51 (m, 2H), 0.11-0.13 (m, 2H). MS (El) for C 26 H 30 N 6 O: 443.8 (MH +). N- (4- {2- [(3- {4- [3- (methylthio) propyl] piperazin-1-yl} phenyl) mino] pyrimidin-4-yl} phenyl) acetamide : RM ^ H (400MHz, d6-DMSO): 10.22 (s, 1H), 9.47 (s, 1H), 8.49 (d, 1H), 8.14 (d, 2H), 7.75 (d, 2H), 7.68 (s) , 1H), 7.33 (d, 1H), 7.20 (d, 1H), 7.14 (t, 1H), 6.56 (d, 1H), 3.15 (m, 4H), 2.56 (m, 4H), 2.41 (t, 4H), 2.09 (s, 3H), 2.06 (s, 3H), 1.71-1.78 (m, 2H). MS (El) for C 26 H 32 N 6 O: 477.5 (MH +). N- (4- { 2- [(3- { 4- [(4. {[[3- (dimethylamino) propyl] oxy} phenyl) methyl] piperazin-1-yl}. phenyl) amino] pyrimidin-4-yl.} phenyl) acetamide: NMR'H (400MHZ, d6-DMSO): 10.22 (s, 1H), 9.46 (s, 1H), 8.48 (d, 1H), 8.13 (d, 2H), 7.74 (d, 2H), 7.62 (s, 1H), 7.33 (d, 1H), 7.23 (m, 3H), 7.13 ( t, 1H), 6.88 (d, 2H), 6. 55 (d, 1H), 3.97 (t, 2H), 3.46 (s, 2H), 3.14 (m, 4H), 2.55 (m, 4H), 2.34 (t, 2H), 2.14 (s, 6H), 2.10 (s, 3H), 1.80-1.85 (m, 2H). MS (El) for C34H41N702: 580.5 (MH +). N-. { 4- [2- ( { 3- [4- ( { 3- [(trifluoromethyl) oxy] phenyl} methyl) piperazin-1-yl] phenyl} -amino) pyrimidin-4-yl ] phenyl } acetamide: RM ^ H (400MHz, d6-DMSO): 10.21 (s, 1H), 9.47 (s, 1H), 8.49 (d, 1H), 8.13 (d, 2H), 7.74 (d, 2H), 7.63 ( s, 1H), 7.47 (t, 1H), 7.41 (d, 1H), 7.33 (d, 2H), 7.22-7.28 (m, 2H), 7.13 (t, 1H), 6.56 (dd, 1H), 3.62 (s, 2H), 3.16 (m, 4H), 2. 56 (m, 4H), 2.09 (s, 3H). MS (El) for C 30 H 29 F 3 N 6 O 2: 563.7 (MH +). 4- [4- ( { 4- (4- (acetylamino) phenyl] pyrimidin-2-yl} amino) phenyl] -N-phenylpiperazine-l-carboxamide: RMIN H (400MHz, d6-DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.63 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.75 (d, 2H), 7.70 (d, 2H), 7.48 (d, 2H), 7.21-7.28 (m, 3H), 7.00 (d, 2H), 6.94 (t, 1H), 3.61 (m, 4H), 3.11 (m, 4H), 2.09 (s, 3H). MS (El) for C29H29N702: 508.6 (MH +). N- [4- (2- { [3- (4-Propanoylpiperazin-1-yl) phenyl] amino.} Pyrimidin-4-yl) phenyl] - acetamide: NMR1 !! (400MHz, d6-DMSO): 10.24 (s, 1H), 9.51 (s, 1H), 8.50 (d, 1H), 8.14 (d, 2H), 7.76 (d, 2H), 7.68 ( s, 1H), 7.34 (d, 1H), 7.26 (d, 1H), 7.16 (t, 1H), 6.59 (dd, 1H), 3.62 (m, 4H), 3.13 (m, 4H), 2. 35-2.39 (m, 2H), 2.09 (s, 3H), 1.02 (t, 3H). MS (El) for C25H28N602: 445.4 (MH +). N-. { 4- [2- ( { 3- [4- (phenylcarbonyl) piperazin-1-yl) phenyl} amino) pyrimidin-4-yl] -phenyl} acetamide: R N1 ^. (400MHz, d6-DMSO): 10.21 (s, 1H), 9.48 (s, 1H), 8.47 (d, 1H), 8.11 (d, 2H), 7.72 (d, 2H), 7.63 (s, 1H), 7.41-7.47 (m, 5H), 7.31 (d, 1H), 7.26 (d, 1H), 7.14 (t, 1H), 6.56 (dd, 1H), 3.78 (m, 2H), 3.48 (m, 2H) , 3.27 (m, 2H), 3.12 (m, 2H), 2.08 (s, 3H). MS (El) for C29H28N602: 493.7 (MH +). N-. { 4- [2- (. {3- [4- (2-phenylacetyl) piperazin-1-yl] phenyl} amino) irimidin-4-yl] -phenyl} acetamide: RMIS ^ H (400MHz, d5-DMSO): 10.25 (s, 1H), 9.50 (s, 1H), 8.49 (d, 1H), 8.13 (d, 2H), 7.76 (d, 2H), 7.63 ( s, 1H), 7.33 (d, 1H), 7.30 (d, 2H), 7.26 (m, 3H), 7.22 (m, 1H), 7.15 (t, 1H), 6.56 (dd, 1H), 3.79 (s) , 2H), 3.66 (m, 4H), 3.11 (m, 2H), 3.05 (m, 2H), 2.09 (s, 3H). MS (El) for C30H30N6O2: 507.7 (MH +). N-. { 4- [2- ( { 3- [4- (cyclopentylcarbonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: RMN1! -. (400MHz, d6-DMSO): 10.24 (s, 1H), 9.52 (s, 1H), 8.49 (d, 1H), 8.14 (d, 2H), 7.76 (d, 2H), 7.71 (s, 1H), 7.34 (d, 1H), 7.24 (d, 1H), 7.16 (t, 1H), 6.59 (dd, 1H), 3.66 (m, 4H), 3.13 (m, 4H), 3.00-3.07 (m, 1H) , 2.09 (s, 3H), 1.80 (m, 2H), 1.51-1.71 (ra, 6H). MS (El) for C28H32N602: 485.7 (MH +). N-. { 4- [2- ( { 3- [4- (2-pyridin-3-ylacetyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] -phenyl} acetamide: RMN1 !! (400MHz, d6-DMSO): 10.24 (s, 1H), 9.51 (s, 1H), 8.50 (d, 1H), 8.43-8.46 (m, 2H), 8.14 (d, 2H), 7.76 (d, 2H) ), 7.63-7.67 (m, 2H), 7.32-7.35 (m, 2H), 7.26 (d, 1H), 7.16 (t, 1H), 6.59 (dd, 1H), 3.84 (s, 2H), 3.73 ( m, 2H), 3.66 (m, 2H), 3.15 (m, 4H), 2.08 (s, 3H). MS (El) for C29H29N702: 508.4 (MH +). N-. { 4- [2- (. {3- [4- (2-Cyclopentylacetyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: RMIS ^ H (400MHz, d6-DMSO): 10.24 (s, 1H), 9.51 (s, 1H), 8.50 (d, 1H), 8.14 (d, 2H), 7.76 (d, 2H), 7.70 ( s, 1H), 7.34 (d, 1H), 7.25 (d, 1H), 7.16 (t, 1H), 6.59 (dd, 1H), 3.61 (m, 4H), 3.12 (m, 4H), 2.39 (d , 2H), 2.11-2.19 (m, 1H), 2.09 (s, 3H), 1.72-7.78 (m, 2H), 1.52-1.59 (m, 2H), 1.47-1.52 (m, 2H), 1.09-1.18 (ra, 2H). MS (El) for C29H34N502: 499.4 (MH +). N- (4- {2 - [(3- { 4- [(2-chlorophenyl) acetamide: RMIS ^ H (400MHz, d6-DMSO): 10.24 (s, 1H), 9.50 (s, 1H ), 8.49 (d, 1H), 8. 13 (d, 2H), 7.74 (d, 2H), 7.63 (s, 1H), 7.56 (d, 1H), 7.42-7.50 (m, 3H), 7.33 (d, 1H), 7.29 (d, 1H) , 7.16 (t, 1H), 6.59 (dd, 1H), 3.79 (m, 2H), 3.50 (m, 2H), 3.24 (m, 2H), 3.15 (m, 2H), 2.09 (s, 3H). MS (El) for C29H27C1N602: 527.9 (MH +). N- (4- { 2- [(3- { 4- [(4-chlorophenyl) carbonyl] piperazin-1-yl}. Phenyl) amino] irimidin-4-yl} phenyl) acetamide : RMNXH (400MHz, d6-DMSO): 10.23 (s, 1H), 9.51 (s, 1H), 8.49 (d, 1H), 8. 14 (d, 2H), 7.74 (d, 2H), 7.66 (s, 1H), 7.53 (d, 2H), 7.49 (d, 2H), 7.34 (d, 1H), 7.27 (d, 1H), 7.17 (t, 1H), 6.59 (dd, 1H), 3.79 (m, 2H), 3.50 (ra, 2H), 3.24 (m, 2H), 3.15 (m, 2H), 2.09 (s, 3H). MS (El) for C29H27ClN602: 528.1 (MH +). N- (4- {2- [(3- {4- [(3,4-dichlorophenyl) carbonyl] piperazin-1-yl}. Phenyl) amino] -pyrimidin-4-yl}. phenyl) acetamide: RMNXH (400MHz, d6-DMS0): 10.23 (s, 1H), 9.51 (s, 1H), 8.49 (d, 1H), 8.13 (d, 2H), 7.74 (m, 4H), 7.60 ( s, 1H), 7.46 (dd, 1H), 7.34 (d, 1H), 7.27 (d, 1H), 7.17 (t, 1H), 6.59 (dd, 1H), 3.79 (m, 2H), 3.50 (m , 2H), 3.24 (m, 2H), 3.15 (m, 2H), 2.09 (S, 3H). MS (El) for C 29 H 26 C 12 N 602: 562.7 (MH +). N- (4- {2 - [(3- {4- [(l-methyl-lH-pyrrol-2-yl) carbonyl] piperazin-1-yl} phenyl) amino] -pyrimidine- 4-yl. Phenyl) acetamide: NMR'H (400MHZ, d6-DMSO): 10.23 (s, 1H), 9.51 (s, 1H), 8.50 (d, 1H), 8.14 (d, 2H), 7.75 (d, 2H), 7.67 (s, 1H), 7.34 (d, 1H), 7.28 (d, 1H), 7.17 (t, 1H), 6.92 (m, 1H), 6.49 (dd, 1H), 6.37 ( dd, 1H), 6.05 (m, 1H), 3.80 (m, 4H), 3.69 (s, 3H), 3.19 (m, 4H), 2.09 (s, 3H). MS (El) for C28H29N702: 450.7 (MH +). N2, N2-dimethyl-N- [4- (2-. {[[3- (methyloxy) -4-morpholin-4-ylphenyl] amino} pyrimidin-4-yl) phenyl] glycinamide: NMRH (400MHz, d6-DMSO): 10.0 (s, 1H), 9.48 (s, 1H), 8.48 (d, 1H), 8. 15 (d, 2H), 7.84 (d, 2H), 7.65 (s, 1H), 7.29-7.33 (m, 2H), 6.86 (d, 1H), 3.81 (s, 3H), 3.72 (m, 4H) , 3.11 (s, 2H), 2.92 (m, 4H), 2.29 (s, 6H). MS (El) for C 25 H 30 N 6 O 3: 463.8 (MH +). 3- (methyloxy) -N- [4- (2. {[[3- (methyloxy) -4-morpholin-4-ylphenyl] amino} pyrimidin-4-yl) phenyl] propanamide RM XH (400MHz, d6-DMSO): 10.21 (s, 1H), 9.46 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.74 (d, 2H), 7.64 (s, 1H), 7.26-7.30 (m, 2H), 6.84 (d, 1H), 3.79 (s, 3H), 3.70 (m, 4H), 3.61 (t, 2H), 3.23 (s, 3H), 2.89 (m, 4H), 2.57 ( t, 2H). MS (El) for C25H29N504: 464.8 (MH +). N- (4-. {2 -.. [.... (4- {4- [(2-chlorophenyl) sulfonyl] piperazin-l-yl} phenyl) amino] pyrimidin-4-yl}. Phenyl) acetamide : RMIN H (400MHz, d6-DMSO): 10.19 (s, 1H), 9.38 (s, 1H), 8.42 (d, 1H), 8.08 (d, 2H), 8.00 (dd, 1H), 7.68-7.74 ( m, 4H), 7.65 (d, 2H), 7.58 (m, 1H), 7.25 (d, 1H), 6.91 (d, 2H), 3.15 (m, 4H), 3.02 (m, 4H), 2.07 (s) , 3H). MS (El) for C28H27C1N603S: 563.9 (MH +). N-. { 4- [2- (. {3- [4- (Cyclopropylcarbonyl) piperazin-1-yl] phenyl} amino) irimidin-4-yl] phenyl} acetamide: RMNXH (400MHz, d6-DMSO): 10.24 (s, 1H), 9.52 (s, 1H), 8.50 (d, 1H), 8.14 (d, 2H), 7.76 (d, 2H), 7.71 (s, 1H), 7.34 (d, 1H), 7.25 (d, 1H), 7.17 (t, 1H), 6.60 (dd, 1H), 3.56 (m, 2H), 3.65 (m, 2H), 3.20 (m, 2H) ), 3.13 (m, 2H), 2.09 (s, 3H), 2.04 (m, 1H), 0.77-0.49 (m, 4H). MS (El) for C 26 H 28 N 602: 457.5 (MH +). N-. { 4- [2- (. {3- [4- (2-Cyclopropylacetyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: NMR1H (400MHz, d6-DMSO): 10.24 (s, 1H), 9.51 (s, 1H), 8.50 (d, 1H), 8.14 (d, 2H), 7.76 (d, 2H), 7.70 (s, 1H), 7.34 (d, 1H), 7.25 (d, 1H), 7.16 (t, 1H), 6.58 (dd, 1H), 3.62 (m, 4H), 3.13 (m, 4H), 2.32 (d, 2H ), 2.09 (s, 3H), 0.99 (m, 1H), 0.45 (m, 2H), 0.14 (m, 2H). MS (El) for C27H30N6O2: 477.5 (MH +). N- [4- (2- { [3- (4-. {[[3- (methyloxy) phenyl] carbonyl}. Piperazin-1-yl) phenyl] amino.} - pyrimidin-4-yl ) phenyl] acetamide: RMNXH (400MHZ, d6-DMSO): 10.22 (s, 1H), 9.48 (s, 1H), 8.47 (d, 1H), 9.11 (d, 2H), 7.72 (d, 2H), 7.62 (s, 1H), 7.35 (t, 1H), 7.31 (d, 1H), 7.26 (d, 1H), 7.14 (t, 1H), 7.01 (m, 1H), 6.97 (m, 2H), 6.56 (dd, 1H), 3.76 (s, 3H ), 3.73 (m, 2H), 3.47 (ra, 2H), 3.14 (m, 4H), 2.07 (s, 3H). MS (El) for C30H30N6O3: 523.7 (MH +). N-. { 4- [2- ( { 4- [4- (2, 2-dimethylpropanoyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: RMN1.! (400MHz, d6-DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.27 (d, 1H), 6.96 (d, 2H), 3.70 (m, 4H), 3.05 (m, 4H), 2.09 (s, 3H), 1.23 (s, 9H). MS (El) for C27H32N602: 473.4 (MH +). 2, 6-dichloro-N- (3- (4- (2,3-dihydrobenzo [b] [1, 4] dioxin-6-yl) pyrimidin-2-ylamino) propyl) benzamide: (400MHz, CDC13): 8.16 (br, 1H), 8.0-8.8 (m, 2H), 7.26 (m, 4H), 6.82 ( d, 1H), 6.75 (br, 1H), 5.4 (t, 1H), 4.29 (m, 4H), 3.68 (m, 2H), 3.56 (m, 2H), 1.92 (m, 2H). MS (El): 459 (MH +). 1- (4- (4- (4-Acetamidophenyl) pyrimidin-2-ylamino) phenyl) piperidine-3-carboxylic acid: MS (El) for C24H25N5032: 432 (MH +). Methyl (2- (4- (2- (4-morpholinophenylamino) irimidin-4-yl) phenylamine) -2-oxoethyl) tert-butyl carbamate: MS (El) for C28H34N604: 519 (MH +). 4- (2- (4- (4-ethylpiperazin-1-yl) phenylamine) pyrimidin-4-yl) phenyl-tert-butyl carbamate: MS (El) for C27H34N602: 475 (MH +). 2- (dimethylamino) -N- (4- (2- (4- (4-ethylpiperazin-1-yl) phenylamine) pyrimidin-4-yl) phenyl) acetamide: NMR (400MHz, d6-DMSO): 10.0 (s) , 1H), 9.37 (s, 1H), 8.41 (d, 1H), 8.11 (d, 1H), 7.85 (d, 2H), 7.63 (f, 2H), 7.46 (d, 1H), 7.25 (d, 1H), 6.83-6.92 (m, 2H), 3.11 (m, 4H), 2.51 (m, 4H), 2.37 (q, 2H), 2.36 (s, 6H), 2.26 (s, 2H), 1.05 (t , 3H). MS (El): 460 (MH +). 4- (4-Aminophenyl) -N- (4- (4-ethylpiperazin-1-yl) phenyl) pyrimidin-2 -amine: MS (E) for C 22 H 26 N 6: 375 (MH +). 1- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenylamine) -l-oxo-3-phenylpropan-2-ylcarbamate (S) -ter-butyl ester: MS (El) for C34H38N604: 595 (MH +). 1- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenylamine) -l-oxo-3-phenylpropan-2-ylcarbamate (R) -ter-butyl ester: MS (El) for C34H38N604: 595 (MH +). (R) -2-amino-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) -3-phenylpropanamide: NMR (400MHz, d6-DMSO): 11.40 (s, 1H), 10.20 (s, 1H), 8.43-8.62 (m, 3H), 8.17 (d, 2H), 7.91 (d, 2H), 7.89 (d, 2H), 7.84 (m, 2H), 7.20-7.38 (m, 4H), 4.10 (m, 4H), 3.63 (m, 2H), 3.40-3.57 (m, 6H), 3.20 (m, 1H), MS (El): 495 (MH +).

(S) -2-amino-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) -3-phenylpropanamide: NMR (400MHz, d6-DMSO): 11.40 (s, 1H), 10.20 (s, 1H), 8.43-8.62 (m, 3H), 8.17 (d, 2H), 7.91 (d, 2H), 7.89 (d, 2H), 7.84 (m, 2H), 7.20-7.38 (m, 4H), 4.10 (m, 4H), 3.63 (m, 2H), 3.40-3.57 (m, 6H), 3.20 (m, 1H), MS (EI): 495 (MH +). (S) -2-amino-N- (4- (2- (4- (4-ethylpiperazin-1-yl) phenylamine) pyrimidin-4-yl) phenyl) -3-methylbutanamide: MS (EI) for C27H35N70: 474 (MH +). (R) -2-amino-N- (4- (2- (4- (4-ethylpiperazin-1-yl) phenylamine) pyrimidin-4-yl) phenyl) -3-methylbutanamide: MS (El) for C27H3SN70: 474 (MH +). l-Ethyl-3- (4- (2- (3-methoxy-4-morpholinophenylamino) pyrimidin-4-yl) phenyl) urea: NMR (400MHz, d6-DMSO): 9.41 (s, 1H), 8.75 (s) , 1H), 8.42 (d, 1H), 8.10 (d, 2H), 7.64 (s, 1H), 7.54 (d, 2H), 7.26 (ra, 2H), 6.85 (d, 1H), 6.21 (br, 1H), 3.79 (s, 3H), 3.70 (m, 4H), 3.11 (q, 2H), 2.89 (ra, 4H), 1.06 (t, 3H). MS (El): 449 (MH +). (R) -N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) piperidine-2-carboxamide: NMR (400MHz, d6-DMSO): 11.36 (s, 1H), 10.0 (s) , 1H), 9.4 (d, 1H), 8.84 (m, 1H), 8.57 (d, 1H), 8.2 (d, 2H), 7.82 (m, 4H), 7.6 (br, 1H), 7.4 (d, 1H), 4.0 (m, 4H), 3.82 (m, 1H), 3.42 (m, 4H), 3.23 (m, 1H), 2.94 (m, 1H), 2.3 (ra, 1H), 1.82 (m, 1H) ), 1.54-1.92 (ra, 4H). MS (El): 458 (MH +).

N- [4- (2- { [4- (4-ethylpiperazin-1-yl) phenyl] amino.} - 5-methylpyrimidin-4-yl) phenyl] -acetamide: RMIS ^ H (400MHz, d6 -DMSO): 10.1 (s, 1H), 9.23 (s, 1H), 8.31 (s, 1H), 7.6-7.7 (m, 6H), 6.87 (d, 2H), 3.04 (m, 4H), 2.48 ( m, 4H), 3.05 (m, 4H), 2.36 (q, 2H), 2.2 (s, 3H), 2.08 (s, 3H), 1.03 (s, 3H). MS (EI): 431 (MH +). 4-. { 4 - [(4- { 4- [(?,? - dimethylglycyl) amino] phenyl} pyrimidin-2-yl) amino] phenyl} -N-ethylpiperazine-1-carboxamide: NMR1H (400MHz, d6-DMSO): 10.0 (s, 1H), 9.4 (s, 1H), 8.43 (d, 1H), 8.12 (d, 2H), 7.82 (d, 2H), 7.68 (d, 2H), 7.27 (d, 1H), 6.97 (d, 2H), 3.42 (m, 4H), 3.12 (s, 2H), 3.06 (q, 2H), 3.02 (m, 4H), 2.3 (s, 6H), 1.11 (t, 3H). MS (EI): 503 (MH +). N-. { 4- [2- ( { 4- [4- (2, 2-dimethylpropanoyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} -N2, N2-dimethylglycinamide: RMK ^ H (400MHz, d6-DMSO): 10.0 (s, 1H), 9.4 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.83 (d, 2H), 7.69 (d, 2H), 7.29 (d, 1H), 6.96 (d, 2H), 3.7 (m, 4H), 3.16 (s, 2H), 3.05 (m, 4H), 2.31 (s, 6H) ), 1.2 (s, 9H). MS (EI): 516 (MH +). N-. { 4- [2- (. {4- [4- (Cyclobutylcarbonyl) piperazin-1-yl] phenyl} amino) pyriraidin-4-yl] phenyl} -N2, N2-dimethylglycinamide: RM ^ H (400MHz, d6-DMSO): 10.0 (s, 1H), 9.4 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.84 (d, 2H), 7.67 (d, 2H), 7.30 (d, 1H), 6.95 (d, 2H), 3.56-3.62 (m, 4H), 3.1 (s, 2H), 2.99-3.05 (m, 4H), 2.31 (S, 6?), 1.8-2.25 (m, 7?). MS (El): 514 (MH +). N2, N2-dimethyl-N-. { 4- [2- (. {4- [4- (2-methylpropanoyl) piperazin-1-yl] phenyl} amino) -pyrimidin-4-yl] phenyl} glycinamide: RMNXH (400MHZ, d6-DMSO): 10.0 (s, 1H), 9.4 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.84 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.95 (d, 2H), 3.58-3.67 (m, 4H), 3.11 (s, 2H), 2.99-3.10 (m, 4H), 2.92 (m, 1H), 2.29 (s, 6H), 1.02 (d, 6H). MS (El): 502 (MH +). N-. { 4- [2- ( { 4- [4- (Cyclopropylcarbonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} -N2, N2-dimethylglycinamide: RMIS ^ H (400MHz, d6-DMSO): 10.0 (s, 1H), 9.4 (s, 1H), 8.43 (d, 1H), 8.14 (d, 2H), 7.68 (d, 2H), 7.26 (d, 1H), 6.97 (d, 2H), 3.8 (m, 2H), 3.6 (m, 2H), 3.18 (m, 4H), 3.07 (m, 2H), 2.28 (s, 6H), 2.02 ( m, 1H), 0.78 (m, 4H). MS (El): 501 (MH +). N- [4- (2- {[4- (4-D-alanylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl] phenyl] -N2,2-dimethylglycinamide: R I ^ H (400MHz, d6-DMSO): 10.0 (s, 1H), 9.4 (s, 1H), 8.55 (d, 1H), 8.23 (d, 2H), 7.84 (d, 2H), 7.71 (d, 2H), 7.28 (d, 1H), 6.97 (d, 2H), 3.8 (m, 2H), 3.84 (q, 1H), 3.62 (m, 4H), 3.12 (s, 2H), 3.05 (m, 4H), 2.31 (s, 6H), 1.12 ( d, 3H). MS (El): 504 (MH +). N- [4- (2- {[4- (4-L-alanylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl] phenyl] -N2,2-dimethylglycinamide: RMIS ^ H ( 400MHz, d6-DMSO): 10.0 (s, 1H), 9.4 (s, 1H), 8.45 (d, 1H), 8. 12 (d, 2H), 7.84 (d, 2H), 7.69 (d, 2H), 7.28 (d, 1H), 6.97 (d, 2H), 3.8 (m, 2H), 3.84 (q, 1H), 3.62 (m, 4H), 3.12 (s, 2H), 3.05 (m, 4H), 2.31 (s, 6H), 1.12 (d, 3H). MS (EI): 504 (MH +). 2,6-dichloro-N- (3- {[4- (4-fluorophenyl) pyrimidin-2-yl] amino} propyl) benzamide: NMR'H (400MHZ, d6-DMSO): 8.705 (t , 1H), 8.354 (d, 1H), 7.136 (br s, 2H), 7.515 (d, 2H), 7.5 (d, 2H), 7.425 (m, 1H), 7.34 (t, 2H), 7.26 (t , 1H), 7.14 (d, 1H), 3.456 (br s, 2H), 3.355 (m, 2H), 1827 (t, 2H). MS (EI): 420.1 (MH +). N- (4-. {-2- [( { L- [(2,6-dichlorophenyl) carbonyl] azetidin-3-yl} methyl) amino] pyriraidin-4-yl} phenyl) acetamide : R IN ^ H (400MHz, DMSO): 11,031 (s, 1H), 8,344 (d, 1H), 8,137 (d, 2H), 7,839 (d, 2H), 7,621 (d, 2H), 7,531 (m, 1H), 7.45 (t, 1H), 7.146 (d, 1H), 4.157 (m, 1H), 3.867 (t, 2H), 3.626-3.556 (m, 3H), 2.842 (br s, 1H), 1.725 ( s, 3H). MS (EI) for C23H21C12N502: 470.2 (MH +). N- (4- { 2- [(3-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) acetamide: NMR'H (400MHz, DMSO): 10.22 (s, 1H), 9.511 (s, 1H), 8.504 (d, 1H), 8.154 (d, 2H), 7.76 (d, 3H), 7.343 (d, 1H), 7.215-7.153 (m, 2H), 6.584 (d, 1H) , 3.775 (t, 4H), 3.14 (t, 4H), 2.094 (s, 3H). MS (El) for C22H23N502: 390.1 (MH +). N- [3- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) cyclohexyl] -2,6-dichloro-benzamide: RMIS ^ H (400MHz, MeOD): 8.25 (d, 1H), 8.08 (d, 2H), 7.7 (d, 2H), 7.45-7.35 (m, 3H), 7.05 (d, 1H), 4.05 (m, 2H), 2.5 (m , 1H), 2.1 (m, 3H), 2.05 (s, 3H), 1.5 (m, 1H), 1.3 (m, 3H). MS (El) for C25H25C12N502: 498.3 (MH +). N-. { 4- [2- ( { [4- (4-Methylpiperazin-1-yl) phenyl] methyl} amino) pyrimidin-4-yl] phenyl} -acetaraide: RMN1 !! (400MHz, DMSO): 10,192 (s, 1H), 8,294 (d, 1H), 8,062 (d, 2H), 7,713 (d, 2H), 7,653 (t, 1H), 7,285 (br d, 2H), 7.09 (d, 1 H), 6,953 (d, 2 H), 4,485 (d, 2 H), 3.3 (br s, 8 H), 2,827 (s, 3 H), 2,079 (s, 3 H). MS (El) for C24H28N60: 417.4 (MH +). N- [4- ( { 4- [4- (acetylaraine) phenyl] pyrimidin-2-yl} amino) phenyl] -2,6-dichloro-benzamide: R NXH (400MHz, DMSO): 10.66 ( s, 1H), 10,324 (s, 1H), 9,638 (s, 1H), 8,501 (d, 1H), 8,144 (d, 2H), 7,782 (m, 4H), 7.65 (d, 2H), 7,597 (d , 2H), 7.498 (m, 1H), 7.349 (d, 1H), 2.11 (s, 3H). MS (El) for C 25 H 19 C 12 N 502: 492 (MH +). N-. { 4- [2- (piperidin-4-ylamino) pyrimidin-4-yl] phenyl} acetamide: R 'H (400MHZ, DMSO): 10,184 (s, 1H), 8,288 (d, 1H), 8,044 (d, 2H), 7.71 (d, 2H), 7,049 (t, 2H), 3.8 (br s , 1H), 2,962 (d, 2H), 2,077 (s, 3H), 1,838 (br d, 2H), 1,372-1,334 (m, 2H). MS (El) for C17H21NsO: 312.3 (MH +). N-. { 4- [2- (. {L - [(2,6-dichlorophenyl) carbonyl] piperidin-4-yl} amino) pyrimidin-4-yl] -phenyl} acetamide: RMN1 !. (400MHz, DMSO): 10,171 (s, 1H), 8,312 (d, 1H), 8,067 (d, 2H), 7.71 (d, 2H), 7,584-7,546 (m, 2H), 7,461 (t, 1H), 7.246 (d, 1H), 7. 093 (d, 1H), 4.468 (m, 1H), 4.1 (br s, 1H), 3.25-3.05 (m, 2H), 2.077 (s, 3H), 2.05 (m, 1H), 1.915 (br S, 1H), 1.58-1.532 (m, 2H). MS (El) for C 24 H 23 C 12 N 502: 485.3 (MH +). N-. { 4- [2- ( { 4- [(2-hydroxyethyl) oxy] phenyl} amino) pyrimidin-4-yl] phenyl} acetamide: RM ^ H (400MHz, DMSO): 10,211 (s, 1H), 9.43 (s, 1H), 8.455 (d, 1H), 8.12 (d, 2H), 7.754-7.69 (m, 4H), 7.292 ( d, 1H), 6.93 (m, 2H), 4.865 (t, 1H), 3.97 (t, 2H), 3.715 (q, 2H), 2.09 (s, 3H). MS (El) for C20H20N4O3: 365.1 (MH +). 1- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -3-phenylurea: RIVIN'H (400MHZ, DMSO): 9.371 (s, 1H), 8,986 (s, 1H), 8,795 (s, 1H), 8,436 (d, 1H), 8,121 (d, 2H), 7,697 (d, 2H), 7,633 (d, 2H), 7.49 (d, 2H) ), 7.321-7.265 (m, 3H), 7.014-6.928 (td, 3H), 3.758 (t, 4H), 3.063 (t, 4H). MS (El) for C27H26N602: 467.3 (MH +). N- [5- ( { 4- [4- (acetylamino) phenyl] pyrimidin-2-yl} amino) -2- (4-ethylpiperazin-1-yl) phenyl] -2,6-dichlorobenzamide: R N'H (400MHZ, DMSO): 10.224 (s, 1H), 9.623 (d, 2H), 8.6 (br s, 1H), 8.48 (d, 1H), 8.237 (d, 2H), 7.735 (d, 2H), 7.598 (d, 2H), 7.521 (m, 2H), 7.35 (d, 1H), 7.181 (d, 1H), 3.36 (br s, 4H), 2.877 (t, 4H), 2.344 (q, 2H), 2.071 (s, 3H), 1.005 (t, 3H). MS (El) for C 31 H 31 C 12 N 702: 604.3 (MH +). 1- [4- (2- { [4- (4-ethylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] -3- (phenylmethyl) urea: NMR! (400MHz, MeOD): 8.082 (t, 3H), 7.53 (d, 2H), 7.422 (m, 3H), 7.236 (m, 4H), 7.159 (m, 1?), 7.037 (d, 2H), 4.32 (s, 2H), 3971 (d, 2H), 3.608 (d, 2H), 3.195 (t, 2H), 3.126 (d, 2H), 3.045 (t, 2H), 1.3 (t, 3H). MS (El) for C30H33N7O: 508.4 (MH +). N2, N2-dimethyl-N-. { 4- [2- ( { 4- [4- (pyridin-3-ylcarbonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} glycinamide: NMR'H (400MHZ, DMSO): 9,994 (s, 1H), 9,418 (s, 1H), 8,667 (m, 2H), 8,454 (d, 1H), 8,127 (d, 2H), 7,907-7,827 ( md, 3H), 7.7 (d, 2H), 7.513 (m, 1H), 7.298 (d, 1H), 6.98 (d, 2H), 3.799 (br s, 2H), 3.489 (br s, 2H), 3.179 (br s, 2H), 3.113 (br s, 4H), 2289 (s, 6H). MS (El) for C30H32N8O2: 537.4 (MH +). N- (3-fluoro-4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -cyclopropanecarboxaraide: NMR1! (400MHz, DMSO): 10,671 (s, 1H), 9,452 (s, 1H), 8.47 (d, 1H), 8,045 (t, 1H), 7,758 (d, 1H), 7,656 (d, 2H), 7.46 ( d, 1H), 7.12 (q, 1H), 6.932 (d, 2H), 3.749 (t, 4H), 3.052 (t, 4H), 1.813 (m, 1H), 0.847 (d, 4H). MS (El) for C24H24FN502: 434.3 (MH +). N- (4- {2 - [(4- (4- [(l-methyl-lH-imidazol-2-yl) methyl] piperazin-1-yl}. Phenyl) amino] -pyriraidin-4- phenyl) cyclopropanecarboxamide: NMR1 (400MHz, DMSO): 7.851 (d, 1H), 7.67 (d, 2H), 7.452 (br d, 2H), 7.285 (d, 2H), 7.091 (d, 1H), 7,763 (d, 1H), 6,688 (d, 2H), 6,291 (br s, 1H), 3,668 (s, 3H), 3,561 (s, 2H), 2,946 (br s, 4H), 2.5 (br s, 4H), 1413 (m, 1H), 0.541 (m, 2H), 0.3 (m, 2H), MS (El) for C29H32N80: 509.4 (MH +).

N- [4- (2- { [4- (4-L-alanylpiperazin-1-yl) phenyl] amino.} Pyrimidin-4-yl) phenyl] -acetamide: NMRH (400MHz, DMSO): 10,212 (s, 1H), 9,407 (s, 1H), 8,449 (d, 1H), 8,121 (d, 2H), 7,732 (d, 2H), 7,698 (d, 2H), 7,282 (d, 1H), 6,978 (d, d, 2 H), 3,804 (q, 1 H), 3,621 (m, 4 H), 3,037 (br m, 4 H), 2,081 (s, 3 H), 1,864 (br s, 2 H), 1.10 (d, 3 H). MS (El) for C 25 H 29 N 702: 460.4 (MH +). N- [4- (2- { [4- (4-L-prolylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] -acetamide: NMR1! -! (400MHz, DMSO): 10,234 (s, 1H), 9,409 (s, 1H), 8,449 (d, 1H), 8,121 (d, 2H), 7,757 (d, 2H), 7,699 (d, 2H), 7,282 ( d, 1H), 6,979 (d, 2H), 3,849 (m, 1H), 3,619 (m, 4H), 2,992 (m, 6H), 2,625 (m, 1H), 2,092 (s, 3H), 1,986 (m , 1H), 1685-1536 (m, 3H). MS (El) for C27H31N702: 486.2 (MH +). N- [4- (2- { [4- (4-D-alanylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl-acetamide: NMRH (400MHz, DMSO): 10.22 ( s, 1H), 9.406 (s, 1H), 8.449 (d, 1H), 8.12 (d, 2H), 7.755 (d, 2H), 7.697 (d, 2H), 7.282 (d, 1H), 6.978 (d , 2H), 3,791 (q, 1H), 3,621 (brs, 4H), 3,081 (br d, 4H), 2,091 (s, 3H), 1,709 (br s, 2H), 1,096 (d, 3H). MS (El) for C2sH29N702: 460.4 (MH +). N- [4- (2- {[4- (4-D-prolylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] -acetamide: NMR! (400MHz, DMSO): 10,211 (s, 1H), 9,407 (s, 1H), 8,449 (d, 1H), 8,121 (d, 2H), 7,754 (d, 2H), 7,698 (d, 2H), 7,282 ( d, 1H), 6,979 (d, 2H), 3,872 (t, 1H), 3,621 (m, 4H), 3,082-2,979 (m, 6H), 2,656 (m, 1H), 2,091 (s, 3H), 2,013 (m, 2H), 1,676-1,522 (m, 3H) ). MS (EI) for C27H31N702: 486.4 (MH +). N-. { 4- [2- ( { 4- [4- (2-piperazin-l-ylacetyl) iperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyljacetamide: RMIS ^ H (400MHz, DMSO ): 10,219 (s, 1H), 9,401 (s, 1H), 8,448 (d, 1H), 8,121 (d, 2H), 7,754 (d, 2H), 7,694 (d, 2H), 7,281 (d, 1H) , 6.977 (d, 2H), 3.707 (t, 2H), 3.59 (t, 2H), 3.319 (s, 2H), 3.1 (t, 2H), 3.018 (t, 2H), 2.702 (s, 4H), 2.336 (br s, 4H), 2.090 (s, 3H). MS (El) for C28H34N802: 515.2 (MH +). N- [4- (2- {[4- (4-L-alanylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] -tetrahydrofuran-2-carboxamide: RMt ^ H ( 400MHz, DMSO): 9,938 (s, 1H), 9,417 (s, 1H), 8,457 (d, 1H), 8,135 (d, 2H), 7,885 (d, 2H), 7,693 (d, 2H), 7,305 (d , 1H), 6,976 (d, 2H), 4,436 (q, 1H), 3,991 (q, 1H), 3,878-3.761 (qq, 4H), 3,622 (br s, 4H), 3,083 (br d, 4H), 2222 (m, 1H), 2.019 (m, 1H), 1.913 (m, 2H), 1843 (br s, 2H). MS (EI) for C28H33N703: 516.3 (MH +). N- [4- (2- { [4- (4-L-prolylpiperazin-1-yl) phenyl] amino.} Pyrimidin-4-yl) phenyl] -tetrahydrofuran-2-carboxaraide: RM 1H (400MHz , DMSO): 9,945 (s, 1H), 9,419 (s, 1H), 8,458 (d, 1H), 8,135 (d, 2H), 7,887 (d, 2H), 7,696 (d, 2H), 7,306 (d, 1H), 6,978 (d, 2H), 4,452 (q, 1H), 4,011 (q, 1H), 3,861 (q, 2H), 3,633 (m, 4H), 3,084-2,968 (m, 6H), 2.62 (m , 1H), 2191 (m, 1H), 2,002 (m, 2H), 1897 (m, 2H), 1691-1544 (m, 3H). MS (E) for C 30 H 35 N 7 O 3: 542.3 (MH +). N- [4- (2- {[4- (4-D-alanylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] -tetrahydrofuran-2-carboxamide: RMIN H (400MHz , DMSO): 9.945 (s, 1H), 9.418 (s, 1H), 8.457 (d, 1H), 8.135 (d, 2H), 7.887 (d, 2H), 7.694 (d, 2H), 7.305 (d, 1H), 6,976 (d, 2H), 4,452 (q, 1H), 4,028 (q, 1H), 3,878-3.768 (m, 2H), 3,633 (m, 4H), 3,083 (br d, 4H), 2,209 ( m, 1H), 2,002 (m, 1H), 1862 (m, 3H), 1.1 (d, 3H). MS (El) for C28H33N703: 516.3 (MH +). N- [4- (2- {[[4- (4-D-prolylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] -tetrahydrofuran-2-carboxamide: RMIN ^ H ( 400MHz, DMSO): 9,954 (s, 1H), 9,421 (s, 1H), 8,458 (d, 1H), 8,136 (d, 2H), 7,889 (d, 2H), 7,697 (d, 2H), 7,306 (d , 1H), 6,978 (d, 2H), 4,454 (q, 1H), 4,028 (q, 1H), 3,889 (m, 2H), 3,645 (m, 4H), 3,083-2,985 (m, 6H), 2,669 ( m, 1H), 2,209 (m, 1H), 2,002 (m, 2H), 1879 (m, 2H), 1681-1548 (m, 3H). MS (El) for C30H35N7O3: 542.3 (MH +). (2,6-dichlorophenyl) (4- (4- (4-methylthiophen-2-yl) pyrimidin-2-ylamino) piperidin-1-yl) methanone: RMIN H (400MHz, d6-DMSO): 8.28 (d, 1H), 7.72 (m, 1H) 7.57 (m, 2H), 7.47 (m, 1H), 7.32 (s, 1H), 7.27 (m, 1H), 7.01 (m, 1H), 4.45 (m, 1H) , 4.03 (m, 1H), 3.28-3.05 (m, 3H), 2.45 (s, 3H), 2.03-1.80 (m, 2H), 1.59-1.48 (m, 2H); MS (El): 447 (MH +). (2,6-dichlorophenyl) (4- (4- (pyridin-3-yl) pyrimidin-2-ylamino) piperidin-1-yl) methanone: NMRH (400MHz, d6-DMSO): 9. 28 (br.s, 1H), 8.69 (m, 1H), 8.41 (m, 2H), 7.59-7.52 (m, 2H), 7.46 (m, 2H), 7.25 (d, 1H), 4.46 (m, 1H), 4.14 (m, 1H), 3.32-3.10 (m, 3H), 2.06-1.89 (m, 2H), 1.63-1.54 (m, 3H); MS (EI): 428 (MH +). (2,6-dichlorophenyl) (4- (4- (5-methylthiophen-2-yl) pyrimidin-2-ylamino) piperidin-1-yl) methanone: NMR1! (400MHz, d6-DMSO): 8.24 (d, 1H), 7.70 (m, 1H), 7.57 (m, 2H), 7.47 (m, 1H), 7.24 (m, 1H), 7.00 (m, 1H), 6.88 (m, 1H), 4.45 (ra, 1H), 4.02 (m, 1H), 3.28-3.05 (m, 3H), 2.47 (s, 3H), 2.03-1.80 (m, 2H), 1.57-1.50 ( ra, 2H); MS (EI): 447 (MH +). 1-methyl-N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -lH-pyrrole-2-carboxamide: NMRH (400MHz, d6 -DMSO): 9.99 (s, 1H), 9.39 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.90 (d, 2H), 7.68 (d, 2H), 7.30 (d, 1H), 7.09-7.08 (m, 1H), 7.05 (t, 1H), 6.97 (d, 2H), 6.13-6.11 (m, 1H), 3.90 (s, 3H), 3.74 (t, 4H), 3.05 (t, 4H). MS (El) for C26H26N602: 455 (MH +). 3-fluoro-N- (4- { 2- [(4-morpholin-4-phenyl) amino] pyrimidin-4-yl} phenyl) pyridine-4-carboxamide: RMIS ^ H (400MHz, ds- DMSO): 10.96 (s, 1H), 9.43 (s, 1H), 8.79 (s, 1H), 8.62 (d, 1H), 8.47 (d, 1H), 8.20 (d, 2H), 7.88 (d, 2H) ), 7.76-7.67 (m, 2H), 7.32 (d, 1H), 6.94 (d, 2H), 6.56 (s, 1H), 3.74 (t, 4H), 3.05 (t, 4H). MS (El) for C 26 H 23 FN 602: 471 (MH +). 6-methyl-N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) pyridine-3-carboxamide: NMRH (400MHz, d6-DMSO): 10.61 (s, 1H), 9.41 (s, 1H), 9.03 (d, 1H), 8.47 (d, 1H), 8.23 (dd, 1H), 8.19 (d, 2H), 7.95 (d , 2H), 7.68 (d, 2H), 7.45 (d, 1H), 7.31 (d, 1H), 6.94 (d, 2H), 3.74 (t, 4H), 3.05 (t, 4H), 2.57 (s, 3H). MS (El) for C27H26N602: 467 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) pyridazine-4-carboxamide: RMI ^ H (400MHz, d6-DMSO): . 98 (s, 1H), 9.67 (s, 1H), 9.52 (d, 1H), 9.42 (s, 1H), 8.47 (d, 1H), 8.21 (d, 2H), 8.16-8.14 (m, 1H) , 7.96 (d, 2H), 7.68 (d, 2H), 7.33 (d, 2H), 7.33 (d, 1H), 6.95 (d, 2H), 3.74 (t, 4H), 3.05 (t, 4H). MS (El) for C 25 H 23 N 702: 454 (MH +). 2-cyclopropyl-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) acetamide: R N1! (400MHz, d6-DMSO): 10.09 (s, 1H), 9.45 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.78 (d, 2H), 7.69 (d, 2H), 7.30 (d, 1H), 7.00 (s, 2H), 3.76 (s, 4H), 3.09 (s, 4H), 2.25 (d, 2H), 1.12-1.02 (m, 1H), 0.50-0.48 (m, 2H), 0.22-0.20 (ra, 2H). MS (El) for C25H27N502: 430 (MH +). N- (4- {2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) isoxazole-5-carboxamide: NMRH (400MHz, d6-DMSO): . 99 (s, 1H), 9.42 (s, 1H), 8.47 (d, 1H), 8.19 (d, 2H), 7.95 (d, 2H), 7.68 (d, 2H), 7.33-7.31 (m 2H), 6.95 (d, 2H), 6.55 (s, 1H), 3.74 (t, 4H), 3.05 (t, 4H). MS (El) for C24H22N603: 443 (MH +). N- (4-. {2- 2- (4-morpholin-4-ylphenyl) amino] pyrimidine-4- il} phenyl) pyridine-3-carboxamide: NMR1 !. (400MHz, d6-DMSO): 10.69 (s, 1H), 9.41 (s, 1H), 9.14 (s, 1H), 8.79 (d, 1H), 8.47 (d, 1H), 8.34-8.31 (m, 1H) ), 8.20 (d, 2H), 7.97 (d, 2H), 7.70 (d, 2H), 7.67-7.58 (m, 1H), 7.33 (d, 1H), 6.95 (d, 2H), 3.78 (t, 4H), 3.05 (t, 4H). MS (El) for C 26 H 24 N 602:453 (MH +). 4-methyl-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -benzamide: R NXH (400MHz, d6-DMSO): 10.42 (s, 1H), 9.53 (s, 1H), 8.47 (s, 1H), 8.17 (d, 2H), 7.98 (s, 2H), 7.91 (d, 2H), 7.72 (s, 2H), 7.37 (s, d, 3H), 7.05 (S, 2H), 3.78 (S, 4H), 3.14 (s, 4H), 2.40 (s, 3H). MS (El) for C28H27N502: 466 (MH +). N- [4- (2- { [4-ethylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] -D-prolinamide: NMR1! (400MHz, ds-DMSO): 11.55 (s, 1H), 11.15 (s, 1H), 10.16 (s, 2H), 8.74 (s, 1H), 8.52 (s, 1H), 8.23 (d, 2H), 7.89 (d, 2H), 7.67 (d, 2H), 7.48 (s, 1H), 7.11 (d, 2H), 4.50 (s, br, 1H), 3.81 (d, 2H), 3.57 (d, 2H) , 3.28-3.11 (m, 8H), 2.05-1.92 (m, 3H), 1.30 (t, 3H). MS (El) for C27H33N70: 472 (MH +). N- [4- (2- {[4- (4-ethylpiperazin-1-yl) phenyl] amino} pyrimidin-4-yl) phenyl] -butanamide: RM ^ H (400MHz, d6-DMSO) : 10.25 (s, 1H), 9.37 (s, 1H), 8.43 (s, 1H), 8.12 (d, 2H), .7.77 (d, 2H), 7.68 (d, 2H), 7.29 (s, 1H) , 6.93 (d, 2H), 3.08 (s, 4H), 2.42-2.30 (m, 4H)), 1.68-1.58 (m, 2H), 1.05 (t, 3H), 0.93 (t, 3H). MS (El) for C 26 H 32 N 60: 445 (MH +). l-Ethyl-3- [4- (2- {[[4- (4-ethylpiperazin-1-yl) phenyl] amino} pyriraidin-4-yl) phenyl] urea: NMR! (400MHz, d6-D SO): 9.32 (s, 1H), 8.85 (s, 1H), 8.40 (d, 1H), 8.05 (d, 2H), 7.68 (d, 2H), 7.54 (d, 2H) , 7.23 (d, 1H), 6.92 (d, 2H), 6.36 (t, 1H), 3.18-3.05 (m, 6H), 2.54 (t, 4H), 2.46-2.38 (m, 2H), 1.09-1.02 (m, 6H). MS (El) for C 25 H 31 N 70: 446 (MH +). N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-ylphenyl) furan-3-carboxamide: NMRH (400MHz, d6-DMSO): 10.17 (s, 1H), 9.46 (S, 1H), 8.47-8.43 (m, 2H), 8.18 (d, 2H), 7.91 (d, 2H), 7.83 (d, 1H), 7.70 (s, 2H), 7.32 (s, 1H) , 7.03-6.95 (m, 3H), 3.76 (s, 4H), 3.09 (s, 4H). MS (El) for C25H23N503: 442 (MH +). N- (4- {2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -1,3-thiazole-4-carboxamide: RM ^ H (400MHz, d6 -DMSO): 10.61 (s, 1H), 9.40 (s, 1H), 9.30 (d, 1H), 8.56 (d, 1H), 8.46 (d, 1H), 8.16 (d, 2H), 8.06 (d, 2H), 7.32 (d, 1H), 6.96 (d, 2H), 6.56 (s, 1H), 3.74 (t, 4H), 3.05 (t, 4H). MS (EI) for C 24 H 22 N 602 S: 459 (MH +). Based on the synthesis examples described hereinabove, the skilled person will be able to elaborate the rest of the proposed compounds to be within the scope of the invention described in the appended claims.

Biological tests Test Example 1 Measurement of JAK-2 Kinase Activity by ATP Hydrolysis The activity of JAK-2 kinase was measured by monitoring the peptide substrate-dependent hydrolysis of ATP by quantification of the remaining ATP with luciferase-based chemoluminescence. For evaluation of the compound, 0.5 μ? of the compound dissolved in DMSO at 10 μ? of JAK-2 dissolved in assay buffer (HEPES 20 mM pH 7.5, gCl2 10 rtiM, Triton at 0.03% and DTT lmM). After preincubation for 30 minutes at room temperature, the reaction was started by the addition of 10 μ? of ATP and the poly-Glu-Tyr substrate peptide in assay buffer. The final enzyme, ATP, and peptide concentrations were 3 nM, 1 μ? and 2 μ ?, respectively. After incubation for 60 minutes at room temperature, the progress of the reaction was quantified by the addition of 10 μ? of kinase-Glo (Promega) and measurement of chemiluminescence in a Victor reader (Perkin Elmer). A reaction was used in which the compound was omitted to determine the maximum progress of the reaction. The omission of the compound and the above reaction was used to determine the zero reaction process.

Test Example 2 Measurement of JAK-3 Kinase Activity by ATP Hydrolysis JAK-3 was evaluated in a similar manner as JAK-2 (see Test Example 1) except that the enzyme reaction was carried out for 180 minutes and the concentrations of the ATP enzyme and the peptide were 30 nM, 2μ ?, and 4 μ ?, respectively. Biological Activity It was determined that the compounds in Table 1 have inhibitory activity for JAK-2 of less than 10 μ. Other more preferred compounds of the invention have inhibitory activity for JAK-2 of less than 100 nm. One skilled in the art can use the descriptions herein as well as those known in the art to test the inhibitory activity of a particular compound.

Examples of Pharmaceutical Composition The following are representative pharmaceutical formulations containing a compound of Formula I.

Table Formulation The following ingredients are intimately mixed and pressed into individual labeled tablets.

Ingredient Amount per tablet, Compound of this invention 400 Corn starch 50 Croscarmellose sodium Lactose Magnesium stearate Capsule Formulation The following ingredients are intimately mixed and loaded into a hard shell gelatin capsule.

Ingredient Amount per tablet, mg Compound of this invention 200 Lactose, spray dried 148 Magnesium Stearate 2 Suspension Formulation The following ingredients are mixed to form a suspension for oral administration.

Ingredient Amount Compound of this invention 1.0 g Fumaric acid 0.5 g Sodium chloride 2.0 g Methylparaben 0.15 g Propylparaben 0.05 g Ingredient Quantity Granulated sugar 25.5 g Sorbitol (70% solution) 12.85 g Veegum K (Vanderbilt Co.) 1.0 g Flavor 0.035 mL Dyes 0.5 mg Distilled water is. for 100 mL Injectable Formulation The following ingredients are mixed to form an injectable formulation Ingredient Amount Compound of this invention 1.2 g Sodium acetate buffer solution 0.4 M 2.0 mL HC1 (1 N) or NaOH (1 M) is. for suitable pH Water (distilled, sterile) q.s. for 20 mL All the above ingredients, except water, are combined and heated to 60 ° -70 ° with agitation. Then a sufficient amount of water is added at 60 ° C with vigorous stirring to emulsify the ingredients, and then water is added in a sufficient amount to 100 g.

Suppository Formulation A suppository of a total weight of 2.5 g is prepared by mixing the compound of the invention with itepsol ™ H15 (triglycerides of saturated vegetable fatty acid, Riches-Nelson, Inc., New York), and has the following composition: Ingredient Amount per tablet, mg Compound of this invention 500 Witepsol ™ H15 The foregoing invention has been described in some detail by way of illustration and example, for purposes of clarity and understanding. The invention has been described with reference to several specific and preferred modalities and techniques. However, it should be understood that many modifications and variations can be made as long as they remain within the spirit and scope of the invention. It would be obvious to one skilled in the art that changes and modifications may be practiced within the scope of the appended claims. Therefore, it is to be understood that the foregoing description is intended to be illustrative and not restrictive. The scope of the invention should therefore be determined not with reference to the foregoing description, but instead should be determined with reference to the following appended claims, together with the full scope of equivalents to which these claims are entitled.

It is noted that in relation to this date, the best method known to the applicant to carry out the aforementioned invention, is that which is clear from the present description of the invention.

Claims (61)

1. CLAIMS Having described the invention as above, the contents of the following claims are claimed as property: 1. Compound of Formula I: I or a pharmaceutically acceptable salt thereof, characterized in that D is hydrogen, halo, -CF3, heterocycloalkyl or alkyl; E is hydrogen, halo, -CF3, heterocycloalkyl or alkyl; or D and E, together with the carbon atoms to which they are attached, form a 5-7 membered heteroaryl or a 5-7 membered heterocycloalkyl, wherein the 5-7 membered heteroaryl or 5-7 membered heterocycloalkyl each is fused to the pyrimidinyl moiety to which D and E are attached; L is a bond, -O- or -N (H) -; Z is selected from alkoxy, cycloalkyl, heteroaryl optionally substituted with alkyl, halo, -C (0) OR26, -C (= N-OH) alkyl, -C (0) R8, -C (0) NR30R30a, -CH2R2, - (CH2) n5NR26R26a, -CF3, -CN, -S02R12, - S-R12a, -OR32a, -NHC (0) R32, aryl, and heterocycloalkyl optionally substituted with 1 or 2 oxo, or Z and R25, together with the carbon atoms to which they are attached, join to form a heterocycloalkyl of 5 or 6 members, a 5- or 6-membered heteroaryl, or a 5- or 6-membered cycloalkyl ring, wherein the 5- or 6-membered heterocycloalkyl, 5- or 6-membered heteroaryl, and 5- or 6-membered cycloalkyl ring are fused to the phenyl portion to which Z and R25 are attached, and wherein the 5- or 6-membered heterocycloalkyl, 5- or 6-membered heteroaryl, or 5- or 6-membered cycloalkyl ring are each optionally substituted with 1, 2 or , or 3 independently selected groups of oxo, alkyl, alkoxy and halo; a ni is 0, 1, 2, 3, or 4, and each ni is independently selected when more than one ni is present; a n2 is 0, 1, 2, 3, or 4, and each n2 is independently selected when more than one n2 is present; a n3 is 0, 1, 2, or 3, and each n3 is independently selected when more than one n3 is present; a n4 is 0, 1, 2, 3 or 4, and each n4 is independently selected when more than one n4 is present; a n5 is O, 1, 2, 3 or 4, and each n5 is selected independently when more than one n5 is present; p is 0-3; r is 1-3; R1 is hydrogen; R2 is selected from one of the following groups: or R2 is selected from one of the following groups: the ring X in the formula (d) of R2 is an unsaturated 5 or 6 membered heterocyclic ring fused to the two carbon atoms of the phenyl portion to which the X ring joins, wherein the X ring contains one or two nitrogen atoms; R7, R7 ', R9, R10, R12 and R15 are each independently hydrogen, alkyl, alkoxy, or alkoxyalkyl; R8 is selected from hydrogen, hydroxy, alkyl, alkenyl, lower alkynyl, hydroxylamino, hydroxyalkyl, alkoxyalkyl, dihydroxyalkyl, alkylamino, dialkylamino, aminoalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, alkylaminoalkyl, dialkylaminoalkyl, - (CH2) rC (0) OR7, - (CH2) rC (0) NRR7 ', aryl, heteroaryl, cycloalkyl, arylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the aryl, heteroaryl, cycloalkyl, arylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl are each independently optionally substituted at the position of the rings with one, two, three, four or five groups independently selected from alkyl, alkenyl, lower alkynyl, halo, hydroxy, haloalkyl, haloalkoxy, lower alkoxy, amino, aryl, alkylamino, dialkylamino, heterocyclylalkoxy, oxo and haloalkyl; each R 11, when R 11 is present, is independently selected from alkyl, alkenyl, lower alkynyl, -CF 3, alkoxy, halo, haloalkoxy, haloalkyl, aminoalkyl, aminoalkoxy, alkylaminoalkyl, alkylaminoalkoxy, dialkylaminoalkyl, dialkylaminoalkoxy, oxo, thioalkyl, alkylthioalkyl, - (CH2) p-OR17, -CN, -0-CH2-C (0) -R17, -C (0) R16, - (CH2) pC (0) OR17, -S (0) 2R17, -S (0) 2NR15R17, aryl, heteroaryl, cycloalkyl, arylalkyl, arylalkoxy, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the aryl, heteroaryl, cycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl are each independently optionally substituted on any ring portion with 1, 2, 3 or 4 R21; R 12 is hydrogen or alkyl; R12a is hydrogen or alkyl; R13 is selected from hydrogen, hydroxy, alkyl, alkenyl, lower alkynyl, hydroxylamino, haloalkyl, alkyl substituted with halo and hydroxy, hydroxyalkyl, alkoxyalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, (CH2) rC (0) OR7, - (CH2) rC (0) NR7R7 ', aryl, heteroaryl, cycloalkyl, arylalkyl, diarylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the aryl, heteroaryl, cycloalkyl, arylalkyl, diarylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl are each optionally independently substituted at the ring position with 1, 2, 3, 4 or 5 groups independently selected from alkyl, alkenyl, lower alkynyl, halo, hydroxy, hydroxyalkyl, alkoxycarbonyl, alkylcarbonyl, haloalkyl, haloalkoxy, alkoxy lower, amino ,. aryl, alkylamino, dialkylamino, heterocyclylalkoxy, oxo and haloalkyl; and wherein the alkyl cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, and heteroarylalkyl are optionally independently substituted with 1, 2, 3, 4, or 5 groups selected from halo and hydroxy; R14 is a bond, heterocycloalkyl or cycloalkyl; R16 is selected from hydrogen, hydroxy, alkyl, alkenyl, lower alkynyl, hydroxyamino, haloalkyl, alkyl substituted with halo and hydroxy, hydroxyalkyl, alkoxyalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, dialkylaminoalkyl, - (CH2) rC (0) OR7, aryl, heteroaryl, cycloalkyl, arylalkyl, diarylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the aryl, heteroaryl, cycloalkyl, arylalkyl, diarylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl are each independently independently substituted at the ring position with one, two, three, four or five groups independently selected from alkyl, alkenyl, lower alkynyl, halo, hydroxy, hydroxyalkyl, alkoxycarbonyl, alkylcarbonyl, haloalkyl, haloalkoxy, alkoxy lower, amino, aryl, alkylamino, dialkylamino, heterocyclylalkoxy, oxo and haloalkyl; and wherein the alkyl of cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, and heteroarylalkyl is optionally substituted with 1, 2, 3, 4, or 5 groups selected from halo and hydroxy; R17 is selected from hydrogen, hydroxy, alkyl, alkenyl, lower alkynyl, hydroxyamino, haloalkyl, alkyl substituted with halo and hydroxy, hydroxyalkyl, alkoxyalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, dialkylaminoalkyl, - (CH2) rC (O) OR7, - ( CH2) rC (O) NR7R7 ', aryl, heteroaryl, cycloalkyl, arylalkyl, diarylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the aryl, heteroaryl, cycloalkyl, arylalkyl, diarylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl are each optionally independently substituted at the ring position with one, two, three, four or five groups independently selected from alkyl, alkenyl, lower alkynyl, halo, hydroxy, hydroxyalkyl, alkoxycarbonyl, alkylcarbonyl, haloalkyl, haloalkoxy, alkoxy lower, amino, aryl, alkylamino, dialkylamino, heterocyclylalkoxy, oxo and haloalkyl; and wherein the alkyl of cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, and heteroarylalkyl is optionally substituted with 1, 2, 3, 4, or 5 groups selected from halo and hydroxy; each R21, when R21 is present, is independently selected from alkyl, alkenyl, lower alkynyl, cyano, halo, haloalkoxy, haloalkyl, hydroxyalkyl, amino, alkylamino, dialkylamino, dialkylaminoalkyl, dialkylaminoalkyloxy, haloalkyl, oxo, -OR13, -NHS ( ) 2R17, -S (0) 2R17, -C (0) R17, -C (0) OR17, -C (0) NR15R17, -NR15C (O) R17, aryl, arylalkyl, heteroarylalkyl, aryloxy, and heteroaryl; wherein each of the aryl, arylalkyl, heteroarylalkyl, aryloxy, and heteroaryl within R21 are optionally substituted at any ring position with 1, 2, or 3 groups selected from alkyl, lower alkoxy-halo, phenyl, heteroaryl, and alkylheteroalkyl; R25 is selected from alkyl, alkenyl, lower alkyl, halo, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, -0R12, cyano, -CH2NHC (0) OR7, -CH2NHC (0) R7, -SR7, -S (0) 2R7, -S (0) 2NR7R8, -C (0) 0R8, -C (0) NR7R8, cycloalkyl, heterocycloalkyl, aryl and heteroaryl; wherein the cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each optionally substituted with one, two or three groups independently selected from alkyl, alkenyl, halo, haloalkoxy, haloalkyl, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, -OR8, -NHS (0) 2R8, cyano, -C (0) R8, -CH2NHC (0) OR7, -CH2NHC (0) R7, -SR7, -S (0) 2R7, -S (0) 2NRR8, -C (0) 0R8, -C (0) NRR8, -NR7'C (0) -CHR3-OR8, -NR7'C (0) -CHR3-NR-R8, and -NR7C (0) R8; R26 is hydrogen, -C (0) -phenyl or alkyl, wherein the -C (0) -phenyl is optionally substituted at any position of rings with 1, 2 or 3 halo; R26a is hydrogen, alkyl, heteroaryl, -C (0) R32, -C (0) NHR32a, -S (0) 2R9, -SR9, -C (0) OR32, or -C (0) NR32aR32; R27 and R28 are each independently selected from alkyl, alkenyl, hydroxy, alkoxy, and alkoxyalkyl; R2 a and R28a are independently selected from hydrogen, alkyl, alkenyl, alkoxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, dialkylaminoalkyl, arylcarbonylalkyl, aryloxyalkyl, dialkylaminoalkyl, alkyl-OC (0) heterocycloalkyl, - (CH2) n4heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, (CH2) n4-C (0) R29, - (CH2) n4NR28R28a, - (CH2) n4NHR28a, -CH (phenyl) 2, -S (0) 2R29, -C (0) R29, -C (0) OR29, and -C (0) NR29aR29, wherein the aryl, arylalkyl, cycloalkyl groups , cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl within R2 and R28a are each independently optionally substituted at any ring position with 1, 2, 3, 4, or 5 groups selected from halo, alkyl, alkoxy, alkylcarbonyl , phenyl, phenoxy, arylcarbonyl, -CF3, oxo, -0CF3, alkoxyphenyl, and heteroaryl optionally substituted with alkyl or halo; or R and R, together with the nitrogen to which they are attached, form heterocycloalkylamino, heterocycloalkyl or heteroaryl, wherein the heterocycloalkylamino and heteroaryl are each independently optionally substituted with 1, 2, 3, 4, or 5 R31; or R28 and R28a together with the nitrogen to which they are attached, form heterocycloalkyl or heteroaryl, wherein the heterocycloalkyl and heteroaryl are each optionally substituted with 1, 2, 3, 4, or 5 R31; R29a is hydrogen or alkyl; R29 is selected from alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl groups within R are each optionally substituted at any ring position with 1, 2, 3, 4, or 5 groups selected from halo, alkyl , alkoxy, alkylcarbonyl, phenyl, phenoxy, arylcarbonyl, CF 3, oxo, -OCF 3, alkoxyphenyl, and heteroaryl optionally substituted with alkyl or halo; R30a is hydrogen or alkyl; R 30 is selected from hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, alkoxycarbonylalkyl, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aryl, arylalkyl, phenoxyalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, arylheteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the aryl, arylalkyl, phenoxyalkyl, cycloalkyl, arylheteroarylalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl groups within R30 are each independently substituted at any position of rings with 1, 2, 3, 4, or 5 groups selected from halo, alkyl, alkoxy, alkoxyalkyl, -C (0) OCH3, -CF3, OCF3, alkylcarbonyl, phenyl, phenoxy, alkylphenoxy, dialkylaminoalkoxy and heteroaryl; R31 is selected from alkyl, hydroxyalkyl, alkoxy, alkoxyalkyl, alkylthioalkyl, -C (0) R30, -C (0) NR30R30a, -C (0) 0R30, -S (0) 2R3 °, amino, dihydroxyalkyl, arylcarbonyl, alkylcarbonylamino, alkoxyphenyl, phenylalkoxyalkyl, arylheteroarylalkyl, alkylamino, -O-dialkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl dialkylaminoalkoxy, oxo, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, cycloalkyl spirocyclic spirocyclic heterocycloalkyl, and heterocycloalkylalkyl, wherein the aryl, arylalkyl, cycloalkyl, arylheteroarylalkyl, arylalkoxyalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl within R31 are each independently optionally substituted at any ring position with 1, 2, 3, 4, or 5 groups selected from halo, alkyl, -CF3, -0CF3 / cyano, alkoxy, alkoxyalkyl, -C (0) 0CH3, alkylcarbonyl, phenyl optionally substituted at any ring position with halo, phenoxy, alkylphenoxy, arylalkoxyalkyl, dialkylaminoalkoxy and heteroaryl; R32a is hydrogen, -OCF3, -CF3, or alkyl; R 32 is selected from aryl, arylalkyl, arylalkoxy, arylcycloalkyl, alkoxycarbonylalkoxy, cycloalkyl, cycloalkylalkyl, cycloalkylhydroxyalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl, wherein aryl, arylalkyl, cycloalkyl, arylcycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl are each optionally independently substituted at any ring position with 1, 2, 3, 4, or 5 groups selected from hydroxy, oxo, alkyl, alkoxy, amino, hydroxyalkyl, alkylcarbonyl, alkoxycarbonyl, halo, CF3, -OCF3, aminoalkyl, alkylaminoalkyl, aryl and dialkylaminoalkyl, and wherein the alkyl portion of the heteroarylalkyl may be substituted with amino; or R 32 is alkyl optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from hydroxy, alkoxycarbonyl, alkoxy, -CF 3, halo, aminocarbonyl, alkylaminocarbonyl, alkoxycarbonylalkylamino, dialkylaminocarbonyl, -NR34R34a and phenyl optionally substituted by 1, 2 , or 3 halo; or R 32 is alkylamino or arylalkylamino; R34 is hydrogen or alkyl; R34a is selected from hydrogen, alkyl, heteroaryl, aryl, aminoalkyl, aminocarbonylalkyl, heteroarylalkyl, arylalkoxy and arylalkyloxycarbonylalkyl; wherein the heteroaryl, aryl, heteroarylalkyl, arylalkoxy or arylalkyloxycarbonylalkyl are each independently independently substituted at any ring position with 1, 2, 3, 4, or 5 groups selected from hydroxy, oxo, alkyl, amino, hydroxyalkyl, alkylcarbonyl , alkoxycarbonyl, halo, aminoalkyl, alkylaminoalkyl, and dialkylaminoalkyl; and R35 is selected from halo, - (CH2) PC (0) ORi7, cycloalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the heterocycloalkyl and heterocycloalkylalkyl are each optionally substituted with 1, 2, 3, 4, or 5 groups each independently selected from alkyl, alkoxy, and halo.
2. 2. Compound according to claim 1, characterized in that it has Formula II:
3. 3. Compound in accordance with the claim 1, characterized in that it has Formula III:
4. 4. Compound according to claim characterized in that
5. 5. Compound according to claim characterized in that R2 is wherein Rzsa is arylalkyl or heteroarylalkyl, wherein the arylalkyl or heteroarylalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halo and lower alkyl.
6. 6. Compound according to claim 1, characterized in that R2 is
7. 7. Compound according to claim 1, characterized in that R2 is wherein R is selected from lower alkyl, dialkylaminoalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, and heterocycloalkylalkyl.
8. 8. Compound according to claim 1, characterized in that R2 is wherein R and n2 are as defined above for the compound of Formula I, and R28 and R28a, together with the nitrogen atom to which they are attached, are joined together to form a ring structure selected from thiazolidinyl, piperazinyl, piperidinyl , morpholinyl, thiomorpholinyl, pyrimidinyl, and pyridinyl, wherein the ring structure is optionally substituted with 1, 2, 3, 4 or 5 substituents selected from halo, lower alkyl or alkoxy.
9. 9. Compound in accordance with the claim characterized because
10. 10. Compound according to claim 1, characterized in that L is a bond, and Z is R26 R26a
11. 11. Compound according to claim 1, characterized in that L is a bond, Z is? R26 R26a and R25 is hydrogen.
12. 12. Compound in accordance with the claim 1, characterized in that L is a bond, Z is ^ R26 R26a ^ r25 is hydrogen and E and D is hydrogen.
13. 13. Compound according to claim 1, characterized in that R25 is in position 3.
14. 14. Compound in accordance with claim 1, characterized in that L is a bond, Z is , and R26a is -C (0) R32.
15. 15. Compound according to claim 1, characterized in that L is a bond, Z is , R26a is -C (0) R32, and RJ is selected from lower alkyl, cycloalkyl, diaminoalkyl, aminoalkyl, arylalkyl, heterocycloalkyl, alkoxyalkyl, alkylamino, and hydroxyalkyl optionally substituted by amino.
16. 16. Compound according to claim 1, characterized in that L is a bond, Z is , R26a is -C (0) R32, and R32 is cycloalkyl.
17. 17. Compound according to claim 1, characterized in that L is a bond, Z is R26 | N 'R26a R26a is -C (0) R32, and R32 is lower alkyl.
18. 18. Compound according to claim 1, characterized in that L is a bond, Z is R26a, R26a is -C (0) R32, R26 is hydrogen, wherein R32 is selected from aryl, arylalkyl, cycloalkyl, alkoxycarbonylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl, wherein R32 optionally substituted with 1, 2, 3, 4 or 5 groups selected from hydroxyl, oxo, alkyl, alkoxy, amino, hydroxyalkyl and halo.
19. 19. Compound in accordance with the claim 1, characterized in that L is a bond, Z is , R26a is -C (0) R, R is hydrogen, wherein R is lower alkyl optionally substituted with 1, 2, 3, 4 or 5 groups selected from dialkylaminocarbonyl, hydroxy and -NR34R3 a.
20. 20. Compound in accordance with claim N 1, characterized in that Z is R a, R 26 a is -C (0) R 32, R 26 is hydrogen, and R 32 selected from tetrahydrofuran, pyrrolidinyl or pyrimidinyl, wherein R 32 optionally substituted by 1, 2, 3, 4 or 5 groups selected from hydroxyl, oxo, alkyl, alkoxy, amino, hydroxyalkyl and halo.
21. 21. Compound in accordance with the claim 1, characterized in that R2 is
22. 22. Compound according to claim 1, characterized in that R32 is methyl.
23. 23. Compound according to claim 1, characterized in that R32 is alkyl substituted with NR3 R3 a.
24. 24. Compound according to claim 3, characterized in that R32 is methyl.
25. 25. Compound according to claim 2, characterized in that R32 is methyl.
26. 26. Compound according to claim 1, characterized in that R32 is U or -CH2-U, and wherein U is selected from pyrolidinyl, thiazolidinyl, morpholinyl, azetidinyl, cyclobutyl, cyclopropyl, tetrahydrofuranyl, pyrazinyl, imidazolyl, piperazinyl, thienyl, thienylmethyl, furanyl, phenyl, prolinamidyl, pyridinyl, tetrahydronaphthalene, tetrazolyl, isoindolinyl, pyranyl, cyclopentyl, and octahydro-lH-indolyl.
27. 27. Compound according to claim 1, characterized in that R11, when present, is halo or lower alkyl.
28. 28. Compound according to claim 1, characterized in that R11, when present, is lower alkyl.
29. 29. Compound according to claim 1, characterized in that R35 is heterocycloalkylalkyl, wherein the heterocyloalkyl is selected from piperazinyl, piperidinyl, morpholinyl and dioxanyl.
30. Compound according to claim 1, characterized in that n2 is 0.
31. 31. Compound in accordance with the claim
32. 32. Compound in accordance with the claim 1, characterized in that R2 is , and where R28 and R28a, together with the nitrogen atom to which they are attached, form a heterocycloalkyl.
33. 33. Compound in accordance with the claim 1, characterized in that it has Formula IV: wherein R28 and R28a, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R31.
34. 34. Compound according to claim 33, characterized in that D, E and R25 are each hydrogen.
35. 35. Compound according to claim 33, characterized in that R32 is heterocycloalkyl.
36. 36. Compound in accordance with the claim 33, characterized in that R 32 is alkyl optionally substituted with alkoxy, hydroxy, amino, alkylamino, or dialkylamino.
37. 37. Compound according to claim 1, characterized in that it has the Formula V: wherein R and R a, together with the nitrogen atom to which they are attached, form a heterocycloalkyl. wherein the heterocycloalkyl is optionally substituted with one or two R31.
38. 38. Compound according to claim 37, characterized in that D, E and R25 are each hydrogen.
39. 39. Compound according to claim 37, characterized in that R32 is heterocycloalkyl.
40. 40. Compound according to claim 37, characterized in that R32 is alkyl optionally substituted with alkoxy, hydroxy, amino, alkylamino, or dialkylamino.
41. 41. Compound in accordance with the claim 1, characterized in that it has Formula VI: where R and R, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R31.
42. 42. Compound according to claim 41, characterized in that D, E and R25 are each hydrogen.
43. 43. Compound according to claim 41, characterized in that R32 is heterocycloalkyl.
44. 44. Compound according to claim 41, characterized in that R32 is alkyl optionally substituted with alkoxy, hydroxy, amino, alkylamino, or dialkylamino.
45. 45. Compound according to claim 1, characterized in that it is selected from O-methyl-N- (4- { 2- [(-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -L-serinamide (S) -3-hydroxy-W- (4- (2- (4-morpholino-phenylamino) -pyrimidin-4-yl) -phenyl) -butanamide (R) -3-hydroxy-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) butanamide (R) -2-amino-3-hydroxy-W- (4- (2- (4-morpholinophenylamino) -pyrimidin-4-yl) phenyl) propanamide
46. 46. Compound according to claim 1, characterized in that it is selected from N- [4 - (2 { [4- (4-ethylpiperazin-1-yl) phenyl] amino.} Pyrimidin-4-yl) phenyl] acetamide; N- (- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-yl}. Phenyl) cyclopropanecarboxamide; N- (4-. {5-methyl-2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl.} Phenyl) cyclopropanecarboxamide; N- (4-. {2- 2- [(4-morpholinyl-phenyl) amino] pyrimidin-4-yl} phenyl) valinamide; N- (4- {2 - [(4- {4- [(l-methyl-lH-imidazol-2-yl) methyl] piperazin-1-yl} phenyl) amino] pyrimidin-4 -i1.} phenyl) acetamide; 2- (dimethylamino) -N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) acetamide; N- (4-. {-2- [(3,5-dimorpholin-4-ylphenyl) amino] -5-methylpyrimidin-4-yl} phenyl) acetamide; N- (4-. {2- [(4-morpholin-1-phenyl) amino] pyrimidin-4-yl] phenyl) -D-alaninamide; N-. { 4- [2- ( { 4- [4- (2-methylpropanoyl) piperazin-l-il] phenyl } araino) pyrimidin- -i1] phenyl} acetamide; 2-amino-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl.} Phenyl) -2-phenylacetamide; N- (4-. {5-methyl-2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) acetamide; 3- (methyloxy) -N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) propanamide; N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) prolinamide; N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -L-alaninamide; N- (4- {2 - [(4. {4- [3- (dimethylamino) -2,2-dimethylpropyl] piperazin-1-yl} phenyl) amino] pyrimidin-4 -i1} phenyl) acetamide; N- (4- {2 - [(4- {4- [3- (methyloxy) propanoyl] piperazin-1-yl} phenyl) amino] pyrimidin-4-yl.} Phenyl) acetamide; 2-Fidroxy-2-methyl-N- (4- (2- (4-morpholinophenylamino) pyrimidin-4-yl) phenyl) propanamide; N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-yl] phenyl) -D-prolinamide; N- [4- (2-. {[[3- (methyloxy) -4-morpholin-4-ylphenyl] amino] pyrimidin-4-yl) phenyl] -D-prolinamide; N- (- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) tetrahydrofuran-3-carboxamide; O-methyl-N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4 -i1} phenyl) -L-serinamide; l-ethyl-3-. { 4- [2- (. {4- [4- (2-methylpropanoyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} urea; N-ethyl-4- (4- { [4- (4-. {[[(Ethylamino) carbonyl] amino} phenyl) pyrimidin-2-yl] amino} phenyl) piperazine-l-carboxamide; N2, N2-dimethyl-N- (4- { 2- [(4- {4- [3- (methyloxy) propanoyl] piperazin-1-yl} phenyl) amino] pyrimidin-4-yl .}. phenyl) glycinamide; N- (4- (2- (3-methoxy-4-morpholino-phenylamino) pyrimidin-4-yl) phenyl) acetamide; N- (4- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -D-serinamide; (3R) -3-hydroxy-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) butanamide; (3S) -3-hydroxy-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) butanamide; N-. { 4- [2- (. {4- [4- (tetrahydrofuran-2-ylcarbonyl) piperazin-1-yl] phenyl} amino) pyrimidin-4-yl] phenyl} -D-prolinamide; 2-hydroxy-2-methyl-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) propanamide; N- (4- { 2- [(4-morpholin-4-phenyl) amino] pyrimidin-4-yl} phenyl) prolinamide; N- (- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl}. Phenyl) -L-prolinamide; N- (- { 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-yl] phenyl) -D-prolinamide; O-methyl-N- (4-. {2- 2- [(4-morpholin-4-phenyl) amino] pyrimidin-4-yl} phenyl) -L-serinamide; O-methyl-N- (4-. {2- 2- [(4-morpholin-4-phenyl) amino] pyrimidin-4-yl] phenyl) -D-serinamide; O-methyl-N- (4-. {2- 2- [(4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl} phenyl) -D-serinamide; and N- (4-. {2- [(3-fluoro-4-morpholin-4-ylphenyl) amino] pyrimidin-4-yl] phenyl) -D-prolinamide.
47. 47. Pharmaceutical composition, characterized in that it comprises a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient or diluent.
48. 48. Method for inhibiting JAK-2 in a cell, characterized in that it comprises contacting the cell, in which inhibition of JAK-2 is desired with a compound according to claim 1, or a pharmaceutically acceptable salt thereof.
49. 49. Method for inhibiting JAK-2 in a cell, characterized in that it comprises contacting the cell, in which the inhibition of JAK-2 is desired with a pharmaceutical composition comprising a compound according to claim 1, or a salt pharmaceutically acceptable thereof.
50. 50. Use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, to make a medicament for treating a disease, disorder or syndrome mediated, at least in part, by the inhibition of JAK-2.
51. 51. Use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, for preparing a medicament for treating a disease, disorder or syndrome mediated, at least, in part by the inhibition of JAK-2.
52. 52. Pharmaceutical composition, characterized in that it comprises a compound in accordance with the claim 45, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient or diluent.
53. 53. Pharmaceutical composition, characterized in that it comprises a compound according to the claim 46, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient or diluent.
54. 54. Use of a conforming compound of claim 1, or a pharmaceutically acceptable salt thereof, to make a medicament for treating a disease, disorder or mediated spindrome, at least in part, by the inhibition of JAK-2.
55. 55. Use according to claim 54, wherein the disease, disorder or syndrome being treated is a myeloproliferative disorder, cancer, cardiovascular disease, and / or hematopoietic abnormality where hyperactivation of the JAK-STAT signaling is present.
56. 56. Use of, according to claim 55, wherein the myeloproliferative disorders are selected from myelofibrosis, thrombocythemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
57. 57. Use according to claim 55, wherein the cancers are selected from leukemias, lymphores, multiple myeloma, prostate cancers, lung cancers, breast cancers, and ovarian cancers
58. 58. Use according to claim 55, in where the cancers are selected from congestive heart failure and hypertension.
59. 59. Use according to claim 55, wherein the hematopoietic abnormality is thrombocytosis.
60. 60. Use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, in combination with one or more treatments selected from surgery, one or more therapeutic agents, plateletpheresis, and radiation to make a medicament. to treat a disease, disorder or mediated syndrome, at least in part by the inhibition of JAK-2.
61. 61. Use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, in combination with one or more treatments selected from surgery, one or more therapeutic agents, plateletpheresis, and radiation to make a medicament for treating a disease, disorder or mediated syndrome, at least in part due to the inhibition of JAK-2.